EU Local Number,Report Type,EV Gateway Receipt Date,Primary Source Qualification,Primary Source Country for Regulatory Purposes,Literature Reference,Patient Age Group,Patient Age Group (as per reporter),Parent Child Report,Patient Sex,Reaction List PT (Duration – Outcome - Seriousness Criteria),Suspect/interacting Drug List (Drug Char - Indication PT - Action taken - [Duration - Dose - Route]),Concomitant/Not Administered Drug List (Drug Char - Indication PT - Action taken - [Duration - Dose - Route]),ICSR Form
EU-EC-10016554954,Spontaneous,2023-12-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,Yes,Male,"Arthralgia (1d - Recovered/Resolved - ),<BR><BR>Chills (1d - Recovered/Resolved - ),<BR><BR>Injection site swelling (3d - Recovered/Resolved - ),<BR><BR>Myalgia (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - Oral use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016554954&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016554964,Spontaneous,2023-12-31 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,Yes,Female,"Neutrophilia (n/a - Recovered/Resolved - Disabling),<BR><BR>Rash (n/a - Recovered/Resolved - Disabling),<BR><BR>Skin exfoliation (n/a - Recovered/Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[DROSPIRENONE, LACTOSE, LACTOSE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016554964&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016553506,Spontaneous,2023-12-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Neck pain (n/a - Recovered/Resolved - ),<BR><BR>Vaccination site pain (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016553506&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016553542,Spontaneous,2023-12-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Hypertension (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016553542&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016546089,Spontaneous,2023-12-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Administration site reaction (15d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016546089&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016546092,Spontaneous,2023-12-29 00:00:00,Healthcare Professional,European Economic Area,Not available,12-17 Years,Not Specified,No,Male,"Erythema (2d - Recovered/Resolved - ),<BR><BR>Injection site swelling (2d - Recovered/Resolved - ),<BR><BR>Motor dysfunction (2d - Recovered/Resolved - ),<BR><BR>Pain in extremity (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016546092&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016546292,Spontaneous,2023-12-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Acute psychosis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Agitation (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Anxiety (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Cerebral palsy (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Condition aggravated (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Disturbance in attention (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Incorrect dose administered (n/a - Unknown - ),<BR><BR>Insomnia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Mania (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Restlessness (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Urinary tract infection (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [1d - 10mg - n/a]),<BR><BR>[BACLOFEN] (C - Cerebral palsy - n/a - [n/a - .5{DF} - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016546292&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016546301,Spontaneous,2023-12-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Drug ineffective (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Menstruation irregular (n/a - Not Recovered/Not Resolved - ),<BR><BR>Suspected COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016546301&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016546553,Spontaneous,2023-12-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Transient global amnesia (2d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Migraine - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016546553&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016546554,Spontaneous,2023-12-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Deep vein thrombosis (n/a - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[COLECALCIFEROL, CALCIUM CARBONATE] (C - Osteoporosis - n/a - [n/a - n/a - n/a]),<BR><BR>[INDAPAMIDE, INDAPAMIDE HEMIHYDRATE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016546554&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016546559,Spontaneous,2023-12-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anxiety (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sleep disorder (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"NORDIMET [METHOTREXATE] (C - Still's disease - n/a - [n/a - 15mg - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016546559&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016546604,Spontaneous,2023-12-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Influenza - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016546604&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016546666,Spontaneous,2023-12-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Loss of consciousness (6d - Recovered/Resolved - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016546666&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016546762,Spontaneous,2023-12-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abnormal uterine bleeding (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Asthma - n/a - [1d - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016546762&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016546932,Spontaneous,2023-12-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016546932&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016547411,Spontaneous,2023-12-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016547411&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016547507,Spontaneous,2023-12-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016547507&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016547758,Spontaneous,2023-12-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016547758&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016547857,Spontaneous,2023-12-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016547857&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016547906,Spontaneous,2023-12-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Synovitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.1 [ELASOMERAN, IMELASOMERAN] (C - COVID-19 immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - Brachytherapy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016547906&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016548044,Spontaneous,2023-12-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Hypertension (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016548044&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016548882,Spontaneous,2023-12-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Male,Herpes zoster (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - Intramuscular use]),"[ALLOPURINOL] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[ATORVASTATIN, EZETIMIBE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[CARBIDOPA, LEVODOPA] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[DIOSMIN] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[FINASTERIDE] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016548882&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016549063,Spontaneous,2023-12-29 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Pulmonary embolism (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Thrombocytopenia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016549063&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016549067,Spontaneous,2023-12-29 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Amnestic disorder (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016549067&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016549152,Spontaneous,2023-12-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Polymyalgia rheumatica (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016549152&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016549305,Spontaneous,2023-12-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Blood pressure increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Immunisation reaction (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tachycardia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016549305&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016549339,Spontaneous,2023-12-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Immunisation reaction (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016549339&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016549345,Spontaneous,2023-12-29 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Amnestic disorder (1d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016549345&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016549412,Spontaneous,2023-12-29 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (1d - Not Recovered/Not Resolved - ),<BR><BR>Vomiting (1d - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016549412&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016550358,Spontaneous,2023-12-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016550358&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016550832,Spontaneous,2023-12-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016550832&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016550856,Spontaneous,2023-12-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016550856&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016551449,Spontaneous,2023-12-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016551449&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016551460,Spontaneous,2023-12-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Aortic stenosis (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pulmonary valve stenosis (n/a - Unknown - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016551460&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016551821,Spontaneous,2023-12-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Blood pressure increased (0d - Fatal - Results in Death),<BR><BR>Cyanosis (0d - Fatal - Results in Death),<BR><BR>Fatigue (1d - Fatal - Results in Death),<BR><BR>Rash (1d - Fatal - Results in Death),<BR><BR>Salivary hypersecretion (0d - Fatal - Results in Death),<BR><BR>Sudden death (n/a - Fatal - Results in Death),<BR><BR>Swollen tongue (0d - Fatal - Results in Death),<BR><BR>Tachycardia (0d - Fatal - Results in Death)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 HAEMAGGLUTININ ANTIGEN, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016551821&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016551935,Spontaneous,2023-12-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Haematuria (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016551935&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016552562,Spontaneous,2023-12-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Male,"Cough (n/a - Recovered/Resolved - ),<BR><BR>Myalgia (1wk - Not Recovered/Not Resolved - ),<BR><BR>Nasal congestion (n/a - Recovered/Resolved - ),<BR><BR>Oropharyngeal pain (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),"[CANDESARTAN, CANDESARTAN CILEXETIL] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016552562&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016552638,Spontaneous,2023-12-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Decreased appetite (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Still's disease (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),"[BENIDIPINE, BENIDIPINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE, BUDESONIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FEXOFENADINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOFLOXACIN] (C - n/a - n/a - [3d - n/a - n/a]),<BR><BR>[PRANLUKAST, PRANLUKAST HYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE, PREDNISOLONE ACETATE] (C - n/a - n/a - [5d - n/a - n/a]),<BR><BR>[RUPATADINE, RUPATADINE FUMARATE] (C - n/a - n/a - [10d - n/a - n/a]),<BR><BR>[THEOPHYLLINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016552638&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016552780,Spontaneous,2023-12-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016552780&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016538391,Spontaneous,2023-12-28 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,Blindness transient (0d - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016538391&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016538460,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Blood pressure increased (n/a - Recovering/Resolving - ),<BR><BR>Chest pain (n/a - Recovering/Resolving - ),<BR><BR>Cough (n/a - Recovering/Resolving - ),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Nasopharyngitis (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Tinnitus (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016538460&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016538777,Spontaneous,2023-12-28 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Disseminated intravascular coagulation (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Movement disorder (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Platelet count decreased (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Pneumonia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Subdural haematoma (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Syncope (n/a - Unknown - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CILOSTAZOL] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[COLECALCIFEROL, CALCIUM, MAGNESIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ISOSORBIDE DINITRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOXOPROFEN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MAGNESIUM OXIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MECOBALAMIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[NICORANDIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[NITRAZEPAM, NITRAZEPAM BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OLMESARTAN, OLMESARTAN MEDOXOMIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[THIAMINE HYDROCHLORIDE, CYANOCOBALAMIN, PYRIDOXINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TOCOPHERYL ACETATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ZOLPIDEM, ZOLPIDEM TARTRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016538777&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016539578,Spontaneous,2023-12-28 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Myocardial infarction (n/a - Fatal - Results in Death, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[FELODIPINE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[NAFTIDROFURYL, NAFTIDROFURYL OXALATE] (C - Peripheral vascular disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[SULFASALAZINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016539578&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016539736,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016539736&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016540521,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016540521&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016540541,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Breast cancer (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016540541&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016540546,Spontaneous,2023-12-28 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - Nasal use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016540546&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016540573,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016540573&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016540589,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016540589&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016540600,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Cough (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[PROGESTERONE, MICRONISED] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016540600&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016540606,Spontaneous,2023-12-28 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Palpitations (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016540606&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016540633,Spontaneous,2023-12-28 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016540633&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016540787,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016540787&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016540861,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016540861&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016540960,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016540960&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016541186,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Disabling),<BR><BR>Dizziness (n/a - Unknown - Disabling),<BR><BR>Myalgia (n/a - Unknown - Disabling),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Vomiting (n/a - Unknown - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - n/a - n/a - [n/a - n/a - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016541186&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016541468,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,Yes,Male,"Chills (2d - Recovered/Resolved - ),<BR><BR>Headache (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),[SODIUM VALPROATE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016541468&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016541570,Spontaneous,2023-12-28 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Dyspnoea (n/a - Fatal - Results in Death),<BR><BR>Hypoxia (n/a - Fatal - Results in Death)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),FASENRA 30 MG SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE [BENRALIZUMAB] (C - Asthma - Dose not changed - [n/a - 1{DF} - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016541570&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016541718,Spontaneous,2023-12-28 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Asthenia (n/a - Recovering/Resolving - ),<BR><BR>Hot flush (n/a - Recovering/Resolving - ),<BR><BR>Tinnitus (n/a - Recovering/Resolving - ),<BR><BR>Vomiting projectile (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016541718&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016541737,Spontaneous,2023-12-28 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Fatigue (1d - Recovered/Resolved - ),<BR><BR>Vaccination site pruritus (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016541737&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016541753,Spontaneous,2023-12-28 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Pyrexia (72h - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016541753&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016541754,Spontaneous,2023-12-28 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Male,"Incorrect dose administered (n/a - Recovered/Resolved - ),<BR><BR>Pain in extremity (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .5mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016541754&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016541769,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016541769&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016541770,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Rash (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rash erythematous (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016541770&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016541781,Spontaneous,2023-12-28 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Influenza immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016541781&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016541801,Spontaneous,2023-12-28 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Macule (6d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016541801&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016541982,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[THIAMINE, PYRIDOXINE HYDROCHLORIDE, VITAMIN B] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016541982&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016541999,Spontaneous,2023-12-28 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Petechiae (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Thrombocytopenia (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>SHINGRIX [RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E, RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E, STIMULON, MONOPHOSPHORYL LIPID A] (S - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[ALGELDRATE, TICK-BORNE ENCEPHALITIS VIRUS (INACTIVATED), NEUDOERFL STRAIN, TICK-BORNE ENCEPHALITIS VIRUS (INACTIVATED), NEUDOERFL STRAIN, TICK-BORNE ENCEPHALITIS VIRUS NEUDOERFL STRAIN ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED PRODUCED IN CHICK EMBRYO CELLS, ALGELDRATE] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016541999&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016542020,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016542020&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016542039,Spontaneous,2023-12-28 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,Deafness bilateral (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),"[BETAHISTINE DIHYDROCHLORIDE, BETAHISTINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016542039&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016542145,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016542145&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016542174,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016542174&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016542297,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016542297&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016542318,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016542318&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016542342,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[ATORVASTATIN] (C - n/a - n/a - [84d - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [87d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016542342&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016542344,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016542344&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016542391,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016542391&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016542410,Spontaneous,2023-12-28 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Influenza like illness (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pleurisy (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016542410&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016542640,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[ALLOPURINOL] (C - Blood uric acid abnormal - n/a - [n/a - 300mg - Oral use]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Blood pressure abnormal - n/a - [n/a - 10mg - Oral use]),<BR><BR>[HYDROCHLOROTHIAZIDE] (C - Blood pressure abnormal - n/a - [n/a - 12.5mg - Oral use]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - Blood pressure abnormal - n/a - [n/a - 40mg - Oral use]),<BR><BR>[METOPROLOL, METOPROLOL TARTRATE] (C - Blood pressure abnormal - n/a - [n/a - 50mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016542640&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016542796,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypersomnia (n/a - Unknown - ),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016542796&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016542869,Spontaneous,2023-12-28 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016542869&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016543583,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Asthenia (n/a - Recovering/Resolving - ),<BR><BR>Atrial fibrillation (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Heart rate increased (n/a - Recovering/Resolving - ),<BR><BR>Hypotension (n/a - Recovering/Resolving - ),<BR><BR>Myocarditis (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016543583&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016543670,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (4d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016543670&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016543839,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016543839&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016544975,Spontaneous,2023-12-28 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016544975&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016544995,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016544995&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016545192,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Polymyalgia rheumatica (n/a - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016545192&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016545271,Spontaneous,2023-12-28 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,Rash (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 3 MICROGRAMS/DOSE CONCENTRATE FOR DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016545271&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016545272,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Influenza like illness (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),"[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE, BUDESONIDE] (C - Asthma - Dose not changed - [n/a - 1{DF} - Inhalation use]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - Hypothyroidism - Dose not changed - [n/a - 50ug - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016545272&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016545582,Spontaneous,2023-12-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Guillain-Barre syndrome (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Unknown - ),<BR><BR>Pneumonia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - n/a - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016545582&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016545631,Spontaneous,2023-12-28 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Monoclonal gammopathy (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016545631&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016545760,Spontaneous,2023-12-28 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Cerebral infarction (n/a - Fatal - Results in Death),<BR><BR>Decreased appetite (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Myocardial infarction (n/a - Fatal - Results in Death)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016545760&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016530802,Spontaneous,2023-12-27 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Body temperature increased (15h - Recovered/Resolved - ),<BR><BR>Bone contusion (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cardiovascular disorder (15h - Recovered/Resolved - ),<BR><BR>Contusion (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fall (15h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Heart rate increased (15h - Recovered/Resolved - ),<BR><BR>Syncope (2d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 HAEMAGGLUTININ ANTIGEN, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [1d - n/a - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016530802&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016532546,Spontaneous,2023-12-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (25d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Disease recurrence (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (25d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016532546&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016532562,Spontaneous,2023-12-27 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dermatitis contact (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypersensitivity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash pruritic (n/a - Recovering/Resolving - Other Medically Important Condition)","ABRYSVO [RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP A, STABILIZED PREFUSION F PROTEIN 847A, RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP B, STABILIZED PREFUSION F PROTEIN 847B] (S - Immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [1d - n/a - n/a])","CELECOXIB [CELECOXIB] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FINASTERIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[GABAPENTIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MINOXIDIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016532562&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016532984,Spontaneous,2023-12-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Injection site pain (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016532984&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016532985,Spontaneous,2023-12-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (n/a - Recovered/Resolved - ),<BR><BR>Cough (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Limb discomfort (n/a - Recovering/Resolving - ),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - ),<BR><BR>Rhinorrhoea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016532985&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016532986,Spontaneous,2023-12-27 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,"Cellulitis (n/a - Fatal - Results in Death),<BR><BR>Muscle necrosis (n/a - Fatal - Results in Death),<BR><BR>Pain in extremity (n/a - Fatal - Results in Death),<BR><BR>Septic shock (1d - Fatal - Results in Death)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016532986&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016533416,Spontaneous,2023-12-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Cough (n/a - Recovering/Resolving - ),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Influenza like illness (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016533416&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016533420,Spontaneous,2023-12-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cerebral venous sinus thrombosis (3d - Fatal - Results in Death, Life Threatening),<BR><BR>Cough (3d - Fatal - Results in Death, Life Threatening),<BR><BR>Death (3d - Fatal - Results in Death, Life Threatening),<BR><BR>Headache (3d - Fatal - Results in Death, Life Threatening),<BR><BR>Influenza like illness (3d - Fatal - Results in Death, Life Threatening),<BR><BR>Limb discomfort (3d - Fatal - Results in Death, Life Threatening),<BR><BR>Pyrexia (3d - Fatal - Results in Death, Life Threatening),<BR><BR>Speech disorder (3d - Fatal - Results in Death, Life Threatening)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016533420&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016533720,Spontaneous,2023-12-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016533720&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016533831,Spontaneous,2023-12-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tendon rupture (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tendon sheath effusion (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016533831&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016533853,Spontaneous,2023-12-27 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Rash (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016533853&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016534088,Spontaneous,2023-12-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Blood pressure increased (n/a - Recovered/Resolved - ),<BR><BR>Heart rate decreased (n/a - Recovered/Resolved - ),<BR><BR>Hemihypoaesthesia (n/a - Recovered/Resolved - ),<BR><BR>Pruritus (n/a - Recovered/Resolved - ),<BR><BR>Throat irritation (n/a - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - n/a - n/a - [n/a - 1{DF} - n/a])","PLAVIX [CLOPIDOGREL, CLOPIDOGREL HYDROGEN SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016534088&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016534108,Spontaneous,2023-12-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016534108&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016534181,Spontaneous,2023-12-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Guillain-Barre syndrome (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 HAEMAGGLUTININ ANTIGEN, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016534181&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016534187,Spontaneous,2023-12-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Limb discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016534187&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016534437,Spontaneous,2023-12-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Anxiety (4d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),"[LERCANIDIPINE, LERCANIDIPINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OLMESARTAN MEDOXOMILO + HIDROCLOROTIAZIDA] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016534437&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016534454,Spontaneous,2023-12-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Headache (n/a - Recovered/Resolved - ),<BR><BR>Injection site erythema (n/a - Recovered/Resolved - ),<BR><BR>Injection site inflammation (n/a - Recovered/Resolved - ),<BR><BR>Injection site pain (n/a - Recovered/Resolved - ),<BR><BR>Injection site warmth (n/a - Recovered/Resolved - ),<BR><BR>Malaise (3d - Recovered/Resolved - ),<BR><BR>Myalgia (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016534454&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016534656,Spontaneous,2023-12-27 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Heart rate irregular (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),ELIQUIS [APIXABAN] (C - n/a - n/a - ),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016534656&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016535111,Spontaneous,2023-12-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Body temperature increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nasal congestion (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site mass (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site warmth (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - n/a - n/a])","RELVAR ELLIPTA [FLUTICASONE FUROATE, VILANTEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ETORICOXIB] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, PARACETAMOL PH. EUR., PARACETAMOL, CODEINE PHOSPHATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016535111&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016536211,Spontaneous,2023-12-27 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Eye disorder (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Herpes zoster reactivation (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Hypophagia (n/a - Unknown - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016536211&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016537032,Spontaneous,2023-12-27 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016537032&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016537580,Spontaneous,2023-12-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,"Cough (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016537580&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016537735,Spontaneous,2023-12-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Heart rate (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Hypotension (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - Unknown - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016537735&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016524154,Spontaneous,2023-12-26 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016524154&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016524159,Spontaneous,2023-12-26 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>TOZINAMERAN [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",MYCOPHENOLATE MOFETIL [MYCOPHENOLATE MOFETIL] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016524159&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016524315,Spontaneous,2023-12-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Adult,No,Female,"Hypersensitivity (n/a - Unknown - Life Threatening),<BR><BR>Near death experience (n/a - Unknown - Life Threatening, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016524315&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016524317,Spontaneous,2023-12-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016524317&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016524339,Spontaneous,2023-12-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Blindness unilateral (n/a - Unknown - Other Medically Important Condition),<BR><BR>Ocular vascular disorder (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016524339&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016524354,Spontaneous,2023-12-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Adult,No,Female,"Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Loss of consciousness (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Unresponsive to stimuli (2min - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ACENOCOUMAROL, ACENOCOUMAROL BP] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016524354&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016524357,Spontaneous,2023-12-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016524357&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016524371,Spontaneous,2023-12-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[FAMOTIDINE, FAMOTIDINE, CALCIUM CARBONATE, MAGNESIUM HYDROXIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016524371&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016524373,Spontaneous,2023-12-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [5051d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016524373&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016524385,Spontaneous,2023-12-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016524385&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016524396,Spontaneous,2023-12-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016524396&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016526770,Spontaneous,2023-12-26 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Atrial fibrillation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),"[AMIODARONE, AMIODARONE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016526770&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016526879,Spontaneous,2023-12-26 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Renal artery dissection (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Renal infarct (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016526879&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016527114,Spontaneous,2023-12-26 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Gait disturbance (24h - Recovered/Resolved - ),<BR><BR>Pain in extremity (24h - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [1d - .5mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016527114&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016527229,Spontaneous,2023-12-26 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Amnesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Confusional state (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vision blurred (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016527229&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016527242,Spontaneous,2023-12-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Male,"Back pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chest discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016527242&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016527253,Spontaneous,2023-12-26 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Rash (7d - Unknown - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016527253&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016527282,Spontaneous,2023-12-26 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Influenza like illness (36h - Recovered/Resolved - ),<BR><BR>Urticaria (36h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016527282&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016527285,Spontaneous,2023-12-26 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Parosmia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016527285&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016527305,Spontaneous,2023-12-26 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Face oedema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016527305&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016527523,Spontaneous,2023-12-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016527523&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016527795,Spontaneous,2023-12-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016527795&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016527796,Spontaneous,2023-12-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,3-11 Years,Not Specified,No,Male,"Adrenal disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Blood pressure decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Death (n/a - Fatal - Results in Death)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016527796&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016527917,Spontaneous,2023-12-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site bruising (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016527917&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016527950,Spontaneous,2023-12-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016527950&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016528289,Spontaneous,2023-12-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016528289&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016528363,Spontaneous,2023-12-26 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016528363&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016529230,Spontaneous,2023-12-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016529230&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016529420,Spontaneous,2023-12-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016529420&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016529462,Spontaneous,2023-12-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Adult,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016529462&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016529546,Spontaneous,2023-12-26 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Multiple sclerosis relapse (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016529546&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016529548,Spontaneous,2023-12-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016529548&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016529618,Spontaneous,2023-12-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Adult,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016529618&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016529827,Spontaneous,2023-12-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Periorbital pain (n/a - Recovered/Resolved With Sequelae - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .5mL - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227)] (S - Influenza immunisation - Not applicable - [1d - .5umol - Intramuscular use])","[ASTAXANTHIN] (C - Blood cholesterol increased - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[BERBERINE] (C - Blood cholesterol increased - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - Blood cholesterol increased - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[POLICOSANOL] (C - Blood cholesterol increased - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[RED YEAST RICE] (C - Blood cholesterol increased - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[UBIDECARENONE] (C - Blood cholesterol increased - Dose not changed - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016529827&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016529835,Spontaneous,2023-12-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Cough (n/a - Unknown - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),<BR><BR>FLUAD TETRA SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Influenza immunisation - Drug withdrawn - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016529835&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016529851,Spontaneous,2023-12-26 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Unknown - ),<BR><BR>Temperature regulation disorder (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227)] (S - Influenza immunisation - Not applicable - [1d - .5mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016529851&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016529975,Spontaneous,2023-12-26 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016529975&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016530643,Spontaneous,2023-12-26 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016530643&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016522990,Spontaneous,2023-12-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016522990&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016523079,Spontaneous,2023-12-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Atrial flutter (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea exertional (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Palpitations (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Transient ischaemic attack (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>SHINGRIX [RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E, RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E, STIMULON, MONOPHOSPHORYL LIPID A] (S - Immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])","TADALAFIL [TADALAFIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BUPROPION] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016523079&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016523080,Spontaneous,2023-12-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Vaginal haemorrhage (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016523080&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016523091,Spontaneous,2023-12-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dyspepsia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site bruising (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"NILOTINIB [NILOTINIB] (C - Chronic myeloid leukaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016523091&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016523102,Spontaneous,2023-12-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016523102&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016523103,Spontaneous,2023-12-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"HYDROCORTISONE [HYDROCORTISONE, HYDROCORTISONE SODIUM SUCCINATE] (C - Addison's disease - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUDROCORTISONE] (C - Addison's disease - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016523103&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016523110,Spontaneous,2023-12-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Adult,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [50d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016523110&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016523151,Spontaneous,2023-12-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Condition aggravated (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Lung carcinoma cell type unspecified stage IV (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Malignant pleural effusion (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pleural effusion (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016523151&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016523152,Spontaneous,2023-12-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Intermenstrual bleeding (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaginal haemorrhage (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016523152&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016523374,Spontaneous,2023-12-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Groin pain (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Iron deficiency (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Lower respiratory tract infection (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Polymyalgia rheumatica (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vitamin B12 deficiency (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016523374&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016523558,Spontaneous,2023-12-25 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016523558&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016523824,Spontaneous,2023-12-25 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Adult,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016523824&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519007,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovered/Resolved - ),<BR><BR>Fatigue (2d - Recovered/Resolved - ),<BR><BR>Malaise (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (13h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519007&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519008,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Arthritis (24h - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519008&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519010,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pulmonary pain (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519010&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519012,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Injection site erythema (6d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (6d - Recovered/Resolved - ),<BR><BR>Injection site pain (6d - Recovered/Resolved - ),<BR><BR>Injection site pruritus (6d - Recovered/Resolved - ),<BR><BR>Injection site warmth (6d - Recovered/Resolved - ),<BR><BR>Vaginal haemorrhage (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519012&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519013,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Myalgia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519013&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519015,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Elderly,No,Male,International normalised ratio increased (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - Dose reduced - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519015&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519016,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Injection site discolouration (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (6d - Recovered/Resolved - ),<BR><BR>Injection site haematoma (6d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (6d - Recovered/Resolved - ),<BR><BR>Injection site pain (6d - Recovered/Resolved - ),<BR><BR>Injection site swelling (6d - Recovered/Resolved - ),<BR><BR>Injection site warmth (6d - Recovered/Resolved - ),<BR><BR>Myalgia (6d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519016&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519017,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Tremor (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519017&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519018,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Herpes zoster (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519018&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519019,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Herpes zoster (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519019&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519020,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Conjunctivitis (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519020&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519022,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (12d - Recovered/Resolved - ),<BR><BR>Fatigue (15d - Recovered/Resolved - ),<BR><BR>Headache (10d - Recovered/Resolved - ),<BR><BR>Hypertension (n/a - Recovering/Resolving - ),<BR><BR>Hypoxia (n/a - Recovering/Resolving - ),<BR><BR>Malaise (10d - Recovered/Resolved - ),<BR><BR>Myalgia (12d - Recovered/Resolved - ),<BR><BR>Nausea (8d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519022&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519023,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[NOT AVAILABLE] (S - Product used for unknown indication - Not applicable - [n/a - 1{DF} - n/a])","METFORMIN HYDROCHLORIDE 850MG TABLET, EMPAGLIFLOZIN 5MG TABLET  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>MICARDIS 80 MG TABLETS [TELMISARTAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INSULIN DEGLUDEC] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519023&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519024,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519024&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519026,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Herpes zoster (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519026&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519027,Spontaneous,2023-12-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Cerebral infarction (4h - Recovered/Resolved - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519027&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519028,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Postmenopausal haemorrhage (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519028&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519029,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Eye swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypersensitivity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lip swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pharyngeal swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Urticaria (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519029&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519030,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Recovered/Resolved - ),<BR><BR>Chills (2d - Recovered/Resolved - ),<BR><BR>Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (3d - Recovered/Resolved - ),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519030&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519031,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Eczema (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519031&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519032,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Feeling cold (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Muscular weakness (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519032&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519033,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Injection site haemorrhage (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519033&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519034,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Head discomfort (2d - Recovered/Resolved - ),<BR><BR>Headache (2d - Recovered/Resolved - ),<BR><BR>Visual acuity reduced (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519034&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519035,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Recovered/Resolved - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519035&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519036,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (4d - Recovered/Resolved - ),<BR><BR>Injection site erythema (1wk - Recovered/Resolved - ),<BR><BR>Injection site inflammation (1wk - Recovered/Resolved - ),<BR><BR>Injection site pain (1wk - Recovered/Resolved - ),<BR><BR>Injection site warmth (1wk - Recovered/Resolved - ),<BR><BR>Malaise (1wk - Recovered/Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519036&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519037,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Nausea (n/a - Recovering/Resolving - ),<BR><BR>Vertigo (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519037&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519038,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"ABASAGLAR 100 UNITS/ML SOLUTION FOR INJECTION IN A PRE-FILLED PEN [INSULIN GLARGINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>INSULIN ASPART 100 U/ML - SOLUTION FOR INJECTION  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN POTASSIUM, HYDROCHLOROTHIAZIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519038&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519039,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519039&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519040,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Gait disturbance (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Musculoskeletal stiffness (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519040&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519041,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Hypersensitivity (n/a - Recovering/Resolving - ),<BR><BR>Pruritus (n/a - Recovering/Resolving - ),<BR><BR>Rash erythematous (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - n/a - Not applicable - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519041&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519042,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (2d - Recovered/Resolved - ),<BR><BR>Hyperpyrexia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE] (C - n/a - Dose not changed - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519042&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519043,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (10d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (3d - Recovered/Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (10d - Recovered/Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519043&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519044,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (2d - Recovered/Resolved - ),<BR><BR>Headache (3d - Recovered/Resolved - ),<BR><BR>Malaise (4d - Recovered/Resolved - ),<BR><BR>Nausea (3d - Recovered/Resolved - ),<BR><BR>Periorbital haemorrhage (3d - Recovered/Resolved - ),<BR><BR>Vomiting (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519044&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016519361,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Deep vein thrombosis (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"LYRICA 25 MG CAPSULES [PREGABALIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE BESILATE] (C - n/a - Drug withdrawn - [n/a - n/a - n/a]),<BR><BR>[CARBASALATE CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016519361&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016520718,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016520718&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016520763,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016520763&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016521006,Spontaneous,2023-12-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016521006&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016509844,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,Puncture site induration (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016509844&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016510054,Spontaneous,2023-12-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blood pressure decreased (n/a - Recovering/Resolving - ),<BR><BR>Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Paraesthesia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016510054&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016510373,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Deep vein thrombosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Not Recovered/Not Resolved - ),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - ),<BR><BR>Thrombosis with thrombocytopenia syndrome (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016510373&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016510374,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Amylase increased (n/a - Unknown - ),<BR><BR>Blood albumin decreased (n/a - Unknown - ),<BR><BR>Blood creatine phosphokinase increased (n/a - Unknown - ),<BR><BR>Blood lactate dehydrogenase increased (n/a - Unknown - ),<BR><BR>Cognitive disorder (n/a - Unknown - ),<BR><BR>Dysphagia (56d - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dysstasia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Gait disturbance (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Glomerular filtration rate decreased (n/a - Unknown - ),<BR><BR>Haematocrit decreased (n/a - Unknown - ),<BR><BR>Haemoglobin decreased (n/a - Unknown - ),<BR><BR>Muscular weakness (56d - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Red blood cell count decreased (n/a - Unknown - ),<BR><BR>White blood cell count decreased (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),"[CILNIDIPINE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[PRAVASTATIN SODIUM] (C - Dyslipidaemia - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016510374&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016510401,Spontaneous,2023-12-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016510401&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016511077,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Interstitial lung disease (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016511077&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016511124,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Abdominal pain upper (n/a - Recovering/Resolving - ),<BR><BR>Dizziness (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Dysphoria (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Feeling abnormal (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Flushing (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Head discomfort (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Heart rate irregular (n/a - Recovering/Resolving - ),<BR><BR>Hiccups (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Muscle tightness (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Neuralgia (n/a - Recovering/Resolving - ),<BR><BR>Pruritus (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016511124&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016511307,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (7d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - Blood pressure increased - n/a - [n/a - 10mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016511307&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016511729,Spontaneous,2023-12-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[ESCITALOPRAM, ESCITALOPRAM OXALATE] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016511729&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016512023,Spontaneous,2023-12-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Emotional distress (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fall (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gingivitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hip fracture (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tooth disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tooth loss (n/a - Unknown - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (I - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (I - Blood pressure measurement - Unknown - [n/a - n/a - n/a]),<BR><BR>[FELODIPINE] (I - Blood pressure measurement - Unknown - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016512023&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016512066,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Internal capsule infarction (n/a - Recovering/Resolving - Disabling),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - n/a - n/a - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016512066&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016512150,Spontaneous,2023-12-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Abdominal pain (0d - Recovered/Resolved - ),<BR><BR>Diarrhoea (0d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016512150&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016512307,Spontaneous,2023-12-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Recovered/Resolved - ),<BR><BR>Dizziness (n/a - Recovered/Resolved - ),<BR><BR>Heart rate increased (n/a - Recovered/Resolved - ),<BR><BR>Hypotension (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Recovered/Resolved - ),<BR><BR>Visual impairment (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016512307&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016512325,Spontaneous,2023-12-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016512325&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016512352,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016512352&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016512430,Spontaneous,2023-12-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Herpes zoster (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Pericarditis (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016512430&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016512752,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Diarrhoea (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Dizziness (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Nausea (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Vomiting projectile (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - n/a - n/a - [n/a - .5mL - n/a])",ELIQUIS [APIXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016512752&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016512782,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Adrenal insufficiency (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016512782&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016512842,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,Yes,Female,"Vaccination site haematoma (33d - Recovered/Resolved - ),<BR><BR>Vaccination site pain (33d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - Not applicable - [n/a - n/a - n/a]),"[COLECALCIFEROL, CALCIUM, COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CYANOCOBALAMIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL VALERATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016512842&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016512935,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Arthralgia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016512935&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016512952,Spontaneous,2023-12-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016512952&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016513196,Spontaneous,2023-12-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,Yes,Male,"Arthralgia (n/a - Unknown - ),<BR><BR>Oedema peripheral (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016513196&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016513197,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,Yes,Female,"Blister (11d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Injection site erythema (12d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (12d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Antiviral prophylaxis - Not applicable - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016513197&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016513214,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Breakthrough COVID-19 (n/a - Recovering/Resolving - Disabling),<BR><BR>C-reactive protein increased (n/a - Recovering/Resolving - Disabling),<BR><BR>Polymyalgia rheumatica (n/a - Recovering/Resolving - Disabling),<BR><BR>Red blood cell sedimentation rate increased (n/a - Recovering/Resolving - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016513214&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016513538,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Ischaemic stroke (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),[NEBIVOLOL] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016513538&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016513540,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Hypertension (n/a - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016513540&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016513631,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Lymphadenopathy (13d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Superficial vein thrombosis (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Influenza immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016513631&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016513736,Spontaneous,2023-12-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Lymphadenopathy (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),[ROPINIROLE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016513736&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016513746,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Abdominal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (6d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016513746&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016513754,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Pruritus (n/a - Recovering/Resolving - ),<BR><BR>Rash maculo-papular (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),"COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [2d - 2{DF} - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016513754&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016514496,Spontaneous,2023-12-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Arrhythmia (n/a - Unknown - ),<BR><BR>COVID-19 immunisation (n/a - Unknown - ),<BR><BR>Dyspnoea (n/a - Unknown - ),<BR><BR>Extrasystoles (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Heart rate decreased (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Panic attack (n/a - Unknown - ),<BR><BR>Tremor (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - 1{DF} - Intramuscular use]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - n/a - n/a - [n/a - 1{DF} - Intramuscular use]),<BR><BR>VAXZEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - n/a - n/a - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - n/a - n/a - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016514496&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016515019,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),[A/CALIFORNIA/7/2009 (H1N1)V-LIKE VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016515019&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016515035,Spontaneous,2023-12-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016515035&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016515064,Spontaneous,2023-12-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016515064&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016515080,Spontaneous,2023-12-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthritis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Gait disturbance (n/a - Unknown - ),<BR><BR>Mobility decreased (n/a - Unknown - ),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rheumatoid arthritis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[RESPIRATORY SYNCYTIAL VIRUS VACCINE (BIVALENT, RECOMBINANT)] (S - Immunisation - Not applicable - [1d - n/a - n/a])","OZEMPIC [SEMAGLUTIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INSULIN, INSULIN HUMAN] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METOPROLOL, METOPROLOL TARTRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016515080&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016515092,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Anaphylactic reaction (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Cardio-respiratory arrest (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Fall (n/a - Fatal - Results in Death),<BR><BR>Feeling abnormal (n/a - Fatal - Results in Death),<BR><BR>Loss of consciousness (n/a - Fatal - Results in Death, Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [n/a - n/a - Subcutaneous use])","[DESLORATADINE] (C - Rhinitis - n/a - [n/a - n/a - Oral use]),<BR><BR>[FAMOTIDINE] (C - Back pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[MAGNESIUM OXIDE] (C - Constipation - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Back pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[PEMAFIBRATE] (C - Dyslipidaemia - n/a - [n/a - n/a - Oral use]),<BR><BR>[RHUBARB, COPTIS, MAGNESIUM OXIDE, MAGNESIUM SULFATE HYDRATE, CASSIA] (C - Constipation - n/a - [n/a - n/a - Oral use]),<BR><BR>[RHUBARB] (C - Constipation - n/a - [n/a - n/a - Oral use]),<BR><BR>[SIMVASTATIN] (C - Dyslipidaemia - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016515092&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016515095,Spontaneous,2023-12-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Aortic aneurysm (n/a - Unknown - Life Threatening),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016515095&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016515103,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Male,"Anaphylactic reaction (13h - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Eye swelling (n/a - Unknown - ),<BR><BR>Rash (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016515103&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016515105,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016515105&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016515157,Spontaneous,2023-12-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,"Diarrhoea (3wk - Recovered/Resolved - ),<BR><BR>Faeces discoloured (3wk - Recovered/Resolved - ),<BR><BR>International normalised ratio increased (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016515157&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016515575,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016515575&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016515610,Spontaneous,2023-12-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Confusional state (n/a - Recovering/Resolving - ),<BR><BR>Disturbance in attention (n/a - Recovering/Resolving - ),<BR><BR>Memory impairment (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016515610&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016515736,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Myelin oligodendrocyte glycoprotein antibody-associated disease (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Optic neuritis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016515736&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016516634,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Male,"Muscle spasms (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Antiviral prophylaxis - Not applicable - [0d - n/a - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016516634&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016517770,Spontaneous,2023-12-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016517770&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016518105,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Pain in extremity (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[ACETYLSALICYLIC ACID, CODEINE PHOSPHATE HEMIHYDRATE, MAGNESIUM OXIDE] (C - Pain - n/a - [n/a - 2{DF} - Oral use]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone therapy - n/a - [n/a - n/a - Vaginal use]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - 25mg - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - 1000mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016518105&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016518108,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Cardiac arrest (0d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary embolism (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016518108&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016518265,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arteriosclerosis coronary artery (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Carotid artery occlusion (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Chronic obstructive pulmonary disease (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Condition aggravated (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Peripheral arterial occlusive disease (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pneumonia klebsiella (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pseudomonas infection (n/a - Unknown - Other Medically Important Condition),<BR><BR>Respiratory disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Syncope (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vertebrobasilar insufficiency (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [1d - n/a - n/a])","LANTUS [INSULIN GLARGINE] (C - Diabetes mellitus - n/a - [n/a - 12[iU] - Subcutaneous use]),<BR><BR>PLAVIX [CLOPIDOGREL, CLOPIDOGREL HYDROGEN SULFATE] (C - Anticoagulant therapy - n/a - [n/a - 75mg - Oral use]),<BR><BR>[CARVEDILOL] (C - Blood pressure abnormal - n/a - [n/a - 12.5mg - Oral use]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Blood pressure abnormal - n/a - [n/a - 100mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016518265&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016518381,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Malaise (1d - Recovered/Resolved - ),<BR><BR>Myalgia (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016518381&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016518395,Spontaneous,2023-12-22 00:00:00,Healthcare Professional,European Economic Area,Not available,3-11 Years,Child,No,Female,"Nausea (n/a - Recovered/Resolved - Life Threatening),<BR><BR>Sepsis (n/a - Recovered/Resolved - Life Threatening),<BR><BR>Vomiting (n/a - Recovered/Resolved - Life Threatening)","COMIRNATY OMICRON XBB.1.5 10 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - n/a - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 20, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 17F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 2, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A] (S - n/a - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016518395&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016501025,Spontaneous,2023-12-21 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Myalgia (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016501025&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016501162,Spontaneous,2023-12-21 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Bone pain (1d - Recovered/Resolved - ),<BR><BR>Chills (1d - Recovered/Resolved - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Oropharyngeal pain (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),"FLUCELVAX TETRA [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (C - Antiviral prophylaxis - n/a - [n/a - 1{DF} - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016501162&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016501192,Spontaneous,2023-12-21 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (3d - Recovered/Resolved - ),<BR><BR>Pain in extremity (3d - Recovered/Resolved - ),<BR><BR>Peripheral swelling (3d - Recovered/Resolved - ),<BR><BR>Pyrexia (3d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016501192&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016501496,Spontaneous,2023-12-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Dizziness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016501496&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016502134,Spontaneous,2023-12-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (6d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016502134&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016502179,Spontaneous,2023-12-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Eyelid disorder (n/a - Unknown - ),<BR><BR>Facial paralysis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Trigeminal neuralgia (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016502179&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016502204,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[CHLORTALIDONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016502204&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016502215,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,COVID-19 (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016502215&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016502831,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"PREGABALIN [PREGABALIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROCHLOROTHIAZIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METOPROLOL SUCCINATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016502831&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016502852,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[LORATADINE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016502852&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016502913,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016502913&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016503107,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,"Limb discomfort (3d - Recovered/Resolved - ),<BR><BR>Nasopharyngitis (3d - Recovered/Resolved - ),<BR><BR>Pyrexia (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016503107&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016503139,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016503139&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016503162,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016503162&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016503165,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016503165&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016503499,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016503499&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016503617,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Inflammatory marker increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Neuralgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016503617&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016503618,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016503618&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016503912,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Ventricular tachycardia (4d - Recovered/Resolved - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"EMPAGLIFLOZIN 10MG TABLET  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>ENTRESTO 97 MG/103 MG FILM-COATED TABLETS [VALSARTAN, SACUBITRIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>EVOLOCUMAB 140MG/ML - SOLUTION FOR INJECTION  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>PANTOPRAZOLE 20 MG - GASTRO-RESISTANT TABLET  (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016503912&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016504180,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016504180&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016504229,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Asthenia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Impaired work ability (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pain in extremity (7d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pruritus (5d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[IBUPROFEN] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016504229&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016504287,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary thrombosis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intravenous use]),"HUMIRA [ADALIMUMAB] (C - Arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>METHOTREXATE [METHOTREXATE] (C - Arthritis - n/a - [n/a - n/a - Oral use]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Pericardial effusion - n/a - [n/a - 4mg - Oral use]),<BR><BR>[COLECALCIFEROL] (C - Mineral supplementation - n/a - [n/a - 800[iU] - Oral use]),<BR><BR>[FOLIC ACID] (C - Arthritis - n/a - [n/a - 5mg - Oral use]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [n/a - 40mg - n/a]),<BR><BR>[SPIRONOLACTONE] (C - Pericardial effusion - n/a - [n/a - 25mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016504287&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016504551,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Guttate psoriasis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016504551&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016504552,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Incorrect dose administered (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016504552&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016504595,Spontaneous,2023-12-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Male,Tinnitus (n/a - Not Recovered/Not Resolved - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010, B/PHUKET/3073/2013-LIKE STRAIN, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/BRISBANE/60/2008, A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, B/MASSACHUSETTS/02/2012, A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010, B/BRISBANE/60/2008, B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010, B/BRISBANE/60/2008-LIKE VIRUS, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Influenza immunisation - Not applicable - [0d - .5mL - Intramuscular use])","[ALLOPURINOL] (C - n/a - n/a - [n/a - 300mg - Oral use]),<BR><BR>[AMLODIPINE BESILATE, PERINDOPRIL ARGININE, PERINDOPRIL TERT-BUTYLAMINE, AMLODIPINE] (C - n/a - n/a - [n/a - 1{DF} - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016504595&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016504606,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Bone pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Productive cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Toothache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (2d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[ANASTROZOLE] (C - Breast cancer - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016504606&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016504608,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016504608&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016504632,Spontaneous,2023-12-21 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,Yes,Male,Arrhythmia (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016504632&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016504924,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Menstrual clots (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016504924&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016504990,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016504990&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016505012,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016505012&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016505039,Spontaneous,2023-12-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,"Diarrhoea (1h - Recovered/Resolved - ),<BR><BR>Syncope (15min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (1h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),"XIGDUO [METFORMIN HYDROCHLORIDE, DAPAGLIFLOZIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[INDAPAMIDE, PERINDOPRIL] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016505039&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016505146,Spontaneous,2023-12-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Oedema peripheral (4h - Recovered/Resolved - ),<BR><BR>Pruritus (4h - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - n/a - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016505146&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016505279,Spontaneous,2023-12-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Myalgia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016505279&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016505326,Spontaneous,2023-12-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Immunisation reaction (n/a - Recovered/Resolved - ),<BR><BR>Wrong product administered (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),"[A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN, A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN, B/FLORIDA/4/2006-LIKE STRAIN, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/VICTORIA/361/2011 (H3N2)–DERIVED STRAIN USED (IVR-165), B/WISCONSIN/1/2010-LIKE STRAIN USED (NYMC BX-39) DERIVED FROM B/HUBEI-WUJIAGANG/158/2009, A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/MOSCOW/10/99 (H3N2) - LIKE STRAIN (A/PANAMA/2007/99 REASS. RESVIR-17), B/SICHUAN/379/99-LIKE STRAIN (B/JOHANNESBURG/5/99), A/SOUTH AUSTRALIA/55/2014 STRAIN, A/SWITZERLAND/9715293/2013 (H3N2) - LIKE STRAIN (A/SOUTH AUSTRALIA/55/2014, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, B/MASSACHUSETTS/02/2012, A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/VICTORIA/361/2011 (H3N2)–DERIVED STRAIN USED (IVR-165), B/WISCONSIN/1/2010-LIKE STRAIN USED (NYMC BX-39) DERIVED FROM B/HUBEI-WUJIAGANG/158/2009, A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/WISCONSIN/67/2005 (H3N2), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN, B/MALAYSIA/2506/2004 - LIKE STRAIN, B/BEIJING/184/93-LIKE STRAIN (B/YAMANASHI/166/98), A/SYDNEY/5/97 (H3N2)-LIKE STRAIN (A/SYDNEY/5/97 REASS. RESVIR 13), A/BEIJING/262/95 (H1N1) - LIKE STRAIN (A/BEIJING/262/95 REASS. X-127), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1), A/PERTH/16/2009 (H3N2) - LIKE STRAIN, B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009(H1N1)-LIKE STRAIN (NYMC X-179A), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NIB-65), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009(H1N1)-LIKE STRAIN (NYMC X-179A), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/MASSACHUSETTS/02/2012, A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE STRAIN, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SOUTH AUSTRALIA/55/2014, IVR-175), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED)] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016505326&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016505345,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (10d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (10d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016505345&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016505346,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Brain injury (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Confusional state (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza (n/a - Unknown - Other Medically Important Condition),<BR><BR>Memory impairment (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (3d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016505346&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016505388,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Herpes zoster (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - 1{DF} - Intramuscular use]),[VALSARTAN] (C - Hypertension - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016505388&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016505504,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016505504&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016505753,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016505753&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016506388,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Abdominal pain upper (n/a - Not Recovered/Not Resolved - ),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Product used for unknown indication - Dose not changed - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - 1000mg - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016506388&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016506601,Spontaneous,2023-12-21 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016506601&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016506810,Spontaneous,2023-12-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Abdominal pain (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - 150ug - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016506810&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016507630,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Near death experience (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016507630&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016508474,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Cough (n/a - Unknown - ),<BR><BR>Insomnia (n/a - Unknown - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016508474&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016508579,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016508579&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016508759,Spontaneous,2023-12-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Blister (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Erythema (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Hypersensitivity (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Lip blister (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Oral mucosal blistering (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pruritus (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Rash macular (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [1d - n/a - Intramuscular use])","[ATORVASTATIN] (C - Chronic kidney disease - n/a - [n/a - 10mg - Oral use]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - Chronic kidney disease - n/a - [n/a - 2.5mg - Oral use]),<BR><BR>[SODIUM HYDROGEN CARBONATE] (C - Chronic kidney disease - n/a - [n/a - 650mg - Oral use - More in ICSR])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016508759&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016509040,Spontaneous,2023-12-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Myalgia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - n/a - [1d - 1{DF} - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016509040&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016509058,Spontaneous,2023-12-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Depressed level of consciousness (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Staring (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Unresponsive to stimuli (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","BRUKINSA [ZANUBRUTINIB] (C - Waldenstrom's macroglobulinaemia - n/a - [n/a - n/a - n/a]),<BR><BR>TRIMBOW [BECLOMETASONE DIPROPIONATE, GLYCOPYRRONIUM BROMIDE, FORMOTEROL FUMARATE DIHYDRATE] (C - Chronic obstructive pulmonary disease - n/a - [n/a - n/a - n/a]),<BR><BR>[MORPHINE SULFATE] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Bronchospasm - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016509058&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016491851,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016491851&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016491943,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Asthenia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Balance disorder (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016491943&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016492052,Spontaneous,2023-12-20 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Headache (n/a - Recovering/Resolving - ),<BR><BR>Herpes zoster (n/a - Recovering/Resolving - ),<BR><BR>Localised oedema (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),"[BISOPROLOL FUMARATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[EZETIMIBE, ROSUVASTATIN, EZETIMIBE, ROSUVASTATIN ZINC] (C - Hypercholesterolaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[FORMOTEROL FUMARATE, FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[GLIMEPIRIDE] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROCHLOROTHIAZIDE, RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - Cholelithiasis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016492052&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016492279,Spontaneous,2023-12-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Anaphylactic reaction (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Blood pressure increased (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Dizziness (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Palpitations (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016492279&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016492486,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Loss of personal independence in daily activities (n/a - Unknown - Disabling),<BR><BR>Migraine (n/a - Recovering/Resolving - Disabling),<BR><BR>Pain (n/a - Unknown - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Autoimmune thyroiditis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016492486&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016492670,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Giant cell arteritis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - n/a - n/a - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016492670&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016493597,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ESCITALOPRAM, ESCITALOPRAM OXALATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016493597&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016493988,Spontaneous,2023-12-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016493988&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016493999,Spontaneous,2023-12-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Allergy to vaccine (n/a - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016493999&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016494070,Spontaneous,2023-12-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Rheumatoid arthritis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>VAXZEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - n/a - Unknown - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016494070&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016494219,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Breast pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Heart rate abnormal (n/a - Not Recovered/Not Resolved - ),<BR><BR>Heart rate increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypoaesthesia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016494219&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016494228,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016494228&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016494316,Spontaneous,2023-12-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - ),<BR><BR>Blood pressure systolic increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - ),<BR><BR>Myocarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - ),<BR><BR>Taste disorder (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN (A/BRISBANE/59/2007 REASS. IVR-148), A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN (A/URUGUAY/716/2007 REASS. NYMC X-175C), B/BRISBANE/60/2008-LIKE VIRUS, A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN (A/BRISBANE/59/2007 REASS. IVR-148), A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN (A/URUGUAY/716/2007 REASS. NYMC X-175C), B/FLORIDA/4/2006-LIKE STRAIN (B/FLORIDA/4/2006), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), B/MALAYSIA/2506/2004 - LIKE STRAIN (B/MALAYSIA/2506/2004), A/WISCONSIN/67/2005 (H3N2) - LIKE STRAIN (A/HIROSHIMA/52/2005 REASS. IVR-142), ANTIGENS OF THE INFLUENZA VIRUS A/CALIFORNIA/7/2009 (H1N1)-LIKE VIRUS PDM09, ANTIGENS OF THE INFLUENZA VIRUS A/VICTORIA/361/2011 (H3N2)-LIKE VIRUS, ANTIGENS OF THE INFLUENZA VIRUS B/WISCONSIN/1/2010-LIKE VIRUS, B/BRISBANE/60/2008-LIKE VIRUS, A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), A/CALIFORNIA/7/2009 (H1N1)-DERIVED STRAIN USED NYMC X-181, B/MALAYSIA/2506/2004 - LIKE STRAIN (B/MALAYSIA/2506/2004), A/WISCONSIN/67/2005 (H3N2) - LIKE STRAIN (A/WISCONSIN/67/2005 REASS. NYMC X-161-B), A/SOLOMON ISLANDS/3/2006 (H1N1) - LIKE STRAIN (A/SOLOMON ISLANDS/3/2006 REASS. IVR-145), SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/GUANDONG-MAONAN/SWL1536/2019 (H1N1)PDM09-LIKE VIRUS (A/VICTORIA/2454/2019 IVR-207), SQUALENE, CITRIC ACID, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), SQUALENE, CITRIC ACID, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, CITRIC ACID ANHYDROUS, A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/GUANDONG-MAONAN/SWL1536/2019 (H1N1)PDM09-LIKE VIRUS (A/VICTORIA/2454/2019 IVR-207), SQUALENE, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, CITRIC ACID ANHYDROUS, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/BRISBANE/9/2014 (WILD TYPE), SQUALENE, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, CITRIC ACID ANHYDROUS, B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), SQUALENE, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, CITRIC ACID ANHYDROUS, B/MASSACHUSETTS/2/2012-LIKE STRAIN USED B/MASSACHUSETTS/2/2012 WILD TYPE, A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223), SQUALENE, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181)] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016494316&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016494324,Spontaneous,2023-12-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016494324&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016494327,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016494327&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016494332,Spontaneous,2023-12-20 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,Herpes zoster (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016494332&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016494359,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Palpitations (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016494359&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016494390,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Not Recovered/Not Resolved - ),<BR><BR>Amnesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Brain fog (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Constipation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Eructation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Gastrooesophageal reflux disease (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypertension (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016494390&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016494468,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016494468&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016494563,Spontaneous,2023-12-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Male,"Dizziness (0d - Recovered/Resolved - ),<BR><BR>Loss of consciousness (0d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Syncope (0d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Antiviral prophylaxis - Not applicable - [n/a - n/a - n/a])","UMECLIDINIUM BROMIDE, VILANTEROL [UMECLIDINIUM BROMIDE, VILANTEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[EZETIMIBE, ROSUVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PERINDOPRIL, PERINDOPRIL TERT-BUTYLAMINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016494563&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016494578,Spontaneous,2023-12-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Movement disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016494578&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016494977,Spontaneous,2023-12-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Haemorrhage (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016494977&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016495361,Spontaneous,2023-12-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Lip swelling (n/a - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[CODEINE PHOSPHATE BP, PARACETAMOL PH. EUR., PARACETAMOL, CODEINE PHOSPHATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[SODIUM HYALURONATE] (C - n/a - n/a - [865d - 6[drp] - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016495361&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016495409,Spontaneous,2023-12-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Mobility decreased (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016495409&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016495463,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Chronic obstructive pulmonary disease (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Injection site swelling (1d - Recovered/Resolved - ),<BR><BR>Myocardial infarction (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FORMOTEROL, FORMOTEROL FUMARATE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[GLYCOPYRRONIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016495463&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016495471,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Body temperature increased (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016495471&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016495480,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,"Chest pain (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - Dose not changed - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016495480&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016495595,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ASCORBIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CETIRIZINE DIHYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ETHINYLESTRADIOL, NORETHISTERONE] (C - Contraception - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUTICASONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016495595&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016495629,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016495629&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016495632,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016495632&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016495721,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016495721&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016495757,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Laryngeal discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oropharyngeal plaque (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tongue discomfort (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016495757&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016495790,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (n/a - Unknown - ),<BR><BR>Feeling cold (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016495790&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016495834,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Herpes zoster (n/a - Not Recovered/Not Resolved - ),<BR><BR>Neuralgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016495834&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016495849,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site movement impairment (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site reaction (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016495849&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016495912,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Retinal detachment (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Visual impairment (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016495912&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016495915,Spontaneous,2023-12-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arrhythmia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Atrial fibrillation (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Atrioventricular block complete (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Cardiac pacemaker insertion (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 3 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016495915&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016495921,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Bursa disorder (n/a - Not Recovered/Not Resolved - ),<BR><BR>Mobility decreased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Sleep disorder (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016495921&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016495927,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Postmenopausal haemorrhage (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016495927&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016495929,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Vaccination site pain (2d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016495929&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016495938,Spontaneous,2023-12-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Anaphylactic shock (0d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (0d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia oral (0d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016495938&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016495943,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Other Medically Important Condition),<BR><BR>Poor peripheral circulation (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016495943&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016495979,Spontaneous,2023-12-20 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,Death (n/a - Fatal - Results in Death),COMIRNATY OMICRON XBB.1.5 3 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016495979&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016495980,Spontaneous,2023-12-20 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Haematemesis (n/a - Fatal - Results in Death),<BR><BR>Pneumonia aspiration (n/a - Fatal - Results in Death)",COMIRNATY OMICRON XBB.1.5 3 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016495980&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016495983,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Asthenia (n/a - Fatal - Results in Death),<BR><BR>Death (n/a - Fatal - Results in Death)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016495983&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016495984,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Chest discomfort (n/a - Fatal - Results in Death),<BR><BR>Respiratory distress (n/a - Fatal - Results in Death),<BR><BR>Vomiting (n/a - Fatal - Results in Death)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016495984&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016495985,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Aphasia (n/a - Fatal - Results in Death),<BR><BR>Coordination abnormal (n/a - Fatal - Results in Death),<BR><BR>Dysphagia (n/a - Fatal - Results in Death),<BR><BR>General physical health deterioration (n/a - Fatal - Results in Death)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016495985&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016496239,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Gait disturbance (n/a - Not Recovered/Not Resolved - ),<BR><BR>Herpes zoster (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypoaesthesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oedema peripheral (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - 1{DF} - n/a])","MICARDIS [TELMISARTAN] (C - Coronary artery disease - n/a - [n/a - 40mg - Oral use]),<BR><BR>[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - 10mg - Oral use]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Arrhythmia - n/a - [n/a - 2.5mg - Oral use]),<BR><BR>[DYDROGESTERONE, ESTRADIOL, DYDROGESTERONE, ESTRADIOL HEMIHYDRATE] (C - Hormone therapy - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[FOLIC ACID] (C - Rheumatoid arthritis - n/a - [n/a - 5mg - Oral use]),<BR><BR>[METHOTREXATE] (C - n/a - n/a - [n/a - 15mg - Oral use]),<BR><BR>[POTASSIUM CHLORIDE] (C - Coronary artery disease - n/a - [n/a - 750mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016496239&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016496501,Spontaneous,2023-12-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (0d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Visual impairment (0d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016496501&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016496603,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016496603&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016496604,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016496604&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016496605,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016496605&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016496606,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016496606&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016496608,Spontaneous,2023-12-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chest pain (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Dizziness (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Fall (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Rib fracture (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016496608&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016496613,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016496613&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016496802,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Rash pruritic (n/a - Not Recovered/Not Resolved - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[NOT AVAILABLE] (S - Root canal infection - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016496802&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016496921,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016496921&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016496922,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016496922&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016496953,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cluster headache (n/a - Unknown - ),<BR><BR>Hyperpyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Paralysis (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016496953&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016496980,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (1h - Recovered/Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Migraine (n/a - Recovering/Resolving - ),<BR><BR>Nasal congestion (n/a - Unknown - ),<BR><BR>Oropharyngeal pain (n/a - Unknown - ),<BR><BR>Pyrexia (29h - Recovered/Resolved - ),<BR><BR>Vaccination site pain (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016496980&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016497075,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016497075&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016497586,Spontaneous,2023-12-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Aortitis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>C-reactive protein increased (n/a - Recovering/Resolving - ),<BR><BR>COVID-19 immunisation (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 - n/a - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016497586&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016497832,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016497832&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016497842,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Malaise (1d - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016497842&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016497957,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016497957&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016498152,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016498152&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016498212,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Cavernous sinus thrombosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Diplopia (19d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [1d - .5mL - Intramuscular use])",[ALFUZOSIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016498212&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016498308,Spontaneous,2023-12-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Injection site pain (5wk - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (5wk - Not Recovered/Not Resolved - ),<BR><BR>Palmar erythema (5wk - Not Recovered/Not Resolved - ),<BR><BR>Peripheral coldness (5wk - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016498308&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016498380,Spontaneous,2023-12-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Foetal death (1d - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 prophylaxis - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016498380&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016498760,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dysacusis (n/a - Recovering/Resolving - ),<BR><BR>Hypoacusis (n/a - Recovering/Resolving - ),<BR><BR>Tinnitus (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016498760&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016498761,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Paraesthesia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NIET GESPECIFICEERD GENEESMIDDEL [NOT AVAILABLE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016498761&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016498764,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016498764&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016498765,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016498765&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016498767,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (2d - Recovered/Resolved - ),<BR><BR>Disorientation (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (3d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (4d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016498767&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016498768,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Tinnitus (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016498768&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016498770,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Body temperature increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Heart rate increased (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016498770&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016499300,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[ATORVASTATIN, ATORVASTATIN CALCIUM] (C - n/a - n/a - [1549d - n/a - n/a]),<BR><BR>[RISEDRONATE SODIUM] (C - n/a - n/a - [1181d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016499300&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016499346,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016499346&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016499353,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"C-reactive protein increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Heart rate increased (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Monocyte count increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[LEVOCETIRIZINE DIHYDROCHLORIDE] (C - n/a - n/a - [n/a - 5mg - n/a]),<BR><BR>[MONTELUKAST] (C - n/a - n/a - [n/a - 10mg - n/a]),<BR><BR>[SERTRALINE] (C - n/a - n/a - [n/a - 50mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016499353&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016499354,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[VITAMIN B12] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VITAMIN D] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016499354&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016499406,Spontaneous,2023-12-20 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,Oedema peripheral (24h - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"ELIQUIS [APIXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>IRBESARTAN [IRBESARTAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DICLOFENAC, DICLOFENAC POTASSIUM, DICLOFENAC SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FENOFIBRATE, FENOFIBRATE MICRONISED] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROCHLOROTHIAZIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016499406&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016499466,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[ACRIVASTINE, DIPHENHYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE, ZINC ACETATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BUPROPION] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OCTREOTIDE, OCTREOTIDE ACETATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016499466&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016499531,Spontaneous,2023-12-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Recovering/Resolving - Disabling),<BR><BR>Bone pain (n/a - Unknown - Disabling),<BR><BR>Chondrocalcinosis (n/a - Unknown - ),<BR><BR>Gait disturbance (n/a - Unknown - Disabling),<BR><BR>Granulocyte count increased (n/a - Unknown - ),<BR><BR>Haematocrit decreased (n/a - Unknown - ),<BR><BR>Hypoaesthesia (n/a - Unknown - Disabling),<BR><BR>Joint effusion (n/a - Unknown - ),<BR><BR>Lymphocyte count decreased (n/a - Unknown - ),<BR><BR>Mean platelet volume decreased (n/a - Unknown - ),<BR><BR>Metamyelocyte count increased (n/a - Unknown - ),<BR><BR>Muscle spasms (n/a - Unknown - Disabling),<BR><BR>Myalgia (n/a - Unknown - Disabling),<BR><BR>Oedema peripheral (n/a - Unknown - ),<BR><BR>Osteoarthritis (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Platelet count increased (n/a - Unknown - ),<BR><BR>Red blood cell count decreased (n/a - Unknown - ),<BR><BR>Red cell distribution width increased (n/a - Unknown - ),<BR><BR>Renal disorder (n/a - Unknown - ),<BR><BR>White blood cell count increased (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[ANHYDROUS NALOXONE HYDROCHLORIDE, NALOXONE, NALOXONE HYDROCHLORIDE] (C - Overdose - n/a - [n/a - 4mg - Nasal use]),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM TRIHYDRATE] (C - Blood cholesterol increased - n/a - [n/a - 80mg - Oral use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE)] (C - Influenza immunisation - n/a - [1d - n/a - Intramuscular use]),<BR><BR>[BUPROPION HYDROCHLORIDE] (C - Major depression - n/a - [n/a - 150mg - Oral use]),<BR><BR>[CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Depression - n/a - [n/a - 40mg - Oral use]),<BR><BR>[CYANOCOBALAMIN, VITAMIN B12] (C - Vitamin B12 deficiency - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>[DICLOFENAC, DICLOFENAC DIETHYLAMINE, DICLOFENAC EPOLAMINE, DICLOFENAC POTASSIUM, DICLOFENAC RESINATE, DICLOFENAC SODIUM] (C - Arthralgia - n/a - [n/a - 150mg - Oral use]),<BR><BR>[FERROUS SULFATE] (C - n/a - n/a - [n/a - 325mg - Oral use]),<BR><BR>[GABAPENTIN] (C - Diabetes mellitus, Nerve injury - n/a - [n/a - 900mg - Oral use]),<BR><BR>[HYDROCHLOROTHIAZIDE, LOSARTAN, LOSARTAN POTASSIUM, HYDROCHLOROTHIAZIDE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[IBUPROFEN, IBUPROFEN LYSINE] (C - n/a - n/a - [n/a - 1800mg - Oral use]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - 150ug - Oral use]),<BR><BR>[MECOBALAMIN] (C - Vitamin B12 deficiency - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - Diabetes mellitus - n/a - [n/a - 2000mg - Oral use]),<BR><BR>[OMEPRAZOLE, OMEPRAZOLE MAGNESIUM] (C - Gastrooesophageal reflux disease - n/a - [n/a - 40mg - Oral use]),<BR><BR>[TRAZODONE HYDROCHLORIDE] (C - Insomnia - n/a - [n/a - 50mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016499531&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016499882,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Atrial fibrillation (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Heart rate increased (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Influenza (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","CLOPIDOGREL KRKA [CLOPIDOGREL, CLOPIDOGREL HYDROCHLORIDE] (C - Thrombosis - n/a - [n/a - n/a - n/a]),<BR><BR>ENTRESTO [SACUBITRIL VALSARTAN SODIUM HYDRATE, VALSARTAN, SACUBITRIL] (C - Cardiac failure - n/a - [n/a - n/a - n/a]),<BR><BR>FORXIGA [DAPAGLIFLOZIN] (C - Cardiac failure - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID, ACETYLSALICYLIC ACID, MAGNESIUM OXIDE] (C - Thrombosis prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[CARVEDILOL] (C - Cardiac disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[EPLERENONE] (C - Cardiac failure - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016499882&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016499919,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Insomnia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Loss of personal independence in daily activities (n/a - Not Recovered/Not Resolved - ),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016499919&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016500046,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016500046&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016500222,Spontaneous,2023-12-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Ovarian neoplasm surgery (n/a - Unknown - Caused/Prolonged Hospitalisation),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - n/a - Drug withdrawn - [n/a - n/a - Intramuscular use])","EFFICIB 50 MG/1000 MG FILM-COATED TABLETS [METFORMIN HYDROCHLORIDE, SITAGLIPTIN PHOSPHATE MONOHYDRATE] (C - n/a - Dose not changed - [n/a - n/a - Oral use]),<BR><BR>NOT AVAILABLE (C - n/a - Dose not changed - [n/a - n/a - Oral use]),<BR><BR>NOT AVAILABLE (C - n/a - Dose not changed - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016500222&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016500504,Spontaneous,2023-12-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[DEXLANSOPRAZOLE, LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016500504&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016484147,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chest discomfort (0d - Recovered/Resolved - ),<BR><BR>Cough (0d - Recovered/Resolved - ),<BR><BR>Vertigo (0d - Recovered/Resolved - ),<BR><BR>Vomiting (0d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 HAEMAGGLUTININ ANTIGEN, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - n/a - [n/a - n/a - Intramuscular use])",CETUXIMAB [CETUXIMAB] (C - Colon neoplasm - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016484147&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016484778,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016484778&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016484780,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Hypertension (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lacunar stroke (2d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])","[ALENDRONATE SODIUM, ALENDRONIC ACID] (C - Osteoporosis - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016484780&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016484828,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Anaphylactic reaction (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Cardiac arrest (725min - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Loss of consciousness (736min - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Seizure (736min - Recovered/Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016484828&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016484848,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anaphylactic shock (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016484848&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016484856,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cardiac failure (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Recovering/Resolving - Life Threatening)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016484856&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016485277,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Herpes zoster (n/a - Recovering/Resolving - ),<BR><BR>Ophthalmic herpes zoster (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016485277&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016485567,Spontaneous,2023-12-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"[BACLOFEN] (C - Muscle spasms - n/a - [n/a - n/a - Oral use]),<BR><BR>[CEFCAPENE PIVOXIL, CEFCAPENE PIVOXIL HYDROCHLORIDE] (C - Bladder spasm - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016485567&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016485581,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Atrial fibrillation (n/a - Fatal - Results in Death),<BR><BR>Cardio-respiratory arrest (n/a - Fatal - Results in Death),<BR><BR>Cerebral infarction (n/a - Fatal - Results in Death),<BR><BR>Physical deconditioning (n/a - Unknown - Other Medically Important Condition),<BR><BR>Thrombosis (n/a - Fatal - Results in Death)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"ELIQUIS [APIXABAN] (C - Atrial fibrillation - n/a - [n/a - n/a - Oral use]),<BR><BR>TELMISARTAN [TELMISARTAN] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - Subcutaneous use]),<BR><BR>[AZOSEMIDE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[FEBUXOSTAT] (C - Hyperuricaemia - n/a - [n/a - n/a - Oral use]),<BR><BR>[NIFEDIPINE] (C - Hypertension - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016485581&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016485874,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dyspnoea (1d - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Sudden death (n/a - Fatal - Results in Death, Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016485874&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016486053,Spontaneous,2023-12-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Dermatomyositis (n/a - Not Recovered/Not Resolved - Disabling),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016486053&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016486384,Spontaneous,2023-12-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Urticaria (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016486384&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016486385,Spontaneous,2023-12-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arthralgia (2d - Recovered/Resolved - ),<BR><BR>Chills (2d - Recovered/Resolved - ),<BR><BR>Diarrhoea (3d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (3d - Recovered/Resolved - ),<BR><BR>Myalgia (2d - Recovered/Resolved - ),<BR><BR>Nausea (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016486385&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016486386,Spontaneous,2023-12-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Bursitis (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016486386&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016486611,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Pain (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),"[NORETHISTERONE ACETATE, ESTRADIOL] (C - Menopause - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016486611&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016486672,Spontaneous,2023-12-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,Cerebrovascular accident (n/a - Unknown - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016486672&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016486708,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016486708&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016487238,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Deep vein thrombosis (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),"[POTASSIUM HYDROGEN CARBONATE] (C - Chest pain - n/a - [n/a - 15mL - n/a]),<BR><BR>[SODIUM ALGINATE] (C - Chest pain - n/a - [n/a - 15mL - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016487238&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016487361,Spontaneous,2023-12-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016487361&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016487892,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,"Circumoral oedema (2wk - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Eye irritation (2wk - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Sneezing (2wk - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 prophylaxis - Not applicable - [n/a - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010, B/PHUKET/3073/2013-LIKE STRAIN, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/BRISBANE/60/2008, A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, B/MASSACHUSETTS/02/2012, A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010, B/BRISBANE/60/2008, B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010, B/BRISBANE/60/2008-LIKE VIRUS, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Antiviral prophylaxis - Not applicable - [n/a - n/a - Intramuscular use])","[DRY EXTRACT OF GINKGO BILOBA LEAF (35-67:1), EXTRACTION SOLVENT: ACETONE 60% (V/V), GINKGO BILOBA LEAF EXTRACT, GINKGO LEAF DRY EXTRACT, REFINED AND QUANTIFIED] (C - Product used for unknown indication - Not applicable - [n/a - n/a - n/a]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - Product used for unknown indication - Not applicable - [n/a - n/a - n/a]),<BR><BR>[NAPROXENO] (C - Product used for unknown indication - Not applicable - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016487892&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016487914,Spontaneous,2023-12-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016487914&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016488251,Spontaneous,2023-12-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,2 Months - 2 Years,Infant,No,Female,"Body temperature increased (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Influenza like illness (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Dose not changed - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016488251&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016488699,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Neutropenia (6d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>RITUXIMAB [RITUXIMAB] (S - Lymphoma - Drug withdrawn - [n/a - n/a - n/a]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016488699&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016488809,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Peripheral ischaemia (4d - Recovering/Resolving - Life Threatening),"COMIRNATY OMICRON XBB.1.5 3 MICROGRAMS/DOSE CONCENTRATE FOR DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>VELMETIA 50 MG/1000 MG FILM-COATED TABLETS [METFORMIN HYDROCHLORIDE, SITAGLIPTIN PHOSPHATE MONOHYDRATE] (S - Type 2 diabetes mellitus - Dose not changed - [n/a - 1{DF} - Oral use]),<BR><BR>[ATORVASTATIN, EZETIMIBE] (S - Dyslipidaemia - Dose not changed - [n/a - 1{DF} - Oral use]),<BR><BR>[D,L-LYSINE ACETYLSALICYLATE] (S - Cardiovascular event prophylaxis - Dose not changed - [n/a - 1{DF} - Oral use]),<BR><BR>[HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL] (S - Hypertension - Dose not changed - [n/a - 1{DF} - Oral use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016488809&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016488885,Spontaneous,2023-12-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Ear discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypoacusis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Polymenorrhoea (n/a - Recovered/Resolved - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016488885&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016488933,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Vaccination site pain (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016488933&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016489044,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anaphylactic reaction (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016489044&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016489411,Spontaneous,2023-12-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arrhythmia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Palpitations (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016489411&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016489413,Spontaneous,2023-12-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016489413&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016489415,Spontaneous,2023-12-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Chest discomfort (2d - Recovered/Resolved - ),<BR><BR>Chest pain (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016489415&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016489624,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Herpes zoster (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016489624&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016489631,Spontaneous,2023-12-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Hyperglycaemia (2wk - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1min - .3mL - Subcutaneous use]),"[BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - Not applicable - [33y - 1.25mg - Oral use]),<BR><BR>[DOCONEXENT, ICOSAPENT, FISH OIL, ICOSAPENT ETHYL, DOCOSAHEXAENOIC ACID ETHYL ESTER, OMEGA-3-ACID ETHYL ESTERS 90, OMEGA-3-ACID ETHYL ESTERS 90, DOCOSAHEXAENOIC ACID ETHYL ESTER] (C - Nutritional supplementation - Not applicable - [n/a - 1000mg - Oral use]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Thyroidectomy - Not applicable - [7y - n/a - Oral use]),<BR><BR>[LOSARTAN POTASSIUM, HYDROCHLOROTHIAZIDE] (C - Hypertension - Not applicable - [14y - 1{DF} - Oral use]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - n/a - Not applicable - [8y - 5mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016489631&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016489697,Spontaneous,2023-12-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016489697&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016489712,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Arrhythmia (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - ),<BR><BR>Respiratory arrest (n/a - Fatal - Results in Death),<BR><BR>Vomiting (n/a - Fatal - Results in Death)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"LEVOFLOXACIN [LEVOFLOXACIN] (C - Urinary tract infection - n/a - [n/a - n/a - n/a]),<BR><BR>[CILNIDIPINE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[MAGNESIUM OXIDE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016489712&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016489944,Spontaneous,2023-12-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Bell's palsy (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016489944&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016489982,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Atrioventricular block second degree (n/a - Unknown - ),<BR><BR>Bradycardia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016489982&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016490019,Spontaneous,2023-12-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Blindness unilateral (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Depression (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Ear pain (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Giant cell arteritis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Hypertension (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Joint stiffness (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Ocular discomfort (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Visual impairment (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016490019&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016490022,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Cardiac dysfunction (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016490022&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016490024,Spontaneous,2023-12-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Fatigue (n/a - Unknown - ),<BR><BR>Listless (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016490024&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016490040,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016490040&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016491454,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Cough (n/a - Recovering/Resolving - ),<BR><BR>Dizziness (10d - Recovered/Resolved - ),<BR><BR>Pyrexia (10d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016491454&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016491465,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Nausea (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - ),<BR><BR>Vomiting (2d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B)] (S - Influenza immunisation - Not applicable - [1d - .5mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016491465&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016491470,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,"Dyspnoea (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [1d - .7mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016491470&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016491472,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Pruritus (n/a - Recovering/Resolving - ),<BR><BR>Rash (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),<BR><BR>FLUCELVAX TETRA SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (S - Influenza immunisation - Not applicable - [1d - .5mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016491472&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016491474,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Palpitations (8d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016491474&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016491476,Spontaneous,2023-12-19 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Female,"Headache (2d - Recovered/Resolved - ),<BR><BR>Myalgia (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016491476&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016476059,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016476059&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016476070,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Adult,No,Not Specified,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016476070&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016476077,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016476077&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016476080,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016476080&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016476098,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Hallucination (n/a - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Unknown - [1d - n/a - n/a]),<BR><BR>[PNEUMOCOCCAL CONJUGATE VACCINE] (S - Immunisation - Not applicable - [1d - n/a - n/a])","EMGALITY [GALCANEZUMAB] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>LEVETIRACETAM [LEVETIRACETAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>TREMFYA [GUSELKUMAB] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALPRAZOLAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BUSPIRONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DEXAMFETAMINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ETHINYLESTRADIOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[GABAPENTIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROCODONE BITARTRATE, PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXYCHLOROQUINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SUMATRIPTAN, SUMATRIPTAN SUCCINATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TIZANIDINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TOPIRAMATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[UBROGEPANT] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016476098&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016476601,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Altered state of consciousness (n/a - Fatal - Results in Death),<BR><BR>Cardiac failure (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Fatal - Results in Death),<BR><BR>Respiratory arrest (n/a - Fatal - Results in Death)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"JARDIANCE [EMPAGLIFLOZIN] (C - Cardiac failure, Type 2 diabetes mellitus - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>SPIRONOLACTONE [SPIRONOLACTONE] (C - Cardiac failure - n/a - [n/a - n/a - Oral use]),<BR><BR>TELMISARTAN [TELMISARTAN] (C - Hypertension - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Vascular graft - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[BISOPROLOL FUMARATE] (C - Cardiac failure chronic - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[DONEPEZIL HYDROCHLORIDE] (C - Dementia Alzheimer's type - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[ESTRAMUSTINE PHOSPHATE, ESTRAMUSTINE SODIUM PHOSPHATE, ESTRAMUSTINE SODIUM PHOSPHATE MONOHYDRATE] (C - Prostate cancer - n/a - [n/a - n/a - Oral use]),<BR><BR>[FUROSEMIDE] (C - Cardiac failure - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[LANSOPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[LINAGLIPTIN] (C - Type 2 diabetes mellitus - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[PIMOBENDAN] (C - Cardiac failure - n/a - [n/a - n/a - Oral use]),<BR><BR>[PITAVASTATIN CALCIUM] (C - Dyslipidaemia - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[RAMELTEON] (C - Insomnia - n/a - [n/a - n/a - Oral use]),<BR><BR>[TAMSULOSIN HYDROCHLORIDE] (C - Benign prostatic hyperplasia - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[TORASEMIDE] (C - Cardiac failure - n/a - [n/a - 1{DF} - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016476601&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016477110,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Recovered/Resolved - ),<BR><BR>Contusion (n/a - Recovered/Resolved - ),<BR><BR>Head injury (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - ),<BR><BR>Syncope (n/a - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),<BR><BR>COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (S - Immunisation - n/a - [n/a - 1{DF} - Intramuscular use])","[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Immunisation - n/a - [n/a - 1{DF} - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016477110&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016477359,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Herpes zoster (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016477359&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016477798,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Erysipelas (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - Not applicable - [n/a - n/a - n/a]),"[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - 75mg - n/a]),<BR><BR>[LERCANIDIPINE, LERCANIDIPINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 10mg - n/a]),<BR><BR>[METOPROLOL, METOPROLOL TARTRATE] (C - n/a - n/a - [n/a - 50mg - n/a]),<BR><BR>[SPIRONOLACTONE] (C - n/a - n/a - [n/a - 50mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016477798&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016477814,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016477814&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016478166,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016478166&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016478210,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Headache (1d - Recovered/Resolved - ),<BR><BR>Transient ischaemic attack (1d - Recovered/Resolved - Life Threatening)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016478210&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016478227,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016478227&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016478232,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Fall (n/a - Unknown - ),<BR><BR>Sudden death (n/a - Fatal - Results in Death)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016478232&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016478639,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016478639&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016479229,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016479229&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016479242,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Body temperature increased (4d - Recovered/Resolved - ),<BR><BR>Fatigue (17d - Recovered/Resolved - ),<BR><BR>Malaise (4d - Recovered/Resolved - ),<BR><BR>Myalgia (2d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016479242&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016479681,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chest discomfort (30min - Recovered/Resolved - ),<BR><BR>Chills (30min - Recovered/Resolved - ),<BR><BR>Dyspnoea (30min - Recovered/Resolved - ),<BR><BR>Palpitations (30min - Recovered/Resolved - ),<BR><BR>Tension headache (30min - Recovered/Resolved - ),<BR><BR>Vaccination site pain (30min - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),"[METOPROLOL TARTRATE] (C - Palpitations - Dose not changed - [n/a - 12.5mg - Oral use]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Hypercholesterolaemia - Dose not changed - [n/a - 20mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016479681&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016479721,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Rash pruritic (11d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016479721&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016479954,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Bell's palsy (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Depression (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dry throat (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (10d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Oral pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia oral (n/a - Unknown - Other Medically Important Condition),<BR><BR>Weight decreased (10d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Blood pH abnormal - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016479954&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016480089,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016480089&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016480090,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016480090&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016480091,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),RINVOQ [UPADACITINIB] (C - n/a - n/a - [110d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016480091&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016480113,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Blood glucose abnormal - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016480113&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016480153,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dyspnoea (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Respiratory failure (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Wheezing (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"SILODOSIN [SILODOSIN] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - n/a - n/a - [1d - n/a - Subcutaneous use]),<BR><BR>[MAGNESIUM OXIDE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[MEMANTINE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[QUETIAPINE, QUETIAPINE FUMARATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[SENNOSIDE A+B] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016480153&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016480174,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthma (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Cardiac failure congestive (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Respiratory tract congestion (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Tachycardia (n/a - Unknown - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016480174&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016480300,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Condition aggravated (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [1d - .5mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016480300&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016480302,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Asthmatic crisis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Condition aggravated (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016480302&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016480320,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Dizziness (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016480320&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016480323,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Influenza like illness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (48h - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016480323&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016480436,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Abortion spontaneous (n/a - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016480436&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016480473,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Pulmonary embolism (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>[LEUPRORELIN, LEUPRORELIN ACETATE] (S - Prostate cancer - Unknown - [n/a - n/a - Intramuscular use])","[MACROGOL STEARATE] (C - n/a - Unknown - [n/a - 1{DF} - Oral use]),<BR><BR>[PARACETAMOL, CODEINE PHOSPHATE, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE] (C - n/a - Unknown - [n/a - 1{DF} - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016480473&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016480501,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Immunisation reaction (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),"COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>[ELASOMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016480501&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016480508,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Motor dysfunction (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Polyneuropathy (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>DARZALEX [DARATUMUMAB] (S - Plasma cell myeloma - Drug withdrawn - [n/a - n/a - Intravenous use]),<BR><BR>VELCADE [BORTEZOMIB] (S - Plasma cell myeloma - Drug withdrawn - [n/a - n/a - Intravenous use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016480508&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016480511,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Myalgia (5d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016480511&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016480515,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Asthenia (9d - Recovered/Resolved - ),<BR><BR>Eczema (7d - Recovered/Resolved - ),<BR><BR>Erythema (11d - Recovered/Resolved - ),<BR><BR>Myalgia (13d - Recovered/Resolved - ),<BR><BR>Pyrexia (9d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016480515&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016480531,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Palmoplantar pustulosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016480531&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016480532,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Immunisation reaction (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016480532&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016480562,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypertensive crisis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016480562&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016480641,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Bradycardia (1d - Recovered/Resolved - ),<BR><BR>Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (1d - Recovered/Resolved - ),<BR><BR>Malaise (1d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [1d - 1{DF} - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Influenza immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])","COMPLEMENT ALIMENTAIRE [NOT AVAILABLE] (C - Vitamin supplementation - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>FEBUXOSTAT [FEBUXOSTAT] (C - Gout - n/a - [n/a - 80mg - Oral use]),<BR><BR>[ALFUZOSIN HYDROCHLORIDE] (C - Benign prostatic hyperplasia - n/a - [n/a - 10mg - Oral use]),<BR><BR>[COLCHICINE, OPIUM, STANDARDIZED POWDERED, TIEMONIUM METHYLSULPHATE] (C - Gout - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[HYDROCHLOROTHIAZIDE, NEBIVOLOL, HYDROCHLOROTHIAZIDE, NEBIVOLOL HYDROCHLORIDE] (C - Hypertension - n/a - [n/a - 1{DF} - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016480641&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016480693,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthritis reactive (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Colitis ulcerative (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Condition aggravated (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - n/a - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA QUADRIVALENT VACCINE (RDNA)] (S - Immunisation - Not applicable - [1d - n/a - n/a])","AZATHIOPRINE [AZATHIOPRINE] (C - Colitis - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - Osteoporosis prophylaxis - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[HYDROXYCHLOROQUINE] (C - Arthritis reactive, Colitis - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[SULFASALAZINE, SULFASALAZINE PH. EUR.] (C - Colitis - Dose not changed - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016480693&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016480876,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Balance disorder (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Confusional state (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fear (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling abnormal (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Gait inability (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Incoherent (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Sedation (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ALUMINIUM HYDROXIDE GEL, DRIED, MAGNESIUM CARBONATE, SODIUM CARBONATE, ALGINIC ACID, ALUMINIUM HYDROXIDE, SODIUM CARBONATE, CALCIUM CARBONATE, SODIUM ALGINATE, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, ALGINIC ACID, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, ALGINIC ACID, ALUMINIUM HYDROXIDE GEL, DRIED, SODIUM HYDROGEN CARBONATE, ALGINIC ACID, ALUMINIUM HYDROXIDE GEL, DRIED USP, SODIUM HYDROGEN CARBONATE, ALGINIC ACID, SODIUM ALGINATE, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, ALUMINIUM HYDROXIDE GEL, CALCIUM CARBONATE, SODIUM ALGINATE, SODIUM HYDROGEN CARBONATE, CALCIUM CARBONATE, SODIUM ALGINATE, SODIUM HYDROGEN CARBONATE, CALCIUM CARBONATE, SODIUM ALGINATE, ALUMINIUM HYDROXIDE, SODIUM HYDROGEN CARBONATE, SODIUM ALGINATE] (C - Dyspepsia, Hiatus hernia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016480876&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016481083,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Headache (12h - Recovered/Resolved - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Malaise (6h - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016481083&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016481093,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Abdominal pain (n/a - Recovering/Resolving - ),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>OOGMEDICATIE [NOT AVAILABLE] (S - Ophthalmological examination - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016481093&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016481596,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Angina pectoris (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymph node pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016481596&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016481602,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),PRALUENT [ALIROCUMAB] (C - Blood cholesterol increased - n/a - [n/a - 75mg - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016481602&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016481604,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Blister (n/a - Recovered/Resolved - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Nausea (n/a - Unknown - ),<BR><BR>Pruritus (n/a - Unknown - ),<BR><BR>Rash (n/a - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016481604&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016481610,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 30ug - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016481610&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016481868,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Asthenia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Gastrointestinal disorder (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016481868&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016481870,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016481870&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016482017,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016482017&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016482075,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016482075&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016482514,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 30ug - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016482514&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016482529,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspepsia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>External ear pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016482529&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016482571,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,COVID-19 (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016482571&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016482833,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Wheezing (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM TRIHYDRATE, ESOMEPRAZOLE SODIUM] (C - n/a - n/a - ),<BR><BR>[RAMIPRIL] (C - n/a - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016482833&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016483227,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Abortion missed (4d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B)] (S - Immunisation - Drug withdrawn - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016483227&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016483249,Spontaneous,2023-12-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (108h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (108h - Recovered/Resolved - Other Medically Important Condition)",RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016483249&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016483368,Spontaneous,2023-12-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Dysarthria (1d - Recovered/Resolved - ),<BR><BR>Fine motor skill dysfunction (1d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),<BR><BR>PANDEMIC INFLUENZA VACCINE H5N1 BAXTER [A/VIETNAM/1203/2004 (H5N1)] (S - Influenza immunisation - Not applicable - [1d - .5mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016483368&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016475477,Spontaneous,2023-12-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Male,"Chills (8h - Recovered/Resolved - ),<BR><BR>Dizziness (25h - Recovered/Resolved - ),<BR><BR>Tinnitus (25h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),"CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>TRAJENTA [LINAGLIPTIN] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATENOLOL, ATENOLOL BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BETAHISTINE DIHYDROCHLORIDE, BETAHISTINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[ISOSORBIDE 5 MONONITRATE, ISOSORBIDE MONONITRATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[LIPIDOSTEROLIC EXTRACT OF SERENOA REPENS, SERENOA REPENS, SERENOA REPENS (BARTRAM) SMALL.] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016475477&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016474540,Spontaneous,2023-12-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Periorbital haematoma (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016474540&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016474622,Spontaneous,2023-12-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016474622&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016474873,Spontaneous,2023-12-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Disturbance in attention (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016474873&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016474874,Spontaneous,2023-12-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016474874&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016474876,Spontaneous,2023-12-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Tinnitus (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016474876&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016474878,Spontaneous,2023-12-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arrhythmia (n/a - Recovering/Resolving - ),<BR><BR>Chest pain (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016474878&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016474880,Spontaneous,2023-12-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016474880&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016474910,Spontaneous,2023-12-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Transient ischaemic attack (1h - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016474910&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016474911,Spontaneous,2023-12-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (2d - Recovered/Resolved - ),<BR><BR>Cough (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016474911&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016474912,Spontaneous,2023-12-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016474912&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016464866,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,Cold urticaria (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016464866&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016465359,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016465359&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016466191,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[A/CHRISTCHURCH/16/2010 NIB-74XP (H1N1) (AN A/CALIFORNIA/7/2009-LIKE VIRUS), B/PHUKET/3073/2013-LIKE STRAIN, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), ANTIGENS OF THE INFLUENZA VIRUS B/BRISBANE/60/2008-LIKE VIRUS, B/PHUKET/3073/2013-LIKE STRAIN, A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), INFLUENZA A VIRUS A/BRISBANE/10/2010 (H1N1) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED)] (C - Immunisation - n/a - [1d - n/a - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016466191&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016466394,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Gastric ulcer haemorrhage (n/a - Fatal - Results in Death),<BR><BR>Pulmonary haemorrhage (n/a - Fatal - Results in Death)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),"ELIQUIS [APIXABAN] (C - n/a - n/a - [n/a - 5mg - Oral use]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - 40mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016466394&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016466592,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Cough (3d - Recovered/Resolved - ),<BR><BR>Headache (3d - Recovered/Resolved - ),<BR><BR>Myalgia (3d - Recovered/Resolved - ),<BR><BR>Pyrexia (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),[MOMETASONE FUROATE] (C - Asthma - Dose reduced - [n/a - 400mg - Inhalation use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016466592&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016466949,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Insomnia (n/a - Recovering/Resolving - ),<BR><BR>Tachycardia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016466949&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016466950,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Cardiac discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Migraine (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oral herpes (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016466950&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016466951,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Balance disorder (3d - Recovered/Resolved - ),<BR><BR>Confusional state (3d - Recovered/Resolved - ),<BR><BR>Gait disturbance (3d - Recovered/Resolved - ),<BR><BR>Mobility decreased (3d - Recovered/Resolved - ),<BR><BR>Pyrexia (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016466951&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016467081,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Paresis (n/a - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016467081&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016467093,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016467093&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016467094,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MOMETASONE FUROATE, MOMETASONE FUROATE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016467094&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016467103,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016467103&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016467123,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Confusional state (n/a - Unknown - ),<BR><BR>Mental disorder (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016467123&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016467460,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Blood pressure increased (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),"PROLIA [DENOSUMAB] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALPRAZOLAM, GRANULATED DRY EXTRACT FROM VALERIANA OFFICINALIS ROOT, EXTRACTION SOLVENT: ETHANOL 70% V/V, ISOVALERIC ACID, SODIUM GLYCEROPHOSPHATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATENOLOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BIOFLAVONOIDS, DIOSMIN, HESPERIDIN, MICRONISED PURIFIED FLAVONOIC FRACTION] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CALCIUM, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ITOPRIDE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, OMEPRAZOLE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PROPAFENONE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TELMISARTAN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016467460&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016467484,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Decreased appetite (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 2{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016467484&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016467862,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Ischaemic stroke (1d - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Thalamic infarction (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016467862&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016467881,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Pneumonia (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY OMICRON XBB.1.5 3 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 HAEMAGGLUTININ ANTIGEN, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016467881&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016468376,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Headache (1d - Recovered/Resolved With Sequelae - ),<BR><BR>Injection site pain (1d - Recovered/Resolved With Sequelae - ),<BR><BR>Nasopharyngitis (1d - Recovered/Resolved With Sequelae - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 3{DF} - Subcutaneous use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - 1{DF} - Subcutaneous use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016468376&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016468693,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016468693&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016468723,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Arthritis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Spondylitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Trigeminal neuralgia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016468723&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016468731,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Herpes zoster (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),"[LEVETIRACETAM] (C - n/a - n/a - [n/a - 500mg - Oral use]),<BR><BR>[OXCARBAZEPINE] (C - Epilepsy - n/a - [n/a - 600mg - Oral use]),<BR><BR>[SIMVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - 10mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016468731&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016468761,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Joint swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - 1{DF} - Intramuscular use]),"PLAVIX [CLOPIDOGREL, CLOPIDOGREL HYDROGEN SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE MALEATE, TEMAZEPAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL FUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FINASTERIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ISOSORBIDE MONONITRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016468761&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016468875,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016468875&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016468890,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Bone pain (n/a - Unknown - ),<BR><BR>Dehydration (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Gait inability (n/a - Recovering/Resolving - ),<BR><BR>Interchange of vaccine products (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Unknown - ),<BR><BR>Pain (n/a - Unknown - ),<BR><BR>Palpitations (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Spinal pain (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016468890&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016469117,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016469117&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016469146,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TAMOXIFEN, TAMOXIFEN CITRATE] (C - Breast cancer in situ - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016469146&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016469261,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016469261&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016469423,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016469423&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016469449,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Female,"Eosinophilia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Oedema peripheral (n/a - Recovered/Resolved - ),<BR><BR>Pruritus (n/a - Recovered/Resolved - ),<BR><BR>Urticaria (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016469449&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016469464,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Deep vein thrombosis (10d - Recovered/Resolved - ),<BR><BR>Superficial vein thrombosis (10d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 HAEMAGGLUTININ ANTIGEN, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - n/a - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016469464&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016469514,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Deep vein thrombosis (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - 1{DF} - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - COVID-19 immunisation - Drug withdrawn - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016469514&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016469639,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Asthenia (n/a - Recovering/Resolving - ),<BR><BR>Incorrect dose administered (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - Incorrect dose administered - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016469639&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016469674,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016469674&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016469676,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Hypotension (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pallor (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[ALENDRONATE SODIUM, ALENDRONIC ACID] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[AMOXICILLIN, AMOXICILLIN TRIHYDRATE] (C - n/a - n/a - [6d - 3{DF} - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - Dyspnoea - n/a - [169d - 4{DF} - Inhalation use]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - 4{DF} - Inhalation use]),<BR><BR>[CARBOCISTEINE] (C - n/a - n/a - [n/a - 4{DF} - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[DILTIAZEM, DILTIAZEM HYDROCHLORIDE] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[GLYCERYL TRINITRATE] (C - n/a - n/a - [n/a - n/a - Sublingual use]),<BR><BR>[LIQUID PARAFFIN] (C - Dry skin - n/a - [n/a - n/a - Topical]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[MEMANTINE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[NITROFURANTOIN] (C - n/a - n/a - [8d - 2{DF} - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[POTASSIUM HYDROGEN CARBONATE, SODIUM ALGINATE] (C - Dyspepsia - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - n/a - n/a - [6d - 6{DF} - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[TIOTROPIUM, TIOTROPIUM BROMIDE, TIOTROPIUM BROMIDE MONOHYDRATE] (C - Dyspnoea - n/a - [n/a - 2{DF} - Inhalation use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016469676&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016469742,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Dyspnoea (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pneumonia (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY OMICRON XBB.1.5 3 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 HAEMAGGLUTININ ANTIGEN, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016469742&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016469938,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Irritability (n/a - Unknown - ),<BR><BR>Oral herpes (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016469938&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016469970,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (6d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[ASCORBIC ACID] (C - Supplementation therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[BETACAROTENE] (C - Supplementation therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[BIOTIN] (C - Supplementation therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[CAPSICUM ANNUUM FRUIT] (C - Supplementation therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - Supplementation therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[COLLAGEN] (C - Supplementation therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[CURCUMA LONGA ROOT] (C - Supplementation therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[CYSTEINE HYDROCHLORIDE] (C - Supplementation therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[EQUISETI HERBA, GLYCEROL. EXTR. 1:2, EQUISETUM ARVENSE] (C - Supplementation therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[HYALURONIC ACID] (C - Supplementation therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[IODINE] (C - Supplementation therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[KERATIN] (C - Supplementation therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[LYSINE] (C - Supplementation therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[METHIONINE] (C - Supplementation therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[PIPER NIGRUM] (C - Supplementation therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[REYNOUTRIA JAPONICA] (C - Supplementation therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[SELENIUM] (C - Supplementation therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[SERENOA REPENS] (C - Supplementation therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[TOCOTRIENOL] (C - Supplementation therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[WITHANIA SOMNIFERA] (C - Supplementation therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[ZINC] (C - Supplementation therapy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016469970&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016469972,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Myelitis (n/a - Unknown - Life Threatening),<BR><BR>Spinal cord injury (n/a - Unknown - Life Threatening)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016469972&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016469978,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arrhythmia supraventricular (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Atrial fibrillation (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Back pain (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Renal pain (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Shoulder girdle pain (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])","LIXIANA [EDOXABAN, EDOXABAN TOSYLATE] (C - Arrhythmia supraventricular - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016469978&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016469989,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016469989&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016469994,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Asthenia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Atrial fibrillation (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Disease recurrence (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Ventricular extrasystoles (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"APIXABAN [APIXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FELODIPINE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016469994&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016470001,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Angina pectoris (n/a - Unknown - Disabling),<BR><BR>Chest pain (n/a - Unknown - Disabling),<BR><BR>Interchange of vaccine products (n/a - Unknown - Disabling),<BR><BR>Palpitations (n/a - Unknown - Disabling),<BR><BR>Pyrexia (n/a - Unknown - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016470001&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016470298,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Blood pressure increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chest discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - ),<BR><BR>Restlessness (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016470298&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016470446,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Erythema (n/a - Unknown - ),<BR><BR>Skin swelling (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [1d - 30ug - Intramuscular use]),<BR><BR>[ERGOTAMINE TARTRATE, CAFFEINE] (S - Product used for unknown indication - Unknown - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016470446&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016471007,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anaphylactic reaction (n/a - Recovered/Resolved - Life Threatening, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016471007&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016471295,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Male,Facial paralysis (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"AZARGA [BRINZOLAMIDE, TIMOLOL, TIMOLOL MALEATE, BRINZOLAMIDE] (C - n/a - n/a - [n/a - n/a - Ocular use]),<BR><BR>TRAVATAN [TRAVOPROST] (C - n/a - n/a - [n/a - n/a - Ocular use]),<BR><BR>XIGDUO [METFORMIN HYDROCHLORIDE, DAPAGLIFLOZIN] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010, B/PHUKET/3073/2013-LIKE STRAIN, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/BRISBANE/60/2008, A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, B/MASSACHUSETTS/02/2012, A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010, B/BRISBANE/60/2008, B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010, B/BRISBANE/60/2008-LIKE VIRUS, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (C - Immunisation - Not applicable - [n/a - n/a - Intramuscular use]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016471295&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016471444,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,Malaise (3d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016471444&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016471721,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Monoplegia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sensory loss (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016471721&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016471729,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Body temperature decreased (2d - Recovered/Resolved - ),<BR><BR>Chills (2d - Recovered/Resolved - ),<BR><BR>Influenza like illness (2d - Recovered/Resolved - ),<BR><BR>Malaise (2d - Recovered/Resolved - ),<BR><BR>Pain (2d - Recovered/Resolved - ),<BR><BR>Palpitations (2h - Recovered/Resolved - ),<BR><BR>Vaccination site pain (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[ACETYLSALICYLIC ACID] (C - Prophylaxis - n/a - [n/a - 80mg - Oral use]),<BR><BR>[CALCIUM CARBONATE] (C - Osteoporosis - n/a - [n/a - 1.25g - Oral use]),<BR><BR>[PRAVASTATIN SODIUM] (C - Blood cholesterol increased - n/a - [n/a - 20mg - Oral use]),<BR><BR>[VITAMIN D] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016471729&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016471731,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination failure (4d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016471731&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016471748,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - ),<BR><BR>Bradyphrenia (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Hypertension (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (3d - Recovered/Resolved - ),<BR><BR>Tremor (n/a - Unknown - ),<BR><BR>Vaccination site pain (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016471748&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016471795,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Back pain (n/a - Unknown - ),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neuropathy peripheral (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Unknown - ),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016471795&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016472714,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - ),<BR><BR>Hypoaesthesia oral (n/a - Unknown - ),<BR><BR>Night sweats (n/a - Unknown - ),<BR><BR>Oral disorder (n/a - Unknown - ),<BR><BR>Skin disorder (n/a - Unknown - ),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016472714&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016473093,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Thrombosis (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016473093&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016473186,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Amnesia (n/a - Recovered/Resolved - ),<BR><BR>Loss of consciousness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Ocular discomfort (n/a - Recovered/Resolved - ),<BR><BR>Visual field defect (2min - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - Rhinitis allergic - n/a - [n/a - n/a - Oral use]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Hyperlipidaemia - n/a - [n/a - n/a - Oral use]),<BR><BR>[TELMISARTAN, AMLODIPINE BESILATE] (C - Hypertension - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016473186&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016473192,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016473192&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016473317,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Blood testosterone decreased (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Body temperature fluctuation (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Breast mass (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Mental disorder (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Tension (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Testicular pain (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Weight decreased (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CODEINE PHOSPHATE BP, PARACETAMOL PH. EUR., PARACETAMOL, CODEINE PHOSPHATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016473317&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016473325,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Hypersomnia (n/a - Recovering/Resolving - ),<BR><BR>Mental impairment (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Carotid endarterectomy - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016473325&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016473397,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Asthenia (n/a - Recovered/Resolved - ),<BR><BR>Chills (n/a - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227)] (S - Influenza immunisation - Not applicable - [1d - .5mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016473397&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016473398,Spontaneous,2023-12-15 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Chronic obstructive pulmonary disease (12d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Condition aggravated (12d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (12d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B)] (S - Immunisation - Drug withdrawn - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016473398&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016473498,Spontaneous,2023-12-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)",RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016473498&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016456499,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016456499&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016456532,Spontaneous,2023-12-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal distension (2d - Recovered/Resolved - ),<BR><BR>Diarrhoea (2d - Recovered/Resolved - ),<BR><BR>Malaise (2d - Recovered/Resolved - ),<BR><BR>Nausea (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016456532&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016456539,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Injection site swelling (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - .3mL - Intramuscular use]),TYSABRI [NATALIZUMAB] (C - n/a - n/a - ),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016456539&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016456583,Spontaneous,2023-12-14 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Vaccination site pain (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use]),[MESALAZINE] (C - Colitis ulcerative - n/a - [n/a - 2400mg - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016456583&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016456586,Spontaneous,2023-12-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016456586&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016456878,Spontaneous,2023-12-14 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Vaccination site pain (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"AGOMELATINE [AGOMELATINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LITHIUM SULFATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016456878&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016457609,Spontaneous,2023-12-14 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Guillain-Barre syndrome (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vocal cord paralysis (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016457609&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016458485,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016458485&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016458834,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016458834&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016458849,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016458849&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016458857,Spontaneous,2023-12-14 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Urticarial vasculitis (n/a - Recovered/Resolved - Disabling),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016458857&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016458863,Spontaneous,2023-12-14 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016458863&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016458869,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Dehydration (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Muscle spasms (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pneumonia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Sepsis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Urinary tract infection (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016458869&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016458996,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Unknown - ),<BR><BR>Movement disorder (n/a - Unknown - ),<BR><BR>Myalgia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - COVID-19 immunisation - n/a - [1d - n/a - n/a]),<BR><BR>SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.1 [ELASOMERAN, IMELASOMERAN] (C - COVID-19 immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[AMILORIDE HYDROCHLORIDE PH. EUR., FUROSEMIDE PH. EUR., AMILORIDE HYDROCHLORIDE, FUROSEMIDE, FUROSEMIDE BP, AMILORIDE HYDROCHLORIDE BP, FUROSEMIDE, ANHYDROUS AMILORIDE HYDROCHLORIDE] (C - Fluid retention - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016458996&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016459051,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Axillary pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016459051&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016459055,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Fatigue (1d - Recovered/Resolved - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Malaise (1d - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016459055&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016459475,Spontaneous,2023-12-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Altered state of consciousness (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>C-reactive protein (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Dermatitis exfoliative generalised (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Erythema (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pruritus (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>White blood cell count increased (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - n/a - n/a - [n/a - n/a - n/a])","ARANESP [DARBEPOETIN ALFA] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALFACALCIDOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CINACALCET] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANTHANUM, LANTHANUM CARBONATE, LANTHANUM CARBONATE HYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LERCANIDIPINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016459475&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016459595,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Dizziness (5h - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016459595&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016459600,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Vitreous floaters (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016459600&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016459606,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Erythema (2d - Recovered/Resolved - ),<BR><BR>Fatigue (2d - Recovered/Resolved - ),<BR><BR>Hypersensitivity (2d - Recovered/Resolved - ),<BR><BR>Oedema peripheral (2d - Recovered/Resolved - ),<BR><BR>Pharyngeal swelling (2d - Recovered/Resolved - ),<BR><BR>Swelling face (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016459606&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016459660,Spontaneous,2023-12-14 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Facial paresis (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Hypoaesthesia (31d - Recovered/Resolved - Disabling),<BR><BR>Musculoskeletal pain (7d - Recovered/Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016459660&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016460337,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Ocular discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Restlessness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016460337&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016460472,Spontaneous,2023-12-14 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016460472&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016460866,Spontaneous,2023-12-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (1d - Recovered/Resolved - ),<BR><BR>Vomiting (6d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016460866&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016461120,Spontaneous,2023-12-14 00:00:00,Healthcare Professional,European Economic Area,Not available,12-17 Years,Not Specified,No,Male,Epilepsy (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 3 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016461120&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016461189,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Vaccination failure (1mo - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>[BECLOMETASONE DIPROPIONATE, BECLOMETASONE DIPROPIONATE MONOHYDRATE] (C - Sinusitis - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016461189&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016461710,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016461710&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016461733,Spontaneous,2023-12-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Confusional state (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dysphagia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Inflammatory marker increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Psychomotor skills impaired (n/a - Unknown - Other Medically Important Condition),<BR><BR>Staphylococcal sepsis (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),"BENEPALI 50 MG [ETANERCEPT] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>IBANDRONIC ACID 150 MG  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE OXIDE] (C - n/a - Unknown - ),<BR><BR>[METHYLPREDNISOLONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - n/a - Unknown - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016461733&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016462077,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Dose not changed - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016462077&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016462087,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016462087&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016462393,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Application site inflammation (3wk - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Application site rash (3wk - Recovered/Resolved - ),<BR><BR>Depression (3wk - Recovered/Resolved With Sequelae - ),<BR><BR>Neck pain (3wk - Recovered/Resolved - ),<BR><BR>Pain in extremity (3wk - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016462393&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016462437,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Polymyalgia rheumatica (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [1d - n/a - n/a])","[COLECALCIFEROL, CALCIUM, COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016462437&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016462440,Spontaneous,2023-12-14 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016462440&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016462441,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Epilepsy (n/a - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016462441&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016462457,Spontaneous,2023-12-14 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Incorrect dose administered (n/a - Unknown - ),<BR><BR>Product communication issue (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016462457&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016463152,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Feeling abnormal (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016463152&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016463153,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (7h - Recovered/Resolved - ),<BR><BR>Headache (7h - Recovered/Resolved - ),<BR><BR>Tachycardia (7h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016463153&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016463158,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (1d - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (30min - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016463158&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016463160,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Body temperature increased (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016463160&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016463162,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Diarrhoea (2d - Recovered/Resolved - ),<BR><BR>Injection site erythema (4d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (4d - Recovered/Resolved - ),<BR><BR>Injection site pain (4d - Recovered/Resolved - ),<BR><BR>Injection site warmth (4d - Recovered/Resolved - ),<BR><BR>Malaise (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - ),<BR><BR>Vaccination site lymphadenopathy (4d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016463162&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016463247,Spontaneous,2023-12-14 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Epistaxis (20min - Recovered/Resolved - ),<BR><BR>Epistaxis (4h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016463247&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016463599,Spontaneous,2023-12-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Facial paralysis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Paralysis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - n/a - n/a])","TALTZ [IXEKIZUMAB] (C - Psoriasis - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>[ATENOLOL PH. EUR., CHLORTALIDONE PH. EUR., ATENOLOL, CHLORTALIDONE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016463599&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016463606,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016463606&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016463691,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chest pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (1d - Recovered/Resolved - ),<BR><BR>Cough (n/a - Recovering/Resolving - ),<BR><BR>Erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (3d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (3d - Recovered/Resolved - ),<BR><BR>Injection site pain (3d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Musculoskeletal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovered/Resolved - ),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016463691&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016463957,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Extensive swelling of vaccinated limb (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>XARELTO 20 MG FILM-COATED TABLETS [RIVAROXABAN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016463957&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016463959,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Body temperature increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),[TRAMADOL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016463959&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016464196,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (2h - Recovered/Resolved - ),<BR><BR>Malaise (3d - Recovered/Resolved - ),<BR><BR>Nausea (1h - Recovered/Resolved - ),<BR><BR>Night sweats (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016464196&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016464200,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Hiccups (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - Dose not changed - [n/a - 500mg - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016464200&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016464219,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Vertigo (10h - Recovered/Resolved - ),<BR><BR>Vomiting (10h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016464219&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016464221,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chills (24h - Recovered/Resolved - ),<BR><BR>Nausea (24h - Recovered/Resolved - ),<BR><BR>Pyrexia (24h - Recovered/Resolved - ),<BR><BR>Syncope (12h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016464221&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016464224,Spontaneous,2023-12-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (24h - Recovered/Resolved - ),<BR><BR>Chills (24h - Recovered/Resolved - ),<BR><BR>Headache (24h - Recovered/Resolved - ),<BR><BR>Malaise (24h - Recovered/Resolved - ),<BR><BR>Myalgia (24h - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rash pruritic (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016464224&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016464241,Spontaneous,2023-12-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Deep vein thrombosis (5d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227)] (S - Influenza immunisation - Not applicable - [1d - .5mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016464241&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016464733,Spontaneous,2023-12-14 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Facial paralysis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Vaccination site swelling (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016464733&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016448495,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Headache (n/a - Recovering/Resolving - ),<BR><BR>Nasopharyngitis (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016448495&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016448757,Spontaneous,2023-12-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Alanine aminotransferase increased (n/a - Unknown - ),<BR><BR>Aspartate aminotransferase increased (n/a - Unknown - ),<BR><BR>Blood bilirubin increased (n/a - Unknown - ),<BR><BR>C-reactive protein increased (n/a - Unknown - ),<BR><BR>Cough (n/a - Recovered/Resolved - ),<BR><BR>Decreased appetite (n/a - Unknown - ),<BR><BR>Dyspnoea (n/a - Recovered/Resolved - ),<BR><BR>Gamma-glutamyltransferase increased (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Oxygen saturation decreased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Productive cough (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Respiratory failure (n/a - Recovered/Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>White blood cell count increased (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[AMLODIPINE, AMLODIPINE BESILATE] (C - Hypertension - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[LORNOXICAM] (C - Back pain - n/a - [n/a - 3{DF} - Oral use]),<BR><BR>[REBAMIPIDE] (C - Back pain - n/a - [n/a - 3{DF} - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016448757&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016448772,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Transient ischaemic attack (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016448772&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016449884,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Alopecia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016449884&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016450228,Spontaneous,2023-12-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Cerebral venous sinus thrombosis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - n/a]),"RIVASTIGMINE [RIVASTIGMINE, RIVASTIGMINE HYDROGEN TARTRATE] (C - n/a - n/a - [n/a - 4.6mg - n/a]),<BR><BR>[ROSUVASTATIN] (C - n/a - n/a - [n/a - 10mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016450228&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016450270,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Injection site pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","COMPETACT 15 MG/850 MG FILM-COATED TABLETS [METFORMIN HYDROCHLORIDE, PIOGLITAZONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[IRBESARTAN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016450270&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016450272,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016450272&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016450346,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,Thrombosis (n/a - Not Recovered/Not Resolved - Life Threatening),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016450346&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016450432,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Disturbance in attention (n/a - Recovering/Resolving - ),<BR><BR>Dyspnoea exertional (n/a - Recovering/Resolving - ),<BR><BR>Sleep disorder (n/a - Recovering/Resolving - ),<BR><BR>Tachycardia (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016450432&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016450437,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Sleep disorder (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016450437&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016450670,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chest pain (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016450670&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016450672,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arrhythmia (2wk - Recovered/Resolved - ),<BR><BR>Condition aggravated (2wk - Recovered/Resolved - ),<BR><BR>Heart rate increased (2wk - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),LIXIANA 60 MG FILM-COATED TABLETS [EDOXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016450672&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016450673,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Chills (2h - Recovered/Resolved - ),<BR><BR>Erysipelas (10d - Recovered/Resolved - ),<BR><BR>Fatigue (8d - Recovered/Resolved - ),<BR><BR>Headache (10d - Recovered/Resolved - ),<BR><BR>Loss of consciousness (10d - Recovered/Resolved - ),<BR><BR>Malaise (5d - Recovered/Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),HARTMEDICATIE [NOT AVAILABLE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016450673&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016450676,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (1d - Recovered/Resolved - ),<BR><BR>Chills (2d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (8h - Recovered/Resolved - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pruritus (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE MONOHYDRATE, LYSINE ASPIRIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016450676&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016450772,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016450772&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016451008,Spontaneous,2023-12-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Erythema (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Swelling face (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),"[AMILORIDE, HYDROCHLOROTHIAZIDE] (C - n/a - n/a - [n/a - 55mg - Oral use]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016451008&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016451073,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Hyperaesthesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016451073&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016451190,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Body temperature increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Feeling abnormal (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in jaw (n/a - Not Recovered/Not Resolved - ),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - ),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pollakiuria (n/a - Not Recovered/Not Resolved - ),<BR><BR>Poor quality sleep (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016451190&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016451192,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016451192&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016451195,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Diarrhoea (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016451195&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016451608,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Hypersensitivity (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Inflammation (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016451608&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016451685,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Transient ischaemic attack (16h - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016451685&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016451687,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Myalgia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016451687&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016451691,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Headache (3d - Recovered/Resolved - ),<BR><BR>Injection site pain (4d - Recovered/Resolved - ),<BR><BR>Malaise (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016451691&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016452292,Spontaneous,2023-12-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypertension (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - .5mL - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016452292&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016452344,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Male,Insomnia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"MELATONIN [MELATONIN] (C - Autism spectrum disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016452344&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016452714,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016452714&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016452750,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016452750&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016452765,Spontaneous,2023-12-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"[DILTIAZEM, DILTIAZEM HYDROCHLORIDE] (C - Supraventricular tachycardia - n/a - [1367d - n/a - n/a - More in ICSR]),<BR><BR>[MESALAZINE] (C - Colitis ulcerative - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Arthritis - n/a - [n/a - n/a - Oral use]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Blood cholesterol increased - n/a - [2087d - n/a - n/a - More in ICSR])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016452765&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016452801,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016452801&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016452833,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Chills (2d - Recovered/Resolved - ),<BR><BR>Fatigue (3d - Recovered/Resolved - ),<BR><BR>Headache (3d - Recovered/Resolved - ),<BR><BR>Reading disorder (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016452833&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016452845,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Groin pain (24h - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016452845&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016452847,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Body temperature increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016452847&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016452986,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Thyroid disorder - n/a - [n/a - 50ug - Oral use]),<BR><BR>[LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - 100mg - Oral use]),<BR><BR>[PRAVASTATIN, PRAVASTATIN SODIUM] (C - Cardiac disorder - n/a - [n/a - 20mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016452986&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016452990,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016452990&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016453144,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016453144&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016453354,Spontaneous,2023-12-13 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Asthenia (n/a - Unknown - ),<BR><BR>Dyspnoea (n/a - Unknown - ),<BR><BR>Nasopharyngitis (n/a - Unknown - ),<BR><BR>Swelling face (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016453354&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016453411,Spontaneous,2023-12-13 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Abdominal pain lower (6d - Recovered/Resolved - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - ),<BR><BR>Sleep disorder (2d - Recovered/Resolved - ),<BR><BR>Uterine haemorrhage (7d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),"[BISOPROLOL FUMARATE, BISOPROLOL FUMARATE PH. EUR., BISOPROLOL HEMIFUMARATE] (C - Hypertension - Dose not changed - [n/a - n/a - Oral use]),<BR><BR>[PSYLLIUM] (C - Constipation - Dose not changed - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016453411&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016453457,Spontaneous,2023-12-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Male,"Hiccups (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (3d - Recovered/Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016453457&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016453580,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Diarrhoea (3d - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Hyperpyrexia (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (7d - Recovered/Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016453580&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016453581,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016453581&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016453584,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Body temperature increased (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Decreased appetite (36h - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (2d - Recovered/Resolved - ),<BR><BR>Nausea (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016453584&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016453585,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Herpes zoster (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (3d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (3d - Recovered/Resolved - ),<BR><BR>Injection site pain (3d - Recovered/Resolved - ),<BR><BR>Injection site warmth (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016453585&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016453682,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nasal congestion (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Throat irritation (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016453682&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016453787,Spontaneous,2023-12-13 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Dyspnoea exertional (n/a - Recovering/Resolving - ),<BR><BR>Exercise tolerance decreased (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016453787&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016453984,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[DORZOLAMIDE HYDROCHLORIDE, TIMOLOL MALEATE, DORZOLAMIDE, TIMOLOL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016453984&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016453993,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016453993&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016454021,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,COVID-19 (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016454021&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016454136,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovered/Resolved - ),<BR><BR>Cough (n/a - Recovering/Resolving - ),<BR><BR>Dyspnoea exertional (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Injection site pruritus (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016454136&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016454137,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Polymenorrhoea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[FORMOTEROL FUMARATE DIHYDRATE, BECLOMETASONE DIPROPIONATE ANHYDROUS] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016454137&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016454138,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Atrial fibrillation (1d - Recovered/Resolved - ),<BR><BR>Hypertension (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016454138&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016454141,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rash papular (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016454141&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016454143,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cough (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016454143&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016454149,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Dysphonia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CARBASALATE CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PANTOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VERAPAMIL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016454149&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016454183,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Acarodermatitis (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Cerebrovascular accident (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Chest discomfort (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Disorientation (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Dry skin (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Dyskinesia (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Eczema (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Skin discolouration (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Skin lesion (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"FLUENZ [A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, MEDI 228029), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN (A/VICTORIA/361/2011, MEDI 231411), B/WISCONSIN/1/2010-LIKE STRAIN (B/WISCONSIN/1/2010, MEDI 028507), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, MEDI 237514), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, MEDI 228029)] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016454183&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016454479,Spontaneous,2023-12-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[DOXAZOSIN, DOXAZOSIN MESILATE] (C - Benign prostatic hyperplasia - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016454479&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016454575,Spontaneous,2023-12-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthritis (6h - Recovered/Resolved - ),<BR><BR>Pyrexia (12h - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016454575&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016454679,Spontaneous,2023-12-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Seizure (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016454679&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016454729,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site warmth (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016454729&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016454765,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (35h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (35h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (35h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Syncope (11h - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[DESOGESTREL] (C - Contraception - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016454765&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016454867,Spontaneous,2023-12-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016454867&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016455040,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Illness (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016455040&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016455128,Spontaneous,2023-12-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016455128&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016455367,Spontaneous,2023-12-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Myelitis (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Neuromyelitis optica spectrum disorder (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Optic neuritis (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"RELVAR ELLIPTA [FLUTICASONE FUROATE, VILANTEROL] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[ICOSAPENT ETHYL] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016455367&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016455372,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016455372&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016455491,Spontaneous,2023-12-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Joint swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Maternal exposure during pregnancy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[FOLIC ACID] (C - Vitamin supplementation - n/a - [n/a - 400ug - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016455491&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016455589,Spontaneous,2023-12-13 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Genital haemorrhage (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"AREXVY [STIMULON, MONOPHOSPHORYL LIPID A, RESPIRATORY SYNCYTIAL VIRUS, GLYCOPROTEIN F, RECOMBINANT, STABILISED IN THE PRE-FUSION CONFORMATION, ADJUVANTED WITH AS01E] (C - Immunisation - n/a - [1d - n/a - Intramuscular use]),<BR><BR>[ACETYLSALICYLIC ACID, D,L-LYSINE ACETYLSALICYLATE, LYSINE ASPIRIN, LYSINE, ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLURBIPROFEN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[IBUPROFEN, IBUPROFEN LYSINE, IBUPROFEN PH. EUR., IBUPROFEN SODIUM, IBUPROFEN SODIUM DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[KETOPROFEN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016455589&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016455731,Spontaneous,2023-12-13 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Lymphadenopathy (29d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016455731&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016439983,Spontaneous,2023-12-12 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Blister (n/a - Recovering/Resolving - ),<BR><BR>Furuncle (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),"[AMLODIPINE, OLMESARTAN, OLMESARTAN MEDOXOMIL, AMLODIPINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016439983&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016440098,Spontaneous,2023-12-12 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (2d - Recovered/Resolved - ),<BR><BR>Injection site pain (2d - Recovered/Resolved - ),<BR><BR>Somnolence (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[ENALAPRIL MALEATE] (C - Hypertension - n/a - [n/a - 20mg - Oral use]),<BR><BR>[EZETIMIBE] (C - Hypercholesterolaemia - n/a - [n/a - 10mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016440098&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016441053,Spontaneous,2023-12-12 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (26310min - Recovered/Resolved - ),<BR><BR>Erythema (n/a - Recovered/Resolved - ),<BR><BR>Neuropathy peripheral (26310min - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016441053&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016441815,Spontaneous,2023-12-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Back pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Breast pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Ear discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hepatic pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Herpes zoster (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pulmonary pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016441815&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016441818,Spontaneous,2023-12-12 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016441818&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016441829,Spontaneous,2023-12-12 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Dizziness (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016441829&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016442050,Spontaneous,2023-12-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Diarrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Illness (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Loss of consciousness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Presyncope (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016442050&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016442472,Spontaneous,2023-12-12 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Cough (n/a - Unknown - Other Medically Important Condition),<BR><BR>Laryngitis (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - 1{DF} - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016442472&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016443423,Spontaneous,2023-12-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest discomfort (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016443423&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016443925,Spontaneous,2023-12-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Muscle twitching (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"DULOXETINE [DULOXETINE, DULOXETINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[DESOGESTREL, ETHINYLESTRADIOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE OXIDE] (C - Irritable bowel syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[LORATADINE] (C - Multiple allergies - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016443925&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016444160,Spontaneous,2023-12-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (10d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (10d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016444160&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016444448,Spontaneous,2023-12-12 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Apathy (n/a - Recovered/Resolved - ),<BR><BR>Asthenia (n/a - Recovered/Resolved - ),<BR><BR>Somnolence (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016444448&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016444449,Spontaneous,2023-12-12 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Apathy (n/a - Recovered/Resolved - ),<BR><BR>Asthenia (n/a - Recovered/Resolved - ),<BR><BR>Hyperthermia (n/a - Recovered/Resolved - ),<BR><BR>Inflammation (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016444449&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016444450,Spontaneous,2023-12-12 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Apathy (n/a - Recovered/Resolved - ),<BR><BR>Asthenia (n/a - Recovered/Resolved - ),<BR><BR>Loss of consciousness (n/a - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016444450&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016444514,Spontaneous,2023-12-12 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Deep vein thrombosis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary embolism (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),"CELLCEPT 500 MG TABLETS [MYCOPHENOLATE MOFETIL] (C - Prophylaxis against transplant rejection - Dose not changed - [n/a - 2{DF} - n/a]),<BR><BR>[EVEROLIMUS] (C - Prophylaxis against transplant rejection - Dose not changed - [n/a - 2{DF} - Oral use]),<BR><BR>[PREDNISOLONE, PREDNISOLONE METASULFOBENZOATE SODIUM] (C - Prophylaxis against transplant rejection - Dose not changed - [n/a - 10mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016444514&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016444603,Spontaneous,2023-12-12 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,"Asthenia (n/a - Recovering/Resolving - ),<BR><BR>Diarrhoea (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016444603&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016444634,Spontaneous,2023-12-12 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Cardiac failure (19d - Recovered/Resolved - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),"ELIQUIS [APIXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>JARDIANCE [EMPAGLIFLOZIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALENDRONATE SODIUM, ALENDRONIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CALCIUM, CALCIUM CARBONATE, CALCIUM CARBONATE, CHOLECALCIFEROL CONCENTRATE (POWDER FORM), COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, CODEINE PHOSPHATE, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, OPIUM, PREPARED] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[POTASSIUM CHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016444634&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016444902,Spontaneous,2023-12-12 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Atrial fibrillation (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Cardiovascular disorder (n/a - Unknown - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016444902&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016444920,Spontaneous,2023-12-12 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Herpes zoster (11d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Scar pain (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016444920&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016444953,Spontaneous,2023-12-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016444953&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016445044,Spontaneous,2023-12-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016445044&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016445642,Spontaneous,2023-12-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016445642&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016445655,Spontaneous,2023-12-12 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016445655&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016445893,Spontaneous,2023-12-12 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,"Asthenia (1d - Recovered/Resolved - ),<BR><BR>Diarrhoea (1d - Recovered/Resolved - ),<BR><BR>Malaise (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - Intramuscular use]),"LIXIANA [EDOXABAN, EDOXABAN TOSYLATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - Not applicable - [0d - .5mL - Intramuscular use]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[AMLODIPINE, PERINDOPRIL] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[BUSPIRONE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[DONEPEZIL] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[ESCITALOPRAM, ESCITALOPRAM OXALATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[HYDROCHLOROTHIAZIDE, NEBIVOLOL] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[TROSPIUM CHLORIDE] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016445893&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016445931,Spontaneous,2023-12-12 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,"Chills (48h - Recovered/Resolved - ),<BR><BR>Headache (48h - Recovered/Resolved - ),<BR><BR>Myalgia (48h - Recovered/Resolved - ),<BR><BR>Nausea (48h - Recovered/Resolved - ),<BR><BR>Pyrexia (48h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016445931&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016445936,Spontaneous,2023-12-12 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Blister (n/a - Unknown - ),<BR><BR>COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Herpes zoster (n/a - Recovering/Resolving - ),<BR><BR>Pruritus (n/a - Unknown - ),<BR><BR>Rash (n/a - Unknown - ),<BR><BR>Rash macular (n/a - Unknown - ),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[EZETIMIBE] (C - Blood cholesterol increased - n/a - [n/a - n/a - Oral use]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[PRAVASTATIN SODIUM] (C - Blood cholesterol increased - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016445936&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016445951,Spontaneous,2023-12-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Unknown - ),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Oropharyngeal pain (n/a - Unknown - ),<BR><BR>Pain (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - ),<BR><BR>Suspected COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016445951&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016445953,Spontaneous,2023-12-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016445953&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016445958,Spontaneous,2023-12-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Vaccination site pain (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016445958&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016445991,Spontaneous,2023-12-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Conjunctival haemorrhage (10d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"PRAVAFENIX [PRAVASTATIN SODIUM, FENOFIBRATE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[LATANOPROST] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016445991&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016446131,Spontaneous,2023-12-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016446131&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016446180,Spontaneous,2023-12-12 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Pulmonary embolism (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary infarction (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Coronary artery stenosis - n/a - [n/a - 75mg - n/a]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Coronary artery stenosis - n/a - [n/a - 40mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016446180&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016446892,Spontaneous,2023-12-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016446892&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016446928,Spontaneous,2023-12-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016446928&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016447728,Spontaneous,2023-12-12 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Coordination abnormal (n/a - Recovered/Resolved - ),<BR><BR>Speech disorder (n/a - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .5mL - Ocular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227)] (S - Influenza immunisation - Not applicable - [1d - .5umol - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016447728&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016447792,Spontaneous,2023-12-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Breast pain (n/a - Recovering/Resolving - ),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),"COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),<BR><BR>[ELASOMERAN] (C - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - Hypothyroidism - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Anxiety - Dose not changed - [n/a - 100mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016447792&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016447847,Spontaneous,2023-12-12 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Feeling hot (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hot flush (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016447847&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016432014,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Headache (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016432014&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016432019,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Hypertension (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ASCORBIC ACID, CALCIUM GLUBIONATE, CALCIUM CARBONATE, CALCIUM, CALCIUM GLUBIONATE, CALCIUM CARBONATE, COLECALCIFEROL, CALCIUM] (C - n/a - n/a - [n/a - 1200mg - n/a - More in ICSR]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - 20mg - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISONE] (C - n/a - n/a - [n/a - 4mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016432019&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016432021,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dyspnoea exertional (6d - Recovered/Resolved - ),<BR><BR>Fatigue (6d - Recovered/Resolved - ),<BR><BR>Headache (6d - Recovered/Resolved - ),<BR><BR>Heart rate increased (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (6d - Recovered/Resolved - ),<BR><BR>Palpitations (6d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[ALENDRONATE SODIUM] (C - Osteoporosis - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Thyroid disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Abdominal discomfort - n/a - [n/a - n/a - n/a]),<BR><BR>[PRAVASTATIN, PRAVASTATIN SODIUM] (C - Blood cholesterol - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISONE] (C - Polymyalgia rheumatica - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016432021&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016432029,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016432029&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016432038,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"COVID-19 (n/a - Unknown - Life Threatening, Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Life Threatening, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016432038&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016432039,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016432039&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016432044,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Fatigue (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - ),<BR><BR>Vaccination site pain (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016432044&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016432069,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016432069&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016432080,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Vaccination site erythema (n/a - Unknown - ),<BR><BR>Vaccination site pruritus (n/a - Unknown - ),<BR><BR>Vaccination site swelling (n/a - Unknown - ),<BR><BR>Vaccination site warmth (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016432080&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016433271,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Blood pressure increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016433271&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016433273,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Erythema (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016433273&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016433424,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Dyspnoea (71d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016433424&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016433845,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Herpes zoster (n/a - Not Recovered/Not Resolved - ),<BR><BR>Post herpetic neuralgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016433845&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016433855,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Pulmonary embolism (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016433855&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016433864,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Headache (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016433864&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016433868,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (2d - Recovered/Resolved - ),<BR><BR>Bone pain (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016433868&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016434601,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Herpes zoster (n/a - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016434601&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016434602,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Dizziness (n/a - Unknown - ),<BR><BR>Hypertension (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016434602&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016434930,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Fatigue (n/a - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016434930&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435011,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435011&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435240,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Migraine (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[DESOGESTREL] (C - Contraception - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435240&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435435,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435435&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435661,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Pulmonary embolism (n/a - Fatal - Results in Death),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - Not applicable - [n/a - n/a - n/a]),"[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - n/a - Not applicable - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435661&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435904,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435904&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435907,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Pericarditis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","EDOXABAN 60MG TABLET  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435907&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435912,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Dyspnoea (n/a - Fatal - Results in Death),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435912&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435913,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435913&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435914,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Pericarditis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435914&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435917,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435917&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435924,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435924&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435926,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (1d - Recovered/Resolved - ),<BR><BR>Body temperature increased (1d - Recovered/Resolved - ),<BR><BR>Chills (3h - Recovered/Resolved - ),<BR><BR>Fatigue (3d - Recovered/Resolved - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site haematoma (7d - Recovered/Resolved - ),<BR><BR>Injection site warmth (7d - Recovered/Resolved - ),<BR><BR>Malaise (3d - Recovered/Resolved - ),<BR><BR>Myalgia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435926&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435938,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Blood glucose increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Diabetes mellitus inadequate control (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435938&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435940,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Male,"Body temperature increased (4d - Recovered/Resolved - ),<BR><BR>Chest pain (4d - Recovered/Resolved - ),<BR><BR>Chills (4d - Recovered/Resolved - ),<BR><BR>Headache (4d - Recovered/Resolved - ),<BR><BR>Malaise (4d - Recovered/Resolved - ),<BR><BR>Myalgia (4d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (S - Pneumococcal immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435940&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435945,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435945&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435952,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (2d - Recovered/Resolved - ),<BR><BR>Chills (2d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (3d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435952&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435955,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435955&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435957,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Abdominal pain (n/a - Fatal - Results in Death),<BR><BR>Chills (1d - Recovered/Resolved - ),<BR><BR>Malaise (1d - Recovered/Resolved - ),<BR><BR>Vomiting (n/a - Fatal - Results in Death)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRIOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435957&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435974,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435974&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435977,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Petechiae (n/a - Recovering/Resolving - ),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>TELMISARTAN 80 MG - TABLET  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BARNIDIPINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CARBASALATE CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ISOSORBIDE MONONITRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ISPAGHULA] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435977&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435978,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Herpes zoster (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435978&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435979,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Death (n/a - Fatal - Results in Death),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435979&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435981,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Dysuria (n/a - Recovering/Resolving - ),<BR><BR>Renal pain (n/a - Recovering/Resolving - ),<BR><BR>Urine abnormality (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435981&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435984,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (n/a - Recovered/Resolved - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435984&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435989,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Palpitations (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435989&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435991,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Epistaxis (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435991&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435992,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Muscle spasms (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rhinorrhoea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435992&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016435998,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Aortic aneurysm rupture (n/a - Fatal - Results in Death),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),LIXIANA 60 MG FILM-COATED TABLETS [EDOXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016435998&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436002,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Herpes zoster (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436002&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436004,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Headache (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436004&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436005,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Cough (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436005&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436011,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Cough (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436011&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436013,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Herpes zoster (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436013&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436014,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (1d - Recovered/Resolved - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Malaise (1d - Recovered/Resolved - ),<BR><BR>Myalgia (1d - Recovered/Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Syncope (1min - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436014&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436016,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arrhythmia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rhinorrhoea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436016&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436018,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Body temperature increased (2d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (2d - Recovered/Resolved - ),<BR><BR>Injection site pain (3d - Recovered/Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oropharyngeal pain (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),[CABERGOLINE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436018&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436022,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (4h - Recovered/Resolved - ),<BR><BR>Injection site discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436022&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436028,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Vertigo (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436028&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436031,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Abdominal pain lower (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[ASCORBIC ACID, PARACETAMOL, ANHYDROUS CAFFEINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436031&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436037,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436037&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436040,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Vasculitis (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436040&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436042,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Skin discolouration (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436042&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436047,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Bell's palsy (8d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","IRBESARTAN 75 MG - TABLET  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOVOMIX 30 PENFILL 100 U/ML SUSPENSION FOR INJECTION [INSULIN ASPART, INSULIN ASPART PROTAMINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOVORAPID PENFILL 100 E/ML [INSULIN ASPART] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436047&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436101,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Glossitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypogeusia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Taste disorder (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436101&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436106,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"COVID-19 (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[ASCORBIC ACID] (C - n/a - n/a - [n/a - 1000mg - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436106&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436121,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Eye pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Ocular hyperaemia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Photophobia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - 1{DF} - Intramuscular use]),"KEVZARA [SARILUMAB] (C - Rheumatoid arthritis - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>[KETOPROFEN] (C - n/a - n/a - [n/a - 50mg - Oral use]),<BR><BR>[SULFASALAZINE] (C - Rheumatoid arthritis - n/a - [n/a - 1000mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436121&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436217,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sleep disorder due to a general medical condition (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site haemorrhage (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site movement impairment (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436217&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436254,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436254&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436392,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436392&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436581,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Arthralgia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),"[CHLORTALIDONE, AZILSARTAN MEDOXOMIL] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436581&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436605,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,Yes,Female,"Epilepsy (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Recovered/Resolved - ),<BR><BR>Vaccination site oedema (n/a - Recovered/Resolved - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pruritus (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),"DULOXETINE [DULOXETINE, DULOXETINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CARBAMAZEPINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CLONAZEPAM] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[GABAPENTIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[GLUCOSAMINE SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, OMEPRAZOLE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436605&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436629,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Confusional state (n/a - Recovered/Resolved - Disabling),<BR><BR>Dizziness (n/a - Recovering/Resolving - Disabling),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Palpitations (n/a - Recovering/Resolving - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436629&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436661,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Dyspnoea (n/a - Fatal - Results in Death),<BR><BR>Feeling of body temperature change (n/a - Unknown - ),<BR><BR>Gait disturbance (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436661&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436664,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Rash pruritic (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436664&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436667,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436667&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436668,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436668&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436669,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Body temperature increased (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"APIXABAN 5MG TABLET  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ASCORBIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BUDESONIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[EZETIMIBE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SOTALOL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436669&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436671,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Body temperature increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypogeusia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hyposmia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rhinorrhoea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436671&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436675,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Flank pain (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436675&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436692,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436692&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436827,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Asthenia (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436827&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436918,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Pulmonary embolism (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436918&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436930,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Vascular purpura (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436930&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436981,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Male,Musculoskeletal chest pain (42d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - n/a - Not applicable - [1d - 1{DF} - Intramuscular use]),"[ACETYLSALICYLIC ACID, D,L-LYSINE ACETYLSALICYLATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN CILEXETIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FENOFIBRATE, FENOFIBRATE MICRONISED] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LERCANIDIPINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436981&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436998,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Ophthalmic herpes zoster (19d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),"[ALPRAZOLAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BENSERAZIDE HYDROCHLORIDE, LEVODOPA, BENSERAZIDE, LEVODOPA] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CETRIMIDE, HYPROMELLOSE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESCITALOPRAM, ESCITALOPRAM OXALATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[NICARDIPINE, NICARDIPINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, CODEINE PHOSPHATE, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[POTASSIUM, POTASSIUM CHLORIDE, POTASSIUM GLYCEROPHOSPHATE, POTASSIUM HYDROGEN CARBONATE, POTASSIUM HYDROGEN TARTRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436998&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016436999,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Ophthalmic herpes zoster (45d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),"RISPERIDONE [RISPERIDONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID, D,L-LYSINE ACETYLSALICYLATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL FUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OXAZEPAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PAROXETINE HYDROCHLORIDE, ANHYDROUS] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[POTASSIUM, SODIUM, MACROGOL 3350, CHLORIDE ION, HYDROGEN CARBONATE, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TRIHEXYPHENIDYL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016436999&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016437231,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Ischaemic stroke (n/a - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016437231&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016437337,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Herpes zoster (n/a - Not Recovered/Not Resolved - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010, B/BRISBANE/60/2008-LIKE VIRUS, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227)] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016437337&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016437355,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Pyrexia (n/a - Recovered/Resolved - ),<BR><BR>Urticaria (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016437355&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016437420,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,3-11 Years,Not Specified,No,Male,"Decreased appetite (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016437420&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016437421,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Asthma (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wheezing (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[FLUTICASONE, SALMETEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016437421&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016437602,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016437602&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016437606,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Hypoacusis (24h - Recovered/Resolved - ),<BR><BR>Tinnitus (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016437606&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016437608,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Bronchial disorder (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (3d - Recovered/Resolved - ),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016437608&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016437658,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Fatigue (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Inflammation (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016437658&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016438024,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Transient ischaemic attack (n/a - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 30ug - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016438024&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016438087,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>CT CONTRASTVLOEISTOF [NOT AVAILABLE] (S - Computerised tomogram - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016438087&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016438088,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Pulmonary embolism (n/a - Recovering/Resolving - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","NOT AVAILABLE (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - Hyperthyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016438088&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016438090,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (4h - Recovered/Resolved - ),<BR><BR>Chills (2h - Recovered/Resolved - ),<BR><BR>Erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site induration (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Skin warm (n/a - Recovering/Resolving - ),<BR><BR>Swelling face (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016438090&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016438310,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Angina pectoris (n/a - Unknown - Other Medically Important Condition),<BR><BR>Blood pressure systolic increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Deep vein thrombosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Muscle spasms (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Sinus tachycardia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ANHYDROUS LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - 75mg - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016438310&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016438336,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Atrial fibrillation (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Confusional state (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Cough (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Liver function test abnormal (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Lower respiratory tract infection (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Lymphopenia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Renal impairment (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])","HYDROXOCOBALAMIN [HYDROXOCOBALAMIN] (C - Vitamin B12 deficiency - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - Myocardial ischaemia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016438336&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016438516,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Gout (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016438516&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016438517,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Urticaria (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016438517&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016438941,Spontaneous,2023-12-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Erythema (n/a - Recovering/Resolving - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016438941&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016438942,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Tongue geographic (n/a - Not Recovered/Not Resolved - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016438942&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016438952,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Giant cell arteritis (n/a - Recovering/Resolving - Life Threatening),<BR><BR>Headache (n/a - Unknown - Life Threatening)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),"[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016438952&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016439418,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Malaise (n/a - Unknown - ),<BR><BR>Vaccination site pain (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),"COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016439418&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016439424,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Female,Rash (n/a - Unknown - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016439424&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016439434,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Pyrexia (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016439434&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016439443,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Tendonitis (n/a - Recovering/Resolving - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),<BR><BR>FLUAD TETRA SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Drug withdrawn - [1d - n/a - Intramuscular use])","[ACETYLSALICYLIC ACID] (C - Prophylaxis - Dose not changed - [n/a - n/a - Oral use]),<BR><BR>[BISOPROLOL HEMIFUMARATE] (C - Hypertension - Dose not changed - [n/a - n/a - Oral use]),<BR><BR>[COLECALCIFEROL, CALCIUM, COLECALCIFEROL, CALCIUM CARBONATE] (C - Vitamin D decreased - Dose not changed - [n/a - n/a - Oral use]),<BR><BR>[ENALAPRIL MALEATE] (C - Hypertension - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - Chronic kidney disease - Dose not changed - [n/a - n/a - Oral use]),<BR><BR>[OMEPRAZOLE] (C - n/a - Dose not changed - [n/a - n/a - Oral use]),<BR><BR>[SIMVASTATIN] (C - Hypercholesterolaemia - Dose not changed - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016439443&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016439446,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Diarrhoea (n/a - Unknown - ),<BR><BR>Insomnia (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Vomiting (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),"COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016439446&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016439455,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Upper respiratory tract infection (n/a - Unknown - Other Medically Important Condition),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016439455&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016439458,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Pyrexia (n/a - Unknown - ),<BR><BR>Rhinorrhoea (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016439458&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016439461,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Immunisation reaction (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),"COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>VAXZEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016439461&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016439462,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Malaise (n/a - Recovering/Resolving - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016439462&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016439466,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (n/a - Unknown - ),<BR><BR>Pain (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),"COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>VAXZEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016439466&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016439476,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Myalgia (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUCELVAX TETRA [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])...","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016439476&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016439478,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Cough (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),"COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016439478&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016439487,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Female,"Malaise (n/a - Unknown - ),<BR><BR>Nausea (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUCELVAX TETRA [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>[ELASOMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016439487&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016439492,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Immunisation reaction (n/a - Recovered/Resolved - ),<BR><BR>Vaccination site pain (n/a - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016439492&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016439500,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Asthenia (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [0d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016439500&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016439501,Spontaneous,2023-12-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Headache (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016439501&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016423047,Spontaneous,2023-12-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Nausea (n/a - Unknown - ),<BR><BR>Vomiting (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016423047&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016423826,Spontaneous,2023-12-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Pyrexia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (n/a - Unknown - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),[DALTEPARIN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016423826&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016424466,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Confusional state (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lethargy (n/a - Recovering/Resolving - ),<BR><BR>Pain of skin (n/a - Not Recovered/Not Resolved - ),<BR><BR>Sensitive skin (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),"[ESCITALOPRAM, ESCITALOPRAM OXALATE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[LAMOTRIGINE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, CAFFEINE] (C - Injury, Pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016424466&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016424472,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Postmenopausal haemorrhage (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016424472&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016424632,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016424632&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016424634,Spontaneous,2023-12-08 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Vaccination site erythema (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016424634&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016424651,Spontaneous,2023-12-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Malaise (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016424651&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016424668,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cardiac disorder (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Finger deformity (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Heart rate increased (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Loss of consciousness (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Oxygen saturation decreased (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Tetany (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 HAEMAGGLUTININ ANTIGEN, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[GABAPENTIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, BELLADONNA DRY EXTRACT, CAFFEINE, OPIUM, PARACETAMOL, CAFFEINE, OPIUM, PARACETAMOL, CAFFEINE, OPIUM EXTRACTS, PARACETAMOL, CAFFEINE, OPIUM, PREPARED] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016424668&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016424671,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016424671&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016424682,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Feeling cold (n/a - Recovered/Resolved - ),<BR><BR>Muscular weakness (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - ),<BR><BR>Vomiting (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016424682&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016425156,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Angina pectoris (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Blood pressure increased (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Heart rate increased (n/a - Unknown - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016425156&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016425166,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspepsia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Gastrooesophageal reflux disease (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pharyngeal inflammation (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016425166&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016425296,Spontaneous,2023-12-08 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Abdominal pain (2d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (2d - Recovered/Resolved - ),<BR><BR>Injection site erythema (2d - Recovered/Resolved - ),<BR><BR>Nausea (2d - Recovered/Resolved - ),<BR><BR>Pain in extremity (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016425296&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016425869,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016425869&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016426419,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Deafness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Ear discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling cold (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypoacusis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[BECLOMETASONE DIPROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOPERAMIDE, LOPERAMIDE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016426419&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016426420,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016426420&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016426591,Spontaneous,2023-12-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Pericarditis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016426591&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016426594,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Death (n/a - Fatal - Results in Death),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016426594&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016426616,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016426616&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016426663,Spontaneous,2023-12-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Rash (5d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 30ug - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016426663&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016426828,Spontaneous,2023-12-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016426828&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016427107,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Contusion (n/a - Not Recovered/Not Resolved - Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Dermatitis allergic (n/a - Not Recovered/Not Resolved - Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Sensation of foreign body (n/a - Not Recovered/Not Resolved - Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Swelling (n/a - Not Recovered/Not Resolved - Life Threatening, Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ALENDRONATE SODIUM, ALENDRONIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ANASTROZOLE] (C - Hormone receptor positive breast cancer - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - Blood iron decreased - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[QUININE] (C - Muscle spasms - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Anxiety - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016427107&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016427174,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Rash pruritic (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016427174&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016427176,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Asthenia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Guillain-Barre syndrome (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Hypoaesthesia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling)","ABRYSVO [RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP A, STABILIZED PREFUSION F PROTEIN 847A, RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP B, STABILIZED PREFUSION F PROTEIN 847B] (S - Immunisation - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])","[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METOPROLOL TARTRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[NIFEDIPINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VALSARTAN, HYDROCHLOROTHIAZIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016427176&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016427187,Spontaneous,2023-12-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Blood pressure systolic increased (n/a - Unknown - Life Threatening),<BR><BR>Cardiac failure (n/a - Unknown - Life Threatening),<BR><BR>Hypoxia (n/a - Unknown - Life Threatening),<BR><BR>Myocardial injury (n/a - Unknown - Life Threatening),<BR><BR>Oedema peripheral (n/a - Unknown - Life Threatening),<BR><BR>Presyncope (n/a - Unknown - Life Threatening),<BR><BR>Pulmonary embolism (n/a - Recovering/Resolving - Life Threatening),<BR><BR>Pulmonary infarction (n/a - Unknown - Life Threatening)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"AZOPT [BRINZOLAMIDE] (C - Glaucoma - n/a - [n/a - n/a - n/a]),<BR><BR>DAPAGLIFLOZIN [DAPAGLIFLOZIN] (C - Diabetes mellitus - n/a - [n/a - 10mg - n/a]),<BR><BR>LATANOPROST [LATANOPROST] (C - Glaucoma - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Diabetes mellitus - n/a - [n/a - 2g - n/a]),<BR><BR>[TIMOLOL, TIMOLOL MALEATE] (C - Glaucoma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016427187&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016427189,Spontaneous,2023-12-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Bell's palsy (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016427189&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016427279,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016427279&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016427341,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016427341&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016427342,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016427342&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016427343,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016427343&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016427401,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Asthenia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),"[FLUTICASONE PROPIONATE, SALMETEROL, FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016427401&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016427461,Spontaneous,2023-12-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Hypertension (17d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016427461&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016427476,Spontaneous,2023-12-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Rash (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016427476&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016427520,Spontaneous,2023-12-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Seizure (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - .3mL - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021] (S - Influenza immunisation - Drug withdrawn - [1d - .7mL - Intramuscular use])",[HALOPERIDOL] (C - Dementia - Drug withdrawn - [n/a - 5[drp] - Oral use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016427520&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016427522,Spontaneous,2023-12-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Vascular purpura (7d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>[A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224)] (S - Influenza immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016427522&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016427890,Spontaneous,2023-12-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - ),<BR><BR>Tachycardia (10min - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[HYDROCHLOROTHIAZIDE] (C - Cardiac failure congestive - n/a - [n/a - n/a - Oral use]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[METOPROLOL, METOPROLOL TARTRATE] (C - Cardiac failure congestive - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016427890&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016427939,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016427939&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016428177,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016428177&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016428247,Spontaneous,2023-12-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016428247&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016428414,Spontaneous,2023-12-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Scrotal pain (n/a - Recovering/Resolving - ),<BR><BR>Scrotal swelling (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016428414&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016428415,Spontaneous,2023-12-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Tachycardia (n/a - Unknown - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016428415&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016428619,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016428619&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016428620,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016428620&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016428956,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Alopecia (n/a - Unknown - ),<BR><BR>Rash (n/a - Unknown - ),<BR><BR>Rash macular (n/a - Unknown - ),<BR><BR>Skin cancer (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - ),<BR><BR>Weight decreased (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016428956&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016429915,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Wound (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016429915&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016429919,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Hallucination (0d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Insomnia (0d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","[ENALAPRIL, ENALAPRIL MALEATE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016429919&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016429940,Spontaneous,2023-12-08 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chest pain (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Myocarditis (n/a - Unknown - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"HYDROCORTISONE [HYDROCORTISONE, HYDROCORTISONE SODIUM SUCCINATE] (C - Addison's disease - n/a - [91d - n/a - Oral use]),<BR><BR>XELJANZ [TOFACITINIB, TOFACITINIB CITRATE] (C - Arthritis - n/a - [n/a - n/a - Oral use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[ENALAPRIL MALEATE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[HYDROCORTISONE] (C - Addison's disease - n/a - [n/a - n/a - Oral use]),<BR><BR>[HYDROXYCHLOROQUINE SULFATE] (C - Systemic lupus erythematosus - n/a - [n/a - n/a - Oral use]),<BR><BR>[TRAMADOL HYDROCHLORIDE] (C - Pain - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016429940&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016430052,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Condition aggravated (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gait inability (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),METHOTREXATE [METHOTREXATE] (C - n/a - n/a - [n/a - 20mg - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016430052&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016430062,Spontaneous,2023-12-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Urticaria papular (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016430062&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016430290,Spontaneous,2023-12-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myocardial infarction (3d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"BRINZOLAMIDE [BRINZOLAMIDE] (C - n/a - n/a - [n/a - 1[drp] - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUCLOXACILLIN, FLUCLOXACILLIN SODIUM, FLUCLOXACILLIN SODIUM MONOHYDRATE] (C - n/a - n/a - [n/a - 500mg - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - 30mg - n/a]),<BR><BR>[TIMOLOL, BIMATOPROST] (C - n/a - n/a - [n/a - 1[drp] - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016430290&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016430292,Spontaneous,2023-12-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Interstitial lung disease (21d - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - ),<BR><BR>Pulmonary fibrosis (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary toxicity (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Respiratory failure (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"CELECOXIB [CELECOXIB] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>PREGABALIN [PREGABALIN] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[BENIDIPINE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[MAGNESIUM OXIDE] (C - Constipation - n/a - [n/a - n/a - Oral use]),<BR><BR>[REBAMIPIDE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[ZOLPIDEM TARTRATE] (C - Insomnia - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016430292&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016430294,Spontaneous,2023-12-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Blood creatine phosphokinase increased (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016430294&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016430362,Spontaneous,2023-12-08 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,Hypertension (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016430362&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016414639,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Aphasia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Balance disorder (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Cognitive disorder (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Embolic stroke (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Visual impairment (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016414639&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016414675,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Disorientation (1d - Recovered/Resolved With Sequelae - ),<BR><BR>Headache (1d - Recovered/Resolved With Sequelae - ),<BR><BR>Hot flush (1d - Recovered/Resolved With Sequelae - ),<BR><BR>Hypertension (1d - Recovered/Resolved With Sequelae - ),<BR><BR>Muscle spasms (1d - Recovered/Resolved With Sequelae - ),<BR><BR>Pyrexia (1d - Recovered/Resolved With Sequelae - ),<BR><BR>Tachycardia (1d - Recovered/Resolved With Sequelae - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),[SULFASALAZINE] (C - n/a - n/a - [n/a - 500mg - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016414675&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016415061,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Allergy to vaccine (n/a - Unknown - ),<BR><BR>Asthenia (n/a - Recovered/Resolved - ),<BR><BR>Back pain (n/a - Recovered/Resolved - ),<BR><BR>Balance disorder (n/a - Recovered/Resolved - ),<BR><BR>Body temperature increased (n/a - Recovered/Resolved - ),<BR><BR>Bone pain (n/a - Recovered/Resolved - ),<BR><BR>Chills (n/a - Recovered/Resolved - ),<BR><BR>Cough (n/a - Recovered/Resolved - ),<BR><BR>Eye pain (n/a - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovered/Resolved - ),<BR><BR>Fine motor skill dysfunction (n/a - Recovered/Resolved - ),<BR><BR>Limb injury (n/a - Recovered/Resolved - ),<BR><BR>Pain (n/a - Recovered/Resolved - ),<BR><BR>Parosmia (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - ),<BR><BR>Swelling face (n/a - Recovered/Resolved - ),<BR><BR>Taste disorder (n/a - Recovered/Resolved - ),<BR><BR>Visual field defect (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016415061&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016415477,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Blister (5d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Disease recurrence (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Urinary tract infection (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - Asthenia - Not applicable - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Immunisation - Not applicable - [1d - n/a - n/a])","[ALENDRONATE SODIUM, ALENDRONIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DOCUSATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VITAMIN D, CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016415477&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016415756,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Product administered at inappropriate site (n/a - Unknown - Other Medically Important Condition),<BR><BR>Shoulder injury related to vaccine administration (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016415756&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016415799,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Death (n/a - Fatal - Results in Death, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016415799&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016415942,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"HUMIRA [ADALIMUMAB] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALPHATOCOPHEROL ACETATE, LUTEIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METOPROLOL TARTRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016415942&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016415982,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016415982&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016416149,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Hypoaesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nerve compression (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016416149&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016416232,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Ketoacidosis (n/a - Unknown - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - Unknown - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.1 [ELASOMERAN, IMELASOMERAN] (S - COVID-19 prophylaxis - Unknown - [1d - 1{DF} - n/a]),<BR><BR>VAXZEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Unknown - [1d - n/a - Intramuscular use]),<BR><BR>VAXZEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - n/a - Unknown - [1d - 1{DF} - Intramuscular use])","DULOXETINE [DULOXETINE, DULOXETINE HYDROCHLORIDE] (C - Major depression - n/a - [n/a - n/a - n/a]),<BR><BR>NOVORAPID [INSULIN ASPART] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>TRESIBA [INSULIN DEGLUDEC] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>TRIMBOW [BECLOMETASONE DIPROPIONATE, GLYCOPYRRONIUM BROMIDE, FORMOTEROL FUMARATE DIHYDRATE] (C - Chronic obstructive pulmonary disease - n/a - [n/a - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - Gout - n/a - [n/a - n/a - n/a]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Diabetic neuropathy - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood cholesterol - n/a - [n/a - n/a - n/a]),<BR><BR>[BUPRENORPHINE] (C - Neuralgia - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Diabetic neuropathy - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Blood pressure measurement - n/a - [n/a - n/a - n/a]),<BR><BR>[NIFEDIPINE] (C - Raynaud's phenomenon - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Chronic obstructive pulmonary disease - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016416232&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016416434,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Maternal exposure during pregnancy (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016416434&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016416518,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Adverse reaction (n/a - Unknown - ),<BR><BR>Angina pectoris (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Bell's palsy (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dysgeusia (n/a - Unknown - ),<BR><BR>Eye pain (n/a - Unknown - ),<BR><BR>Facial asymmetry (n/a - Unknown - ),<BR><BR>Facial paresis (n/a - Unknown - ),<BR><BR>Glossodynia (n/a - Unknown - ),<BR><BR>Hypogeusia (n/a - Unknown - ),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia oral (n/a - Unknown - ),<BR><BR>Taste disorder (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - n/a])","ADVAGRAF 3 MG PROLONGED-RELEASE HARD CAPSULES [TACROLIMUS] (C - Immunosuppressant drug therapy - n/a - [n/a - 3.5mg - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Ischaemic heart disease prophylaxis - n/a - [n/a - 75mg - n/a]),<BR><BR>[DRIED FERROUS SULFATE, FERROUS SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM TRIHYDRATE] (C - Gastric ulcer - n/a - [n/a - 40mg - n/a]),<BR><BR>[ISOSORBIDE 5 MONONITRATE, ISOSORBIDE MONONITRATE] (C - Ischaemic heart disease prophylaxis - n/a - [n/a - 30mg - n/a]),<BR><BR>[METOPROLOL, METOPROLOL TARTRATE] (C - Ischaemic heart disease prophylaxis - n/a - [n/a - 50mg - n/a]),<BR><BR>[MYCOPHENOLIC ACID] (C - Immunosuppressant drug therapy - n/a - [n/a - 350mg - n/a]),<BR><BR>[PRAVASTATIN SODIUM] (C - Ischaemic heart disease prophylaxis - n/a - [n/a - 40mg - n/a]),<BR><BR>[PREDNISOLONE] (C - Immunosuppressant drug therapy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016416518&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016416692,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Arthritis (n/a - Unknown - ),<BR><BR>Chills (2d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovered/Resolved - ),<BR><BR>Headache (2d - Recovered/Resolved - ),<BR><BR>Hyperhidrosis (2d - Recovered/Resolved - ),<BR><BR>Inflammation (n/a - Unknown - ),<BR><BR>Pain (2d - Recovered/Resolved - ),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (1wk - Recovered/Resolved - ),<BR><BR>Sensory disturbance (n/a - Unknown - ),<BR><BR>Swelling (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),"IRON [IRON] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ASCORBIC ACID, MAGNESIUM OXIDE, HEAVY, MAGNESIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE, BUDESONIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SENNOSIDE B, SENNOSIDES] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SUMATRIPTAN SUCCINATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016416692&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016416699,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blood pressure decreased (1d - Recovered/Resolved - ),<BR><BR>Feeling abnormal (n/a - Unknown - ),<BR><BR>Neuropathy peripheral (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016416699&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016416757,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Asthenia (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Chest pain (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Muscle strain (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Myocardial infarction (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"PLAVIX [CLOPIDOGREL, CLOPIDOGREL HYDROGEN SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE BESILATE, BENAZEPRIL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METOPROLOL, METOPROLOL TARTRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016416757&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016416778,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"C-reactive protein increased (n/a - Unknown - ),<BR><BR>Dysphonia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Feeling abnormal (n/a - Unknown - ),<BR><BR>Herpes zoster (n/a - Unknown - ),<BR><BR>Hypotension (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Memory impairment (n/a - Unknown - ),<BR><BR>Pain (n/a - Unknown - ),<BR><BR>Pruritus (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Rash (n/a - Unknown - ),<BR><BR>Sleep disorder due to a general medical condition (n/a - Unknown - ),<BR><BR>Speech disorder (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Syncope (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Urticaria (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"[CARVEDILOL] (C - n/a - n/a - [n/a - 12.5mg - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Hypertension - n/a - [n/a - 5mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016416778&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016417142,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,"Pruritus (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Rash (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Rash macular (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016417142&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016417171,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Male,Injection site pruritus (5h - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),"PLAVIX [CLOPIDOGREL, CLOPIDOGREL HYDROGEN SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN, EZETIMIBE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL FUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[WARFARIN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016417171&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016417383,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Atrial fibrillation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Back pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Depressed mood (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - n/a - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016417383&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016417581,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Guttate psoriasis (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PANTOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016417581&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016417582,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Pericarditis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016417582&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016417583,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Thrombosis (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016417583&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016417770,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Feeling hot (0d - Recovered/Resolved - ),<BR><BR>Headache (0d - Recovered/Resolved - ),<BR><BR>Injection site pain (0d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{asnecessary} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016417770&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418038,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cardiac arrest (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Chest discomfort (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary embolism (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),"ESOMEPRAZOLE [ESOMEPRAZOLE] (C - n/a - n/a - [n/a - 40mg - n/a]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID, ACETYLSALICYLIC ACID PH. EUR.] (C - n/a - n/a - [n/a - 75mg - n/a]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - n/a - n/a - [n/a - 10mg - n/a]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - 10mg - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - 1g - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - n/a - n/a - [n/a - 40mg - n/a]),<BR><BR>[SODIUM VALPROATE, VALPROIC ACID, SODIUM VALPROATE] (C - n/a - n/a - [n/a - 1000mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418038&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418047,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Heavy menstrual bleeding (n/a - Recovering/Resolving - ),<BR><BR>Polymenorrhoea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418047&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418049,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Vestibular neuronitis (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418049&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418052,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418052&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418055,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Dyspnoea (4h - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Rhinorrhoea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418055&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418061,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Diarrhoea (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418061&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418063,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Myalgia (1d - Recovered/Resolved - ),<BR><BR>Thrombophlebitis (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418063&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418069,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Angioedema (1h - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418069&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418070,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Chest pain (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418070&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418074,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Abdominal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Asthma (n/a - Not Recovered/Not Resolved - ),<BR><BR>Body temperature increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Haemorrhage (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Rhinorrhoea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),[SALBUTAMOL] (C - n/a - n/a - [n/a - 400ug - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418074&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418075,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Herpes zoster (n/a - Recovering/Resolving - ),<BR><BR>Swollen tongue (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418075&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418121,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418121&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418214,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenopia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN, A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN, B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1) V REASS. X - 179 A, A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/NANCHANG 933/95 (H3N2), A/BAYERN/7/95 (H1N1) - LIKE STRAIN (A/JOHANNESBURG/82/96), B/BEIJING/184/93-LIKE STRAIN (B/HARBIN/7/94), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/CALIFORNIA/7/2004 (H3N2) - LIKE STRAIN (A/NEW YORK/55/2004 REASS. NYMC X-157), B/SHANGHAI/361/2002 - LIKE STRAIN (B/JIANGSU/10/2003), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/MOSCOW/10/99 (H3N2) - LIKE STRAIN (A/PANAMA/2007/99 REASS. RESVIR-17), B/SICHUAN/379/99-LIKE STRAIN (B/JOHANNESBURG/5/99), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), A/CALIFORNIA/7/2009 (H1N1)-DERIVED STRAIN USED NYMC X-181, B/BRISBANE/60/2008, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1)V-LIKE VIRUS, A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H1N1), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H3N2), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418214&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418375,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Abdominal pain (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>General physical health deterioration (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Hypotension (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Multiple organ dysfunction syndrome (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Oliguria (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Pancytopenia (n/a - Fatal - Results in Death, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418375&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418446,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Lichen planus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"RELVAR ELLIPTA [FLUTICASONE FUROATE, VILANTEROL] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Anxiety - n/a - [n/a - 10mg - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418446&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418447,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Decreased appetite (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Paranoia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[ALPRAZOLAM] (C - Anxiety - n/a - [n/a - 1mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418447&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418448,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Eye inflammation (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Blood pressure increased - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM TRIHYDRATE] (C - Blood pressure increased - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418448&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418478,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418478&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418479,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418479&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418521,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Myocarditis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"DAPAGLIFLOZIN [DAPAGLIFLOZIN] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>DULOXETINE [DULOXETINE, DULOXETINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>IVABRADINE [IVABRADINE, IVABRADINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>OXYBUTYNIN [OXYBUTYNIN, OXYBUTYNIN HYDROCHLORIDE] (C - Hyperhidrosis - n/a - [n/a - 4{DF} - n/a]),<BR><BR>PRAMIPEXOLE [PRAMIPEXOLE, PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>SPIRONOLACTONE [SPIRONOLACTONE] (C - n/a - n/a - [1020d - .5{DF} - n/a]),<BR><BR>TADALAFIL [TADALAFIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>TRULICITY [DULAGLUTIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALUMINIUM CHLORIDE HEXAHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[BENZALKONIUM CHLORIDE, CHLORHEXIDINE DIHYDROCHLORIDE, ISOPROPYL MYRISTATE, LIQUID PARAFFIN, BENZALKONIUM CHLORIDE, ISOPROPYL MYRISTATE, LIQUID PARAFFIN, NEOMYCIN SULFATE, PREDNISOLONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BETAMETHASONE VALERATE] (C - n/a - n/a - [2wk - 1{DF} - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[CLOBETASOL PROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CODEINE PHOSPHATE BP, PARACETAMOL PH. EUR., PARACETAMOL BP, CODEINE PHOSPHATE BP, PARACETAMOL DC, PARACETAMOL PH. EUR., CODEINE PHOSPHATE PH.EUR., PARACETAMOL PH. EUR., CODEINE PHOSPHATE PH.EUR., PARACETAMOL, CODEINE PHOSPHATE, PARACETAMOL, CODEINE PHOSPHATE BP, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLCHICINE] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[DIAZEPAM] (C - Poor quality sleep - n/a - [n/a - 3{DF} - n/a]),<BR><BR>[EZETIMIBE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[FAMOTIDINE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[GLICLAZIDE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[GLYCERYL TRINITRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ISOPROPYL MYRISTATE, LIQUID PARAFFIN, LIQUID PARAFFIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LIQUID PARAFFIN, PARAFFIN, LIGHT LIQUID, PARAFFIN, LIGHT LIQUID, PARAFFIN WHITE SOFT] (C - Dry skin - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[LOPERAMIDE, LOPERAMIDE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MEBEVERINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 3{DF} - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Diabetes mellitus - n/a - [n/a - 4{DF} - n/a]),<BR><BR>[NAPROXEN, NAPROXEN SODIUM] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[NYSTATIN, HYDROCORTISONE, NYSTATIN, HYDROCORTISONE, BENZALKONIUM CHLORIDE SOLUTION, DIMETHICONE 350] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [1232d - 1{DF} - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[PEPPERMINT OIL] (C - n/a - n/a - [n/a - 3{DF} - n/a]),<BR><BR>[POTASSIUM HYDROGEN CARBONATE, SODIUM ALGINATE] (C - n/a - n/a - [n/a - 3{DF} - n/a]),<BR><BR>[QUETIAPINE, QUETIAPINE FUMARATE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[ROPINIROLE] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TAMSULOSIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - Pain - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[UREA] (C - n/a - n/a - [n/a - n/a - n/a])...","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418521&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418522,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418522&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418544,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418544&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418545,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (6d - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypersomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418545&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418546,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,Hypertension (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418546&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418584,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,Transient ischaemic attack (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418584&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418668,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site pruritus (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (6h - Recovered/Resolved - ),<BR><BR>Pyrexia (12h - Recovered/Resolved - ),<BR><BR>Vomiting (6h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418668&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418676,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Anaphylactic reaction (1d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 30ug - Intramuscular use]),"[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - 6{DF} - Inhalation use]),<BR><BR>[DESOGESTREL] (C - n/a - n/a - [n/a - 75ug - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 360mg - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - n/a - n/a - [n/a - 10mg - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - 20mg - n/a]),<BR><BR>[PREDNISOLONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - 1.25mg - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - Inhalation use]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 100mg - n/a - More in ICSR]),<BR><BR>[SODIUM CROMOGLICATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TIOTROPIUM, TIOTROPIUM BROMIDE, TIOTROPIUM BROMIDE MONOHYDRATE] (C - n/a - n/a - [n/a - 2.5mg - Inhalation use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418676&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418845,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418845&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418846,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Somnolence (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"APIXABAN [APIXABAN] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>PAXLOVID [NIRMATRELVIR, RITONAVIR, RITONAVIR, NIRMATRELVIR] (C - COVID-19 - n/a - [4d - n/a - n/a]),<BR><BR>SPIRONOLACTONE [SPIRONOLACTONE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[CODEINE PHOSPHATE BP, PARACETAMOL PH. EUR., PARACETAMOL BP, CODEINE PHOSPHATE BP, PARACETAMOL DC, PARACETAMOL PH. EUR., CODEINE PHOSPHATE PH.EUR., PARACETAMOL PH. EUR., CODEINE PHOSPHATE PH.EUR., PARACETAMOL, CODEINE PHOSPHATE, PARACETAMOL, CODEINE PHOSPHATE BP, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE] (C - Polyarthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[DIGOXIN] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[SOTALOL, SOTALOL HYDROCHLORIDE] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418846&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418890,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418890&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418942,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Illness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Migraine with aura (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418942&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016418944,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Angioedema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Disease recurrence (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Ill-defined disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[CHLORPHENAMINE] (C - Ill-defined disorder - n/a - [11d - n/a - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - Ill-defined disorder - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016418944&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016419004,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,"Autoimmune haemolytic anaemia (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016419004&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016419031,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Menstruation delayed (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016419031&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016419161,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cataract (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Intraocular pressure increased (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vision blurred (10min - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),LATANOPROST [LATANOPROST] (C - Angle closure glaucoma - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016419161&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016419214,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphadenitis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Cardiac failure acute - n/a - [n/a - n/a - n/a]),<BR><BR>[DIGOXIN] (C - Cardiac failure acute - n/a - [n/a - n/a - n/a]),<BR><BR>[PERINDOPRIL, PERINDOPRIL TERT-BUTYLAMINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016419214&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016419290,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Ear infection (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Localised infection (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016419290&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016419326,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Mouth ulceration (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016419326&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016419342,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Dizziness (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016419342&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016419491,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016419491&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016419506,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"COAPROVEL [HYDROCHLOROTHIAZIDE, IRBESARTAN] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID, D,L-LYSINE ACETYLSALICYLATE] (C - Cardiovascular symptom - n/a - [n/a - n/a - n/a]),<BR><BR>[INSULIN, INSULIN HUMAN] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016419506&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016419557,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Vaccination site haematoma (n/a - Not Recovered/Not Resolved - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>XARELTO [RIVAROXABAN] (S - Product used for unknown indication - Not applicable - [n/a - 1{DF} - Oral use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016419557&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016419575,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Female,Immunisation reaction (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016419575&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016419625,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Cough (n/a - Unknown - ),<BR><BR>Dyshidrotic eczema (n/a - Unknown - ),<BR><BR>Rash (n/a - Unknown - ),<BR><BR>Thermal burn (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016419625&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016419798,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Fall (n/a - Unknown - Other Medically Important Condition),<BR><BR>Head injury (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypertension (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - n/a - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016419798&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016419891,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016419891&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016419986,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016419986&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016420016,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Application site pain (n/a - Recovered/Resolved - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016420016&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016420020,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Vomiting (n/a - Unknown - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016420020&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016420111,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Condition aggravated (n/a - Not Recovered/Not Resolved - ),<BR><BR>Guttate psoriasis (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[CETOMACROGOL 1000] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016420111&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016420112,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Syncope (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016420112&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016420114,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Migraine (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016420114&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016420119,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site rash (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016420119&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016420121,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Body temperature increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOVORAPID FLEXPEN 100 U/ML SOLUTION FOR INJECTION IN PRE-FILLED PEN [INSULIN ASPART] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016420121&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016420122,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016420122&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016420123,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arrhythmia (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016420123&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016420160,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016420160&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016420206,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016420206&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016420215,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016420215&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016420603,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Aphonia (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Mutism (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Productive cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016420603&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016420646,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Female,Herpes zoster (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016420646&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016420649,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pulmonary pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016420649&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016420712,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016420712&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016420771,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Hallucination, visual (2s - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016420771&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016421024,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Limb mass (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pharyngeal mass (n/a - Not Recovered/Not Resolved - ),<BR><BR>Thyroid mass (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Blood glucose abnormal - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016421024&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016421253,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016421253&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016421452,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Angina pectoris (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gastrooesophageal reflux disease (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"RANOLAZINE [RANOLAZINE] (C - Heart rate abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Heart rate abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Heart rate abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[CARBIMAZOLE] (C - Hyperthyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - Cardiac disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[GLYCERYL TRINITRATE] (C - Angina pectoris - n/a - [n/a - n/a - n/a]),<BR><BR>[ISOSORBIDE] (C - Heart rate abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Abdominal discomfort - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Heart rate abnormal - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016421452&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016421461,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Lower respiratory tract infection (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Mobility decreased (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pneumonia (n/a - Unknown - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016421461&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016421739,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Hypertension (n/a - Unknown - ),<BR><BR>Lacunar stroke (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"[CODEINE PHOSPHATE BP, PARACETAMOL PH. EUR., PARACETAMOL BP, CODEINE PHOSPHATE BP, PARACETAMOL DC, PARACETAMOL PH. EUR., CODEINE PHOSPHATE PH.EUR., PARACETAMOL PH. EUR., CODEINE PHOSPHATE PH.EUR., PARACETAMOL, CODEINE PHOSPHATE, PARACETAMOL, CODEINE PHOSPHATE BP, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE] (C - Osteoarthritis - n/a - [n/a - n/a - Oral use]),<BR><BR>[INFLUENZA QUADRIVALENT VACCINE (RDNA)] (C - Influenza immunisation - n/a - [1d - n/a - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016421739&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016421819,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Incorrect dose administered (n/a - Unknown - ),<BR><BR>Mobility decreased (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pneumonia (n/a - Unknown - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016421819&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016421957,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Back pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Breast pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Breast tenderness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chondritis (n/a - Unknown - ),<BR><BR>Costochondritis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Discomfort (n/a - Unknown - ),<BR><BR>Gastritis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Herpes zoster (n/a - Not Recovered/Not Resolved - ),<BR><BR>Sleep disorder due to a general medical condition (n/a - Recovered/Resolved - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"KETOCONAZOLE [KETOCONAZOLE] (C - n/a - n/a - [n/a - n/a - Topical]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - 81mg - Oral use]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - n/a - n/a - [n/a - 800mg - Oral use]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - 10mg - Oral use]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - 10mg - Oral use]),<BR><BR>[CICLOPIROX] (C - n/a - n/a - [n/a - n/a - Topical]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - 2000[iU] - Oral use]),<BR><BR>[DOCUSATE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FISH OIL] (C - n/a - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[HYDROCHLOROTHIAZIDE] (C - n/a - n/a - [n/a - 25mg - Oral use]),<BR><BR>[ISPAGHULA, ISPAGHULA HUSK, PSYLLIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - 88ug - Oral use]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - 25mg - Oral use]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[NAPROXEN, NAPROXEN SODIUM] (C - n/a - n/a - [n/a - 750mg - Oral use]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - 40mg - Oral use]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[POVIDONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[THIAMINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ZINC SULPHATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016421957&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016422254,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Hypoxia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016422254&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016422323,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Vaccination site dysaesthesia (n/a - Unknown - ),<BR><BR>Vaccination site pain (n/a - Unknown - ),<BR><BR>Vaccination site pruritus (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>[ELASOMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016422323&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016422325,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Malaise (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),"COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016422325&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016422326,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Malaise (n/a - Unknown - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>VAXZEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016422326&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016422327,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chest discomfort (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>[ELASOMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016422327&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016422333,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Ischaemic stroke (3d - Recovered/Resolved - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),[OLMESARTAN MEDOXOMIL] (C - Hypertension - Dose not changed - [n/a - n/a - Oral use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016422333&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016422344,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Lymphadenopathy (5d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016422344&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016422346,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Fatigue (n/a - Unknown - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016422346&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016422350,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Diarrhoea (n/a - Unknown - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUCELVAX TETRA [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])",COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016422350&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016422353,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Malaise (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUCELVAX TETRA [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>[ELASOMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016422353&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016422355,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Cough (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016422355&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016422361,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Fatigue (n/a - Unknown - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUCELVAX TETRA [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","VAXZEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>[ELASOMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016422361&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016422371,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Pruritus (24d - Recovered/Resolved - ),<BR><BR>Urticaria (14d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),<BR><BR>FLUAD TETRA SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - n/a - Drug withdrawn - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016422371&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016422374,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dizziness (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Vomiting (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),"COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016422374&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016422376,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Malaise (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUCELVAX TETRA [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>[ELASOMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016422376&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016422386,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Myalgia (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUCELVAX TETRA [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016422386&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016422390,Spontaneous,2023-12-07 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Influenza like illness (n/a - Unknown - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>VAXZEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>[ELASOMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016422390&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016422391,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Rash (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016422391&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016422708,Spontaneous,2023-12-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016422708&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016406243,Spontaneous,2023-12-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Binocular visual dysfunction (n/a - Not Recovered/Not Resolved - ),<BR><BR>Blood pressure increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dysphemia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Immunisation reaction (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - .5mL - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - n/a - n/a - [n/a - .5mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016406243&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016406289,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Asthenia (n/a - Unknown - ),<BR><BR>Pain (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - ),<BR><BR>Respiratory symptom (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016406289&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016406300,Spontaneous,2023-12-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Pain in extremity (2d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mg - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016406300&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016406444,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 30ug - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016406444&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016406959,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Deafness (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Influenza (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Peripheral sensory neuropathy (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Tinnitus (n/a - Unknown - Disabling, Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016406959&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016407720,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (1d - Recovered/Resolved - ),<BR><BR>Injection site haematoma (n/a - Not Recovered/Not Resolved - ),<BR><BR>Maternal exposure during pregnancy (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016407720&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016408091,Spontaneous,2023-12-06 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Vaccination site cellulitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016408091&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016408119,Spontaneous,2023-12-06 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Hypertension (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - Not applicable - [1d - n/a - n/a])","[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE DIHYDRATE, BECLOMETASONE DIPROPIONATE ANHYDROUS] (C - Asthma - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016408119&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016408157,Spontaneous,2023-12-06 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Chest pain (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[DOXEPIN, DOXEPIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MELPERONE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016408157&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016408216,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"REPATHA [EVOLOCUMAB] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATENOLOL, ATENOLOL BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CLONAZEPAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ZOLPIDEM, ZOLPIDEM TARTRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016408216&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016408227,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>TOZINAMERAN [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016408227&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016408238,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>TOZINAMERAN, FAMTOZINAMERAN [TOZINAMERAN, FAMTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016408238&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016408309,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Chronic obstructive pulmonary disease (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[WARFARIN, WARFARIN SODIUM] (C - Heart valve stenosis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016408309&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016408568,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Musculoskeletal disorder (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - 150ug - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016408568&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016408650,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (366d - Recovered/Resolved - Disabling),<BR><BR>Fatigue (366d - Recovered/Resolved - Disabling),<BR><BR>Feeling abnormal (366d - Recovered/Resolved - Disabling),<BR><BR>Feeling cold (366d - Recovered/Resolved - Disabling),<BR><BR>Headache (366d - Recovered/Resolved - Disabling),<BR><BR>Injection site pain (366d - Recovered/Resolved - Disabling),<BR><BR>Malaise (1d - Recovered/Resolved - Disabling),<BR><BR>Myalgia (366d - Recovered/Resolved - Disabling),<BR><BR>Nausea (366d - Recovered/Resolved - Disabling),<BR><BR>Pyrexia (366d - Recovered/Resolved - Disabling),<BR><BR>Retching (366d - Recovered/Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016408650&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016408656,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Psoriasis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash erythematous (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash papular (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash pruritic (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site rash (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ASCORBIC ACID, CALCIUM GLUBIONATE, CALCIUM CARBONATE, CALCIUM, CALCIUM GLUBIONATE, CALCIUM CARBONATE, COLECALCIFEROL, CALCIUM] (C - Osteoporosis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016408656&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016409359,Spontaneous,2023-12-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,"Hypertension (22d - Recovered/Resolved - ),<BR><BR>Tremor (22d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016409359&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016409573,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Muscle spasms (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Neuralgia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016409573&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016409576,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Disturbance in attention (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Feeling cold (n/a - Not Recovered/Not Resolved - ),<BR><BR>Memory impairment (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016409576&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016409634,Spontaneous,2023-12-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Injection site pain (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016409634&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016409650,Spontaneous,2023-12-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chest pain (n/a - Recovered/Resolved - ),<BR><BR>Cough (n/a - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016409650&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016409690,Spontaneous,2023-12-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Chest pain (n/a - Recovered/Resolved - ),<BR><BR>Cough (n/a - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016409690&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016410412,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Asthenia (n/a - Unknown - ),<BR><BR>Interchange of vaccine products (n/a - Unknown - Disabling),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016410412&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016410420,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Deafness (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016410420&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016410429,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016410429&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016410454,Spontaneous,2023-12-06 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Rash (1d - Recovered/Resolved - ),<BR><BR>Tonsillar disorder (2h - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),"[VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016410454&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016410597,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Ophthalmic herpes zoster (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash vesicular (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 2{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016410597&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016410804,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,3-11 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Joint range of motion decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016410804&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016410941,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,"Multiple organ dysfunction syndrome (n/a - Fatal - Results in Death),<BR><BR>Septic shock (n/a - Fatal - Results in Death)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),"[AMLODIPINE, AMLODIPINE BESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VALSARTAN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016410941&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016410957,Spontaneous,2023-12-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Deep vein thrombosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016410957&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411100,Spontaneous,2023-12-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Aphonia (n/a - Recovering/Resolving - ),<BR><BR>Influenza like illness (n/a - Recovering/Resolving - ),<BR><BR>Productive cough (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411100&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411526,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Ophthalmic migraine (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411526&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411534,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Extensive swelling of vaccinated limb (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411534&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411539,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Facial discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Paraesthesia oral (n/a - Not Recovered/Not Resolved - ),<BR><BR>Swelling face (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411539&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411545,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arthralgia (3d - Recovered/Resolved - ),<BR><BR>Eye pain (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (3s - Recovered/Resolved - ),<BR><BR>Malaise (7d - Recovered/Resolved - ),<BR><BR>Myalgia (3d - Recovered/Resolved - ),<BR><BR>Tachycardia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411545&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411547,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Elderly,No,Female,Back pain (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411547&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411548,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Migraine (n/a - Recovering/Resolving - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411548&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411549,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Elderly,No,Male,Atrial fibrillation (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"APIXABAN 5MG TABLET  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411549&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411551,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Abdominal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411551&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411563,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (18h - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (48h - Recovered/Resolved - ),<BR><BR>Hyposmia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injected limb mobility decreased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Memory impairment (n/a - Recovering/Resolving - ),<BR><BR>Movement disorder (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (30h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411563&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411565,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (1d - Recovered/Resolved - ),<BR><BR>Chills (5h - Recovered/Resolved - ),<BR><BR>Headache (2d - Recovered/Resolved - ),<BR><BR>Malaise (1d - Recovered/Resolved - ),<BR><BR>Myalgia (1d - Recovered/Resolved - ),<BR><BR>Nausea (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - ),<BR><BR>Syncope (15min - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411565&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411571,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Eyelid oedema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lip oedema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411571&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411575,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Elderly,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chest pain (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Eye swelling (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Photophobia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>PANTOPRAZOLE 20 MG - GASTRO-RESISTANT TABLET  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE, ESTRADIOL, MICRONIZED] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411575&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411576,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Abdominal pain (2wk - Recovered/Resolved - ),<BR><BR>Appetite disorder (2wk - Recovered/Resolved - ),<BR><BR>Nausea (2wk - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411576&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411580,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Cough (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Vertigo (1h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411580&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411588,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Palpitations (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411588&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411590,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (5d - Recovered/Resolved - ),<BR><BR>Fatigue (14d - Recovered/Resolved - ),<BR><BR>Headache (14d - Recovered/Resolved - ),<BR><BR>Malaise (14d - Recovered/Resolved - ),<BR><BR>Myalgia (14d - Recovered/Resolved - ),<BR><BR>Nasopharyngitis (14d - Recovered/Resolved - ),<BR><BR>Nausea (14d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411590&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411593,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Syncope (3d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411593&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411596,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"APIXABAN 5MG TABLET  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411596&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411597,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Dizziness (2d - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovered/Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411597&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411598,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Sudden hearing loss (5d - Recovered/Resolved - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411598&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411600,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Elderly,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Body temperature increased (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (2d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411600&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411602,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Condition aggravated (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (7d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (7d - Recovered/Resolved - ),<BR><BR>Injection site pain (7d - Recovered/Resolved - ),<BR><BR>Injection site pruritus (7d - Recovered/Resolved - ),<BR><BR>Injection site swelling (7d - Recovered/Resolved - ),<BR><BR>Injection site warmth (7d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Post-acute COVID-19 syndrome (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TOPIRAMATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411602&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411603,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411603&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411642,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Insomnia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Myalgia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Palpitations (n/a - Unknown - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411642&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411944,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (2wk - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411944&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411945,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Herpes virus infection (n/a - Unknown - ),<BR><BR>Injection site pain (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411945&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411946,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Fatigue (3d - Recovered/Resolved - ),<BR><BR>Headache (3d - Recovered/Resolved - ),<BR><BR>Malaise (3d - Recovered/Resolved - ),<BR><BR>Nausea (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - ),<BR><BR>Tinnitus (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411946&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016411955,Spontaneous,2023-12-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Gastrointestinal disorder (3d - Recovered/Resolved - ),<BR><BR>Influenza like illness (3d - Recovered/Resolved - ),<BR><BR>Injection site pain (3d - Recovered/Resolved - ),<BR><BR>Injection site pruritus (3d - Recovered/Resolved - ),<BR><BR>Irregular breathing (3d - Recovered/Resolved - ),<BR><BR>Palpitations (3d - Recovered/Resolved - )",COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016411955&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016412166,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Chest pain (n/a - Unknown - Disabling),<BR><BR>Decreased appetite (n/a - Unknown - Disabling),<BR><BR>Dyspnoea exertional (n/a - Unknown - Disabling),<BR><BR>Feeling cold (n/a - Unknown - Disabling),<BR><BR>Mobility decreased (n/a - Unknown - Disabling),<BR><BR>Myocarditis (n/a - Unknown - Disabling),<BR><BR>Palpitations (n/a - Unknown - Disabling),<BR><BR>Pericarditis (n/a - Unknown - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016412166&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016412377,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Tooth fracture (n/a - Unknown - ),<BR><BR>Vaccination site pain (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - n/a - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016412377&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016412649,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Cough (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016412649&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016412650,Spontaneous,2023-12-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016412650&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016412658,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Immune system disorder (n/a - Unknown - ),<BR><BR>Musculoskeletal disorder (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016412658&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016412659,Spontaneous,2023-12-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Headache (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[BENDROFLUMETHIAZIDE, POTASSIUM CHLORIDE] (C - Hypertension - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[ENALAPRIL MALEATE] (C - Hypertension - n/a - [n/a - 1mg - Oral use]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone therapy - n/a - [n/a - .5mg - Transdermal use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - 1000mg - Oral use]),<BR><BR>[SODIUM HYDROGEN CARBONATE, CALCIUM CARBONATE, SODIUM ALGINATE] (C - Gastrooesophageal reflux disease - n/a - [n/a - 2{DF} - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016412659&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016412660,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Heavy menstrual bleeding (n/a - Recovering/Resolving - ),<BR><BR>Intermenstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Muscle tightness (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016412660&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016413068,Spontaneous,2023-12-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Heavy menstrual bleeding (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016413068&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016398642,Spontaneous,2023-12-05 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthmatic crisis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Laryngeal oedema (0d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Laryngospasm (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - Unknown - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016398642&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016398738,Spontaneous,2023-12-05 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Malaise (n/a - Unknown - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016398738&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016398744,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016398744&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016398762,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016398762&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016399932,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Facial paralysis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016399932&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016400001,Spontaneous,2023-12-05 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthritis (n/a - Unknown - ),<BR><BR>Hepatitis (30d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (5wk - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [1d - n/a - n/a])",[ATORVASTATIN] (C - Myocardial ischaemia - n/a - [600d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016400001&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016400005,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Arrhythmia (1d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - n/a - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016400005&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016400770,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (0d - Recovered/Resolved - ),<BR><BR>Dizziness (0d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site erythema (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016400770&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016400994,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Amenorrhoea (n/a - Recovered/Resolved With Sequelae - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 3{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016400994&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016401205,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016401205&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016401344,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016401344&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016401522,Spontaneous,2023-12-05 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Pericarditis (n/a - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])...,Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016401522&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016401557,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Bronchitis chronic (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypertension (n/a - Unknown - Other Medically Important Condition),<BR><BR>Injection site erythema (4d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016401557&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016401598,Spontaneous,2023-12-05 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Pericarditis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016401598&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016401663,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"APIXABAN [APIXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016401663&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016402073,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Colitis microscopic (2wk - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016402073&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016402074,Spontaneous,2023-12-05 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Haematemesis (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lower respiratory tract infection (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lymphopenia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pulmonary congestion (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Rales (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016402074&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016402126,Spontaneous,2023-12-05 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Retinal tear (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vitreous haemorrhage (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016402126&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016402203,Spontaneous,2023-12-05 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lip swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Swollen tongue (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"COLESEVELAM HYDROCHLORIDE [COLESEVELAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - 6{DF} - n/a]),<BR><BR>DULOXETINE [DULOXETINE, DULOXETINE HYDROCHLORIDE] (C - n/a - n/a - [7d - 1{DF} - n/a]),<BR><BR>HYDROCORTISONE [HYDROCORTISONE, HYDROCORTISONE SODIUM SUCCINATE] (C - n/a - n/a - [15d - 2{DF} - Topical]),<BR><BR>LINAGLIPTIN [LINAGLIPTIN] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>PREGABALIN [PREGABALIN] (C - Neuralgia - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[CYANOCOBALAMIN] (C - n/a - n/a - [n/a - 3{DF} - n/a]),<BR><BR>[FLUCLOXACILLIN, FLUCLOXACILLIN SODIUM, FLUCLOXACILLIN SODIUM MONOHYDRATE] (C - n/a - n/a - [8d - 4{DF} - n/a]),<BR><BR>[FLUCONAZOLE] (C - n/a - n/a - [163d - 1{DF} - n/a]),<BR><BR>[FLUOXETINE] (C - n/a - n/a - [184d - 2{DF} - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[GLICLAZIDE] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - 2{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016402203&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016402285,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016402285&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016402287,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016402287&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016402318,Spontaneous,2023-12-05 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Acute kidney injury (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Hyponatraemia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Hypotension (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Inflammatory marker increased (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Liver function test abnormal (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vomiting (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),"HYDROXOCOBALAMIN [HYDROXOCOBALAMIN] (C - Pernicious anaemia - n/a - [n/a - 1mg - n/a]),<BR><BR>SILDENAFIL [SILDENAFIL] (C - n/a - n/a - [n/a - 100mg - n/a]),<BR><BR>SITAGLIPTIN [SITAGLIPTIN] (C - n/a - n/a - [n/a - 100mg - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - 20mg - n/a]),<BR><BR>[GABAPENTIN] (C - n/a - n/a - [n/a - 1800mg - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - 15mg - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - 2000mg - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - 1.25mg - n/a]),<BR><BR>[ROPINIROLE] (C - Restless legs syndrome - n/a - [n/a - 1mg - n/a]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - 400ug - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016402318&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016402483,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016402483&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016402675,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016402675&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016402817,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016402817&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016402876,Spontaneous,2023-12-05 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Rash erythematous (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site cellulitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site erythema (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site induration (5d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016402876&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016402916,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016402916&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016403071,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Diarrhoea (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Memory impairment (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016403071&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016403355,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Nausea (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016403355&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016403360,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016403360&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016403364,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site pruritus (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016403364&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016403396,Spontaneous,2023-12-05 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,Yes,Female,Erythema (n/a - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016403396&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016403453,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Nasopharyngitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - n/a - Not applicable - [n/a - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - n/a - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016403453&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016403479,Spontaneous,2023-12-05 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,Myalgia (3d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016403479&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016403614,Spontaneous,2023-12-05 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Dizziness (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016403614&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016403683,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016403683&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016404047,Spontaneous,2023-12-05 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Herpes zoster reactivation (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 6{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016404047&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016404395,Spontaneous,2023-12-05 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"General physical health deterioration (n/a - Unknown - ),<BR><BR>Muscle haemorrhage (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - ),<BR><BR>Pain (n/a - Unknown - ),<BR><BR>Periarthritis (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016404395&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016404931,Spontaneous,2023-12-05 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Dizziness (0d - Recovered/Resolved - ),<BR><BR>Presyncope (0d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016404931&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016404934,Spontaneous,2023-12-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Migraine (5d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016404934&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016405227,Spontaneous,2023-12-05 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016405227&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016405597,Spontaneous,2023-12-05 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,"Leukocytosis (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (5d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227)] (S - Influenza immunisation - Not applicable - [1d - .5mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016405597&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016405599,Spontaneous,2023-12-05 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),"COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>[ELASOMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016405599&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016405603,Spontaneous,2023-12-05 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Cough (n/a - Unknown - ),<BR><BR>Increased viscosity of upper respiratory secretion (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUCELVAX TETRA [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>VAXZEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>[ELASOMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016405603&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016405623,Spontaneous,2023-12-05 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Dysuria (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>[ELASOMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016405623&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016405639,Spontaneous,2023-12-05 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Diarrhoea (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUCELVAX TETRA [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>[ELASOMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016405639&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016405647,Spontaneous,2023-12-05 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Diarrhoea (n/a - Unknown - ),<BR><BR>Nausea (n/a - Unknown - ),<BR><BR>Vomiting (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUCELVAX TETRA [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016405647&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016405653,Spontaneous,2023-12-05 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Malaise (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUCELVAX TETRA [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016405653&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016405659,Spontaneous,2023-12-05 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Malaise (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUCELVAX TETRA [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016405659&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016405664,Spontaneous,2023-12-05 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Pyrexia (n/a - Unknown - ),<BR><BR>Vomiting (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUCELVAX TETRA [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016405664&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016405678,Spontaneous,2023-12-05 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Cough (n/a - Unknown - Other Medically Important Condition),<BR><BR>Increased viscosity of upper respiratory secretion (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Odynophagia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sneezing (n/a - Unknown - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>[ELASOMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016405678&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016390757,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Vaccination site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site induration (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site papule (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site warmth (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016390757&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016390763,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Pancreatitis (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016390763&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016390775,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016390775&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016390777,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Pain in extremity (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016390777&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016390785,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Visual impairment (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016390785&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016390790,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Interchange of vaccine products (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site discomfort (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016390790&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016390827,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016390827&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016390830,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016390830&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016390855,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Respiratory disorder (n/a - Unknown - Caused/Prolonged Hospitalisation),RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016390855&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016390973,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Neoplasm malignant (n/a - Unknown - Life Threatening),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016390973&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016391342,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Pneumonia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary embolism (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Right ventricular failure (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [1d - n/a - Intramuscular use]),[LEVOTHYROXINE] (C - Hypothyroidism - n/a - [n/a - n/a - Oral use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016391342&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016391490,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Chest discomfort (n/a - Recovered/Resolved - Life Threatening),<BR><BR>Dyspnoea (n/a - Recovered/Resolved - Life Threatening),<BR><BR>Face oedema (n/a - Recovered/Resolved - Life Threatening),<BR><BR>Fatigue (n/a - Recovered/Resolved - Life Threatening),<BR><BR>Headache (n/a - Recovered/Resolved - Life Threatening),<BR><BR>Hyperhidrosis (n/a - Recovered/Resolved - Life Threatening),<BR><BR>Muscle spasms (n/a - Recovered/Resolved - Life Threatening),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Life Threatening),<BR><BR>Sudden hearing loss (n/a - Recovered/Resolved - Life Threatening)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [1d - n/a - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - n/a - n/a - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016391490&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016391826,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,COVID-19 (n/a - Recovering/Resolving - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - n/a - n/a - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016391826&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016391861,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,COVID-19 (n/a - Recovering/Resolving - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [1d - n/a - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - n/a - n/a - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016391861&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016392251,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Body temperature increased (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016392251&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016392254,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Lymphadenopathy (3d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26)] (C - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016392254&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016392257,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (4h - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016392257&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016392613,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Burning sensation (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lung disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site papule (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016392613&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016392630,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Autoimmune disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[WARFARIN, WARFARIN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016392630&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016392839,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Bell's palsy (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016392839&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016392842,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (n/a - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Multiple sclerosis relapse (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016392842&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016393049,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Hypoaesthesia (n/a - Recovering/Resolving - ),<BR><BR>Sensory disturbance (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016393049&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016393309,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Dysacusis (5h - Recovered/Resolved - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016393309&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016393313,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (2d - Recovered/Resolved - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016393313&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016393506,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Facial pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Neuralgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 3 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016393506&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016393509,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cerebrovascular accident (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Hemiparesis (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling)","COMIRNATY OMICRON XBB.1.5 3 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 HAEMAGGLUTININ ANTIGEN, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - n/a])",KEYTRUDA [PEMBROLIZUMAB] (C - Neoplasm malignant - n/a - ),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016393509&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016393836,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Atrial fibrillation (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016393836&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016393876,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,"Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016393876&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016393917,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dysmenorrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Intermenstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Menstrual disorder (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),"[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[NORETHISTERONE, NORETHISTERONE BP] (C - Dysmenorrhoea, Endometriosis - n/a - [n/a - 5mg - n/a]),<BR><BR>[SPIRONOLACTONE] (C - Dysmenorrhoea, Endometriosis - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016393917&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016394024,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Decreased appetite (10d - Recovered/Resolved - ),<BR><BR>Dysgeusia (10d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016394024&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016394090,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Abdominal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Abnormal faeces (n/a - Not Recovered/Not Resolved - ),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016394090&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016394297,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Injection site haematoma (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016394297&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016394299,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Palpitations (16h - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016394299&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016394306,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Epistaxis (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016394306&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016394315,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016394315&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016394316,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Feeling abnormal (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Hypertension (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016394316&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016394317,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Axillary pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Night sweats (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016394317&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016394320,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Abdominal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Body temperature increased (n/a - Recovered/Resolved - ),<BR><BR>Chills (6h - Recovered/Resolved - ),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (6h - Recovered/Resolved - ),<BR><BR>Nausea (4h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016394320&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016394321,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Rash pruritic (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),XARELTO 20 MG FILM-COATED TABLETS [RIVAROXABAN] (C - n/a - n/a - [n/a - 20mg - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016394321&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016394364,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,"Blood creatine phosphokinase increased (17d - Recovered/Resolved - ),<BR><BR>Confusional state (17d - Recovered/Resolved - ),<BR><BR>Dizziness (17d - Recovered/Resolved - ),<BR><BR>Memory impairment (17d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016394364&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016394407,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016394407&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016394469,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,Yes,Female,"Chills (4d - Recovered/Resolved - ),<BR><BR>Vaccination site induration (4d - Recovered/Resolved - ),<BR><BR>Vaccination site pain (4d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Antiviral prophylaxis - n/a - [0d - n/a - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016394469&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016394485,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Erythema (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016394485&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016394680,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016394680&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016394840,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Influenza like illness (3d - Recovered/Resolved - ),<BR><BR>Vaccination site joint pain (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016394840&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016394923,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Cardiac failure acute (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Respiratory failure (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016394923&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016394927,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Cardiac failure (15d - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Diabetic metabolic decompensation (15d - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dyspnoea (15d - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hypertension (15d - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Oedema peripheral (15d - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Weight increased (15d - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - 1{DF} - Intramuscular use]),"COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - n/a - [1d - 1{DF} - Intramuscular use]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - n/a - [1d - 1{DF} - Intramuscular use]),<BR><BR>VAXZEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - COVID-19 immunisation - n/a - [69d - 2{DF} - Intramuscular use]),<BR><BR>[ELASOMERAN] (C - COVID-19 immunisation - n/a - [1d - 1{DF} - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016394927&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016394943,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,European Economic Area,Not available,3-11 Years,Child,No,Female,"Pancytopenia (13d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 10 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016394943&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016395068,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Anaphylactic reaction (10695min - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016395068&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016395116,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016395116&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016395193,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016395193&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016395280,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016395280&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016395378,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Agitation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypertension (6d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016395378&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016395384,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Alopecia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016395384&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016395387,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Abdominal distension (n/a - Recovering/Resolving - ),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Nasopharyngitis (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016395387&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016395390,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016395390&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016395438,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Eye pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Eye swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Urticaria (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016395438&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016395586,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>IRON [IRON] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016395586&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016395602,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Amaurosis fugax (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (2d - Recovered/Resolved - ),<BR><BR>Malaise (2d - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016395602&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016395615,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Neuralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sciatica (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016395615&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016396173,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016396173&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016396189,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016396189&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016396219,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016396219&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016396271,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Pain in extremity (n/a - Unknown - ),<BR><BR>Peripheral swelling (n/a - Unknown - ),<BR><BR>Superficial vein thrombosis (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),"[AMLODIPINE, AMLODIPINE BESILATE] (C - Hypertension - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[ATORVASTATIN] (C - Lipoprotein (a) increased, Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[CETIRIZINE DIHYDROCHLORIDE] (C - Hypersensitivity - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016396271&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016396289,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Contusion (n/a - Unknown - ),<BR><BR>Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Syncope (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - n/a - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016396289&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016396398,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Influenza like illness (n/a - Recovering/Resolving - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 HAEMAGGLUTININ ANTIGEN, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016396398&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016396669,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Pain in extremity (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016396669&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016396708,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016396708&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016396719,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pain in extremity (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016396719&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016396726,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Balance disorder (n/a - Unknown - ),<BR><BR>Nausea (n/a - Unknown - ),<BR><BR>Pain (36h - Recovered/Resolved - ),<BR><BR>Pyrexia (36h - Recovered/Resolved - ),<BR><BR>Vertigo (n/a - Unknown - ),<BR><BR>Vestibular neuronitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016396726&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016397057,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Application site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016397057&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016397572,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016397572&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016397587,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Feeling abnormal (3d - Recovered/Resolved - ),<BR><BR>Maternal exposure during pregnancy (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[ACETYLSALICYLIC ACID, ACETYLSALICYLIC ACID, MAGNESIUM OXIDE] (C - n/a - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016397587&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016397588,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Nausea (n/a - Unknown - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - ),<BR><BR>Vomiting (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),[BUDESONIDE] (C - Asthma - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016397588&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016397783,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Back pain (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016397783&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016397809,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site haematoma (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Rash (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016397809&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016397861,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Pneumonia (n/a - Recovering/Resolving - Life Threatening),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Prophylaxis - Drug withdrawn - [1d - n/a - n/a])","BRETARIS GENUAIR [ACLIDINIUM BROMIDE] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>ESOMEPRAZOLE 20MG CAPSULE  (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>SEMAGLUTIDE 14MG TABLET  (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>XIGDUO 5 MG/850 MG FILM-COATED TABLETS [METFORMIN HYDROCHLORIDE, DAPAGLIFLOZIN] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE MONOHYDRATE] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[IRON PROTEIN SUCCINYLATE] (C - n/a - Dose not changed - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016397861&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016397867,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Male,"Back pain (n/a - Unknown - ),<BR><BR>Nausea (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>VAXZEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>[ELASOMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016397867&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016397868,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Asthenia (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016397868&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016397875,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Malaise (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),"COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>[ELASOMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016397875&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016397886,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Malaise (n/a - Unknown - ),<BR><BR>Vomiting (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016397886&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016397896,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Abdominal pain upper (n/a - Unknown - ),<BR><BR>Nausea (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - ),<BR><BR>Vomiting (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016397896&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016397898,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Vaccination site inflammation (n/a - Unknown - ),<BR><BR>Vaccination site pain (n/a - Unknown - ),<BR><BR>Vaccination site reaction (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016397898&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016397904,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Paraesthesia oral (n/a - Recovering/Resolving - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUCELVAX TETRA [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>JCOVDEN SUSPENSION FOR INJECTION [COVID-19 VACCINE JANSSEN (AD26.COV2.S)] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>[ELASOMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016397904&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016397915,Spontaneous,2023-12-04 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Urticaria (4d - Recovered/Resolved - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - n/a]),<BR><BR>FLUAD TETRA SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Drug withdrawn - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016397915&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016397941,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Intermenstrual bleeding (2d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016397941&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016398094,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016398094&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016398095,Spontaneous,2023-12-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016398095&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016390429,Spontaneous,2023-12-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site haematoma (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016390429&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016390466,Spontaneous,2023-12-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Myalgia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016390466&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016389046,Spontaneous,2023-12-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016389046&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016389047,Spontaneous,2023-12-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Body temperature increased (8h - Recovered/Resolved - ),<BR><BR>Chills (4h - Recovered/Resolved - ),<BR><BR>Fatigue (1d - Recovered/Resolved - ),<BR><BR>Headache (4h - Recovered/Resolved - ),<BR><BR>Malaise (1d - Recovered/Resolved - ),<BR><BR>Myalgia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),[CITALOPRAM] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016389047&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016389048,Spontaneous,2023-12-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Injection site pain (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016389048&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016389049,Spontaneous,2023-12-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016389049&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016389050,Spontaneous,2023-12-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Asthma (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Urticaria (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016389050&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016389051,Spontaneous,2023-12-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016389051&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016389052,Spontaneous,2023-12-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016389052&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016389305,Spontaneous,2023-12-02 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Atrial fibrillation (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Chest pain (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Myocardial necrosis marker increased (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Nausea (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Vertigo (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),"IRBESARTAN HYDROCHLOROTHIAZIDE ZENTIVA [HYDROCHLOROTHIAZIDE, IRBESARTAN] (C - n/a - n/a - ),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - ),<BR><BR>[ATENOLOL] (C - n/a - Drug withdrawn - ),<BR><BR>[FUROSEMIDE, FUROSEMIDE SODIUM] (C - n/a - n/a - ),<BR><BR>[NIFEDIPINE] (C - n/a - n/a - ),<BR><BR>[PANTOPRAZOLE] (C - n/a - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016389305&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016389332,Spontaneous,2023-12-02 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Recovered/Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Neuritis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Prophylaxis - Not applicable - [n/a - .3mL - Intramuscular use]),<BR><BR>FLUCELVAX TETRA [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (S - Antiviral prophylaxis - Not applicable - [n/a - .5mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016389332&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016389379,Spontaneous,2023-12-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Paraesthesia (0d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016389379&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016389633,Spontaneous,2023-12-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016389633&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016390024,Spontaneous,2023-12-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016390024&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016390158,Spontaneous,2023-12-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Malaise (1d - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016390158&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016390159,Spontaneous,2023-12-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Amenorrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Arthralgia (1d - Recovered/Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Constipation (2d - Recovered/Resolved - ),<BR><BR>Diabetes mellitus inadequate control (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Injection site erythema (2d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (2d - Recovered/Resolved - ),<BR><BR>Injection site pain (2d - Recovered/Resolved - ),<BR><BR>Injection site pruritus (2d - Recovered/Resolved - ),<BR><BR>Injection site warmth (2d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016390159&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016390206,Spontaneous,2023-12-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Atrial fibrillation (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016390206&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016390208,Spontaneous,2023-12-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Hypertension (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016390208&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016390209,Spontaneous,2023-12-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016390209&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016390210,Spontaneous,2023-12-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chills (5d - Recovered/Resolved - ),<BR><BR>Fatigue (1wk - Recovered/Resolved - ),<BR><BR>Malaise (4d - Recovered/Resolved - ),<BR><BR>Myalgia (3d - Recovered/Resolved - ),<BR><BR>Pyrexia (5d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016390210&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016390213,Spontaneous,2023-12-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Injection site pain (1d - Recovered/Resolved - ),<BR><BR>Pain in extremity (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016390213&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016390214,Spontaneous,2023-12-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (n/a - Recovered/Resolved - ),<BR><BR>Diarrhoea (n/a - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016390214&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016390370,Spontaneous,2023-12-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Myalgia (5h - Recovered/Resolved - ),<BR><BR>Nausea (5h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016390370&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016381407,Spontaneous,2023-12-01 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cough (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use]),"[D,L-LYSINE ACETYLSALICYLATE] (C - n/a - n/a - ),<BR><BR>[LACIDIPINE] (C - n/a - n/a - ),<BR><BR>[LOVASTATIN] (C - n/a - n/a - ),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - n/a - n/a - ),<BR><BR>[RAMIPRIL] (C - n/a - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016381407&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016381410,Spontaneous,2023-12-01 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (1d - Recovered/Resolved - ),<BR><BR>Myalgia (1d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224)] (S - Influenza immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016381410&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016381633,Spontaneous,2023-12-01 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Altered state of consciousness (n/a - Fatal - Results in Death),<BR><BR>Blood disorder (n/a - Unknown - ),<BR><BR>Cerebral haemorrhage (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Coagulopathy (n/a - Unknown - ),<BR><BR>Coma scale abnormal (n/a - Unknown - ),<BR><BR>Ecchymosis (n/a - Unknown - ),<BR><BR>Haematemesis (n/a - Fatal - Results in Death),<BR><BR>Leukaemia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Monocyte count increased (n/a - Unknown - ),<BR><BR>Muscular weakness (n/a - Unknown - ),<BR><BR>Nausea (n/a - Unknown - ),<BR><BR>Platelet count decreased (n/a - Unknown - ),<BR><BR>Subdural haematoma (n/a - Fatal - Results in Death)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016381633&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016381655,Spontaneous,2023-12-01 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Diarrhoea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Enterocolitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"EFIENT [PRASUGREL, PRASUGREL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Acute myocardial infarction - n/a - [n/a - n/a - Oral use]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Hyperlipidaemia - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016381655&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016381689,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Elderly,No,Male,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016381689&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016382223,Spontaneous,2023-12-01 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Anaphylactic reaction (n/a - Recovering/Resolving - Life Threatening),<BR><BR>COVID-19 immunisation (n/a - Recovering/Resolving - Life Threatening)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [1d - n/a - Intramuscular use]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>VAXZEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016382223&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016382418,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain upper (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Body temperature increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016382418&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016382553,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Trigeminal neuralgia (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016382553&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016382606,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dyspepsia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nervousness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Syncope (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016382606&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016383111,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Pyrexia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site oedema (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016383111&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016383117,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Disease recurrence (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved With Sequelae - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - Blood pressure measurement - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - Blood cholesterol - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016383117&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016383152,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Lichen planus (n/a - Unknown - ),<BR><BR>Oral lichen planus (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016383152&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016383188,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Herpes zoster (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016383188&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016383200,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016383200&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016383308,Spontaneous,2023-12-01 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","[OMEPRAZOLE, OMEPRAZOLE MAGNESIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016383308&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016383309,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Arrhythmia (n/a - Unknown - Other Medically Important Condition),RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016383309&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016383313,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Pulmonary thrombosis (n/a - Fatal - Results in Death),RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016383313&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016383320,Spontaneous,2023-12-01 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dysstasia (28min - Recovered/Resolved - ),<BR><BR>Feeling hot (11min - Recovered/Resolved - ),<BR><BR>Palpitations (31min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Presyncope (n/a - Unknown - ),<BR><BR>Stress (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016383320&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016383333,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Sleep disorder (n/a - Unknown - ),<BR><BR>Vaccination site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pruritus (n/a - Unknown - ),<BR><BR>Vaccination site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site warmth (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - n/a - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016383333&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016383339,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016383339&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016383356,Spontaneous,2023-12-01 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Anaphylactic reaction (n/a - Unknown - Other Medically Important Condition),<BR><BR>Anaphylactic shock (n/a - Unknown - Other Medically Important Condition),<BR><BR>Face oedema (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016383356&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016383361,Spontaneous,2023-12-01 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest discomfort (n/a - Unknown - ),<BR><BR>Choking (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cough (n/a - Unknown - ),<BR><BR>Erythema (n/a - Unknown - ),<BR><BR>Pruritus (n/a - Unknown - ),<BR><BR>Rash (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[INSULIN, INSULIN HUMAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016383361&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016383477,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016383477&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016383479,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site haematoma (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016383479&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016383482,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Heart rate increased (24h - Recovered/Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016383482&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016383483,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"COVID-19 (12d - Recovered/Resolved - ),<BR><BR>Chills (8h - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (3d - Recovered/Resolved - ),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - ),<BR><BR>Malaise (11d - Recovered/Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016383483&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016383703,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Cough (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - ),<BR><BR>Influenza like illness (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 HAEMAGGLUTININ ANTIGEN, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016383703&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016384306,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Ear swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>External ear pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Secretion discharge (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"AVAMYS 27.5 MICROGRAMS/SPRAY, NASAL SPRAY SUSPENSION [FLUTICASONE FUROATE] (C - Chronic sinusitis - n/a - [n/a - n/a - n/a]),<BR><BR>IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - Ear swelling - n/a - [6d - 200mg - n/a]),<BR><BR>[ASCORBIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COD-LIVER OIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[EVENING PRIMROSE OIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FERROUS FUMARATE, FERROUS FUMARATE BP] (C - Anaemia, Coeliac disease - n/a - [n/a - n/a - Oral use]),<BR><BR>[FLUDROCORTISONE] (C - Hypotension - n/a - [n/a - n/a - n/a]),<BR><BR>[GLUCOSAMINE, GLUCOSAMINE SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastritis - n/a - [n/a - 40mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016384306&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016384773,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016384773&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016384872,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Pain in extremity (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016384872&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016384882,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,Lip swelling (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016384882&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016384886,Spontaneous,2023-12-01 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Asthenia (n/a - Recovering/Resolving - ),<BR><BR>Initial insomnia (n/a - Recovering/Resolving - ),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - ),<BR><BR>Palpitations (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Subcutaneous use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327)] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016384886&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016384997,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Hypertensive crisis (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 3 MICROGRAMS/DOSE CONCENTRATE FOR DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016384997&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016385100,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachypnoea (2d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[FLUTICASONE PROPIONATE, SALMETEROL, FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUTICASONE PROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[POTASSIUM HYDROGEN CARBONATE, SODIUM ALGINATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016385100&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016385228,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (6h - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site pruritus (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Recovered/Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016385228&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016385301,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Autophony (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Deafness (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016385301&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016385492,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Fatigue (n/a - Recovering/Resolving - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [1d - n/a - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - n/a - n/a - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016385492&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016385504,Spontaneous,2023-12-01 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Application site rash (n/a - Unknown - ),<BR><BR>Rash (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [10min - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016385504&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016385536,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Herpes zoster (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016385536&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016385540,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Illness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Musculoskeletal chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - Product used for unknown indication - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.1 [ELASOMERAN, IMELASOMERAN] (S - COVID-19 prophylaxis - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>[COVID-19 VACCINE] (S - Product used for unknown indication - Unknown - [n/a - 1{DF} - n/a])","[ATORVASTATIN] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - 1{DF} - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016385540&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016385738,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Bell's palsy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016385738&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016385804,Spontaneous,2023-12-01 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Bursitis (25d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[BISOPROLOL FUMARATE, HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE, BISOPROLOL, HYDROCHLOROTHIAZIDE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - ),<BR><BR>[FELODIPINE] (C - n/a - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016385804&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016385994,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Gait disturbance (n/a - Not Recovered/Not Resolved - ),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - ),<BR><BR>Mobility decreased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),"[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[EBASTINE] (C - Hypersensitivity, Urticaria - n/a - [n/a - n/a - n/a]),<BR><BR>[EPROSARTAN MESILATE, HYDROCHLOROTHIAZIDE, EPROSARTAN, HYDROCHLOROTHIAZIDE] (C - Hypertension - n/a - ),<BR><BR>[ESOMEPRAZOLE, ESOMEPRAZOLE, NAPROXEN, NAPROXEN, NAPROXEN, ESOMEPRAZOLE MAGNESIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, PARACETAMOL, ASPARTAME] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016385994&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016385999,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Chest pain (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Gait disturbance (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Palpitations (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pericarditis (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Syncope (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Tachycardia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016385999&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016386045,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Deafness unilateral (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [1d - n/a - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - n/a - n/a - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016386045&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016386051,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Balance disorder (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Head discomfort (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vision blurred (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - Joint injury - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016386051&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016386272,Spontaneous,2023-12-01 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016386272&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016386410,Spontaneous,2023-12-01 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arterial disorder (n/a - Fatal - Results in Death, Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Brain stem haemorrhage (n/a - Fatal - Results in Death, Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Cardiac arrest (n/a - Fatal - Results in Death, Life Threatening, Disabling, Other Medically Important Condition),<BR><BR>Subarachnoid haemorrhage (n/a - Fatal - Results in Death, Life Threatening, Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a]),"[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Back pain - n/a - [n/a - 100mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016386410&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016386505,Spontaneous,2023-12-01 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Cerebrovascular accident (7d - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Thrombosis (7d - Fatal - Results in Death, Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"HYDROCORTISONE [HYDROCORTISONE, HYDROCORTISONE SODIUM SUCCINATE] (C - Steroid therapy - n/a - [n/a - 15mbar/L/s - Oral use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[ALENDRONATE SODIUM, ALENDRONIC ACID] (C - Osteoporosis - n/a - [n/a - 70mg - Oral use]),<BR><BR>[CASSIA] (C - Constipation - n/a - [n/a - 7.5mg - Oral use]),<BR><BR>[DICLOFENAC SODIUM] (C - Actinic keratosis - n/a - [n/a - n/a - Cutaneous use]),<BR><BR>[DIFLUCORTOLONE VALERATE, ISOCONAZOLE NITRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ETOFENAMATE] (C - Inflammation - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - 30mg - Oral use]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - 24ug - Oral use]),<BR><BR>[MICONAZOLE, MICONAZOLE NITRATE] (C - Impetigo - n/a - [n/a - n/a - n/a]),<BR><BR>[MIDODRINE, MIDODRINE HYDROCHLORIDE] (C - Hypertension - n/a - [n/a - 15mg - Oral use]),<BR><BR>[PARACETAMOL] (C - Analgesic therapy - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARAFFIN WHITE SOFT, PARAFFIN WHITE SOFT, EMULSIFYING WAX] (C - Dry skin - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - Inhalation use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016386505&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016386693,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016386693&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016386731,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Myocardial infarction (n/a - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016386731&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016386986,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Male,"Abdominal pain upper (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016386986&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016387168,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016387168&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016387595,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Sudden death (n/a - Fatal - Results in Death),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"ENTRESTO 24 MG/26 MG FILM-COATED TABLETS [VALSARTAN, SACUBITRIL] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>FORXIGA 10 MG FILM-COATED TABLETS [DAPAGLIFLOZIN] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - 3mg - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - 40mg - n/a]),<BR><BR>[EZETIMIBE, ROSUVASTATIN] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016387595&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016387962,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Atrial fibrillation (4d - Recovered/Resolved - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016387962&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016387978,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Feeling abnormal (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Gastrointestinal disorder (10d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Syncope (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016387978&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016387988,Spontaneous,2023-12-01 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Arthropathy (n/a - Unknown - Disabling),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Sacral pain (n/a - Unknown - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016387988&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016387996,Spontaneous,2023-12-01 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Abnormal behaviour (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Confusional state (6d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Leukopenia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Thrombocytopenia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016387996&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016388299,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016388299&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016388302,Spontaneous,2023-12-01 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Blood pressure increased (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Erythema (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016388302&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016388523,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Vaccination site lymphadenopathy (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[CYANOCOBALAMIN, FOLIC ACID, POTASSIUM IODIDE, FOLIC ACID, POTASSIUM IODIDE, VITAMIN B12] (C - Pregnancy - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - Pregnancy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016388523&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016388543,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Vertigo labyrinthine (n/a - Not Recovered/Not Resolved - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),<BR><BR>PANDEMIC INFLUENZA VACCINE H5N1 BAXTER [A/VIETNAM/1203/2004 (H5N1)] (S - Influenza immunisation - Drug withdrawn - [1d - n/a - Intramuscular use])","[ECHINACEA PURPUREA ROOT, CRYOGROUND] (C - n/a - n/a - [167d - n/a - n/a]),<BR><BR>[TRAMADOL HYDROCHLORIDE, PARACETAMOL] (C - n/a - n/a - [28d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016388543&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016388545,Spontaneous,2023-12-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dizziness (4d - Recovered/Resolved - ),<BR><BR>Malaise (4d - Recovered/Resolved - ),<BR><BR>Pyrexia (4d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016388545&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016388549,Spontaneous,2023-12-01 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Herpes zoster (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [2d - n/a - Intramuscular use]),<BR><BR>FLUAD TETRA SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Drug withdrawn - [2d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016388549&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016373081,Spontaneous,2023-11-30 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Herpes zoster (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [n/a - .3mL - Intramuscular use]),"FLUCELVAX TETRA [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (C - Influenza immunisation - Drug withdrawn - [n/a - .5mL - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016373081&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016373334,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016373334&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016373377,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Chills (n/a - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016373377&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016373409,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Cardiac failure (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016373409&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016373417,Spontaneous,2023-11-30 00:00:00,Healthcare Professional,European Economic Area,Not available,2 Months - 2 Years,Not Specified,No,Female,"Cough (n/a - Unknown - ),<BR><BR>Overdose (n/a - Unknown - ),<BR><BR>Product administered to patient of inappropriate age (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>[A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN, A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN, B/FLORIDA/4/2006-LIKE STRAIN, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/VICTORIA/361/2011 (H3N2)–DERIVED STRAIN USED (IVR-165), B/WISCONSIN/1/2010-LIKE STRAIN USED (NYMC BX-39) DERIVED FROM B/HUBEI-WUJIAGANG/158/2009, A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/MOSCOW/10/99 (H3N2) - LIKE STRAIN (A/PANAMA/2007/99 REASS. RESVIR-17), B/SICHUAN/379/99-LIKE STRAIN (B/JOHANNESBURG/5/99), A/SOUTH AUSTRALIA/55/2014 STRAIN, A/SWITZERLAND/9715293/2013 (H3N2) - LIKE STRAIN (A/SOUTH AUSTRALIA/55/2014, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, B/MASSACHUSETTS/02/2012, A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/VICTORIA/361/2011 (H3N2)–DERIVED STRAIN USED (IVR-165), B/WISCONSIN/1/2010-LIKE STRAIN USED (NYMC BX-39) DERIVED FROM B/HUBEI-WUJIAGANG/158/2009, A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/WISCONSIN/67/2005 (H3N2), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN, B/MALAYSIA/2506/2004 - LIKE STRAIN, B/BEIJING/184/93-LIKE STRAIN (B/YAMANASHI/166/98), A/SYDNEY/5/97 (H3N2)-LIKE STRAIN (A/SYDNEY/5/97 REASS. RESVIR 13), A/BEIJING/262/95 (H1N1) - LIKE STRAIN (A/BEIJING/262/95 REASS. X-127), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1), A/PERTH/16/2009 (H3N2) - LIKE STRAIN, B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009(H1N1)-LIKE STRAIN (NYMC X-179A), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NIB-65), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009(H1N1)-LIKE STRAIN (NYMC X-179A), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/MASSACHUSETTS/02/2012, A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE STRAIN, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SOUTH AUSTRALIA/55/2014, IVR-175), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED)] (S - Influenza - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016373417&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016373753,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Bone pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cough (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in jaw (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sinus disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016373753&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016373882,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016373882&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016374388,Spontaneous,2023-11-30 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Bell's palsy (n/a - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[AMOXICILLIN, AMOXICILLIN TRIHYDRATE] (C - n/a - n/a - [7d - 3{DF} - n/a]),<BR><BR>[BACLOFEN] (C - n/a - n/a - [n/a - 3{DF} - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE] (C - n/a - n/a - [n/a - 8{DF} - Inhalation use]),<BR><BR>[CARBOCISTEINE] (C - n/a - n/a - [n/a - 6{DF} - n/a]),<BR><BR>[CETOMACROGOL 1000, CHLOROCRESOL, PARAFFIN, CETOSTEARYL ALCOHOL, LIQUID PARAFFIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CLOTRIMAZOLE] (C - n/a - n/a - [1d - 1{DF} - Vaginal use]),<BR><BR>[CODEINE PHOSPHATE] (C - n/a - n/a - [n/a - 4{DF} - n/a]),<BR><BR>[DESOGESTREL] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[DIAZEPAM] (C - n/a - n/a - [n/a - 3{DF} - n/a]),<BR><BR>[ESSENTIAL OIL OF PEPPERMINT, PEPPERMINT OIL] (C - n/a - n/a - [n/a - 3{DF} - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - n/a - n/a - [367d - 1{DF} - n/a]),<BR><BR>[FLUCLOXACILLIN, FLUCLOXACILLIN SODIUM, FLUCLOXACILLIN SODIUM MONOHYDRATE] (C - n/a - n/a - [7d - 4{DF} - n/a]),<BR><BR>[FORMOTEROL FUMARATE] (C - n/a - n/a - [n/a - 2{DF} - Inhalation use]),<BR><BR>[LEVONORGESTREL, LEVONORGESTREL MICRONISED] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOPERAMIDE, LOPERAMIDE HYDROCHLORIDE] (C - Diarrhoea - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[LORATADINE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[MEBEVERINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 3{DF} - n/a]),<BR><BR>[MIRTAZAPINE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[MOMETASONE] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[NYSTATIN] (C - Fungal infection - n/a - [8d - 4mL - Oral use]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARAFFIN WHITE SOFT, LIQUID PARAFFIN] (C - Dry skin - n/a - [n/a - n/a - n/a]),<BR><BR>[PHENOXYMETHYLPENICILLIN] (C - n/a - n/a - [6d - 8{DF} - n/a]),<BR><BR>[PREDNISOLONE] (C - n/a - n/a - [5d - 8{DF} - n/a]),<BR><BR>[SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - 2{DF} - Inhalation use]),<BR><BR>[SODIUM HYDROGEN CARBONATE PHEUR, CALCIUM CARBONATE PH. EUR., SODIUM ALGINATE PH. EUR., SODIUM HYDROGEN CARBONATE, CALCIUM CARBONATE, SODIUM ALGINATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM PHOSPHATE] (C - Dry mouth - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016374388&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016374407,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016374407&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016374493,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Eczema (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016374493&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016374566,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Diarrhoea (n/a - Unknown - ),<BR><BR>Dyspnoea (n/a - Unknown - ),<BR><BR>Fall (n/a - Unknown - ),<BR><BR>Loss of consciousness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Unknown - ),<BR><BR>Tinnitus (n/a - Unknown - ),<BR><BR>Vomiting (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INDAPAMIDE, INDAPAMIDE HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VERAPAMIL, VERAPAMIL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016374566&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016374944,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Dyspnoea (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Heart rate abnormal (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Left ventricular failure (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Tachycardia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016374944&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016374976,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Malaise (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - ),<BR><BR>Vertigo (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016374976&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016374978,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Blood pressure increased (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Heart rate increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016374978&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016374982,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Cough (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Diabetes mellitus inadequate control (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Hypotonia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Muscular weakness (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Paraesthesia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Respiratory distress (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Sensory disturbance (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Urinary incontinence (n/a - Unknown - Caused/Prolonged Hospitalisation)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - n/a - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016374982&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016375043,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Reaction to previous exposure to any vaccine (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016375043&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016375156,Spontaneous,2023-11-30 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Blood pressure increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovered/Resolved - ),<BR><BR>Feeling abnormal (n/a - Unknown - ),<BR><BR>Presyncope (n/a - Unknown - ),<BR><BR>Vertigo (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016375156&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016375159,Spontaneous,2023-11-30 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016375159&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016375170,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Abdominal pain upper (n/a - Unknown - Other Medically Important Condition),<BR><BR>Facial spasm (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypertension (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tetanus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Trismus (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016375170&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016375279,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[TOZINAMERAN NOS] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",[OLMESARTAN MEDOXOMIL] (C - Hypertension - n/a - [n/a - 20mg - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016375279&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016375307,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016375307&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016375405,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016375405&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016375453,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Confusional state (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Syncope (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[CODEINE PHOSPHATE BP, PARACETAMOL PH. EUR., PARACETAMOL, CODEINE PHOSPHATE] (C - Analgesic therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Hypersensitivity - n/a - [n/a - n/a - n/a]),<BR><BR>[LORATADINE] (C - Hypersensitivity - n/a - [n/a - n/a - n/a]),<BR><BR>[NAPROXEN, NAPROXEN SODIUM] (C - Analgesic therapy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016375453&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016375912,Spontaneous,2023-11-30 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Administration site erythema (n/a - Recovered/Resolved - ),<BR><BR>Administration site oedema (6d - Recovering/Resolving - ),<BR><BR>Administration site pain (n/a - Recovered/Resolved - ),<BR><BR>Body temperature increased (n/a - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovered/Resolved - ),<BR><BR>Insomnia (n/a - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 20, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 17F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 2, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A, PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT), PNEUMOCOCCAL VACCINE] (S - Immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016375912&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016376062,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Cardiac discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Intercostal neuralgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016376062&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016376116,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016376116&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016376120,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016376120&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016376591,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016376591&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016377206,Spontaneous,2023-11-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Acute myocardial infarction (n/a - Fatal - Results in Death),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016377206&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016377249,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016377249&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016377253,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Blood pressure increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dehydration (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Electrolyte imbalance (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016377253&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016377419,Spontaneous,2023-11-30 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dermatitis allergic (3d - Recovered/Resolved - ),<BR><BR>Rash (3d - Recovered/Resolved - ),<BR><BR>Rash macular (3d - Recovered/Resolved - ),<BR><BR>Skin disorder (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[SODIUM VALPROATE, VALPROIC ACID] (C - n/a - Dose not changed - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016377419&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016377616,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Elderly,No,Female,Hypothyroidism (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016377616&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016377643,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Immunisation reaction (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),"[LOSARTAN POTASSIUM, HYDROCHLOROTHIAZIDE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016377643&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016377644,Spontaneous,2023-11-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Malaise (6h - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016377644&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016377654,Spontaneous,2023-11-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Cholestasis (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>General physical health deterioration (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Thrombocytosis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),"IRBESARTAN [IRBESARTAN] (C - Hypertension - Dose not changed - [n/a - 150mg - Oral use]),<BR><BR>[BENSERAZIDE, LEVODOPA] (C - Parkinson's disease - Dose not changed - [n/a - 1{DF} - Oral use]),<BR><BR>[CELIPROLOL, CELIPROLOL HYDROCHLORIDE] (C - Hypertension - Dose not changed - [n/a - 200mg - Oral use]),<BR><BR>[LERCANIDIPINE HYDROCHLORIDE] (C - Hypertension - Dose not changed - [n/a - 20mg - Oral use]),<BR><BR>[SIMVASTATIN, EZETIMIBE] (C - Dyslipidaemia - Dose not changed - [n/a - 1{DF} - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016377654&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016377660,Spontaneous,2023-11-30 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Diarrhoea (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016377660&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016377662,Spontaneous,2023-11-30 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Myocardial infarction (n/a - Fatal - Results in Death),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - Immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - Not applicable - [1d - n/a - Intramuscular use])","[FLUINDIONE] (C - n/a - n/a - [n/a - 10mg - Oral use]),<BR><BR>[FLUINDIONE] (C - n/a - n/a - [n/a - 40mg - Oral use]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - 10mg - Oral use]),<BR><BR>[SPIRONOLACTONE] (C - n/a - n/a - [n/a - 25mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016377662&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016377669,Spontaneous,2023-11-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Ageusia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016377669&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016377676,Spontaneous,2023-11-30 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Pulmonary embolism (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016377676&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016377703,Spontaneous,2023-11-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Tremor (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016377703&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016377745,Spontaneous,2023-11-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Ischaemic stroke (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),"ELIQUIS 5 MG FILM-COATED TABLETS [APIXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LERCANIDIPINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016377745&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016377755,Spontaneous,2023-11-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Presyncope (1h - Recovered/Resolved - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327)] (S - Influenza immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])","[BENSERAZIDE HYDROCHLORIDE, LEVODOPA, BENSERAZIDE, LEVODOPA] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016377755&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016377790,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Balance disorder (n/a - Not Recovered/Not Resolved - ),<BR><BR>Deafness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Immunisation reaction (n/a - Recovered/Resolved - ),<BR><BR>Mixed anxiety and depressive disorder (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016377790&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016378103,Spontaneous,2023-11-30 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,Yes,Female,Erythema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016378103&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016378278,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Abdominal pain upper (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016378278&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016378297,Spontaneous,2023-11-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Tachycardia (2d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),[FLECAINIDE ACETATE] (C - Arrhythmia - n/a - [n/a - n/a - Oral use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016378297&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016378299,Spontaneous,2023-11-30 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,Herpes zoster (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016378299&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016378310,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Incorrect route of product administration (n/a - Unknown - ),<BR><BR>Thrombosis (n/a - Unknown - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intravenous use]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016378310&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016378400,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Influenza like illness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016378400&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016378718,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016378718&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016378891,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Product administered at inappropriate site (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 30ug - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016378891&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016378933,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016378933&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016379070,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ACICLOVIR, ACICLOVIR SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[POTASSIUM CHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016379070&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016379100,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016379100&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016379112,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Pericarditis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016379112&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016379113,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (3d - Recovered/Resolved - ),<BR><BR>Injection site pain (3d - Recovered/Resolved - ),<BR><BR>Injection site swelling (3d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (2wk - Recovered/Resolved - ),<BR><BR>Pyrexia (3wk - Recovered/Resolved - ),<BR><BR>Vaccination site lymphadenopathy (1wk - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016379113&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016379177,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016379177&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016379327,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Abdominal distension (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Abdominal pain upper (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[BUTYLSCOPOLAMINE, HYOSCINE BUTYLBROMIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016379327&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016379351,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Elderly,No,Female,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016379351&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016379564,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Erythema (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash macular (n/a - Unknown - Other Medically Important Condition),<BR><BR>Swelling face (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[DIHYDROCODEINE, DIHYDROCODEINE TARTRATE BP] (C - Osteoarthritis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016379564&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016379662,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016379662&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016379746,Spontaneous,2023-11-30 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Asthenia (n/a - Recovered/Resolved - ),<BR><BR>Chills (n/a - Recovered/Resolved - ),<BR><BR>Dizziness (n/a - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Insomnia (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),[NEBIVOLOL] (C - Hypertension - n/a - [n/a - 2.5mg - Oral use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016379746&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016379864,Spontaneous,2023-11-30 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016379864&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016379937,Spontaneous,2023-11-30 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Intermenstrual bleeding (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016379937&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016379938,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Visual impairment (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016379938&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016379941,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Facial pain (n/a - Unknown - ),<BR><BR>Glossodynia (n/a - Recovering/Resolving - ),<BR><BR>Tongue discomfort (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016379941&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016379943,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Myalgia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016379943&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016379945,Spontaneous,2023-11-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Back pain (n/a - Recovering/Resolving - ),<BR><BR>Confusional state (n/a - Recovering/Resolving - ),<BR><BR>Gait disturbance (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"FORXIGA [DAPAGLIFLOZIN] (C - Type 2 diabetes mellitus - n/a - [n/a - 10mg - Oral use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[BUDESONIDE] (C - Asthma - n/a - [n/a - 1{DF} - Inhalation use]),<BR><BR>[CYANOCOBALAMIN] (C - Vitamin supplementation - n/a - [n/a - 1mg - Oral use]),<BR><BR>[ENALAPRIL MALEATE, HYDROCHLOROTHIAZIDE] (C - Hypertension - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone therapy - n/a - [n/a - 10mg - Vaginal use]),<BR><BR>[LETROZOLE] (C - Breast cancer - n/a - [n/a - 2.5mg - Oral use]),<BR><BR>[METFORMIN HYDROCHLORIDE, VILDAGLIPTIN] (C - Type 2 diabetes mellitus - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[SIMVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - 20mg - Oral use]),<BR><BR>[TERBUTALINE SULFATE] (C - Asthma - n/a - [n/a - .5mg - Inhalation use]),<BR><BR>[VITAMIN D, CALCIUM] (C - Mineral supplementation - n/a - [n/a - 1{DF} - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016379945&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016380441,Spontaneous,2023-11-30 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,"Pyrexia (1d - Fatal - Results in Death),<BR><BR>Respiratory distress (1d - Fatal - Results in Death)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - .3mL - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - Drug withdrawn - [1d - .7mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016380441&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016380442,Spontaneous,2023-11-30 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Pneumonia respiratory syncytial viral (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016380442&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016380454,Spontaneous,2023-11-30 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Lymphadenopathy (2d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [n/a - n/a - Intramuscular use]),"[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma - Dose not changed - [n/a - n/a - Route of administration not applicable]),<BR><BR>[DIENOGEST, ETHINYLESTRADIOL, LACTOSE MONOHYDRATE] (C - Contraception - Dose not changed - [n/a - n/a - Oral use]),<BR><BR>[IBUPROFEN] (C - Menstruation irregular - Dose not changed - [n/a - n/a - Oral use]),<BR><BR>[IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE MONOHYDRATE] (C - Asthma - Dose not changed - [n/a - n/a - Route of administration not applicable]),<BR><BR>[TRANEXAMIC ACID] (C - Intermenstrual bleeding - Dose not changed - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016380454&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016380471,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Diarrhoea (n/a - Recovering/Resolving - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B)] (S - Immunisation - Drug withdrawn - [1d - n/a - Intramuscular use])","[EXEMESTANE] (C - HER2 low breast cancer - Dose not changed - [n/a - 25mg - Oral use]),<BR><BR>[LETROZOLE] (C - HER2 low breast cancer - Drug withdrawn - [383d - 2.5mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016380471&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016380539,Spontaneous,2023-11-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Injection site pain (2d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016380539&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016364175,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Epilepsy (0d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010, B/PHUKET/3073/2013-LIKE STRAIN, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/BRISBANE/60/2008, A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, B/MASSACHUSETTS/02/2012, A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010, B/BRISBANE/60/2008, B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010, B/BRISBANE/60/2008-LIKE VIRUS, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, NIB-121), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Influenza immunisation - n/a - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016364175&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016364225,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Facial pain (n/a - Recovered/Resolved - ),<BR><BR>Paraesthesia (n/a - Recovered/Resolved - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224)] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016364225&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016364274,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,Pericarditis (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016364274&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016364448,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016364448&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016364452,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Cerebrovascular accident (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016364452&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016365005,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Blister (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Headache (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Hypersensitivity (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Rash (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016365005&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016365244,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Lung neoplasm malignant (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016365244&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016365624,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Arthralgia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Myalgia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Nausea (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - Not applicable - [n/a - n/a - n/a]),"ABASAGLAR KWIKPEN [INSULIN GLARGINE] (C - n/a - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>ELIQUIS [APIXABAN] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>JARDIANCE [EMPAGLIFLOZIN] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[ENALAPRIL MALEATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[FELODIPINE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[HYDROCHLOROTHIAZIDE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[METOPROLOL, METOPROLOL SUCCINATE, METOPROLOL TARTRATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[VENLAFAXINE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[ZOPICLONE] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016365624&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016365749,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Angioedema (n/a - Recovering/Resolving - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [1d - n/a - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - n/a - n/a - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016365749&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016365776,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Injection site reaction (n/a - Recovering/Resolving - ),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[IBUPROFEN, IBUPROFEN ARGININE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016365776&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016365930,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (1d - Recovered/Resolved - ),<BR><BR>Myalgia (1d - Recovered/Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROCHLOROTHIAZIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METOPROLOL SUCCINATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016365930&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016365933,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016365933&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016365934,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Abdominal distension (2d - Recovered/Resolved - ),<BR><BR>Abdominal pain upper (2d - Recovered/Resolved - ),<BR><BR>Diarrhoea (2d - Recovered/Resolved - ),<BR><BR>Injection site erythema (2d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (2d - Recovered/Resolved - ),<BR><BR>Injection site pain (2d - Recovered/Resolved - ),<BR><BR>Injection site warmth (2d - Recovered/Resolved - ),<BR><BR>Malaise (2d - Recovered/Resolved - ),<BR><BR>Myalgia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016365934&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016365937,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Haematoma (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [1d - n/a - Intramuscular use]),"[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - n/a - n/a - [1d - n/a - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016365937&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016365954,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Amnesia (n/a - Recovered/Resolved - ),<BR><BR>Fall (n/a - Recovered/Resolved - ),<BR><BR>Feeling abnormal (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use - More in ICSR]),"AZILECT [RASAGILINE, RASAGILINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>OPRYMEA [PRAMIPEXOLE, PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>STALEVO [CARBIDOPA, ENTACAPONE, LEVODOPA] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BENSERAZIDE HYDROCHLORIDE, LEVODOPA, BENSERAZIDE, LEVODOPA] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CARBIDOPA, LEVODOPA, LEVODOPA, ANHYDROUS CARBIDOPA, LEVODOPA, CARBIDOPA MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CLONAZEPAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESCITALOPRAM, ESCITALOPRAM OXALATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[GABAPENTIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LERCANIDIPINE, LERCANIDIPINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PROPRANOLOL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016365954&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016366062,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Muscle fibrosis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016366062&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016366181,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Decreased appetite (28d - Recovered/Resolved - Disabling),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Disabling),<BR><BR>Habit cough (n/a - Recovering/Resolving - Disabling),<BR><BR>Heart rate increased (13d - Recovered/Resolved - Disabling),<BR><BR>Joint swelling (n/a - Unknown - Disabling),<BR><BR>Swelling (n/a - Recovering/Resolving - Disabling)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [1d - n/a - n/a])","IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - Joint swelling - n/a - [7d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016366181&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016366199,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Female,"Head injury (n/a - Recovering/Resolving - ),<BR><BR>Syncope (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tooth fracture (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016366199&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016366201,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthma (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016366201&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016366288,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Vaccination site bruising (1h - Recovered/Resolved - ),<BR><BR>Vaccination site swelling (1h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN, A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN, B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1) V REASS. X - 179 A, A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/NANCHANG 933/95 (H3N2), A/BAYERN/7/95 (H1N1) - LIKE STRAIN (A/JOHANNESBURG/82/96), B/BEIJING/184/93-LIKE STRAIN (B/HARBIN/7/94), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/CALIFORNIA/7/2004 (H3N2) - LIKE STRAIN (A/NEW YORK/55/2004 REASS. NYMC X-157), B/SHANGHAI/361/2002 - LIKE STRAIN (B/JIANGSU/10/2003), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/MOSCOW/10/99 (H3N2) - LIKE STRAIN (A/PANAMA/2007/99 REASS. RESVIR-17), B/SICHUAN/379/99-LIKE STRAIN (B/JOHANNESBURG/5/99), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), A/CALIFORNIA/7/2009 (H1N1)-DERIVED STRAIN USED NYMC X-181, B/BRISBANE/60/2008, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1)V-LIKE VIRUS, A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H1N1), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H3N2), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B] (C - Influenza immunisation - n/a - [n/a - .5mL - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016366288&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016366299,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Feeling cold (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Migraine (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site swelling (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016366299&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016366301,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016366301&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016366319,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Male,Nephrotic syndrome (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016366319&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016366478,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Condition aggravated (n/a - Recovering/Resolving - ),<BR><BR>Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),ANTICONCEPTIEPIL [NOT AVAILABLE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016366478&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016366731,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Asthenia (n/a - Recovered/Resolved - Life Threatening),<BR><BR>Dizziness (n/a - Recovered/Resolved - Life Threatening),<BR><BR>Fall (n/a - Recovered/Resolved - Life Threatening),<BR><BR>Muscular weakness (n/a - Recovered/Resolved - Life Threatening),<BR><BR>Somnolence (n/a - Recovered/Resolved - Life Threatening)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [1d - n/a - Intramuscular use]),"ELIQUIS [APIXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016366731&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016366737,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Hypertension (n/a - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - n/a]),"[ENALAPRIL, ENALAPRIL MALEATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016366737&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016366792,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016366792&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016366834,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016366834&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016367196,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Asthenia (n/a - Unknown - Disabling),<BR><BR>Pain in extremity (n/a - Unknown - Disabling),<BR><BR>Pyrexia (n/a - Unknown - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - 500mg - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - 2.5mg - n/a - More in ICSR]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - 10mg - n/a - More in ICSR])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016367196&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016367207,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Vertigo (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - n/a - Not applicable - [n/a - n/a - n/a]),"[ALFUZOSIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[PAROXETINE, PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE, ANHYDROUS] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016367207&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016367277,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Confusional state (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nightmare (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vision blurred (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Visual impairment (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016367277&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016367350,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Pruritus (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rash (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rash erythematous (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Skin burning sensation (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"HYDROCORTISONE [HYDROCORTISONE, HYDROCORTISONE SODIUM SUCCINATE] (C - n/a - n/a - [5d - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [63d - 1{DF} - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[PARAFFIN, LIGHT LIQUID, PARAFFIN, LIGHT LIQUID, PARAFFIN WHITE SOFT] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016367350&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016367466,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Bursitis (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Weight bearing difficulty (n/a - Unknown - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016367466&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016367501,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Heavy menstrual bleeding (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Menstruation irregular (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Autoimmune thyroiditis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016367501&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016367502,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Blood urine present (24h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Renal pain (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016367502&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016367503,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sinusitis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Toothache (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016367503&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016367545,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016367545&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016367546,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain lower (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cold sweat (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016367546&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016367576,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Thrombosis (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ETHINYLESTRADIOL, NORGESTIMATE, LACTOSE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016367576&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016367577,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016367577&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016367582,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Middle insomnia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Rheumatoid arthritis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016367582&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016367697,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"FLUCELVAX TETRA [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016367697&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016367768,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (1d - Unknown - Other Medically Important Condition),<BR><BR>Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (1d - Unknown - Other Medically Important Condition),<BR><BR>Rash (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016367768&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016367800,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Tinnitus (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016367800&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016367929,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Deep vein thrombosis (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"RIVAROXABAN [RIVAROXABAN] (C - Deep vein thrombosis - n/a - [66d - n/a - n/a]),<BR><BR>[ENOXAPARIN SODIUM] (C - Deep vein thrombosis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016367929&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016367956,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Application site pain (n/a - Unknown - ),<BR><BR>Arthralgia (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016367956&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016368071,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016368071&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016368121,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Pleural effusion (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Blood pressure increased - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - Osteopenia - n/a - [n/a - n/a - n/a]),<BR><BR>[ENALAPRIL, ENALAPRIL MALEATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Goitre - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - Paroxysmal arrhythmia - n/a - [n/a - n/a - n/a]),<BR><BR>[TRAMADOL HYDROCHLORIDE] (C - Back pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016368121&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016368410,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Dermatitis contact (n/a - Unknown - Other Medically Important Condition),<BR><BR>Erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gout (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash pruritic (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Swelling (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),[ALLOPURINOL] (C - Gout - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016368410&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016368449,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Disturbance in attention (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dysstasia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Exercise tolerance decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lower respiratory tract infection (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016368449&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016368665,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Aortic valve incompetence (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Asthenia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Atrial fibrillation (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (0d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Sinus bradycardia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"BRINTELLIX [VORTIOXETINE] (C - Depression - n/a - [n/a - 20mg - n/a]),<BR><BR>EXFORGE [VALSARTAN, AMLODIPINE, VALSARTAN, AMLODIPINE BESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Hyperlipidaemia - n/a - [n/a - 10mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016368665&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016368837,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016368837&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016368839,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Haemoptysis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lower respiratory tract infection (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Productive cough (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rales (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016368839&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016368840,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (10d - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Vaccination failure (10d - Recovered/Resolved With Sequelae - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Blood cholesterol abnormal - n/a - [486d - n/a - n/a - More in ICSR])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016368840&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016368869,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Rash (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site macule (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [1d - n/a - n/a]),"[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - n/a - n/a - [1d - n/a - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016368869&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016368899,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Atrial fibrillation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (10d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Migraine (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016368899&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016368907,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Cardiac flutter (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Heart rate irregular (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Myocardial infarction (n/a - Unknown - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[COLECALCIFEROL, CALCIUM CARBONATE] (C - Inflammatory bowel disease - n/a - [n/a - n/a - n/a]),<BR><BR>[DOXAZOSIN, DOXAZOSIN MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INDAPAMIDE, INDAPAMIDE HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LERCANIDIPINE, LERCANIDIPINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MESALAZINE] (C - Crohn's disease - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Inflammatory bowel disease - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016368907&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016368911,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Condition aggravated (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"[ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM TRIHYDRATE, ESOMEPRAZOLE SODIUM] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - Oral use]),<BR><BR>[TOCOPHEROL] (C - Osteoporosis - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016368911&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016368919,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Neuralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016368919&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016368936,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[HYDROCHLOROTHIAZIDE] (C - n/a - n/a - [n/a - 25mg - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 25mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016368936&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016368944,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[LETROZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016368944&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016368957,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Arthralgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Middle insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016368957&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016368991,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Blood creatine phosphokinase increased (n/a - Unknown - ),<BR><BR>Blood phosphorus decreased (n/a - Unknown - ),<BR><BR>Blood pressure increased (n/a - Unknown - ),<BR><BR>Blood triglycerides increased (n/a - Unknown - ),<BR><BR>Chills (n/a - Unknown - ),<BR><BR>Diarrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Infection (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016368991&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016369182,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Diarrhoea (3d - Recovered/Resolved - ),<BR><BR>Injection site oedema (3d - Recovered/Resolved - ),<BR><BR>Oedema peripheral (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - .3ug - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016369182&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016369662,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sleep disorder due to a general medical condition (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016369662&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016369738,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Peripheral swelling (n/a - Not Recovered/Not Resolved - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Influenza immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016369738&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016369748,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Hypertension (10d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016369748&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016369753,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Cardiac failure acute (2wk - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016369753&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016369901,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,Dizziness (n/a - Not Recovered/Not Resolved - Disabling),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"APIXABAN [APIXABAN] (C - Ill-defined disorder - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Ill-defined disorder - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[CALCIUM CARBONATE] (C - Ill-defined disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[CARBOMER, CARBOMER 980] (C - Ill-defined disorder - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016369901&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016369904,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dry mouth (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Erythema (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Hypotonia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Loss of consciousness (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Respiratory rate increased (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Speech disorder (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Syncope (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition),<BR><BR>Tongue dry (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016369904&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016369946,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Asthenia (2d - Recovered/Resolved - ),<BR><BR>Confusional state (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016369946&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016370146,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ALLOPURINOL] (C - Arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Migraine - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CODEINE PHOSPHATE BP, PARACETAMOL PH. EUR., PARACETAMOL, CODEINE PHOSPHATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016370146&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016370347,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Confusional state (8d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Migraine (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Monoplegia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Muscle contractions involuntary (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Mutism (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tremor (6d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016370347&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016370570,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Female,"Abdominal pain upper (2h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (2h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (2h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hypoaesthesia (2h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia (2h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pharyngeal swelling (2h - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"[FLUOXETINE] (C - Anxiety - n/a - [n/a - n/a - Oral use]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016370570&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016371420,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypoaesthesia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[ENALAPRIL MALEATE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[LANSOPRAZOLE] (C - Peptic ulcer - n/a - [n/a - n/a - Oral use]),<BR><BR>[LEVOCABASTINE] (C - Rhinitis allergic - n/a - [502d - n/a - Ocular use]),<BR><BR>[METRONIDAZOLE] (C - Inflammation - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - Constipation - n/a - [669d - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016371420&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016371421,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Hypoacusis (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016371421&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016371422,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Diarrhoea (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),[METFORMIN HYDROCHLORIDE] (C - Type 2 diabetes mellitus - n/a - [n/a - 500mg - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016371422&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016371423,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Headache (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"APEXXNAR [ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15B CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE] (C - Immunisation - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>[BETAMETHASONE DIPROPIONATE, CALCIPOTRIOL, BETAMETHASONE DIPROPIONATE, CALCIPOTRIOL MONOHYDRATE, BETAMETHASONE, CALCIPOTRIOL] (C - Psoriasis - n/a - [n/a - 1{DF} - Cutaneous use]),<BR><BR>[BETAMETHASONE DIPROPIONATE, CALCIPOTRIOL, BETAMETHASONE DIPROPIONATE, CALCIPOTRIOL MONOHYDRATE, BETAMETHASONE, CALCIPOTRIOL] (C - Psoriasis - n/a - [n/a - n/a - Cutaneous use]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[LEVONORGESTREL, LEVONORGESTREL MICRONISED] (C - Contraception - n/a - [n/a - n/a - Intrauterine use]),<BR><BR>[METHOTREXATE, METHOTREXATE DISODIUM, METHOTREXATE SODIUM] (C - Psoriasis - n/a - [n/a - 15mg - Subcutaneous use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016371423&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016371424,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016371424&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016371425,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Urticaria (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),"[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016371425&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016371426,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Contusion (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016371426&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016371429,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypokinesia (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016371429&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016371431,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"CIALIS [TADALAFIL] (C - Erectile dysfunction - n/a - [n/a - 5mg - Oral use]),<BR><BR>SILDENAFIL TEVA [SILDENAFIL, SILDENAFIL CITRATE] (C - Erectile dysfunction - n/a - [n/a - 50mg - Oral use]),<BR><BR>[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - 20mg - Oral use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016371431&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016371432,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Arthralgia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016371432&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016371435,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Herpangina (15d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016371435&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016371436,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Oedema peripheral (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016371436&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016371437,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Asthenia (n/a - Recovering/Resolving - ),<BR><BR>Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016371437&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016371438,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Feeling hot (10d - Recovered/Resolved - ),<BR><BR>Peripheral swelling (10d - Recovered/Resolved - ),<BR><BR>Rash erythematous (10d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"MYFENAX [MYCOPHENOLATE MOFETIL] (C - Immunosuppression - n/a - [n/a - 250mg - n/a]),<BR><BR>MYFENAX [MYCOPHENOLATE MOFETIL] (C - Immunosuppression - n/a - [n/a - 500mg - n/a]),<BR><BR>[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - 20mg - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[DOXAZOSIN, DOXAZOSIN MESILATE] (C - Hypertension - n/a - [n/a - 4mg - n/a]),<BR><BR>[EVEROLIMUS] (C - Immunosuppression - n/a - [n/a - 2.25mg - n/a]),<BR><BR>[FUROSEMIDE] (C - Diuretic therapy - n/a - [n/a - 40mg - n/a]),<BR><BR>[METOPROLOL TARTRATE] (C - Hypertension - n/a - [n/a - 50mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016371438&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016371439,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Limb discomfort (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016371439&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016371440,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Feeling hot (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Swelling face (n/a - Not Recovered/Not Resolved - ),<BR><BR>Swollen tongue (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016371440&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016371737,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovering/Resolving - Disabling),<BR><BR>Cough (n/a - Recovering/Resolving - Disabling),<BR><BR>Decreased appetite (n/a - Unknown - Disabling),<BR><BR>Influenza (n/a - Recovering/Resolving - Disabling),<BR><BR>Influenza like illness (n/a - Recovering/Resolving - Disabling),<BR><BR>Nasopharyngitis (n/a - Recovering/Resolving - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUTAMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LACTULOSE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016371737&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016371972,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Vaccination site reaction (n/a - Unknown - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - n/a - Drug withdrawn - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016371972&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016371977,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Herpes zoster (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY OMICRON XBB.1.5 3 MICROGRAMS/DOSE CONCENTRATE FOR DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),<BR><BR>FLUAD TETRA SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Drug withdrawn - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016371977&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016371995,Spontaneous,2023-11-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Vaccination site reaction (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 10 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016371995&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016372585,Spontaneous,2023-11-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016372585&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016356386,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Myopericarditis (n/a - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016356386&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016356446,Spontaneous,2023-11-28 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,COVID-19 (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016356446&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016356814,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Blood magnesium decreased (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Fall (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016356814&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016357212,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain lower (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>C-reactive protein increased (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Diverticular perforation (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Diverticulitis (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Injection site reaction (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016357212&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016357276,Spontaneous,2023-11-28 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Abdominal pain upper (n/a - Fatal - Results in Death),<BR><BR>Sudden death (n/a - Fatal - Results in Death)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[ACETYLSALICYLIC ACID] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[ACICLOVIR, ACICLOVIR SODIUM] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[BUMETANIDE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[FENTANYL] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, OMEPRAZOLE SODIUM] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016357276&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016357283,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Palpitations (6d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016357283&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016357284,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Menstrual disorder (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016357284&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016357285,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Alopecia areata (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),"[B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010, B/BRISBANE/60/2008-LIKE VIRUS, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227)] (C - Immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016357285&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016357525,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (3d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (3d - Recovered/Resolved - ),<BR><BR>Herpes zoster (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (6d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (6d - Recovered/Resolved - ),<BR><BR>Injection site pain (6d - Recovered/Resolved - ),<BR><BR>Injection site warmth (6d - Recovered/Resolved - ),<BR><BR>Pyrexia (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - Not applicable - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016357525&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016357528,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (2d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (2d - Recovered/Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016357528&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016357529,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Incontinence (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016357529&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016357530,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Diarrhoea (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>OZEMPIC SOLUTION FOR INJECTION IN PRE-FILLED PEN [SEMAGLUTIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OLMESARTAN MEDOXOMIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016357530&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016357535,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Diarrhoea (1d - Recovered/Resolved - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Muscle spasms (1d - Recovered/Resolved - ),<BR><BR>Myalgia (2d - Recovered/Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016357535&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016357741,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dysgeusia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Ear discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Ear pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Parosmia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Taste disorder (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016357741&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016357743,Spontaneous,2023-11-28 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Rash (5d - Recovered/Resolved - ),<BR><BR>Swelling (5d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016357743&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016357747,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Epistaxis (n/a - Recovered/Resolved - ),<BR><BR>Immune thrombocytopenia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Skin discolouration (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016357747&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016357849,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Blood pressure abnormal (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Cardiac failure (n/a - Unknown - Life Threatening, Other Medically Important Condition),<BR><BR>Viral myocarditis (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)",RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016357849&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016357904,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cough (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Influenza like illness (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - ),<BR><BR>Rhinorrhoea (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - n/a - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016357904&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016358029,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Herpes zoster (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016358029&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016358031,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016358031&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016358035,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Dysgeusia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016358035&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016358043,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Condition aggravated (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016358043&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016358045,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016358045&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016358047,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Headache (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Vertigo (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016358047&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016358049,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Malaise (6d - Recovered/Resolved - ),<BR><BR>Palpitations (6d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016358049&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016358147,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Brain fog (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016358147&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016358348,Spontaneous,2023-11-28 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Syncope (n/a - Recovered/Resolved - ),<BR><BR>Vomiting (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [1d - n/a - Intramuscular use]),"[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - n/a - n/a - [1d - n/a - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016358348&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016358520,Spontaneous,2023-11-28 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Adrenocortical insufficiency acute (4h - Recovered/Resolved - Life Threatening),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016358520&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016359142,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Granuloma annulare (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lichen planopilaris (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016359142&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016359346,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 6{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016359346&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016359646,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016359646&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016359649,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016359649&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016359865,Spontaneous,2023-11-28 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Erythema nodosum (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - ),<BR><BR>Swelling (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 HAEMAGGLUTININ ANTIGEN, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - Subcutaneous use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016359865&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016359933,Spontaneous,2023-11-28 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Encephalomyelitis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016359933&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016359948,Spontaneous,2023-11-28 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Herpes zoster (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 30ug - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016359948&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016360190,Spontaneous,2023-11-28 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,"Injected limb mobility decreased (4wk - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (4wk - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016360190&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016360192,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nasopharyngitis (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site reaction (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - Immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016360192&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016360193,Spontaneous,2023-11-28 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Acute respiratory failure (3wk - Recovering/Resolving - ),<BR><BR>Cardiac failure (3wk - Recovering/Resolving - ),<BR><BR>Chest pain (3wk - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016360193&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016360241,Spontaneous,2023-11-28 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Extensive swelling of vaccinated limb (n/a - Recovering/Resolving - ),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - ),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - ),<BR><BR>Skin disorder (n/a - Recovering/Resolving - ),<BR><BR>Urticaria (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016360241&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016360751,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Visual impairment (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vitreous detachment (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016360751&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016360886,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016360886&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016360982,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016360982&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016361187,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Cerebral venous sinus thrombosis (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Epilepsy (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Subarachnoid haemorrhage (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016361187&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016361380,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chromaturia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Delirium (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling of body temperature change (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Urinary tract infection (n/a - Unknown - Other Medically Important Condition),<BR><BR>Urine odour abnormal (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),[FOLIC ACID] (C - Folate deficiency - n/a - [n/a - 5mg - Oral use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016361380&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016361408,Spontaneous,2023-11-28 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cerebrovascular accident (n/a - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Diplopia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"JARDIANCE [EMPAGLIFLOZIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>TRAJENTA [LINAGLIPTIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM TRIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[GLIMEPIRIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016361408&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016361533,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016361533&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016361564,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Herpes zoster (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Mass (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Neuralgia (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Pruritus (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Rash (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Rash macular (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016361564&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016361586,Spontaneous,2023-11-28 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Male,"Asthenia (1d - Recovered/Resolved - Disabling),<BR><BR>Disorientation (1d - Recovered/Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),"CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>METFORMIN HYDROCHLORIDE, VILDAGLIPTIN [METFORMIN HYDROCHLORIDE, VILDAGLIPTIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[INDAPAMIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[ISOSORBIDE MONONITRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[OLMESARTAN MEDOXOMIL, AMLODIPINE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016361586&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016361939,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Joint swelling (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016361939&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016361941,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypoaesthesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016361941&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016361942,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Male,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016361942&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016361946,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (210min - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (3h - Recovered/Resolved - ),<BR><BR>Injection site inflammation (3h - Recovered/Resolved - ),<BR><BR>Injection site pain (3h - Recovered/Resolved - ),<BR><BR>Injection site swelling (3h - Recovered/Resolved - ),<BR><BR>Injection site warmth (3h - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (3h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016361946&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016361953,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rhinorrhoea (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (S - Pneumococcal immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016361953&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016362618,Spontaneous,2023-11-28 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Hypertransaminasaemia (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (8d - Recovered/Resolved - ),<BR><BR>Nausea (8d - Recovered/Resolved - ),<BR><BR>Neutropenia (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (8d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016362618&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016362622,Spontaneous,2023-11-28 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016362622&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016362639,Spontaneous,2023-11-28 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Lymphadenopathy (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016362639&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016362685,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Lymphadenopathy (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016362685&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016362987,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Constipation (n/a - Recovering/Resolving - ),<BR><BR>Intermenstrual bleeding (n/a - Recovering/Resolving - ),<BR><BR>Muscle spasms (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[DYDROGESTERONE, ESTRADIOL] (S - Menopausal symptoms - Dose not changed - [n/a - n/a - n/a])",[LEUPRORELIN ACETATE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016362987&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016363700,Spontaneous,2023-11-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Asthenia (n/a - Fatal - Results in Death),<BR><BR>Bedridden (n/a - Fatal - Results in Death),<BR><BR>Death (11d - Fatal - Results in Death),<BR><BR>Dysphagia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Fatal - Results in Death),<BR><BR>Muscular weakness (n/a - Fatal - Results in Death)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - n/a - n/a])","[CLEMIZOLE PENICILLIN] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL, CAFFEINE, PARACETAMOL, CAFFEINE, CODEINE PHOSPHATE, PARACETAMOL, CAFFEINE, CODEINE PHOSPHATE HEMIHYDRATE, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE, ANHYDROUS CAFFEINE] (C - Pain - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016363700&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016348510,Spontaneous,2023-11-27 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,Yes,Female,"Hyperhidrosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypertensive crisis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016348510&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016348785,Spontaneous,2023-11-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dyspnoea exertional (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016348785&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016348842,Spontaneous,2023-11-27 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016348842&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016348987,Spontaneous,2023-11-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cardiac failure acute (n/a - Fatal - Results in Death),<BR><BR>Multiple organ dysfunction syndrome (n/a - Fatal - Results in Death),<BR><BR>Pulmonary congestion (n/a - Fatal - Results in Death)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),"AZOPT [BRINZOLAMIDE] (C - n/a - n/a - [n/a - 1[drp] - Ocular use]),<BR><BR>[ACETYLCYSTEINE] (C - n/a - n/a - [n/a - 200mg - Oral use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - n/a - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>[LATANOPROST] (C - n/a - n/a - [n/a - 1[drp] - Ocular use]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - 1{DF} - Inhalation use]),<BR><BR>[TIOTROPIUM, TIOTROPIUM BROMIDE, TIOTROPIUM BROMIDE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - Inhalation use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016348987&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016349640,Spontaneous,2023-11-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Herpes zoster (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - .3mL - Intramuscular use]),"[CHLORTALIDONE] (C - Hypertension - n/a - [n/a - 12.5mg - Oral use]),<BR><BR>[METOPROLOL, METOPROLOL TARTRATE] (C - Hypertension - n/a - [n/a - 95mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016349640&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016349787,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Diarrhoea (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016349787&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016349790,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Injection site haematoma (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016349790&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016349875,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016349875&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016349985,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Menstruation irregular (3d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016349985&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016349987,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Male,"Asthenia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Feeling cold (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Heart rate increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypoaesthesia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016349987&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016350020,Spontaneous,2023-11-27 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016350020&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016350164,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Presyncope (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[DILTIAZEM HYDROCHLORIDE] (C - Palpitations - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, CODEINE PHOSPHATE] (C - Back pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016350164&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016350264,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016350264&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016350268,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Oedema peripheral (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE] (C - Anxiety - Dose not changed - [n/a - 225mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016350268&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016350452,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Gait disturbance (n/a - Recovering/Resolving - ),<BR><BR>Limb discomfort (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016350452&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016350679,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016350679&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016350685,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016350685&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016350688,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016350688&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016350692,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016350692&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016350693,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"FORXIGA 10 MG FILM-COATED TABLETS [DAPAGLIFLOZIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUNARIZINE, FLUNARIZINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016350693&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016350879,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Retching (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016350879&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016350882,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Limb discomfort (n/a - Recovering/Resolving - ),<BR><BR>Paraesthesia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016350882&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016351132,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Vaccination site lymphadenopathy (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016351132&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016351338,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[CICLOSPORIN] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016351338&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016351346,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arrhythmia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Atrial fibrillation (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Blood pressure increased (1d - Recovered/Resolved - ),<BR><BR>Heart rate increased (1d - Recovered/Resolved - ),<BR><BR>Tachycardia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016351346&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016351410,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016351410&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016351437,Spontaneous,2023-11-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pruritus (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016351437&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016351616,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016351616&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016351911,Spontaneous,2023-11-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Male,Paraesthesia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),"[CHLORTALIDONE, AZILSARTAN MEDOXOMIL] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[EZETIMIBE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016351911&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016351969,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dyspnoea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Dyspnoea exertional (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Feeling cold (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Hot flush (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Migraine (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [1d - n/a - n/a]),"RAPAMUNE [SIROLIMUS] (C - Lymphangioleiomyomatosis - n/a - [n/a - n/a - n/a]),<BR><BR>[CALCIUM, CALCIUM CARBONATE, COLECALCIFEROL, CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FELODIPINE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[LORATADINE] (C - Seasonal allergy - n/a - [n/a - n/a - n/a]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016351969&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016352085,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Hypoaesthesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016352085&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016352090,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rash pruritic (n/a - Unknown - ),<BR><BR>Skin infection (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016352090&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016352375,Spontaneous,2023-11-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pericarditis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 3 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016352375&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016352429,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016352429&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016352553,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Immunisation reaction (n/a - Unknown - Life Threatening),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016352553&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016352608,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (1d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016352608&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016352616,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Swelling face (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016352616&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016352821,Spontaneous,2023-11-27 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016352821&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016352950,Spontaneous,2023-11-27 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthma (n/a - Recovering/Resolving - ),<BR><BR>Head discomfort (n/a - Recovering/Resolving - ),<BR><BR>Hypoaesthesia (1d - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),JYSELECA [FILGOTINIB] (C - Arthritis - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016352950&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016353024,Spontaneous,2023-11-27 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016353024&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016353155,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Nausea (n/a - Recovering/Resolving - ),<BR><BR>Vertigo (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016353155&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016353160,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,Hypoglycaemia (1d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),ACTRAPID PENFILL 100 IE/ML OPLOSSING VOOR INJECTIE IN EEN PATROON [INSULIN HUMAN (RDNA)] (C - n/a - Dose reduced - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016353160&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016353164,Spontaneous,2023-11-27 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Pneumonia (n/a - Fatal - Results in Death),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016353164&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016353174,Spontaneous,2023-11-27 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Malaise (n/a - Unknown - ),<BR><BR>Syncope (2min - Recovered/Resolved - ),<BR><BR>Vomiting (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016353174&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016353177,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pain (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016353177&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016353180,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Taste disorder (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016353180&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016353181,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Fatigue (14d - Recovered/Resolved - ),<BR><BR>Headache (2d - Recovered/Resolved - ),<BR><BR>Myalgia (2d - Recovered/Resolved - ),<BR><BR>Nasal congestion (n/a - Recovered/Resolved - ),<BR><BR>Oropharyngeal pain (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016353181&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016353182,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Dizziness (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016353182&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016353191,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (S - Pneumococcal immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016353191&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016353318,Spontaneous,2023-11-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Hypertension (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016353318&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016353473,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Arthritis (n/a - Unknown - ),<BR><BR>Back pain (n/a - Recovering/Resolving - ),<BR><BR>Disease recurrence (n/a - Unknown - Other Medically Important Condition),<BR><BR>Inflammation (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Systemic lupus erythematosus (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"LEVOFLOXACIN [LEVOFLOXACIN] (C - Anticoagulant therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[ENOXAPARIN, ENOXAPARIN SODIUM] (C - Anticoagulant therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXYCHLOROQUINE] (C - Systemic lupus erythematosus - n/a - [n/a - n/a - Oral use]),<BR><BR>[LOSARTAN POTASSIUM] (C - Blood pressure measurement - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016353473&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016353506,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Presyncope (n/a - Fatal - Results in Death),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016353506&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016353547,Spontaneous,2023-11-27 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Headache (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016353547&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016353709,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016353709&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016353882,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016353882&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016353890,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016353890&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016354452,Spontaneous,2023-11-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Cerebral infarction (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Cerebral thrombosis (7d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [256d - n/a - Oral use]),<BR><BR>[BETAMETHASONE, BETAMETHASONE DIPROPIONATE] (C - Eczema - n/a - [n/a - n/a - Cutaneous use]),<BR><BR>[CLOPIDOGREL, CLOPIDOGREL BESILATE, CLOPIDOGREL HYDROGEN SULFATE] (C - Thrombosis prophylaxis - n/a - [276d - n/a - Oral use]),<BR><BR>[LERCANIDIPINE HYDROCHLORIDE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016354452&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016354453,Spontaneous,2023-11-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Ataxia (n/a - Unknown - Life Threatening),<BR><BR>Balance disorder (n/a - Unknown - Life Threatening),<BR><BR>Cerebral ischaemia (n/a - Unknown - Life Threatening),<BR><BR>Cerebrovascular accident (n/a - Recovering/Resolving - Life Threatening),<BR><BR>Dysarthria (n/a - Unknown - Life Threatening),<BR><BR>Facial paresis (n/a - Unknown - Life Threatening)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016354453&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016354473,Spontaneous,2023-11-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016354473&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016354957,Spontaneous,2023-11-27 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Diarrhoea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Eyelid oedema (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tongue oedema (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B)] (S - Influenza immunisation - Drug withdrawn - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016354957&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016354989,Spontaneous,2023-11-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (12d - Recovered/Resolved - ),<BR><BR>Arthritis (n/a - Recovered/Resolved - ),<BR><BR>Oedema peripheral (12d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016354989&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016354993,Spontaneous,2023-11-27 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Vaccination site erythema (6d - Recovered/Resolved - ),<BR><BR>Vaccination site oedema (6d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"DAPAGLIFLOZIN [DAPAGLIFLOZIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>LIRAGLUTIDE [LIRAGLUTIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016354993&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016355160,Spontaneous,2023-11-27 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Malaise (11d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - ),<BR><BR>Tremor (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016355160&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016348363,Spontaneous,2023-11-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (1wk - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016348363&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016348475,Spontaneous,2023-11-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016348475&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016348476,Spontaneous,2023-11-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Fatigue (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016348476&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346598,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Myalgia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346598&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346600,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Vaccination site lymphadenopathy (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346600&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346601,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Tachycardia (30min - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346601&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346602,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Herpes zoster (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"LATANOPROST [LATANOPROST] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DORZOLAMIDE HYDROCHLORIDE, TIMOLOL MALEATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346602&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346603,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Hypertension (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (7d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXYCHLOROQUINE SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PANTOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PAROXETINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346603&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346604,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Dizziness (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346604&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346605,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346605&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346607,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Hypoglycaemia (n/a - Recovered/Resolved - Life Threatening),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOVOMIX 30 FLEXPEN 100 UNITS/ML SUSPENSION FOR INJECTION IN PRE-FILLED PEN [INSULIN ASPART] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346607&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346608,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Constipation (120h - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346608&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346609,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Body temperature abnormal (3min - Recovered/Resolved - ),<BR><BR>Chills (3min - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Tonsillar hypertrophy (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346609&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346610,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Gout (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"DABIGATRAN ETEXILATE ACCORD 75 MG HARD CAPSULES [DABIGATRAN ETEXILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BARNIDIPINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CLOPAMIDE, RESERPINE, DIHYDROERGOCRISTINE, CLOPAMIDE, RESERPINE, DIHYDROERGOCRISTINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROCHLOROTHIAZIDE, QUINAPRIL, QUINAPRIL HYDROCHLORIDE, HYDROCHLOROTHIAZIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MOXONIDINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SOTALOL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SPIRONOLACTONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346610&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346611,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>PANTOPRAZOLE 20 MG - GASTRO-RESISTANT TABLET  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>XARELTO 15 MG FILM-COATED TABLETS [RIVAROXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FERROUS FUMARATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346611&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346612,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lacrimation increased (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346612&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346613,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Breast discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Constipation (n/a - Recovering/Resolving - ),<BR><BR>Feeling abnormal (n/a - Not Recovered/Not Resolved - ),<BR><BR>Gastrointestinal pain (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pruritus (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346613&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346615,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arrhythmia (3d - Recovering/Resolving - ),<BR><BR>Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Dizziness (3d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (3d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (3d - Recovered/Resolved - ),<BR><BR>Injection site pain (3d - Recovered/Resolved - ),<BR><BR>Injection site warmth (3d - Recovered/Resolved - ),<BR><BR>Malaise (3d - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Scrotal swelling (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346615&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346616,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Ageusia (n/a - Recovering/Resolving - ),<BR><BR>Anosmia (n/a - Recovering/Resolving - ),<BR><BR>Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (7d - Recovered/Resolved - ),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - ),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site haematoma (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Musculoskeletal stiffness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346616&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346617,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arthralgia (1d - Recovered/Resolved - ),<BR><BR>Chills (2d - Recovered/Resolved - ),<BR><BR>Fatigue (3wk - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (2wk - Recovered/Resolved - ),<BR><BR>Injection site haematoma (2wk - Recovered/Resolved - ),<BR><BR>Injection site inflammation (2wk - Recovered/Resolved - ),<BR><BR>Injection site warmth (2wk - Recovered/Resolved - ),<BR><BR>Malaise (2d - Recovered/Resolved - ),<BR><BR>Myalgia (3d - Recovered/Resolved - ),<BR><BR>Palpitations (1wk - Recovered/Resolved - ),<BR><BR>Rash pruritic (4h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346617&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346618,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (72h - Recovered/Resolved - ),<BR><BR>Chills (120h - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (96h - Recovered/Resolved - ),<BR><BR>Injection site inflammation (96h - Recovered/Resolved - ),<BR><BR>Injection site pain (96h - Recovered/Resolved - ),<BR><BR>Injection site warmth (96h - Recovered/Resolved - ),<BR><BR>Intermenstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (96h - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (72h - Recovered/Resolved - ),<BR><BR>Pyrexia (72h - Recovered/Resolved - ),<BR><BR>Vaccination site lymphadenopathy (96h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"SPIRAAL (SPIRAALTJE, INTRAUTERINE DEVICE, IUD, INTRAUTERINE CONTRACEPTIVE DEVICE) [NOT AVAILABLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346618&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346620,Spontaneous,2023-11-25 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Dyspnoea exertional (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pulmonary embolism (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>XARELTO 15 MG FILM-COATED TABLETS [RIVAROXABAN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346620&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346622,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chills (3h - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346622&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346623,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Extensive swelling of vaccinated limb (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346623&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346624,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Dry mouth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346624&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346625,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346625&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346626,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (S - Pneumococcal immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346626&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346627,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (4h - Recovered/Resolved - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - ),<BR><BR>Vertigo (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346627&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346628,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (n/a - Recovered/Resolved - ),<BR><BR>Fatigue (5d - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Nausea (n/a - Recovered/Resolved - ),<BR><BR>Palpitations (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346628&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346630,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (36h - Recovered/Resolved - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (20h - Recovered/Resolved - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Malaise (48h - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346630&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346631,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arrhythmia (n/a - Recovering/Resolving - ),<BR><BR>Chills (2d - Recovered/Resolved - ),<BR><BR>Cough (n/a - Recovering/Resolving - ),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (2d - Recovered/Resolved - ),<BR><BR>Nausea (2d - Recovered/Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346631&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346632,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346632&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346633,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),ELIQUIS 2.5 MG FILM-COATED TABLETS [APIXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346633&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346634,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346634&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346635,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Postmenopausal haemorrhage (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346635&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346636,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Body temperature increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346636&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346637,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (3d - Recovered/Resolved - ),<BR><BR>Chills (2d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (3d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (3d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346637&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346638,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PAROXETINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346638&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346640,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (1d - Recovered/Resolved - ),<BR><BR>Chills (35min - Recovered/Resolved - ),<BR><BR>Fatigue (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346640&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346641,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346641&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346642,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Gastrointestinal pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (S - Pneumococcal immunisation - Not applicable - [n/a - 1{DF} - n/a])",[OMEPRAZOLE MAGNESIUM] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346642&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346643,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Headache (1d - Recovered/Resolved - ),<BR><BR>Injection site swelling (1d - Recovered/Resolved - ),<BR><BR>Malaise (18h - Recovered/Resolved - ),<BR><BR>Myalgia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346643&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346644,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346644&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346783,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Dyspepsia (56d - Recovered/Resolved - ),<BR><BR>Dyspepsia (80d - Recovered/Resolved - ),<BR><BR>Dyspepsia (n/a - Recovering/Resolving - ),<BR><BR>Gastritis (56d - Recovered/Resolved - ),<BR><BR>Gastritis (80d - Recovered/Resolved - ),<BR><BR>Gastritis (n/a - Recovering/Resolving - ),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - ),<BR><BR>Loss of consciousness (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use])","[A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010, B/PHUKET/3073/2013-LIKE STRAIN, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/BRISBANE/60/2008, A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, B/MASSACHUSETTS/02/2012, A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010, B/BRISBANE/60/2008, B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010, B/BRISBANE/60/2008-LIKE VIRUS, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, NIB-121), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - 1{DF} - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346783&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346882,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Vitreous haemorrhage (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346882&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346883,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346883&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346884,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Papule (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346884&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346885,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346885&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346886,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (24h - Recovered/Resolved - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346886&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346887,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Cough (n/a - Not Recovered/Not Resolved - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346887&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346888,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Haematoma (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site haematoma (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346888&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346889,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Pain in extremity (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346889&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346890,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (8h - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hyperhidrosis (8h - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (8h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346890&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346891,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346891&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346892,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Body temperature increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346892&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346893,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (2d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (2d - Recovered/Resolved - ),<BR><BR>Injection site warmth (2d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Rhinorrhoea (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (S - Pneumococcal immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346893&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346894,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (2d - Recovered/Resolved - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Injection site pain (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346894&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016347527,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (12h - Recovered/Resolved - ),<BR><BR>Headache (12h - Recovered/Resolved - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016347527&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016347719,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016347719&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016347784,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016347784&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016347883,Spontaneous,2023-11-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (2d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016347883&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016338053,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Amaurosis (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Retinal artery thrombosis (n/a - Recovered/Resolved With Sequelae - Disabling)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224)] (S - Influenza immunisation - n/a - [n/a - 1{DF} - Intramuscular use])","INSULIN GLARGINE [INSULIN GLARGINE] (C - Diabetes mellitus - n/a - [n/a - 8[iU] - n/a]),<BR><BR>TRAJENTA [LINAGLIPTIN] (C - Diabetes mellitus - n/a - [n/a - 5mg - Oral use]),<BR><BR>[ALLOPURINOL] (C - Hyperuricaemia - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[AMLODIPINE, INDAPAMIDE, PERINDOPRIL, PERINDOPRIL TERT-BUTYLAMINE, AMLODIPINE, INDAPAMIDE] (C - Hypertension - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[CABERGOLINE] (C - Prolactin-producing pituitary tumour - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[EZETIMIBE] (C - Hypercholesterolaemia - n/a - [n/a - 1{DF} - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016338053&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016338317,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Male,"Asthenia (n/a - Recovered/Resolved - ),<BR><BR>Chills (n/a - Recovered/Resolved - ),<BR><BR>Dizziness (n/a - Recovered/Resolved - ),<BR><BR>Hyperhidrosis (n/a - Recovered/Resolved - ),<BR><BR>Nausea (n/a - Recovered/Resolved - ),<BR><BR>Paraesthesia (n/a - Recovered/Resolved - ),<BR><BR>Syncope (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovered/Resolved - ),<BR><BR>Vision blurred (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"GARDASIL 9 [HUMAN PAPILLOMAVIRUS TYPE 31 L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 33 L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 45 L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 52 L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 58 L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6 L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11 L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16 L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18 L1 PROTEIN, AMORPHOUS ALUMINIUM HYDROXYPHOSPHATE SULPHATE] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS, STRAIN B/PHUKET/3073/2013, HAEMAGGLUTININ, VIRUS-LIKE PARTICLE, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A VIRUS A/CALIFORNIA/7/2009 X-179A (H1N1) HEMAGGLUTININ ANTIGEN (UV, FORMALDEHYDE INACTIVATED), INFLUENZA B VIRUS B/BRISBANE/60/2008 HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED), A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA A VIRUS VACCINE, H1N1, INACTIVATED] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016338317&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016338385,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016338385&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016338403,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Anaphylactic shock (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Feeling cold (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperventilation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pallor (n/a - Unknown - Other Medically Important Condition),<BR><BR>Shock (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension, Myocardial ischaemia - n/a - [n/a - n/a - Oral use]),<BR><BR>[BISOPROLOL FUMARATE] (C - Myocardial ischaemia - n/a - [n/a - n/a - Oral use]),<BR><BR>[FUROSEMIDE, FUROSEMIDE SODIUM] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[PRAVASTATIN, PRAVASTATIN SODIUM] (C - Dyslipidaemia - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016338403&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016338474,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016338474&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016339784,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Alopecia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Skin disorder (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016339784&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016339785,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Ear discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Ear pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>General physical health deterioration (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - n/a])",[CETIRIZINE DIHYDROCHLORIDE] (C - Urticaria - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016339785&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016339924,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Cerebrovascular accident (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016339924&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016340210,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016340210&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016340355,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016340355&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016340515,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Chest pain (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Gastrooesophageal reflux disease (n/a - Recovering/Resolving - ),<BR><BR>Influenza like illness (n/a - Unknown - ),<BR><BR>Parosmia (n/a - Unknown - ),<BR><BR>Tachycardia (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - Neuralgia - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>PANTOPRAZOLE 20 MG - GASTRO-RESISTANT TABLET  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BARNIDIPINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016340515&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016340821,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Troponin T increased (9d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016340821&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016340996,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016340996&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016340998,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016340998&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016341001,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016341001&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016341004,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (4h - Recovered/Resolved - ),<BR><BR>Fatigue (3d - Recovered/Resolved - ),<BR><BR>Headache (36h - Recovered/Resolved - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Malaise (3d - Recovered/Resolved - ),<BR><BR>Myalgia (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - ),<BR><BR>Sensitive skin (1d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (S - Pneumococcal immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016341004&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016341006,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016341006&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016341855,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Herpes zoster (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016341855&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016341856,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Limb discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016341856&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016342190,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016342190&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016342989,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Transient ischaemic attack (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016342989&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016343009,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Pulmonary embolism (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])","[ALLOPURINOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALPRAZOLAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CYAMEMAZINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PAROXETINE HYDROCHLORIDE, ANHYDROUS] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PERINDOPRIL, PERINDOPRIL TERT-BUTYLAMINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016343009&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016343018,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Aphasia (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Confusional state (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016343018&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016343058,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Herpes zoster (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016343058&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016343187,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Injection site reaction (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016343187&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016343203,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Injected limb mobility decreased (3wk - Recovered/Resolved - ),<BR><BR>Pain in extremity (3wk - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - Injection - Not applicable - [1d - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016343203&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016343220,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Asthenia (10d - Recovered/Resolved - ),<BR><BR>Headache (10d - Recovered/Resolved - ),<BR><BR>Pruritus (10d - Recovered/Resolved - ),<BR><BR>Rash morbilliform (10d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016343220&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016343247,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Influenza like illness (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),"XARELTO 20 MG FILM-COATED TABLETS [RIVAROXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[EPLERENONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016343247&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016343248,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Urticaria (n/a - Recovered/Resolved - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [1d - 1{DF} - Intramuscular use]),<BR><BR>[A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN, A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN, B/FLORIDA/4/2006-LIKE STRAIN, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/VICTORIA/361/2011 (H3N2)–DERIVED STRAIN USED (IVR-165), B/WISCONSIN/1/2010-LIKE STRAIN USED (NYMC BX-39) DERIVED FROM B/HUBEI-WUJIAGANG/158/2009, A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/MOSCOW/10/99 (H3N2) - LIKE STRAIN (A/PANAMA/2007/99 REASS. RESVIR-17), B/SICHUAN/379/99-LIKE STRAIN (B/JOHANNESBURG/5/99), A/SOUTH AUSTRALIA/55/2014 STRAIN, A/SWITZERLAND/9715293/2013 (H3N2) - LIKE STRAIN (A/SOUTH AUSTRALIA/55/2014, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, B/MASSACHUSETTS/02/2012, A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/VICTORIA/361/2011 (H3N2)–DERIVED STRAIN USED (IVR-165), B/WISCONSIN/1/2010-LIKE STRAIN USED (NYMC BX-39) DERIVED FROM B/HUBEI-WUJIAGANG/158/2009, A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/WISCONSIN/67/2005 (H3N2), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN, B/MALAYSIA/2506/2004 - LIKE STRAIN, B/BEIJING/184/93-LIKE STRAIN (B/YAMANASHI/166/98), A/SYDNEY/5/97 (H3N2)-LIKE STRAIN (A/SYDNEY/5/97 REASS. RESVIR 13), A/BEIJING/262/95 (H1N1) - LIKE STRAIN (A/BEIJING/262/95 REASS. X-127), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1), A/PERTH/16/2009 (H3N2) - LIKE STRAIN, B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009(H1N1)-LIKE STRAIN (NYMC X-179A), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NIB-65), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009(H1N1)-LIKE STRAIN (NYMC X-179A), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/MASSACHUSETTS/02/2012, A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE STRAIN, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SOUTH AUSTRALIA/55/2014, IVR-175), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED)] (S - Influenza immunisation - n/a - [1d - 1{DF} - Intramuscular use])","[ETHINYLESTRADIOL, LEVONORGESTREL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016343248&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016343263,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Influenza like illness (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016343263&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016343287,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Vaccination site pain (1d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016343287&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016343289,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Myocardial necrosis (n/a - Fatal - Results in Death),<BR><BR>Myocardial rupture (n/a - Fatal - Results in Death),<BR><BR>Pericardial effusion (n/a - Fatal - Results in Death)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),KEPPRA [LEVETIRACETAM] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016343289&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016343294,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Pyrexia (1d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),"[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016343294&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016343300,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Male,"Arthralgia (13d - Recovered/Resolved - ),<BR><BR>Dyspnoea (13d - Recovered/Resolved - ),<BR><BR>Fatigue (13d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),"UROREC [SILODOSIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>XARELTO [RIVAROXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL FUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DUTASTERIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016343300&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016343372,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Musculoskeletal stiffness (n/a - Unknown - Disabling),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016343372&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016343555,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016343555&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016343656,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016343656&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016343932,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Abdominal pain upper (n/a - Recovering/Resolving - ),<BR><BR>Breast pain (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016343932&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016344208,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Rash (n/a - Unknown - Other Medically Important Condition),<BR><BR>Swelling face (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016344208&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016344316,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Influenza like illness (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Thrombocytosis (n/a - Unknown - Caused/Prolonged Hospitalisation)",COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),ELIQUIS [APIXABAN] (C - Pulmonary embolism - Dose not changed - [n/a - 5mg - Oral use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016344316&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016344421,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Hypotonia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016344421&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016344688,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016344688&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016344689,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Disabling),<BR><BR>Headache (n/a - Recovering/Resolving - Disabling),<BR><BR>Heart rate increased (n/a - Recovered/Resolved - Disabling),<BR><BR>Illness (n/a - Recovering/Resolving - Disabling),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016344689&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016344690,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016344690&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016344703,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"TESTOSTERONE [TESTOSTERONE] (C - Menopause - n/a - [n/a - n/a - Vaginal use]),<BR><BR>[ESCITALOPRAM, ESCITALOPRAM OXALATE] (C - Depression - n/a - [n/a - n/a - Oral use]),<BR><BR>[ESTRADIOL] (C - Menopause - n/a - [n/a - n/a - Oral use - More in ICSR]),<BR><BR>[GABAPENTIN] (C - Depression - n/a - [n/a - n/a - Oral use]),<BR><BR>[PROGESTERONE] (C - Menopause - n/a - [n/a - n/a - Oral use - More in ICSR]),<BR><BR>[THYROID] (C - Autoimmune thyroiditis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016344703&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016344712,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),CELLCEPT [MYCOPHENOLATE MOFETIL] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016344712&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016344721,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016344721&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016344748,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Diplopia (n/a - Not Recovered/Not Resolved - ),<BR><BR>VIth nerve paralysis (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016344748&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016344749,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016344749&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016344759,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,"Asthenia (3d - Recovered/Resolved - Disabling),<BR><BR>Malaise (3d - Recovered/Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),"[ALPRAZOLAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016344759&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016345746,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - ),<BR><BR>Flushing (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Hyperhidrosis (n/a - Unknown - ),<BR><BR>Lymphadenopathy (n/a - Unknown - ),<BR><BR>Pain (n/a - Unknown - ),<BR><BR>Vaccination site erythema (n/a - Unknown - ),<BR><BR>Vaccination site warmth (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[CELECOXIB] (C - Rheumatoid arthritis - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016345746&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016345749,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,Illness (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016345749&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016345755,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Incorrect dose administered (n/a - Unknown - ),<BR><BR>Nausea (n/a - Recovered/Resolved - ),<BR><BR>Vomiting (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"ESOMEPRAZOLE [ESOMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>FESOTERODINE [FESOTERODINE] (C - Urge incontinence - n/a - [n/a - n/a - Oral use]),<BR><BR>HYDROCHLOROTHIAZIDE, TELMISARTAN [HYDROCHLOROTHIAZIDE, TELMISARTAN] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[ALPRAZOLAM] (C - Anxiety - n/a - [n/a - n/a - Oral use]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[ESCITALOPRAM, ESCITALOPRAM OXALATE] (C - Depression - n/a - [n/a - n/a - Oral use]),<BR><BR>[INDACATEROL] (C - Chronic obstructive pulmonary disease - n/a - [n/a - n/a - Inhalation use]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - Oral use]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - Urinary tract infection - n/a - [7d - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016345755&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016345978,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Cardiac arrest (0d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Feeling abnormal (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016345978&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016345986,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Cerebrovascular accident (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Headache (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Lethargy (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Neck pain (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016345986&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346005,Spontaneous,2023-11-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Anaphylactic reaction (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346005&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346008,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Burning sensation (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Dizziness (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Nausea (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Pain (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])","[GABAPENTIN] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Prophylaxis against gastrointestinal ulcer - n/a - [n/a - n/a - n/a]),<BR><BR>[MORPHINE SULFATE] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[POTASSIUM CHLORIDE] (C - Hypocalcaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[PROPRANOLOL HYDROCHLORIDE] (C - Tremor - n/a - [n/a - n/a - n/a]),<BR><BR>[SPIRONOLACTONE] (C - Diuretic therapy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346008&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346124,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Lymphadenopathy (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346124&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016346147,Spontaneous,2023-11-24 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Lymphadenopathy (n/a - Recovering/Resolving - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B)] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016346147&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016329811,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Nausea (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - ),<BR><BR>Vomiting (1d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224)] (S - Influenza immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016329811&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016329886,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Hypersensitivity (n/a - Recovering/Resolving - ),<BR><BR>Pain (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),"XARELTO [RIVAROXABAN] (C - n/a - n/a - ),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE] (C - n/a - n/a - ),<BR><BR>[BIOFLAVONOIDS, DIOSMIN, BIOFLAVONOIDS, DIOSMIN, HESPERIDIN, FLAVONOIDS EXTRACTED FROM RUTACAE (AURANTIAE), MICRONISED PURIFIED FLAVONOIC FRACTION] (C - n/a - n/a - ),<BR><BR>[FLECAINIDE ACETATE] (C - n/a - n/a - ),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - ),<BR><BR>[RAMIPRIL] (C - n/a - n/a - ),<BR><BR>[RIFAXIMIN] (C - n/a - n/a - ),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - n/a - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016329886&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016330334,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Ill-defined disorder (n/a - Unknown - Life Threatening, Other Medically Important Condition),<BR><BR>Near death experience (n/a - Unknown - Life Threatening, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016330334&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016331225,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Thunderclap headache (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>IMRALDI [ADALIMUMAB] (S - Psoriatic arthropathy - Drug withdrawn - [1d - 40mg - Intramuscular use])","LATANOPROST [LATANOPROST] (C - n/a - n/a - [n/a - 2[drp] - n/a]),<BR><BR>METHOTREXATE [METHOTREXATE] (C - Psoriatic arthropathy - n/a - [n/a - 20mg - Subcutaneous use]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - 20mg - Oral use]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[HYDROXYCHLOROQUINE] (C - n/a - n/a - [n/a - 200ug - Oral use]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - 100ug - Oral use]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - 20mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016331225&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016331278,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016331278&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016331310,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>General physical health deterioration (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Loss of personal independence in daily activities (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),"[ESCITALOPRAM, ESCITALOPRAM OXALATE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016331310&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016331539,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Vaccination site erythema (2d - Recovered/Resolved - ),<BR><BR>Vaccination site induration (2d - Recovered/Resolved - ),<BR><BR>Vaccination site pain (2d - Recovered/Resolved - ),<BR><BR>Vaccination site warmth (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016331539&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016332051,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Facial paralysis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016332051&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016332104,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Heart rate decreased (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Loss of consciousness (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016332104&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016332105,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016332105&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016332121,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Cerebrovascular accident (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - ),<BR><BR>Decreased appetite (n/a - Unknown - ),<BR><BR>Erythema (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - ),<BR><BR>Vaccination site mass (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016332121&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016332142,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Aortic intramural haematoma (n/a - Not Recovered/Not Resolved - Life Threatening),<BR><BR>Platelet count decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Thrombosis (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"HYDROCORTISONE [HYDROCORTISONE, HYDROCORTISONE SODIUM SUCCINATE] (C - Addison's disease - n/a - [n/a - n/a - n/a]),<BR><BR>PLENADREN [HYDROCORTISONE] (C - Addison's disease - n/a - [n/a - n/a - n/a]),<BR><BR>[ALENDRONATE SODIUM, ALENDRONIC ACID] (C - Osteoporosis - n/a - [n/a - n/a - n/a]),<BR><BR>[CALCIUM CARBONATE, CHOLECALCIFEROL CONCENTRATE (POWDER FORM), COLECALCIFEROL, CALCIUM CARBONATE] (C - Osteoporosis - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[SUMATRIPTAN, SUMATRIPTAN SUCCINATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TAPENTADOL] (C - Osteoporosis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016332142&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016332156,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"LYRICA [PREGABALIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>OXYBUTYNIN [OXYBUTYNIN, OXYBUTYNIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CYCLOBENZAPRINE, CYCLOBENZAPRINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[IPRATROPIUM, IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE ANHYDROUS, IPRATROPIUM BROMIDE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MELOXICAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OXYCODONE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OXYCODONE, OXYCODONE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ZOLPIDEM TARTRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016332156&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016332242,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (2d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (4d - Recovered/Resolved - ),<BR><BR>Injection site pain (4d - Recovered/Resolved - ),<BR><BR>Injection site swelling (4d - Recovered/Resolved - ),<BR><BR>Injection site warmth (4d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (3d - Recovered/Resolved - ),<BR><BR>Nerve injury (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016332242&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016332280,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Vaccination site mass (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [1d - n/a - Intramuscular use]),"XARELTO [RIVAROXABAN] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016332280&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016332302,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Male,Myalgia (2wk - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016332302&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016332319,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Chest pain (n/a - Recovered/Resolved - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - n/a - n/a - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016332319&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016332429,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Influenza like illness (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016332429&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016332676,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Headache (3d - Recovered/Resolved - ),<BR><BR>Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (1wk - Recovered/Resolved - ),<BR><BR>Injection site inflammation (1wk - Recovered/Resolved - ),<BR><BR>Injection site pain (1wk - Recovered/Resolved - ),<BR><BR>Injection site warmth (1wk - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"AERIUS 5 MG FILM-COATED TABLETS [DESLORATADINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AZELASTINE HYDROCHLORIDE, FLUTICASONE PROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ETHINYLESTRADIOL, LEVONORGESTREL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016332676&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016332677,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Chest pain (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016332677&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016332688,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016332688&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016332692,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Herpes zoster (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016332692&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016332697,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016332697&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016332710,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Malaise (3d - Recovered/Resolved - ),<BR><BR>Nasopharyngitis (3d - Recovered/Resolved - ),<BR><BR>Pyrexia (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016332710&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016332736,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"COVID-19 immunisation (n/a - Unknown - ),<BR><BR>Myokymia (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016332736&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016332877,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Supraventricular tachycardia (1d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Nerve injury - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016332877&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016332971,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Asthenia (n/a - Recovering/Resolving - ),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - ),<BR><BR>Pruritus (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016332971&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016332980,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Condition aggravated (n/a - Not Recovered/Not Resolved - ),<BR><BR>Sjogren's syndrome (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016332980&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016333183,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arrhythmia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Cardiovascular disorder (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016333183&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016333248,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Female,"Brain fog (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016333248&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016333254,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Heart rate increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site pruritus (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (3d - Recovered/Resolved - ),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site lymphadenopathy (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016333254&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016333530,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arrhythmia (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Atrial fibrillation (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Presyncope (0d - Recovered/Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016333530&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016333897,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypertension (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016333897&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016333925,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dermatitis infected (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Skin lesion (n/a - Unknown - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016333925&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016334064,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016334064&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016334178,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016334178&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016334637,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016334637&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016334716,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Mastication disorder (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Tenderness (n/a - Unknown - ),<BR><BR>Toothache (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),"[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016334716&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016334717,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Head discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Increased bronchial secretion (n/a - Not Recovered/Not Resolved - ),<BR><BR>Increased upper airway secretion (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lower respiratory tract congestion (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nasal congestion (n/a - Not Recovered/Not Resolved - ),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - ),<BR><BR>Upper respiratory tract congestion (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),"[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[CICLESONIDE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[TIOTROPIUM BROMIDE MONOHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016334717&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016334938,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Apathy (n/a - Recovered/Resolved - ),<BR><BR>Asthenia (n/a - Recovered/Resolved - ),<BR><BR>Hyperthermia (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016334938&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016334939,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Ischaemic stroke (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016334939&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016334943,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Disturbance in attention (n/a - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016334943&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016335027,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Vaccination site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site swelling (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016335027&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016335030,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"General physical health deterioration (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Hemiparesis (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY OMICRON XBB.1.5 10 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [1d - 1{DF} - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - n/a - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016335030&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016335043,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,"General physical health deterioration (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Ischaemic stroke (n/a - Not Recovered/Not Resolved - Disabling)","COMIRNATY OMICRON XBB.1.5 10 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [1d - 1{DF} - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - n/a - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016335043&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016335109,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Decreased appetite (n/a - Not Recovered/Not Resolved - ),<BR><BR>Influenza like illness (2d - Not Recovered/Not Resolved - ),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016335109&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016335186,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oxygen saturation decreased (n/a - Fatal - Results in Death),<BR><BR>Pyrexia (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>PANTOPRAZOLE 20 MG - GASTRO-RESISTANT TABLET  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CETOMACROGOL 1000] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016335186&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016335389,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016335389&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016335496,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016335496&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016335786,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Transient ischaemic attack (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016335786&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016335992,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Erythema (n/a - Unknown - ),<BR><BR>Pruritus (n/a - Unknown - ),<BR><BR>Rash (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016335992&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016336014,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest discomfort (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016336014&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016336054,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arnold-Chiari malformation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Disease recurrence (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Pain (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[SUPROFEN, TRAMADOL HYDROCHLORIDE] (C - Arnold-Chiari malformation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016336054&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016336128,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anaphylactic reaction (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Incorrect route of product administration (n/a - Unknown - Other Medically Important Condition),<BR><BR>Overdose (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .5mL - Subcutaneous use]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (N - n/a - Not applicable - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016336128&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016336188,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Injection site pain (n/a - Recovering/Resolving - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (S - Pneumococcal immunisation - Not applicable - [n/a - 1{DF} - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016336188&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016336427,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,"Erythema (16d - Recovered/Resolved - ),<BR><BR>Vaccination site oedema (16d - Recovered/Resolved - ),<BR><BR>Vaccination site swelling (16d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),"AERIUS [DESLORATADINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>AVAMYS [FLUTICASONE FUROATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METHOTREXATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[PRAVASTATIN, PRAVASTATIN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016336427&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016337327,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Maternal exposure during pregnancy (n/a - Unknown - ),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016337327&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016337333,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Vaccination site discolouration (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site exfoliation (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227)] (S - Influenza immunisation - Not applicable - [n/a - .5mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016337333&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016337358,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Influenza like illness (n/a - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016337358&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016337384,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dizziness (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - ),<BR><BR>Vaccination site inflammation (n/a - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227)] (S - n/a - Not applicable - [1d - .5mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016337384&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016337407,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Urticaria (6d - Recovering/Resolving - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016337407&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016337409,Spontaneous,2023-11-23 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Myocarditis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016337409&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016337776,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CLONAZEPAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MEDROXYPROGESTERONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PANTOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016337776&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016337777,Spontaneous,2023-11-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016337777&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016320926,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Fatigue (n/a - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Herpes zoster (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016320926&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016321011,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Fatigue (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016321011&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016321949,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Limb mass (n/a - Unknown - Other Medically Important Condition),<BR><BR>Mobility decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[CLONAZEPAM] (C - Bipolar disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[LAMOTRIGINE] (C - Bipolar disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, OMEPRAZOLE SODIUM] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Bipolar disorder - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016321949&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016322409,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016322409&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016322892,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Body temperature increased (n/a - Unknown - ),<BR><BR>Exposure during pregnancy (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016322892&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016322894,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Bone cancer (n/a - Unknown - Other Medically Important Condition),<BR><BR>Metastases to bone (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016322894&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016322897,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016322897&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016322906,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Dysstasia (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Guillain-Barre syndrome (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypotonia (n/a - Unknown - ),<BR><BR>Pain (n/a - Unknown - ),<BR><BR>Paralysis (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016322906&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016323125,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Gastrointestinal necrosis (2d - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Intestinal infarction (2d - Fatal - Results in Death, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016323125&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016323464,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Osteoarthritis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016323464&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016323654,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypersomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[BECLOMETASONE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[LORATADINE] (C - Hypersensitivity - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016323654&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016323750,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Multiple sclerosis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016323750&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016323851,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Limb discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[PNEUMOCOCCAL VACCINE] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016323851&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016323855,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Chills (1d - Recovered/Resolved - ),<BR><BR>Influenza like illness (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016323855&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016324103,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Abdominal distension (n/a - Unknown - Other Medically Important Condition),<BR><BR>Body temperature increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspepsia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Gastroenteritis viral (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"AVASTIN [BEVACIZUMAB] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016324103&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016324227,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Male,"Diarrhoea (4d - Recovered/Resolved - ),<BR><BR>Vomiting (4d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),"[ACETYLSALICYLIC ACID] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[CHLORTALIDONE, AZILSARTAN MEDOXOMIL] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[DIAZEPAM] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[LERCANIDIPINE, LERCANIDIPINE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[NEBIVOLOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[PITAVASTATIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016324227&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016324482,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,Yes,Male,Vaccination site swelling (36h - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016324482&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016324610,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Vaccination site erythema (3d - Recovered/Resolved - ),<BR><BR>Vaccination site pain (3d - Recovered/Resolved - ),<BR><BR>Vaccination site pruritus (3d - Recovered/Resolved - ),<BR><BR>Vaccination site swelling (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016324610&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016324687,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[NAPROXEN, NAPROXEN SODIUM] (C - Arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016324687&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016324781,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Body temperature increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016324781&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016324914,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Hyperaesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016324914&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016324915,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016324915&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016324995,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016324995&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016324999,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Influenza (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016324999&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016325085,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Influenza like illness (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016325085&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016325289,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Pyrexia (12d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016325289&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016325363,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Bone pain (3d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Dysgeusia (3d - Recovered/Resolved - ),<BR><BR>Joint swelling (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vaccination site induration (2wk - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vaccination site pain (2wk - Recovered/Resolved - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),"[NEBIVOLOL, NEBIVOLOL HYDROCHLORIDE] (C - Hypertension - n/a - [n/a - 20mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016325363&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016325504,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (2d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site haematoma (n/a - Recovering/Resolving - ),<BR><BR>Malaise (4d - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Oral herpes (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016325504&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016325507,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Osteoarthritis (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Product used for unknown indication - Unknown - [n/a - n/a - n/a]),[ENALAPRIL MALEATE] (C - Product used for unknown indication - Unknown - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016325507&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016325534,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Cerebral infarction (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Cerebrovascular accident (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Malaise (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a]),"[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016325534&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016325636,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Injection site pain (1d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016325636&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016325718,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Bell's palsy (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Facial paralysis (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[LANSOPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - 15mg - n/a - More in ICSR]),<BR><BR>[MIRTAZAPINE] (C - Depression - n/a - [n/a - 15mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016325718&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016325849,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016325849&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016326044,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Angina pectoris (n/a - Unknown - Disabling),<BR><BR>Cardiac disorder (n/a - Unknown - Disabling),<BR><BR>Chest discomfort (n/a - Unknown - Disabling),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Limb discomfort (n/a - Unknown - Disabling),<BR><BR>Pain (n/a - Unknown - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016326044&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016326078,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Rash pruritic (1wk - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[BECLOMETASONE DIPROPIONATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016326078&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016326105,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Female,"Joint stiffness (24h - Recovered/Resolved - ),<BR><BR>Myalgia (24h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016326105&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016326116,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Guillain-Barre syndrome (n/a - Recovered/Resolved With Sequelae - Disabling),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016326116&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016326118,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Heavy menstrual bleeding (3d - Recovered/Resolved - ),<BR><BR>Pelvic pain (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016326118&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016326157,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Vaccination site reaction (3d - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016326157&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016326164,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Influenza like illness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016326164&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016326179,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Vaccination site pain (6wk - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016326179&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016326199,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Fall (1d - Recovered/Resolved - ),<BR><BR>Influenza like illness (n/a - Recovering/Resolving - ),<BR><BR>Limb injury (n/a - Recovering/Resolving - ),<BR><BR>Malaise (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016326199&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016326296,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Headache (n/a - Recovering/Resolving - ),<BR><BR>Hypertension (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016326296&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016326298,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016326298&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016326317,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Ophthalmic herpes zoster (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016326317&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016326465,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Bursitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (24h - Recovered/Resolved - ),<BR><BR>Fatigue (24h - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Malaise (24h - Recovered/Resolved - ),<BR><BR>Myalgia (24h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016326465&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016326470,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Ophthalmic herpes zoster (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016326470&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016326471,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Swelling face (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016326471&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016326472,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016326472&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016326697,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Crohn's disease (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"ESOMEPRAZOLE [ESOMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016326697&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016326895,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Back pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea exertional (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pericarditis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"MELATONIN [MELATONIN] (C - Post-acute COVID-19 syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[AMINO ACIDS] (C - Post-acute COVID-19 syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[FAMOTIDINE] (C - Post-acute COVID-19 syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[LORATADINE] (C - Post-acute COVID-19 syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[NATTOKINASE] (C - Post-acute COVID-19 syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM CHLORIDE] (C - Post-acute COVID-19 syndrome, Postural orthostatic tachycardia syndrome - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016326895&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016326953,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Swelling (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"PEMBROLIZUMAB [PEMBROLIZUMAB] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[IBUPROFEN, IBUPROFEN BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, OMEPRAZOLE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016326953&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016326988,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Recovered/Resolved - ),<BR><BR>Feeling cold (n/a - Unknown - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (1h - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"HYDROCORTISONE [HYDROCORTISONE, HYDROCORTISONE SODIUM SUCCINATE] (C - Pneumonia - n/a - [n/a - 30mg - Oral use]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016326988&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016327050,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Intermenstrual bleeding (n/a - Recovered/Resolved - ),<BR><BR>Menstruation delayed (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016327050&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016327097,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,3-11 Years,Child,No,Female,"Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016327097&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016327115,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016327115&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016327195,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Asthenia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cold sweat (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Night sweats (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016327195&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016327233,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016327233&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016327251,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Constipation (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016327251&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016327501,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Back pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fracture pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Movement disorder (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016327501&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016327598,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016327598&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016327601,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Condition aggravated (n/a - Unknown - ),<BR><BR>Ophthalmic migraine (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016327601&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016327603,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Rash pruritic (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016327603&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016327604,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Condition aggravated (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hot flush (n/a - Not Recovered/Not Resolved - ),<BR><BR>Seborrhoeic dermatitis (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016327604&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016327881,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Male,"Inappropriate schedule of product administration (n/a - Unknown - ),<BR><BR>Vaccination site pain (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),[TAMSULOSIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Oral use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016327881&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016328000,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,Monoplegia (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Immunisation - Not applicable - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016328000&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016328050,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Abdominal pain (2d - Recovered/Resolved - ),<BR><BR>Chills (n/a - Recovered/Resolved - ),<BR><BR>Diarrhoea (2d - Recovered/Resolved - ),<BR><BR>Malaise (2d - Recovered/Resolved - ),<BR><BR>Nausea (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016328050&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016328216,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016328216&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016328397,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Rash erythematous (n/a - Not Recovered/Not Resolved - ),<BR><BR>Swelling face (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016328397&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016328398,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Groin pain (n/a - Recovering/Resolving - ),<BR><BR>Oedema (n/a - Unknown - ),<BR><BR>Penile swelling (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"LIXIANA [EDOXABAN, EDOXABAN TOSYLATE] (C - Anticoagulant therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[METOPROLOL TARTRATE] (C - Arrhythmia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016328398&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016328401,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Feeling cold (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Limb discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Limb immobilisation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Poor quality sleep (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site swelling (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","OZEMPIC [SEMAGLUTIDE] (C - Type 2 diabetes mellitus - n/a - [n/a - 1mg - Subcutaneous use]),<BR><BR>[FLUOCORTOLONE PIVALATE PH. EUR., ANHYDROUS LIDOCAINE HYDROCHLORIDE, FLUOCORTOLONE PIVALATE PH. EUR., LIDOCAINE HYDROCHLORIDE, FLUOCORTOLONE PIVALATE, ANHYDROUS LIDOCAINE HYDROCHLORIDE, FLUOCORTOLONE PIVALATE, LIDOCAINE HYDROCHLORIDE] (C - Haemorrhoids - n/a - [n/a - 1{DF} - Rectal use]),<BR><BR>[IBUPROFEN] (C - Myalgia - n/a - [n/a - 400mg - Oral use]),<BR><BR>[LITHIUM, LITHIUM CITRATE TETRAHYDRATE] (C - Mood swings - n/a - [n/a - 18mmol - Oral use]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - Type 2 diabetes mellitus - n/a - [n/a - 1000mg - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - 1000mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016328401&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016328480,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (1h - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016328480&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016328670,Spontaneous,2023-11-22 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Abdominal pain upper (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Gingival pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Gingival swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Herpes zoster (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lip swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lip swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lower respiratory tract infection (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pruritus (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Rash macular (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tinea pedis (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - 15mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016328670&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016329133,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Myalgia (n/a - Unknown - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016329133&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016329134,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Immunisation reaction (n/a - Unknown - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016329134&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016329139,Spontaneous,2023-11-22 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Injection site erythema (n/a - Unknown - ),<BR><BR>Vaccination site induration (n/a - Unknown - ),<BR><BR>Vaccination site warmth (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),"COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016329139&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016311651,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Tongue oedema (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Prophylaxis - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016311651&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016311747,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Pruritus (n/a - Recovering/Resolving - ),<BR><BR>Rash (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224)] (S - Influenza immunisation - n/a - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016311747&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016312033,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Terminal state (n/a - Unknown - Life Threatening, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016312033&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016312357,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cardiac failure (n/a - Fatal - Results in Death),<BR><BR>Degenerative mitral valve disease (n/a - Fatal - Results in Death),<BR><BR>Hypertensive heart disease (n/a - Fatal - Results in Death)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"ARIPIPRAZOLE [ARIPIPRAZOLE] (C - n/a - n/a - [n/a - 5mg - n/a]),<BR><BR>[CALCIUM CARBONATE, CHOLECALCIFEROL CONCENTRATE (POWDER FORM)] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[CASSIA] (C - Constipation - n/a - [n/a - n/a - n/a]),<BR><BR>[FERROUS FUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Dyspepsia - n/a - [n/a - 30mg - n/a]),<BR><BR>[SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - Constipation - n/a - [n/a - n/a - n/a]),<BR><BR>[SOLIFENACIN] (C - n/a - n/a - [n/a - 5mg - n/a]),<BR><BR>[VERAPAMIL, VERAPAMIL HYDROCHLORIDE] (C - n/a - n/a - [n/a - 120mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016312357&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016312833,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Cough (n/a - Not Recovered/Not Resolved - Life Threatening),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Life Threatening),<BR><BR>Erythema (n/a - Not Recovered/Not Resolved - Life Threatening),<BR><BR>Rhinitis (n/a - Not Recovered/Not Resolved - Life Threatening),<BR><BR>Urticaria (n/a - Not Recovered/Not Resolved - Life Threatening)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016312833&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016313050,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Altered state of consciousness (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Cardiac failure acute (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016313050&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016313394,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Pulmonary embolism (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016313394&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016313465,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Hypokinesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016313465&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016313730,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Tinnitus (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016313730&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016313731,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Paraesthesia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016313731&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016313732,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Body temperature increased (1d - Recovered/Resolved - ),<BR><BR>Nasopharyngitis (1d - Unknown - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),ANTIHYPERTENSIVUM (BLOEDDRUKVERLAGER) [NOT AVAILABLE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016313732&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016313733,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Vertigo positional (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016313733&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016313735,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (10h - Recovered/Resolved - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Headache (5h - Recovered/Resolved - ),<BR><BR>Multiple sclerosis (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (8h - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016313735&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016313898,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016313898&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016313900,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Hypersensitivity (1d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 3{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016313900&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016313901,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dry mouth (15d - Recovered/Resolved - ),<BR><BR>Malaise (15d - Recovered/Resolved - ),<BR><BR>Oral discomfort (15d - Recovered/Resolved - ),<BR><BR>Oral disorder (15d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 3{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016313901&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016314170,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (2d - Recovered/Resolved - ),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016314170&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016314175,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Vertigo (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Product used for unknown indication - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016314175&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016314179,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Presyncope (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Vision blurred (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016314179&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016314186,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Postmenopausal haemorrhage (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016314186&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016314188,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Back pain (n/a - Recovering/Resolving - ),<BR><BR>Chills (30min - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - ),<BR><BR>Taste disorder (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016314188&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016314192,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016314192&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016314202,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Extrasystoles (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[CARBASALATE CALCIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESOMEPRAZOLE MAGNESIUM TRIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[THIAMINE, PYRIDOXINE HYDROCHLORIDE, VITAMIN B] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016314202&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016314446,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dyspnoea (n/a - Unknown - ),<BR><BR>Interstitial lung disease (15d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - ),<BR><BR>Respiratory failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016314446&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016314470,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Anaphylactic reaction (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE, BUDESONIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CLARITHROMYCIN] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[LORATADINE] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[POLAPREZINC] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[PREDNISOLONE] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[SODIUM FERROUS CITRATE] (C - n/a - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[SUPLATAST TOSILATE] (C - n/a - n/a - [n/a - 3{DF} - n/a]),<BR><BR>[THEOPHYLLINE] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[TIOTROPIUM, TIOTROPIUM BROMIDE, TIOTROPIUM BROMIDE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TIZANIDINE] (C - n/a - n/a - [n/a - 3{DF} - n/a]),<BR><BR>[TULOBUTEROL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016314470&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016314594,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Dermatitis allergic (n/a - Not Recovered/Not Resolved - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 HAEMAGGLUTININ ANTIGEN, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016314594&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016314597,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016314597&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016314869,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Herpes zoster (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016314869&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016314870,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016314870&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016314874,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016314874&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016314876,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Hypertension (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016314876&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016314881,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Bursitis (n/a - Recovering/Resolving - ),<BR><BR>Rotator cuff syndrome (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016314881&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016315082,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Chest pain (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"APIXABAN [APIXABAN] (C - Pulmonary embolism - n/a - [n/a - n/a - n/a]),<BR><BR>UMECLIDINIUM BROMIDE, FLUTICASONE FUROATE, VILANTEROL [UMECLIDINIUM BROMIDE, FLUTICASONE FUROATE, VILANTEROL] (C - Chronic obstructive pulmonary disease - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Chronic obstructive pulmonary disease, Dyspnoea - n/a - [n/a - n/a - n/a]),<BR><BR>[TRAZODONE, TRAZODONE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[VITAMIN D] (C - Vitamin D decreased - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016315082&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016315083,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[BISOPROLOL FUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CICLESONIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016315083&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016315104,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Back pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Bone pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (1d - Recovered/Resolved - ),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (1d - Recovered/Resolved - ),<BR><BR>Limb discomfort (n/a - Unknown - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016315104&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016315171,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016315171&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016315514,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Pulmonary pain (n/a - Not Recovered/Not Resolved - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (S - Pneumococcal immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016315514&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016315515,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Injection site pain (n/a - Unknown - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[VENLAFAXINE HYDROCHLORIDE] (S - Persistent depressive disorder - Dose not changed - [n/a - 150mg - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016315515&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016315628,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Coma (n/a - Fatal - Results in Death),<BR><BR>Vaccination complication (n/a - Fatal - Results in Death)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - 1{DF} - Intramuscular use])...,"ABASAGLAR [INSULIN GLARGINE] (C - n/a - Not applicable - [n/a - n/a - n/a]),<BR><BR>APIDRA [INSULIN GLULISINE] (C - n/a - Not applicable - [n/a - n/a - n/a]),<BR><BR>[ESCITALOPRAM, ESCITALOPRAM OXALATE] (C - n/a - Not applicable - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE] (C - n/a - Not applicable - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016315628&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016315713,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Menstruation delayed (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016315713&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016315999,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Cardiovascular disorder (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Chronic gastritis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Gastrointestinal disorder (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016315999&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016316264,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"SPIRONOLACTONE [SPIRONOLACTONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ETODOLAC] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MORPHINE SULFATE, MORPHINE SULPHATE BP] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RIZATRIPTAN, RIZATRIPTAN BENZOATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016316264&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016316278,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Dizziness (2d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016316278&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016316448,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Atrial fibrillation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oedema peripheral (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])","HYLAK [ENTEROCOCCUS FAECALIS METABOLITES, ESCHERICHIA COLI METABOLITES, LACTOBACILLUS ACIDOPHILUS METABOLITES, LACTOBACILLUS HELVETICUS METABOLITES] (C - n/a - n/a - ),<BR><BR>[AMLODIPINE BESILATE] (C - n/a - n/a - ),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM, TULIP] (C - n/a - n/a - ),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - ),<BR><BR>[RAMIPRIL] (C - n/a - n/a - ),<BR><BR>[TAMSULOSIN HYDROCHLORIDE] (C - n/a - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016316448&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016316487,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Headache (2d - Recovered/Resolved - ),<BR><BR>Injection site pain (4d - Recovered/Resolved - ),<BR><BR>Lymphadenopathy (2d - Recovered/Resolved - ),<BR><BR>Pain in extremity (4d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016316487&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016316757,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Amenorrhoea (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Heavy menstrual bleeding (n/a - Unknown - Other Medically Important Condition),<BR><BR>Menstruation irregular (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016316757&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016316843,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Facial pain (3d - Recovered/Resolved - ),<BR><BR>Facial paralysis (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Recovered/Resolved - ),<BR><BR>Pain in jaw (3d - Recovered/Resolved - ),<BR><BR>Swelling face (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016316843&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016317219,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness postural (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016317219&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016317251,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Drug eruption (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Erythema (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Insomnia (54h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Miliaria (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rash maculo-papular (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash pruritic (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Skin burning sensation (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Swelling face (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016317251&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016317306,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dysmenorrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heavy menstrual bleeding (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Injected limb mobility decreased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Menstruation irregular (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016317306&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016317602,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),"[METHOTREXATE, METHOTREXATE SODIUM] (C - Rheumatic disorder - n/a - [n/a - 15mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016317602&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016317650,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Asthenia (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Chest discomfort (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Musculoskeletal chest pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016317650&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016317912,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Joint swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Mass (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash macular (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Skin lesion (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sleep disorder due to a general medical condition (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),METHOTREXATE [METHOTREXATE] (C - n/a - n/a - [n/a - 6{DF} - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016317912&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016317913,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Fall (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016317913&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016318118,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthma (n/a - Unknown - Disabling),<BR><BR>Chills (1d - Recovered/Resolved - Disabling),<BR><BR>Chromaturia (n/a - Unknown - Disabling),<BR><BR>Diarrhoea (2d - Recovered/Resolved - Disabling),<BR><BR>Dyspnoea (1d - Recovered/Resolved - Disabling),<BR><BR>Fatigue (n/a - Recovering/Resolving - Disabling),<BR><BR>Headache (3d - Recovered/Resolved - Disabling),<BR><BR>Pharyngeal swelling (n/a - Unknown - Disabling),<BR><BR>Pyrexia (3d - Recovered/Resolved - Disabling),<BR><BR>Urine abnormality (n/a - Unknown - Disabling),<BR><BR>Vomiting (1d - Recovered/Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016318118&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016318322,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Hyperpyrexia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Tremor (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Vaccination site hypoaesthesia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016318322&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016318589,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016318589&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016318590,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016318590&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016318732,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Back pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Illness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (2d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016318732&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016319274,Spontaneous,2023-11-21 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (6h - Recovered/Resolved - ),<BR><BR>Chills (3h - Recovered/Resolved - ),<BR><BR>Headache (8h - Recovered/Resolved - ),<BR><BR>Myalgia (6h - Recovered/Resolved - ),<BR><BR>Nausea (12h - Recovered/Resolved - ),<BR><BR>Pyrexia (24h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016319274&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016320232,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Diarrhoea (n/a - Unknown - ),<BR><BR>Nausea (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - ),<BR><BR>Vomiting (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016320232&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016320234,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,"Cough (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Productive cough (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])",COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016320234&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016320235,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Feeling hot (n/a - Unknown - Other Medically Important Condition),<BR><BR>Injection site urticaria (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nightmare (n/a - Unknown - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])",COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016320235&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016320239,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Constipation (n/a - Recovering/Resolving - ),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - ),<BR><BR>Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Nasopharyngitis (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016320239&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016320254,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Abdominal pain (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Nausea (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - ),<BR><BR>Vaccination site pain (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),"COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016320254&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016320256,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,"Pyrexia (n/a - Unknown - ),<BR><BR>Vaccination site pain (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016320256&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016320264,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Asthenia (2d - Recovered/Resolved - ),<BR><BR>Dizziness (2d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227)] (S - Influenza immunisation - Not applicable - [1d - .5mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016320264&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016320269,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","VAXZEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>[ELASOMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016320269&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016320276,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Immunisation reaction (n/a - Unknown - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUCELVAX TETRA [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>[ELASOMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016320276&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016320281,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Headache (n/a - Unknown - ),<BR><BR>Nausea (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 HAEMAGGLUTININ ANTIGEN, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016320281&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016320286,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Headache (n/a - Recovering/Resolving - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016320286&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016320297,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,"Herpes zoster (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Weight decreased (n/a - Unknown - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [8d - n/a - Intramuscular use]),<BR><BR>FLUAD TETRA SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Drug withdrawn - [8d - n/a - Intramuscular use])","EXFORGE 10 MG/160 MG FILM-COATED TABLETS [VALSARTAN, AMLODIPINE] (C - n/a - Dose not changed - [n/a - n/a - Oral use]),<BR><BR>NOT AVAILABLE (C - n/a - Dose not changed - [n/a - n/a - Oral use]),<BR><BR>NOT AVAILABLE (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[CARVEDILOL] (C - n/a - Dose not changed - [n/a - n/a - Oral use]),<BR><BR>[COLECALCIFEROL, CALCIUM PIDOLATE] (C - n/a - Dose not changed - [n/a - n/a - Oral use]),<BR><BR>[DOXAZOSIN, DOXAZOSIN MESILATE] (C - n/a - Dose not changed - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL, CODEINE] (C - n/a - Dose not changed - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016320297&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016320299,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Pyrexia (n/a - Unknown - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016320299&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016320301,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Rash (n/a - Recovering/Resolving - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),<BR><BR>FLUAD TETRA SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Drug withdrawn - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016320301&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016320309,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Pyrexia (n/a - Unknown - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUCELVAX TETRA [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>SHINGRIX [RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E, RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E, STIMULON, MONOPHOSPHORYL LIPID A] (S - Herpes zoster immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>[ELASOMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016320309&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016320313,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Vaccination site pain (n/a - Unknown - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016320313&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016320315,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Male,"Atrioventricular block complete (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016320315&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016320318,Spontaneous,2023-11-21 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Vaccination site haematoma (n/a - Unknown - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016320318&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016302667,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (7h - Recovered/Resolved - ),<BR><BR>Feeling cold (7h - Recovered/Resolved - ),<BR><BR>Hepatic pain (7h - Recovered/Resolved - ),<BR><BR>Vaccination site oedema (0d - Recovered/Resolved - ),<BR><BR>Vaccination site pain (0d - Recovered/Resolved - ),<BR><BR>Vomiting (0d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016302667&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016303024,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Clonic convulsion (n/a - Unknown - Other Medically Important Condition),<BR><BR>Loss of consciousness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Seizure (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016303024&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016303150,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Depressed mood (n/a - Recovered/Resolved - Life Threatening),<BR><BR>Suicidal ideation (n/a - Recovered/Resolved - Life Threatening, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[PAROXETINE, PAROXETINE HYDROCHLORIDE HEMIHYDRATE, PAROXETINE HYDROCHLORIDE, ANHYDROUS] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[SUMATRIPTAN, SUMATRIPTAN SUCCINATE] (C - Migraine - n/a - [n/a - n/a - n/a]),<BR><BR>[TESTOSTERONE] (C - Hypogonadism - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016303150&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016303244,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Hypertension (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 30ug - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016303244&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016303677,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dyspnoea (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pneumonia (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016303677&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016303742,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Angina pectoris (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016303742&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016303973,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016303973&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016304120,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Ageusia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (5d - Recovered/Resolved - ),<BR><BR>Injection site reaction (5d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"ELIQUIS 2.5 MG [APIXABAN] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[ANHYDROUS LEVOTHYROXINE SODIUM] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[DIAZEPAM] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[PERINDOPRIL ARGININE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[TRAMADOL HYDROCHLORIDE, PARACETAMOL] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016304120&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016304353,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Chest discomfort (n/a - Recovering/Resolving - ),<BR><BR>Chills (1d - Recovered/Resolved - ),<BR><BR>Injection site erythema (3d - Recovered/Resolved - ),<BR><BR>Malaise (1d - Recovered/Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Pruritus (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (S - Pneumococcal immunisation - Not applicable - [n/a - 1{DF} - n/a])","NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016304353&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016304543,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Cerebral infarction (n/a - Not Recovered/Not Resolved - Life Threatening, Disabling),<BR><BR>Hemiparesis (n/a - Not Recovered/Not Resolved - Life Threatening, Disabling)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 30ug - Intramuscular use]),"[METAMIZOLE, METAMIZOLE SODIUM, METAMIZOLE SODIUM MONOHYDRATE] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[METOPROLOL SUCCINATE] (C - Hypertension - n/a - [n/a - 47.5mg - Oral use]),<BR><BR>[VALSARTAN] (C - Hypertension - n/a - [n/a - 80mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016304543&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016304569,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Palpitations (1d - Recovered/Resolved - Disabling),<BR><BR>Tachycardia (1d - Recovered/Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016304569&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016304931,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,"Abdominal pain (n/a - Recovering/Resolving - ),<BR><BR>Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016304931&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016304933,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Depressed mood (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016304933&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016304944,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (1d - Recovered/Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"IMATINIB 400MG TABLET  (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MAGNESIUM PIDOLATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MINERALS NOS, VITAMINS NOS] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016304944&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016304957,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016304957&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016304996,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Decreased appetite (n/a - Unknown - ),<BR><BR>Dyspnoea (n/a - Unknown - ),<BR><BR>Interstitial lung disease (n/a - Unknown - Life Threatening),<BR><BR>Pyrexia (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016304996&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016305099,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Application site pain (n/a - Recovered/Resolved - ),<BR><BR>Dizziness (n/a - Recovered/Resolved - ),<BR><BR>Pain in extremity (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016305099&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016305458,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (120h - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (24h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016305458&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016305479,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016305479&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016305994,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Haematoma (n/a - Not Recovered/Not Resolved - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>ELIQUIS 2.5 MG FILM-COATED TABLETS [APIXABAN] (S - Anticoagulant therapy - Dose not changed - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016305994&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016306002,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Diarrhoea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling abnormal (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016306002&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016306980,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016306980&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016307251,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (3d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (4d - Recovered/Resolved - ),<BR><BR>Hypogeusia (n/a - Recovering/Resolving - ),<BR><BR>Hyposmia (n/a - Recovering/Resolving - ),<BR><BR>Increased appetite (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (10d - Recovered/Resolved - ),<BR><BR>Insomnia (8d - Recovered/Resolved - ),<BR><BR>Malaise (7d - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),[LORATADINE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016307251&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016307266,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Amnesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Arthralgia (1wk - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (1wk - Recovered/Resolved - ),<BR><BR>Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (4d - Recovered/Resolved - ),<BR><BR>Myalgia (1wk - Recovered/Resolved - ),<BR><BR>Pyrexia (8h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016307266&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016307290,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Vertigo (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016307290&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016307515,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Diarrhoea (4h - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016307515&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016307668,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Muscle spasms (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016307668&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016307725,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[ESTRADIOL] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016307725&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016308106,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Balance disorder (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Parosmia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Weight decreased (n/a - Unknown - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016308106&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016308158,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Lip oedema (1h - Recovered/Resolved - ),<BR><BR>Pruritus (1h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - n/a - n/a - [1d - 1{DF} - Intramuscular use]),[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016308158&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016308159,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Vision blurred (4h - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016308159&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016308174,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Infant,No,Male,Tinnitus (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016308174&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016308258,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016308258&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016308321,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Asthenia (7d - Recovered/Resolved - ),<BR><BR>Headache (7d - Recovered/Resolved - ),<BR><BR>Nausea (7d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016308321&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016308392,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cardiac failure (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rales (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016308392&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016308408,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Taste disorder (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016308408&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016308411,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Rhinorrhoea (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016308411&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016308421,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Headache (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - n/a - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016308421&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016308778,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016308778&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016308844,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Bronchitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Catarrh (n/a - Not Recovered/Not Resolved - ),<BR><BR>Interchange of vaccine products (n/a - Unknown - ),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Productive cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rhinorrhoea (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])","[LANSOPRAZOLE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[OMEGA-3 FATTY ACIDS, OMEGA-3-ACID ETHYL ESTERS 90] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[TAMSULOSIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016308844&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016308996,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pulmonary embolism (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ACETYLSALICYLIC ACID] (C - Myocardial ischaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Myocardial ischaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Myocardial ischaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[MEMANTINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Myocardial ischaemia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016308996&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016309007,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,Haematoma (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016309007&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016309063,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Injection site pain (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016309063&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016309115,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016309115&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016309127,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016309127&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016309244,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Condition aggravated (n/a - Unknown - ),<BR><BR>Cutaneous vasculitis (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Diabetic foot (n/a - Unknown - ),<BR><BR>Extremity necrosis (n/a - Unknown - ),<BR><BR>Haemoglobin decreased (n/a - Unknown - ),<BR><BR>Haemorrhage (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"ELIQUIS [APIXABAN] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>TROMCARDIN COMPLEX [CYANOCOBALAMIN, FOLIC ACID, MAGNESIUM ASPARTATE DIHYDRATE, MAGNESIUM OXIDE, NICOTINAMIDE, POTASSIUM CHLORIDE, UBIDECARENONE] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[DOXAZOSIN, DOXAZOSIN MESILATE] (C - Blood pressure abnormal - n/a - [n/a - 4mg - n/a]),<BR><BR>[HYDROCHLOROTHIAZIDE, METOPROLOL TARTRATE PH. EUR., METOPROLOL TARTRATE, HYDROCHLOROTHIAZIDE] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[OLMESARTAN MEDOXOMIL, AMLODIPINE, HYDROCHLOROTHIAZIDE, OLMESARTAN MEDOXOMIL, HYDROCHLOROTHIAZIDE, AMLODIPINE BESILATE] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[TORASEMIDE] (C - Oedema - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016309244&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016309796,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Cardiac arrest (0d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016309796&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016309817,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Dyspnoea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Fatigue (n/a - Recovering/Resolving - Disabling),<BR><BR>Headache (n/a - Recovering/Resolving - Disabling),<BR><BR>Pain (n/a - Recovering/Resolving - Disabling),<BR><BR>Pyrexia (10d - Recovered/Resolved - Disabling)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016309817&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016310197,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Aortic dissection (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Heart rate decreased (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Myocardial infarction (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Seizure (n/a - Unknown - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016310197&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016310346,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016310346&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016310521,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Pyrexia (n/a - Unknown - ),<BR><BR>Vaccination site swelling (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016310521&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016310523,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Pyrexia (n/a - Unknown - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016310523&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016310524,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Malaise (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - n/a - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>VAXZEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>[ELASOMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016310524&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016310527,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Vaccination site pain (n/a - Unknown - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016310527&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016310530,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Malaise (n/a - Recovering/Resolving - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016310530&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016310532,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Pyrexia (n/a - Unknown - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016310532&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016310539,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Vaccination site reaction (n/a - Unknown - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 HAEMAGGLUTININ ANTIGEN, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016310539&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016310545,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Gait disturbance (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016310545&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016310554,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Pyrexia (3d - Recovered/Resolved - ),<BR><BR>Vomiting (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016310554&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016310559,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Malaise (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>[ELASOMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016310559&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016310563,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Catarrh (n/a - Unknown - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016310563&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016310584,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Injection site erythema (n/a - Unknown - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>[ELASOMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016310584&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016310585,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Vaccination site erythema (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [0d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016310585&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016310586,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Diarrhoea (1d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [0d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016310586&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016310590,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Myalgia (3d - Recovered/Resolved - ),<BR><BR>Pyrexia (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [0d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016310590&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016310610,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Myalgia (n/a - Unknown - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016310610&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016310614,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Pyrexia (2d - Recovered/Resolved - ),<BR><BR>Vertigo (2d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016310614&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016310619,Spontaneous,2023-11-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Myalgia (3d - Recovered/Resolved - ),<BR><BR>Nasal congestion (3d - Recovered/Resolved - ),<BR><BR>Pyrexia (4d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016310619&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016310686,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Torticollis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>RIVAROXABAN [RIVAROXABAN] (S - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (S - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (S - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[VERAPAMIL, VERAPAMIL HYDROCHLORIDE] (S - n/a - Unknown - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016310686&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016310699,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Headache (n/a - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016310699&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016310726,Spontaneous,2023-11-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (1h - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (6h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016310726&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016302393,Spontaneous,2023-11-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (120h - Recovered/Resolved - ),<BR><BR>Fatigue (120h - Recovered/Resolved - ),<BR><BR>Injection site erythema (n/a - Recovered/Resolved - ),<BR><BR>Injection site inflammation (n/a - Recovered/Resolved - ),<BR><BR>Injection site pain (n/a - Recovered/Resolved - ),<BR><BR>Injection site warmth (n/a - Recovered/Resolved - ),<BR><BR>Malaise (120h - Recovered/Resolved - ),<BR><BR>Myalgia (120h - Recovered/Resolved - ),<BR><BR>Nausea (48h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016302393&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016302423,Spontaneous,2023-11-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016302423&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016300760,Spontaneous,2023-11-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Shoulder injury related to vaccine administration (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016300760&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016300973,Spontaneous,2023-11-18 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Asthenia (1d - Recovered/Resolved - ),<BR><BR>Hyperhidrosis (1d - Recovered/Resolved - ),<BR><BR>Myalgia (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - ),<BR><BR>Vaccination site pain (1d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016300973&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016300993,Spontaneous,2023-11-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Heart rate increased (5d - Unknown - ),<BR><BR>Nausea (5d - Unknown - ),<BR><BR>Vomiting (5d - Unknown - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - n/a - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 HAEMAGGLUTININ ANTIGEN, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Unknown - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016300993&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016301010,Spontaneous,2023-11-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Asthenia (0d - Unknown - ),<BR><BR>Dyspnoea (0d - Unknown - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - n/a - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 HAEMAGGLUTININ ANTIGEN, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Unknown - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016301010&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016302215,Spontaneous,2023-11-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (96h - Recovered/Resolved - ),<BR><BR>Headache (24h - Recovered/Resolved - ),<BR><BR>Injection site inflammation (48h - Recovered/Resolved - ),<BR><BR>Injection site pain (48h - Recovered/Resolved - ),<BR><BR>Injection site warmth (48h - Recovered/Resolved - ),<BR><BR>Malaise (48h - Recovered/Resolved - ),<BR><BR>Myalgia (48h - Recovered/Resolved - ),<BR><BR>Pyrexia (12h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016302215&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016291482,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Asthenia (2d - Recovered/Resolved - ),<BR><BR>Hyperpyrexia (2d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016291482&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016291640,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Illness (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016291640&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016291650,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016291650&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016291945,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Cardiac flutter (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016291945&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016293198,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Abdominal pain upper (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016293198&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016293199,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016293199&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016293529,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - n/a]),<BR><BR>TOZINAMERAN [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>TOZINAMERAN, FAMTOZINAMERAN [TOZINAMERAN, FAMTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016293529&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016293642,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (n/a - Unknown - ),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016293642&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016293808,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Herpes zoster (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016293808&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016294384,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Angina pectoris (17h - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Chest pain (17h - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Condition aggravated (17h - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dyspnoea (17h - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Hypertension (17h - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Palpitations (17h - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - Intramuscular use])","JANUMET [METFORMIN HYDROCHLORIDE, SITAGLIPTIN, METFORMIN HYDROCHLORIDE, SITAGLIPTIN PHOSPHATE, METFORMIN HYDROCHLORIDE, SITAGLIPTIN PHOSPHATE MONOHYDRATE, METFORMIN, SITAGLIPTIN] (C - Diabetes mellitus - n/a - [n/a - n/a - Oral use]),<BR><BR>TELMISARTAN [TELMISARTAN] (C - Hypertension - n/a - [n/a - 40mg - Oral use]),<BR><BR>[ACETYLSALICYLIC ACID, ACETYLSALICYLIC ACID PH. EUR.] (C - Acute myocardial infarction - n/a - [n/a - 75mg - Oral use]),<BR><BR>[ATORVASTATIN CALCIUM] (C - n/a - n/a - [n/a - 10mg - Oral use]),<BR><BR>[BISOPROLOL FUMARATE] (C - Acute myocardial infarction - n/a - [n/a - 2.5mg - Oral use]),<BR><BR>[ISOSORBIDE MONONITRATE] (C - Cardiac disorder - n/a - [n/a - 60mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016294384&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016294748,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"CLOPIDOGREL KRKA 75 MG FILM-COATED TABLETS [CLOPIDOGREL, CLOPIDOGREL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016294748&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016294900,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016294900&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016294901,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Malaise (1d - Recovered/Resolved - ),<BR><BR>Pain (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Antiviral prophylaxis - Not applicable - [0d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016294901&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016295021,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016295021&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016295307,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,"Chills (24h - Recovered/Resolved - ),<BR><BR>Myalgia (24h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016295307&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016295314,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016295314&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016295337,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Extensive swelling of vaccinated limb (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016295337&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016295341,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Body temperature increased (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016295341&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016295830,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016295830&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016295844,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain (0d - Fatal - Results in Death),<BR><BR>Cardiovascular disorder (0d - Fatal - Results in Death)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - n/a - n/a])","JANUVIA [SITAGLIPTIN, SITAGLIPTIN PHOSPHATE, SITAGLIPTIN PHOSPHATE MONOHYDRATE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>LANTUS [INSULIN GLARGINE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[GLIQUIDONE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[INDAPAMIDE, PERINDOPRIL ARGININE, PERINDOPRIL TERT-BUTYLAMINE, INDAPAMIDE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[LERCANIDIPINE, LERCANIDIPINE HYDROCHLORIDE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[SOTALOL, SOTALOL HYDROCHLORIDE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[TERAZOSIN, TERAZOSIN HYDROCHLORIDE DIHYDRATE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[XYLOMETAZOLINE HYDROCHLORIDE] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016295844&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016295869,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Bronchitis (n/a - Recovering/Resolving - ),<BR><BR>Chills (2d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016295869&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016296162,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arrhythmia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Palpitations - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016296162&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016296511,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Raynaud's phenomenon (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016296511&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016296556,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Liver injury (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rash (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>REPATHA 140 MG SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE [EVOLOCUMAB] (S - Hypercholesterolaemia - Not applicable - [14d - 140mg - Subcutaneous use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021] (S - Influenza immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016296556&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016296584,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Rash maculo-papular (2d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),"COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [196d - 1{DF} - Intramuscular use]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016296584&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016296589,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Anaemia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site haematoma (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>ELIQUIS 5 MG FILM-COATED TABLETS [APIXABAN] (S - Atrial fibrillation - Drug withdrawn - [n/a - 1{DF} - Oral use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016296589&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016296940,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Headache (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Rash pruritic (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Sensory disturbance (n/a - Recovered/Resolved With Sequelae - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 3{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016296940&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016296950,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Feeling cold (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Hyperhidrosis (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016296950&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016296972,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Pityriasis rosea (n/a - Not Recovered/Not Resolved - ),"COMIRNATY OMICRON XBB.1.5 3 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016296972&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016297101,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Vaccination site pain (2d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016297101&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016297184,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Circulatory collapse (20min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (20min - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 3 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016297184&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016297341,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Joint stiffness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oedema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016297341&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016297356,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,Parosmia (n/a - Not Recovered/Not Resolved - Disabling),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ALPRAZOLAM] (C - Anxiety - n/a - [n/a - n/a - n/a]),<BR><BR>[DUTASTERIDE] (C - Prostatic disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[MINOXIDIL] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016297356&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016297371,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Somnolence (n/a - Unknown - ),<BR><BR>Vaccination site pain (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016297371&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016297452,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Conjunctivitis (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016297452&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016297459,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016297459&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016297468,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Blood pressure increased (1d - Recovered/Resolved - ),<BR><BR>Chills (1d - Recovered/Resolved - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Hot flush (1d - Recovered/Resolved - ),<BR><BR>Palpitations (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016297468&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016297469,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (2d - Recovered/Resolved - ),<BR><BR>Headache (2d - Recovered/Resolved - ),<BR><BR>Injection site pain (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016297469&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016297475,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Amenorrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Asthenia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chronic fatigue syndrome (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016297475&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016297494,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Anaphylactic shock (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Back pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Disturbance in attention (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Gait disturbance (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypoaesthesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Limb discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lip swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Peripheral vascular disorder (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Respiratory distress (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swollen tongue (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016297494&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016297500,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,"Deep vein thrombosis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Peripheral swelling (n/a - Unknown - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016297500&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016297513,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chest discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (11d - Recovered/Resolved - ),<BR><BR>Tachycardia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016297513&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016297519,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Urticaria (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 3 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016297519&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016297521,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Lymphadenopathy (7d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016297521&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016297541,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Balance disorder (n/a - Unknown - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016297541&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016297551,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Headache (5d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016297551&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016297560,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Asthma (5d - Recovered/Resolved - ),<BR><BR>Dizziness (5d - Recovered/Resolved - ),<BR><BR>Lymphadenopathy (5d - Recovered/Resolved - ),<BR><BR>Migraine (5d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016297560&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016297561,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Abdominal distension (2d - Recovered/Resolved - ),<BR><BR>Diarrhoea (2d - Recovered/Resolved - ),<BR><BR>Pain in extremity (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016297561&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016297592,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Angina pectoris (n/a - Unknown - Other Medically Important Condition),<BR><BR>Blood pressure increased (n/a - Recovered/Resolved - ),<BR><BR>Feeling hot (n/a - Unknown - ),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Pain in extremity (n/a - Unknown - ),<BR><BR>Palpitations (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 HAEMAGGLUTININ ANTIGEN, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016297592&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016297649,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Cough (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (8d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Muscular weakness (10d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (9d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Wheezing (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma - n/a - [n/a - n/a - Oral use]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016297649&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016297654,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Panic attack (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016297654&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016297728,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016297728&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016297733,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Muscular weakness (n/a - Recovering/Resolving - ),<BR><BR>Musculoskeletal chest pain (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016297733&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016297759,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Dermatitis allergic (n/a - Not Recovered/Not Resolved - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 HAEMAGGLUTININ ANTIGEN, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016297759&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016297766,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Hypersensitivity (1d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 3{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016297766&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016297767,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Vaccination site paraesthesia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 3 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 HAEMAGGLUTININ ANTIGEN, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016297767&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016298196,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Fatigue (17d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LAMOTRIGINE] (C - Bipolar disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[MOCLOBEMIDE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016298196&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016298235,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Confusional state (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Hallucination (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRIOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FAMOTIDINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016298235&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016298271,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (S - Pneumococcal immunisation - Not applicable - [n/a - 1{DF} - n/a])","[ASCORBIC ACID, MAGNESIUM OXIDE, HEAVY, MAGNESIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016298271&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016298367,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[SODIUM VALPROATE] (C - Epilepsy - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016298367&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016298442,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Joint swelling (n/a - Not Recovered/Not Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a]),"IBRUTINIB [IBRUTINIB] (C - Chronic lymphocytic leukaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - Thyroid cancer - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016298442&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016298478,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Syncope (n/a - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016298478&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016298510,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Recovered/Resolved - ),<BR><BR>Diarrhoea (n/a - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Syncope (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016298510&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016298795,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Cough (n/a - Unknown - Disabling),<BR><BR>Diarrhoea (n/a - Unknown - Disabling),<BR><BR>Malaise (n/a - Unknown - Disabling),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016298795&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016298934,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Herpes zoster (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[BECLOMETASONE DIPROPIONATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Thyroxine - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016298934&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016298996,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dysstasia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Presyncope (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[INFLUENZA A VIRUS A/CALIFORNIA/7/2009 X-179A (H1N1) HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED), INFLUENZA B VIRUS B/BRISBANE/60/2008 HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016298996&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016299183,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Ear pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Eye pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016299183&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016299257,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,Pyrexia (2d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - Intramuscular use]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - Not applicable - [0d - .5mL - Intramuscular use]),<BR><BR>[BETAHISTINE, BETAHISTINE DIHYDROCHLORIDE, BETAHISTINE MESILATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[FOSINOPRIL] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016299257&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016299289,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016299289&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016299395,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,"Asthenia (n/a - Recovering/Resolving - ),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - ),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016299395&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016299876,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Feeling abnormal (n/a - Not Recovered/Not Resolved - ),<BR><BR>Heart rate increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypoaesthesia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[METOPROLOL, METOPROLOL TARTRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, OMEPRAZOLE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RIZATRIPTAN, RIZATRIPTAN BENZOATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016299876&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016300198,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Malaise (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - n/a]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B)] (S - Influenza immunisation - Not applicable - [0d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016300198&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016300199,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Acute myocardial infarction (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Atrioventricular block second degree (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pericardial effusion (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016300199&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016300206,Spontaneous,2023-11-17 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Depressed level of consciousness (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (2d - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUCELVAX TETRA SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (S - Influenza immunisation - Not applicable - [1d - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016300206&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016300534,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Urticaria (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016300534&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016300671,Spontaneous,2023-11-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pruritus (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016300671&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016283337,Spontaneous,2023-11-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (2d - Recovering/Resolving - ),<BR><BR>Gingival pain (2d - Recovering/Resolving - ),<BR><BR>Malaise (2d - Recovering/Resolving - ),<BR><BR>Night sweats (2d - Recovering/Resolving - ),<BR><BR>Oral herpes (2d - Recovering/Resolving - ),<BR><BR>Oral pain (2d - Recovering/Resolving - ),<BR><BR>Pyrexia (2d - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - n/a - n/a - [n/a - n/a - Intramuscular use])",METHOTREXATE [METHOTREXATE] (C - Rheumatoid arthritis - n/a - [n/a - n/a - Subcutaneous use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016283337&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016283438,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Opsoclonus myoclonus (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016283438&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016284899,Spontaneous,2023-11-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Abdominal pain (11d - Recovered/Resolved - ),<BR><BR>Chills (2d - Recovered/Resolved - ),<BR><BR>Hepatic enzyme increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (11d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016284899&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016285004,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Asthenia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Diarrhoea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Night sweats (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"APIXABAN [APIXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016285004&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016285222,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - ),<BR><BR>Balance disorder (n/a - Unknown - ),<BR><BR>Condition aggravated (n/a - Unknown - ),<BR><BR>Dysstasia (n/a - Unknown - ),<BR><BR>Gait disturbance (n/a - Unknown - ),<BR><BR>Glossodynia (n/a - Unknown - ),<BR><BR>Hallucination (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Renal disorder (n/a - Unknown - ),<BR><BR>Speech disorder (n/a - Unknown - ),<BR><BR>Tremor (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016285222&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016285239,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Cardiac discomfort (n/a - Unknown - ),<BR><BR>Chills (n/a - Unknown - ),<BR><BR>Cough (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Heart rate increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate variability decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - ),<BR><BR>Pain (n/a - Unknown - ),<BR><BR>Rapid eye movements sleep abnormal (n/a - Unknown - ),<BR><BR>Respiratory rate increased (n/a - Unknown - Other Medically Important Condition)",RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016285239&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016285307,Spontaneous,2023-11-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Bell's palsy (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"SYNJARDY [METFORMIN HYDROCHLORIDE, EMPAGLIFLOZIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>TRULICITY [DULAGLUTIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA A VIRUS A/BRISBANE/10/2010 (H1N1) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED), INFLUENZA A VIRUS A/TEXAS/50/2012 X-223A (H3N2) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED), INFLUENZA B VIRUS B/MASSACHUSETTS/2/2012 ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED)] (C - Immunisation - n/a - [1d - n/a - Intramuscular use]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016285307&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016285354,Spontaneous,2023-11-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Abscess (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Cardiovascular disorder (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Coagulopathy (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Haemodynamic instability (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Multiple organ dysfunction syndrome (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Pancreatitis necrotising (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Renal disorder (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Thrombocytopenia (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"NOT AVAILABLE (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[HYDROCHLOROTHIAZIDE, BISOPROLOL HEMIFUMARATE] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016285354&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016285494,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arthralgia (4d - Recovered/Resolved - ),<BR><BR>Chills (1d - Recovered/Resolved - ),<BR><BR>Condition aggravated (4d - Recovered/Resolved - ),<BR><BR>Fatigue (4d - Recovered/Resolved - ),<BR><BR>Headache (4d - Recovered/Resolved - ),<BR><BR>IgA nephropathy (4d - Recovered/Resolved - ),<BR><BR>Malaise (4d - Recovered/Resolved - ),<BR><BR>Myalgia (4d - Recovered/Resolved - ),<BR><BR>Pyrexia (4d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016285494&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016285678,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Body temperature increased (n/a - Unknown - ),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Sleep disorder (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016285678&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016285975,Spontaneous,2023-11-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Atrial fibrillation (6d - Recovered/Resolved - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016285975&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016285980,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016285980&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016285986,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Malaise (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016285986&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016285987,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016285987&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016285994,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[NOT AVAILABLE] (S - Vitamin B12 deficiency - Dose not changed - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016285994&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016286160,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Urticaria (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016286160&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016286197,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016286197&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016286578,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016286578&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016286645,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site haematoma (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016286645&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016286655,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Axillary pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Extensive swelling of vaccinated limb (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016286655&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016286747,Spontaneous,2023-11-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Blood alkaline phosphatase increased (n/a - Unknown - Life Threatening),<BR><BR>Eosinophilic pneumonia (n/a - Unknown - Life Threatening),<BR><BR>Gamma-glutamyltransferase increased (n/a - Unknown - Life Threatening),<BR><BR>Organising pneumonia (n/a - Not Recovered/Not Resolved - Life Threatening)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[AMOXICILLIN, AMOXICILLIN TRIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016286747&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016286750,Spontaneous,2023-11-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arterial disorder (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Cerebral haemorrhage (n/a - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Cough (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a]),"[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016286750&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016286828,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Arrhythmia (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016286828&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016286883,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Rash pruritic (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016286883&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016287185,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Body temperature increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (2d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (2d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016287185&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016287189,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016287189&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016287236,Spontaneous,2023-11-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Abdominal pain (n/a - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Injection site pain (n/a - Recovered/Resolved - ),<BR><BR>Nausea (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - n/a]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Antiviral prophylaxis - Dose not changed - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016287236&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016287441,Spontaneous,2023-11-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Diarrhoea (1d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"NOT AVAILABLE (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>XARELTO [RIVAROXABAN] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN CALCIUM] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016287441&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016287448,Spontaneous,2023-11-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Anaphylactic reaction (1d - Recovered/Resolved - Life Threatening),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016287448&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016287699,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (S - Pneumococcal immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016287699&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016287770,Spontaneous,2023-11-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Diarrhoea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Muscle spasms (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vertigo (2d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016287770&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016287782,Spontaneous,2023-11-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Influenza like illness (3d - Recovered/Resolved - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [1d - 1{DF} - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - n/a - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016287782&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016287783,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016287783&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016287784,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Injection site pain (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016287784&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016287786,Spontaneous,2023-11-16 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chest pain (5d - Recovered/Resolved - ),<BR><BR>Dyspnoea (5d - Recovered/Resolved - ),<BR><BR>Influenza like illness (5d - Recovered/Resolved - ),<BR><BR>Nausea (5d - Recovered/Resolved - ),<BR><BR>Vertigo (5d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016287786&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016287789,Spontaneous,2023-11-16 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - ),<BR><BR>Thermal burn (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [1d - 1{DF} - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - n/a - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016287789&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016287790,Spontaneous,2023-11-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Feeling cold (n/a - Recovered/Resolved - ),<BR><BR>Tremor (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016287790&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016287802,Spontaneous,2023-11-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Deafness (2d - Recovered/Resolved With Sequelae - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016287802&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016287820,Spontaneous,2023-11-16 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Asthenia (1d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),IRBESARTAN [IRBESARTAN] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016287820&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016287838,Spontaneous,2023-11-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Facial paralysis (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016287838&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016287965,Spontaneous,2023-11-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Blood potassium increased (n/a - Fatal - Results in Death),<BR><BR>Blood pressure decreased (n/a - Fatal - Results in Death),<BR><BR>Depressed level of consciousness (n/a - Fatal - Results in Death),<BR><BR>Discoloured vomit (n/a - Fatal - Results in Death),<BR><BR>Gastrointestinal haemorrhage (n/a - Fatal - Results in Death),<BR><BR>Hypoglycaemia (n/a - Fatal - Results in Death),<BR><BR>Intestinal obstruction (n/a - Fatal - Results in Death),<BR><BR>Oxygen saturation decreased (n/a - Fatal - Results in Death),<BR><BR>Pneumonia aspiration (n/a - Fatal - Results in Death),<BR><BR>Pyrexia (n/a - Fatal - Results in Death)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Cerebral infarction - n/a - [n/a - n/a - n/a]),<BR><BR>ESOMEPRAZOLE [ESOMEPRAZOLE] (C - Therapeutic procedure - n/a - [n/a - n/a - n/a]),<BR><BR>TELMISARTAN [TELMISARTAN] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[CARBAMAZEPINE, CARBAMAZEPINE (PH. EUR.)] (C - Cerebral haemorrhage - n/a - [n/a - n/a - n/a]),<BR><BR>[MANIDIPINE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[MEXILETINE HYDROCHLORIDE] (C - Cerebral haemorrhage - n/a - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - Asthma-chronic obstructive pulmonary disease overlap syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[PHENYTOIN, PHENYTOIN SODIUM] (C - Cerebral haemorrhage - n/a - [n/a - n/a - n/a]),<BR><BR>[QUETIAPINE, QUETIAPINE FUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[THEOPHYLLINE] (C - Asthma-chronic obstructive pulmonary disease overlap syndrome - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016287965&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016288012,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,"Influenza like illness (5d - Recovered/Resolved - ),<BR><BR>Oropharyngeal pain (5d - Recovered/Resolved - ),<BR><BR>Productive cough (5d - Recovered/Resolved - ),<BR><BR>Pyrexia (5d - Recovered/Resolved - ),<BR><BR>Vaccination site erythema (5d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016288012&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016288039,Spontaneous,2023-11-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Bedridden (n/a - Fatal - Results in Death),<BR><BR>Fall (13d - Fatal - Results in Death),<BR><BR>General physical health deterioration (n/a - Fatal - Results in Death)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),"[MIRTAZAPINE] (C - Depression - n/a - ),<BR><BR>[NITRAZEPAM] (C - n/a - n/a - ),<BR><BR>[RISPERIDONE] (C - Schizophrenia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016288039&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016288264,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Influenza (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Pericarditis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016288264&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016288279,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anaphylactic reaction (n/a - Unknown - Other Medically Important Condition),<BR><BR>Circulatory collapse (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypertensive crisis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - ),<BR><BR>Syncope (n/a - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016288279&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016288280,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Deafness (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperacusis (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016288280&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016288515,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016288515&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016288915,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Asthenia (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Recovered/Resolved With Sequelae - Disabling, Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved With Sequelae - Disabling, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[AMOXICILLIN, AMOXICILLIN TRIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016288915&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016289023,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (2d - Recovered/Resolved - ),<BR><BR>Hyperpyrexia (4d - Recovered/Resolved - ),<BR><BR>Injection site erythema (7d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (7d - Recovered/Resolved - ),<BR><BR>Injection site swelling (7d - Recovered/Resolved - ),<BR><BR>Injection site warmth (7d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Migraine (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Myalgia (3d - Recovered/Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016289023&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016289224,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016289224&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016289430,Spontaneous,2023-11-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dyspnoea (0d - Recovered/Resolved - ),<BR><BR>Erythema (30min - Recovered/Resolved - ),<BR><BR>Fatigue (0d - Recovered/Resolved - ),<BR><BR>Hypertension (20min - Recovered/Resolved - ),<BR><BR>Malaise (0d - Recovered/Resolved - ),<BR><BR>Respiratory disorder (0d - Recovered/Resolved - ),<BR><BR>Skin disorder (0d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[METFORMIN, METFORMIN HYDROCHLORIDE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016289430&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016290233,Spontaneous,2023-11-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Urticaria (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[CHONDROITIN POLYSULFATE, CHONDROITIN SULFATE - BOVINE, CHONDROITIN SULFATE SODIUM, GLUCOSAMINOGLYCAN POLYSULFATE, GLYCOSAMINOGLYCAN POLYSULFATE, HEPARINOID, MUCOPOLYSACCHARIDE POLYSULFURIC ACID ESTER, MUCOPOLYSACCHARIDES] (C - Phlebitis - n/a - [n/a - 1{DF} - Cutaneous use]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - 50mg - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - 1000mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016290233&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016290622,Spontaneous,2023-11-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016290622&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016291005,Spontaneous,2023-11-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Body temperature increased (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016291005&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016275894,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Oedema peripheral (1d - Recovering/Resolving - ),<BR><BR>Urticaria (1d - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010, B/PHUKET/3073/2013-LIKE STRAIN, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/BRISBANE/60/2008, A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, B/MASSACHUSETTS/02/2012, A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010, B/BRISBANE/60/2008, B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010, B/BRISBANE/60/2008-LIKE VIRUS, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, NIB-121), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016275894&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016276688,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dyspnoea (0d - Recovered/Resolved - Life Threatening),<BR><BR>Erythema (0d - Recovered/Resolved - Life Threatening),<BR><BR>Wheezing (0d - Recovered/Resolved - Life Threatening)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - n/a - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 20, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 17F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 2, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A, PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (S - n/a - n/a - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016276688&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016276785,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"C-reactive protein increased (n/a - Recovering/Resolving - ),<BR><BR>Cardiac failure (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cough (11d - Recovered/Resolved - ),<BR><BR>Dyspnoea exertional (n/a - Recovering/Resolving - ),<BR><BR>Gait disturbance (n/a - Unknown - ),<BR><BR>N-terminal prohormone brain natriuretic peptide increased (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"ENTRESTO [SACUBITRIL VALSARTAN SODIUM HYDRATE, VALSARTAN, SACUBITRIL] (C - n/a - n/a - [n/a - 2{DF} - Oral use]),<BR><BR>[BISOPROLOL FUMARATE] (C - n/a - n/a - [n/a - 8.75mg - Oral use]),<BR><BR>[EPLERENONE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016276785&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016276802,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Hypoaesthesia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Insomnia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Muscle spasms (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016276802&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016277287,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cough (0d - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lip oedema (0d - Recovering/Resolving - Other Medically Important Condition)",COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016277287&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016277784,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Back pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"ADALIMUMAB [ADALIMUMAB] (C - Colitis ulcerative, Rheumatoid arthritis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016277784&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016278009,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Nightmare (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016278009&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016278023,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Haematoma (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),[VINPOCETINE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016278023&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016278281,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Blood pressure decreased (n/a - Unknown - ),<BR><BR>Dizziness (n/a - Unknown - ),<BR><BR>Syncope (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),"[AMLODIPINE, AMLODIPINE BESILATE] (C - Hypertension - n/a - [n/a - 5mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016278281&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016278339,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016278339&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016278457,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Injection site pain (24h - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016278457&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016278480,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Cardiac arrest (n/a - Fatal - Results in Death),<BR><BR>Circulatory collapse (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016278480&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016278529,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Injection site pain (1d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016278529&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016278626,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Injection site pain (1d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016278626&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016278916,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Influenza like illness (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016278916&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016278923,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Injection site pain (48h - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016278923&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016279116,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Asthenia (1d - Recovered/Resolved - ),<BR><BR>Injection site pain (1d - Recovered/Resolved - ),<BR><BR>Myalgia (36h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016279116&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016279289,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Lip swelling (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016279289&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016279290,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Lymph node pain (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016279290&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016279291,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Arthralgia (1d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016279291&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016279296,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016279296&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016279386,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,"Asthenia (2d - Recovered/Resolved - ),<BR><BR>Diarrhoea (2d - Recovered/Resolved - ),<BR><BR>Headache (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Antiviral prophylaxis - Not applicable - [0d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016279386&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016279525,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,"Cold sweat (1d - Recovered/Resolved - ),<BR><BR>Limb discomfort (1h - Recovered/Resolved - ),<BR><BR>Malaise (1d - Recovered/Resolved - ),<BR><BR>Pain (2d - Recovered/Resolved - ),<BR><BR>Rectal haemorrhage (5d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Antiviral prophylaxis - Not applicable - [0d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016279525&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016279688,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Dizziness (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016279688&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016279692,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Neuralgia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016279692&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016279695,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Swelling face (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[NOT AVAILABLE] (S - Neuropathy peripheral - Dose not changed - [n/a - n/a - n/a])","NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - Dose not changed - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016279695&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016279766,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Arthralgia (22d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymphoma (14d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016279766&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016279795,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016279795&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016279865,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dizziness (15d - Not Recovered/Not Resolved - ),<BR><BR>Purpura (15d - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016279865&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016279889,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Headache (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016279889&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016279909,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Death (n/a - Fatal - Results in Death),<BR><BR>General physical health deterioration (n/a - Fatal - Results in Death)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016279909&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016279916,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Back pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tendonitis (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016279916&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016279932,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Immunisation reaction (n/a - Recovering/Resolving - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Influenza immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016279932&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016279934,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Abdominal pain (18h - Recovered/Resolved - ),<BR><BR>Dyspepsia (18h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016279934&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016279937,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Angioedema (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - 1{DF} - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Drug withdrawn - [1d - 1{DF} - Intramuscular use]),<BR><BR>[RAMIPRIL] (S - Hypertension - Drug withdrawn - [956d - 7.5mg - Oral use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016279937&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016279938,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Influenza like illness (2d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 10 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016279938&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016279944,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Hypertension (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Recovered/Resolved - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016279944&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016280266,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])","FEBUXOSTAT [FEBUXOSTAT] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[BEZAFIBRATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[COIX LACRYMA-JOBI WHOLE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[THEOPHYLLINE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[VONOPRAZAN, VONOPRAZAN FUMARATE, VONOPRAZAN HYDROGEN FUMARATE] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016280266&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016280373,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Gingival blister (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oral mucosal blistering (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oral pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tongue blistering (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016280373&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016280418,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Injection site pain (0d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016280418&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016280474,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016280474&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016280475,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016280475&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016280501,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Injection site pain (0d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016280501&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016280553,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dysgeusia (1d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016280553&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016280555,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Visual acuity reduced (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016280555&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016280563,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Pyrexia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site warmth (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016280563&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016280577,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Vaccination site pain (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016280577&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016280763,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (12h - Recovered/Resolved - ),<BR><BR>Headache (12h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016280763&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016280994,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Condition aggravated (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Post-acute COVID-19 syndrome (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016280994&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016280996,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016280996&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016280997,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Pruritus (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016280997&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016280999,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016280999&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016281000,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Erythema (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016281000&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016281003,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (2h - Recovered/Resolved - ),<BR><BR>Condition aggravated (n/a - Not Recovered/Not Resolved - ),<BR><BR>Feeling cold (4h - Recovered/Resolved - ),<BR><BR>Headache (3d - Recovered/Resolved - ),<BR><BR>Post-acute COVID-19 syndrome (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tremor (1h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016281003&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016281005,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (4h - Recovered/Resolved - ),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016281005&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016281011,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Body temperature increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypertension (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injected limb mobility decreased (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>SPIRONOLACTONE [SPIRONOLACTONE] (S - Hypokalaemia - Unknown - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016281011&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016281016,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (3d - Recovered/Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (9d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (9d - Recovered/Resolved - ),<BR><BR>Injection site pain (9d - Recovered/Resolved - ),<BR><BR>Injection site swelling (9d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (5d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016281016&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016281183,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Abdominal pain upper (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Back pain (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Erythema (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016281183&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016281466,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Postmenopausal haemorrhage (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016281466&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016281467,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (16h - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016281467&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016282122,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Elderly,No,Female,"Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Dyspnoea exertional (n/a - Recovering/Resolving - ),<BR><BR>Malaise (8d - Unknown - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016282122&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016282123,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Herpes zoster (n/a - Not Recovered/Not Resolved - ),<BR><BR>Neuralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Sensory disturbance (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016282123&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016282124,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Papule (n/a - Recovering/Resolving - ),<BR><BR>Pruritus (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - Hypersensitivity - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016282124&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016282127,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Psoriasis (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016282127&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016282128,Spontaneous,2023-11-15 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Thirst (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),BETMIGA [MIRABEGRON] (C - Hypertonic bladder - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016282128&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016282578,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arthralgia (2d - Recovered/Resolved - ),<BR><BR>Fatigue (2d - Recovered/Resolved - ),<BR><BR>Nasal congestion (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[ATENOLOL] (C - Essential hypertension - Dose not changed - [n/a - n/a - Oral use]),<BR><BR>[HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL] (C - Hypertension - Dose not changed - [n/a - n/a - Oral use]),<BR><BR>[SIMVASTATIN] (C - Type IIa hyperlipidaemia - Dose not changed - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016282578&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016282631,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016282631&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016282637,Spontaneous,2023-11-15 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Male,Nasal congestion (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[ALLOPURINOL] (C - Gout - Not applicable - [n/a - n/a - Oral use]),<BR><BR>[ALPRAZOLAM] (C - Anxiety - Not applicable - [n/a - n/a - Oral use]),<BR><BR>[DELAPRIL HYDROCHLORIDE, MANIDIPINE DIHYDROCHLORIDE] (C - Essential hypertension - Not applicable - [n/a - n/a - Oral use]),<BR><BR>[HYDROCHLOROTHIAZIDE] (C - Essential hypertension - Not applicable - [n/a - n/a - Oral use]),<BR><BR>[TAMSULOSIN HYDROCHLORIDE] (C - Prophylactic chemotherapy - Not applicable - [n/a - n/a - Oral use]),<BR><BR>[TIOTROPIUM BROMIDE MONOHYDRATE] (C - Tobacco abuse - Not applicable - [n/a - n/a - Route of administration not applicable])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016282637&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016268666,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Erythema (5d - Recovering/Resolving - ),<BR><BR>Pruritus (5d - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - Drug withdrawn - [n/a - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016268666&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016268781,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal distension (n/a - Recovered/Resolved - ),<BR><BR>Arthralgia (n/a - Recovered/Resolved - ),<BR><BR>Pain (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - .3mg - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016268781&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016268812,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Asthenia (2d - Recovered/Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 30ug - Intramuscular use]),"FLUCELVAX TETRA [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (C - Influenza immunisation - n/a - [n/a - 15ug - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016268812&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016269010,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Bedridden (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Illness (n/a - Unknown - ),<BR><BR>Joint stiffness (n/a - Unknown - ),<BR><BR>Underdose (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1ug - n/a]),"[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016269010&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016269021,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (2wk - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016269021&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016269044,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Hyperhidrosis (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - ),<BR><BR>Tremor (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016269044&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016269166,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Alanine aminotransferase increased (19d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),APIXABAN [APIXABAN] (C - Thoracic outlet surgery - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016269166&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016269571,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Inflammation (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016269571&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016269662,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Injection related reaction (90min - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[COVID-19 VACCINE] (C - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016269662&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016269701,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Chest pain (0d - Recovered/Resolved - Life Threatening),<BR><BR>Vomiting projectile (0d - Recovered/Resolved - Life Threatening)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - n/a - n/a - [n/a - .5mL - Intramuscular use])",ELIQUIS [APIXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016269701&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016269747,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (2d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016269747&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016269759,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Male,Rash pruritic (n/a - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016269759&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016269814,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Fall (n/a - Unknown - ),<BR><BR>Subarachnoid haemorrhage (n/a - Not Recovered/Not Resolved - Life Threatening, Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[CALCIUM CARBONATE, CHOLECALCIFEROL CONCENTRATE (POWDER FORM)] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUOXETINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016269814&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016269883,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016269883&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016269945,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016269945&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016269971,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016269971&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016270003,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arrhythmia (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016270003&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016270118,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[CHLORAMPHENICOL] (C - Cataract operation - n/a - [n/a - n/a - n/a]),<BR><BR>[DEXAMETHASONE PHOSPHATE] (C - Cataract operation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016270118&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016270192,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Haemorrhage (n/a - Unknown - Life Threatening),<BR><BR>Thrombocytopenia (n/a - Recovered/Resolved - Life Threatening, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016270192&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016270232,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,Joint swelling (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016270232&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016270299,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Balance disorder (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016270299&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016270317,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (1d - Recovered/Resolved - ),<BR><BR>Chills (5h - Recovered/Resolved - ),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pain in extremity (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016270317&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016270318,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Bursitis (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (2d - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - ),<BR><BR>Tenosynovitis (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016270318&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016270364,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016270364&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016270651,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (7170min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (7170min - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016270651&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016270804,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Paraesthesia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016270804&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016270807,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Feeling abnormal (3h - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016270807&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016270811,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Heart rate abnormal (11d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016270811&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016270862,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Abdominal pain upper (n/a - Unknown - Disabling),<BR><BR>Chills (n/a - Unknown - Disabling),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Influenza like illness (n/a - Unknown - Disabling),<BR><BR>Tremor (n/a - Unknown - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016270862&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016271032,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tremor (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016271032&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016271107,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (14d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Burning sensation (14d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 30ug - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016271107&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016271144,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Fatigue (2d - Recovered/Resolved - ),<BR><BR>Malaise (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016271144&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016271170,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Pyrexia (1d - Recovered/Resolved - ),<BR><BR>Tremor (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016271170&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016271204,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,Yes,Male,Injection site pain (1d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016271204&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016271213,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016271213&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016271218,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016271218&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016271222,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016271222&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016271227,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016271227&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016271228,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016271228&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016271244,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Polymenorrhoea (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016271244&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016271246,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016271246&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016271250,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Body temperature increased (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016271250&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016271252,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016271252&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016271525,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Injection site pain (2d - Recovered/Resolved - ),<BR><BR>Malaise (2d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Antiviral prophylaxis - Not applicable - [0d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016271525&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016271839,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Injection site pain (2d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016271839&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016271901,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Elderly,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016271901&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016272043,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (24h - Recovered/Resolved - ),<BR><BR>Headache (24h - Recovered/Resolved - ),<BR><BR>Malaise (24h - Recovered/Resolved - ),<BR><BR>Nausea (24h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016272043&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016272049,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),[MAGNESIUM CITRATE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016272049&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016272055,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Palpitations (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016272055&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016272129,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Death (n/a - Fatal - Results in Death),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>DESLORATADINE [DESLORATADINE] (S - Cough - Not applicable - [n/a - 1{DF} - Oral use]),<BR><BR>TOVIAZ 4 MG PROLONGED-RELEASE TABLETS [FESOTERODINE, FESOTERODINE FUMARATE] (S - Bladder dysfunction - Not applicable - [n/a - 1{DF} - Oral use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021] (S - Influenza immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>[FENOFIBRATE, FENOFIBRATE MICRONISED] (S - Dyslipidaemia - Not applicable - [n/a - 200mg - Oral use]),<BR><BR>[LEVOTHYROXINE SODIUM] (S - Hypothyroidism - Not applicable - [n/a - 1{DF} - Oral use]),<BR><BR>[MOMETASONE FUROATE] (S - Cough - Not applicable - [n/a - 1{DF} - Inhalation use]),<BR><BR>[OXOMEMAZINE] (S - Cough - Not applicable - [n/a - 1{DF} - Oral use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016272129&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016272137,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Pruritus (2d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016272137&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016272184,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Asthenia (2d - Recovered/Resolved - ),<BR><BR>Partial seizures (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),"[AMISULPRIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CLOBAZAM] (C - n/a - n/a - [n/a - 10mg - n/a]),<BR><BR>[CLOZAPINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DIAZEPAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OXCARBAZEPINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM VALPROATE, VALPROIC ACID] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016272184&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016272186,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,"Face oedema (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 10 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016272186&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016272213,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Female,"Injection site erythema (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Injection site oedema (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Injection site pruritus (7d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),"XARELTO [RIVAROXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN EMBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[POTASSIUM, SODIUM, MACROGOL 3350, CHLORIDE ION, HYDROGEN CARBONATE, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016272213&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016272389,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cardiac failure (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Palpitations (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary thrombosis (n/a - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Syncope (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016272389&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016272566,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Elderly,No,Female,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016272566&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016272622,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Body temperature increased (n/a - Recovered/Resolved - ),<BR><BR>Chills (n/a - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016272622&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016272697,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Hypoaesthesia (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016272697&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016272701,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Epistaxis (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016272701&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016272704,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Cough (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016272704&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016272706,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Cough (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016272706&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016272707,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Nipple pain (3d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016272707&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016272709,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Haematoma (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016272709&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016272714,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Extensive swelling of vaccinated limb (1d - Recovered/Resolved - ),<BR><BR>Injection site erythema (1d - Recovered/Resolved - ),<BR><BR>Injection site pruritus (1d - Recovered/Resolved - ),<BR><BR>Injection site warmth (1d - Recovered/Resolved - ),<BR><BR>Urticaria (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016272714&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016272981,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (n/a - Unknown - ),<BR><BR>Dizziness (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Illness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nasopharyngitis (n/a - Recovered/Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"HUMALOG [INSULIN LISPRO] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>LANTUS [INSULIN GLARGINE] (C - n/a - n/a - [n/a - 40[iU] - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016272981&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273087,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Male,Paraesthesia (19d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [0d - .5mL - Intramuscular use])","SILODOSIN [SILODOSIN] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[RABEPRAZOLE SODIUM] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273087&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273112,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Abdominal pain upper (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Asthenia (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Back pain (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Blood pressure systolic increased (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Dizziness (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Fatigue (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Gastrointestinal disorder (n/a - Not Recovered/Not Resolved - ),<BR><BR>Heart rate decreased (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Musculoskeletal pain (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovered/Resolved With Sequelae - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[CANDESARTAN, CANDESARTAN CILEXETIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INSULIN, INSULIN HUMAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273112&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273166,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cardiovascular disorder (0d - Recovered/Resolved - ),<BR><BR>Tachycardia (30min - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273166&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273172,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chillblains (3d - Recovered/Resolved - ),<BR><BR>Therapeutic response unexpected (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273172&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273175,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Pruritus (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273175&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273176,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Herpes zoster (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273176&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273178,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site haematoma (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273178&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273185,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Body temperature increased (n/a - Recovered/Resolved - ),<BR><BR>Chills (n/a - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273185&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273186,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Hyperglycaemia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),INSULIN LISPRO 100 U/ML - SOLUTION FOR INJECTION  (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273186&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273188,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Rosacea (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273188&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273190,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Headache (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273190&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273191,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,"Arthralgia (1d - Recovered/Resolved - ),<BR><BR>Myalgia (1d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[NOT AVAILABLE] (S - Hypercholesterolaemia - Drug withdrawn - [n/a - 5ug - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273191&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273193,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Constipation (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273193&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273195,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Ear infection (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (4d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (4d - Recovered/Resolved - ),<BR><BR>Injection site pain (4d - Recovered/Resolved - ),<BR><BR>Injection site swelling (4d - Recovered/Resolved - ),<BR><BR>Injection site warmth (4d - Recovered/Resolved - ),<BR><BR>Vaccination site lymphadenopathy (6d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273195&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273199,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Body temperature increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273199&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273202,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Eye irritation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Visual impairment (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[NOT AVAILABLE] (S - Hypertension - Drug withdrawn - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273202&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273203,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Injection site pain (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273203&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273256,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Body temperature increased (20d - Recovered/Resolved - Disabling),<BR><BR>COVID-19 (24d - Recovered/Resolved - Disabling),<BR><BR>Decreased appetite (n/a - Unknown - Disabling),<BR><BR>Ear pain (n/a - Recovered/Resolved - Disabling),<BR><BR>Fatigue (n/a - Unknown - Disabling),<BR><BR>Neck pain (25d - Recovered/Resolved - Disabling),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - Disabling),<BR><BR>Rhinorrhoea (24d - Recovered/Resolved - Disabling),<BR><BR>Sinus congestion (n/a - Unknown - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273256&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273259,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Ear pain (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Night sweats (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273259&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273267,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Muscle fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"ESOMEPRAZOLE [ESOMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[ATENOLOL, ATENOLOL BP] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273267&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273275,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Acute respiratory failure (n/a - Fatal - Results in Death, Other Medically Important Condition),<BR><BR>Blood pressure decreased (n/a - Fatal - Results in Death),<BR><BR>Cyanosis (n/a - Fatal - Results in Death),<BR><BR>General physical health deterioration (n/a - Fatal - Results in Death),<BR><BR>Irregular breathing (n/a - Fatal - Results in Death),<BR><BR>Pancreatic carcinoma (n/a - Fatal - Results in Death),<BR><BR>Peripheral circulatory failure (n/a - Fatal - Results in Death),<BR><BR>Pneumonia (n/a - Fatal - Results in Death),<BR><BR>Pneumonia aspiration (n/a - Fatal - Results in Death),<BR><BR>Pyrexia (n/a - Fatal - Results in Death),<BR><BR>Respiratory arrest (n/a - Fatal - Results in Death)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[GLUCOSE, ANHYDROUS, SODIUM CHLORIDE] (C - Fluid replacement - n/a - [39d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273275&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273298,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Eye inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Ocular hyperaemia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Visual impairment (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FENOFIBRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[GLICLAZIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PERINDOPRIL, PERINDOPRIL TERT-BUTYLAMINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273298&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273309,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Blister (n/a - Unknown - Other Medically Important Condition),<BR><BR>Erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pemphigoid (n/a - Unknown - Other Medically Important Condition),<BR><BR>Urticaria (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DONEPEZIL] (C - Dementia - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE] (C - Anxiety - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273309&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273390,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dysmenorrhoea (n/a - Recovering/Resolving - ),<BR><BR>Heavy menstrual bleeding (n/a - Recovering/Resolving - ),<BR><BR>Symptom recurrence (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),[MEDROXYPROGESTERONE ACETATE] (C - Dysmenorrhoea - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273390&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273526,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,Varicose vein (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[AMLODIPINE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[ESTRIOL] (C - n/a - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273526&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273570,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Neuralgia (n/a - Recovering/Resolving - ),<BR><BR>Pruritus (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273570&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273614,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anxiety (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Body tinea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273614&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273835,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Back pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Body temperature increased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Sinus headache (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273835&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273984,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Limb discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (3d - Recovered/Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273984&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016273985,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (6h - Recovered/Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Maternal exposure during pregnancy (n/a - Unknown - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016273985&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016274503,Spontaneous,2023-11-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,COVID-19 (199h - Recovered/Resolved - ),RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[ASCORBIC ACID, MAGNESIUM OXIDE, HEAVY, MAGNESIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ASCORBIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CINACALCET] (C - n/a - n/a - [720d - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CYANOCOBALAMIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LORATADINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[POTASSIUM, POTASSIUM CHLORIDE, POTASSIUM GLYCEROPHOSPHATE, POTASSIUM HYDROGEN CARBONATE, POTASSIUM HYDROGEN TARTRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016274503&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016274523,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Fulminant type 1 diabetes mellitus (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016274523&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016274681,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Cerebrovascular accident (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016274681&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016275000,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"C-reactive protein increased (n/a - Recovered/Resolved - ),<BR><BR>Pleural effusion (n/a - Recovered/Resolved - ),<BR><BR>Pneumonia bacterial (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pneumonitis (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016275000&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016275044,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Blood albumin decreased (n/a - Unknown - ),<BR><BR>Blood glucose increased (n/a - Unknown - ),<BR><BR>Blood lactic acid increased (n/a - Unknown - ),<BR><BR>COVID-19 (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fall (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Glycosylated haemoglobin increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Haematocrit decreased (n/a - Unknown - ),<BR><BR>Haemoglobin decreased (n/a - Unknown - ),<BR><BR>Hypoproteinaemia (n/a - Unknown - ),<BR><BR>Platelet count decreased (n/a - Unknown - ),<BR><BR>Red blood cell count decreased (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"EMPAGLIFLOZIN [EMPAGLIFLOZIN] (C - n/a - n/a - [n/a - 10mg - n/a]),<BR><BR>IRON [IRON] (C - n/a - n/a - [n/a - 300mg - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Arterial stent insertion - n/a - [n/a - 81mg - n/a]),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM TRIHYDRATE] (C - Atrial fibrillation, Transient ischaemic attack - n/a - [n/a - 10mg - n/a]),<BR><BR>[DONEPEZIL] (C - Cognitive disorder - n/a - [n/a - 10mg - n/a]),<BR><BR>[FLUOXETINE, FLUOXETINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - 30mg - n/a]),<BR><BR>[METOPROLOL, METOPROLOL TARTRATE] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016275044&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016275110,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Hyperhidrosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Supraventricular tachycardia (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016275110&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016275197,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016275197&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016275331,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Pyrexia (n/a - Recovered/Resolved - ),<BR><BR>Vaccination site pain (n/a - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 10 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),<BR><BR>FLUAD TETRA SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Drug withdrawn - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016275331&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016275351,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Syncope (1d - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),<BR><BR>FLUAD TETRA SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Influenza immunisation - Drug withdrawn - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016275351&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016275363,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Lymphadenopathy (n/a - Recovering/Resolving - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187)] (S - Influenza immunisation - Drug withdrawn - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016275363&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016275692,Spontaneous,2023-11-14 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cystitis (n/a - Fatal - Results in Death),<BR><BR>Decreased appetite (n/a - Unknown - ),<BR><BR>Dyslalia (n/a - Unknown - ),<BR><BR>Dyspnoea (n/a - Unknown - ),<BR><BR>Feeling hot (n/a - Unknown - ),<BR><BR>Gait disturbance (n/a - Unknown - ),<BR><BR>General physical health deterioration (n/a - Fatal - Results in Death),<BR><BR>Hepatic function abnormal (n/a - Unknown - ),<BR><BR>Hepatic steatosis (n/a - Unknown - ),<BR><BR>Injected limb mobility decreased (n/a - Unknown - ),<BR><BR>Lip swelling (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Muscular weakness (n/a - Unknown - ),<BR><BR>Pollakiuria (n/a - Unknown - ),<BR><BR>Pruritus (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - ),<BR><BR>Rash (n/a - Unknown - ),<BR><BR>Rhabdomyolysis (n/a - Fatal - Results in Death)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016275692&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016259630,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Fatigue (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site lymphadenopathy (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (2d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[COLECALCIFEROL, CALCIUM CARBONATE] (C - Osteopenia - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM HYDROGEN CARBONATE PHEUR, CALCIUM CARBONATE PH. EUR., SODIUM ALGINATE PH. EUR., SODIUM HYDROGEN CARBONATE, CALCIUM CARBONATE, SODIUM ALGINATE] (C - Hiatus hernia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016259630&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016259966,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Vaccination site rash (n/a - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"OZEMPIC [SEMAGLUTIDE] (C - Ill-defined disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Ill-defined disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[EZETIMIBE] (C - Ill-defined disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Ill-defined disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - Ill-defined disorder - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016259966&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016259970,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (2d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - n/a - n/a]),"[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LAMOTRIGINE] (C - Seizure - n/a - [n/a - n/a - n/a]),<BR><BR>[ZOLMITRIPTAN] (C - Migraine - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016259970&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016260188,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Pain in extremity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site haemorrhage (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[ETHINYLESTRADIOL, GESTODENE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VITAMIN D] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ZINC] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016260188&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016260189,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016260189&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016260207,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Not Specified,"Balance disorder (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Dysstasia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FINASTERIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PROMETHAZINE, PROMETHAZINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VITAMIN D] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016260207&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016260211,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Diplopia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vision blurred (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016260211&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016260271,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Haemorrhage subcutaneous (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016260271&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016260282,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Elderly,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition)",RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016260282&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016260324,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016260324&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016260341,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Vaccination site haematoma (2d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016260341&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016261026,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Fatigue (60h - Recovered/Resolved - ),<BR><BR>Myalgia (48h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016261026&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016261031,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chills (2h - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016261031&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016261033,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016261033&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016261034,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016261034&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016261036,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016261036&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016261037,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016261037&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016261039,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (3h - Recovered/Resolved - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016261039&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016261040,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016261040&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016261041,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (1d - Recovered/Resolved - ),<BR><BR>Chills (3h - Recovered/Resolved - ),<BR><BR>Fatigue (3d - Recovered/Resolved - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (3d - Recovered/Resolved - ),<BR><BR>Injection site pain (3d - Recovered/Resolved - ),<BR><BR>Injection site swelling (3d - Recovered/Resolved - ),<BR><BR>Malaise (3d - Recovered/Resolved - ),<BR><BR>Myalgia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016261041&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016261042,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Extensive swelling of vaccinated limb (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016261042&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016261044,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016261044&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016261045,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"INSULIN ASPART 100 U/ML - SOLUTION FOR INJECTION  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>TRESIBA 200 UNITS/ML [INSULIN DEGLUDEC] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016261045&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016261046,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Injection site pain (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016261046&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016261047,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Body temperature increased (24h - Recovered/Resolved - ),<BR><BR>Fatigue (24h - Recovered/Resolved - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016261047&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016261121,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tonic clonic movements (3d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (C - COVID-19 immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016261121&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016261127,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Postmenopausal haemorrhage (n/a - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016261127&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016261137,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016261137&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016263217,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Chest discomfort (1h - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016263217&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016263258,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016263258&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016263266,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Respiratory disorder (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016263266&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016263278,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016263278&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016263284,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Fatigue (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016263284&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016263286,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Herpes zoster (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016263286&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016263311,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (2d - Recovered/Resolved - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site pruritus (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Malaise (1d - Recovered/Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016263311&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016263326,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016263326&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016263335,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016263335&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016263504,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Injection site pain (2d - Recovered/Resolved - ),<BR><BR>Nausea (3h - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - n/a - [n/a - n/a - Intramuscular use])",[BECLOMETASONE DIPROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016263504&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016263800,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (3d - Recovered/Resolved - ),<BR><BR>Chills (2d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (3d - Recovered/Resolved - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site pruritus (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Malaise (3d - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Oral herpes (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (S - Pneumococcal immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016263800&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016264285,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Dizziness (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016264285&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016264470,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Pulmonary embolism (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016264470&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016264477,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Purpura (10d - Not Recovered/Not Resolved - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - n/a - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016264477&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016264632,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Diplegia (40h - Recovered/Resolved - ),<BR><BR>Eye pain (40h - Recovered/Resolved - ),<BR><BR>Headache (40h - Recovered/Resolved - ),<BR><BR>Loss of consciousness (40h - Recovered/Resolved - ),<BR><BR>Monoplegia (40h - Recovered/Resolved - ),<BR><BR>Nausea (40h - Recovered/Resolved - ),<BR><BR>Tongue biting (40h - Recovered/Resolved - ),<BR><BR>Vertigo (40h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016264632&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016264762,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,Pruritus (1mo - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016264762&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016264839,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Vertigo (n/a - Recovering/Resolving - Disabling),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[AMYLASE, LIPASE, PROTEASE, PANCREALIPASE, PANCREAS POWDER, PANCREAS POWDER FROM PORCINE, PANCREATIN, PANCREATIN BP, PANCRELIPASE AMYLASE, PANCRELIPASE PROTEASE, LIPASE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CLOMIPRAMINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PROGESTERONE, PROGESTERONE, MICRONISED] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016264839&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016264859,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Hypertension (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Labile blood pressure (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"NOT AVAILABLE (C - n/a - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>[ANHYDROUS LEVOTHYROXINE SODIUM] (C - n/a - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>[APIXABAN] (C - n/a - Unknown - [n/a - 2{DF} - n/a]),<BR><BR>[PAROXETINE] (C - n/a - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>[SOTALOL HYDROCHLORIDE] (C - n/a - Unknown - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016264859&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265023,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Atopy (n/a - Unknown - ),<BR><BR>Condition aggravated (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Mental impairment (n/a - Unknown - Other Medically Important Condition),<BR><BR>Toxicity to various agents (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265023&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265050,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oesophageal pain (n/a - Recovering/Resolving - ),<BR><BR>Rash papular (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265050&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265056,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Polymenorrhoea (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265056&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265062,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Rhinorrhoea (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265062&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265067,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dyskinesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Muscle spasms (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (S - Pneumococcal immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265067&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265070,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265070&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265074,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Body temperature increased (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Dizziness (24h - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265074&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265228,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Hypoaesthesia (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265228&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265260,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (n/a - Recovered/Resolved - ),<BR><BR>Loss of consciousness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265260&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265672,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling of body temperature change (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265672&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265695,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Headache (1d - Recovered/Resolved - ),<BR><BR>Injection site pain (1d - Recovered/Resolved - ),<BR><BR>Injection site swelling (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265695&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265726,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Asthenia (1d - Recovered/Resolved - ),<BR><BR>Back pain (4d - Recovered/Resolved - ),<BR><BR>Chills (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265726&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265729,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Primary stabbing headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Skin reaction (n/a - Not Recovered/Not Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"COMIRNATY [TOZINAMERAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.1 [ELASOMERAN, IMELASOMERAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265729&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265752,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (2wk - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (1wk - Recovered/Resolved - ),<BR><BR>Urticaria (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265752&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265753,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Erysipelas (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265753&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265757,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Headache (12h - Recovered/Resolved - ),<BR><BR>Multiple sclerosis (10h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265757&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265766,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Nausea (20h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265766&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265769,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Elderly,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Hypertension (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265769&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265773,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Dyspnoea (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265773&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265775,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[CHARCOAL, ACTIVATED] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265775&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265777,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (5h - Recovered/Resolved - ),<BR><BR>Fatigue (2d - Recovered/Resolved - ),<BR><BR>Headache (2d - Recovered/Resolved - ),<BR><BR>Malaise (2d - Recovered/Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - ),<BR><BR>Vomiting (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265777&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265781,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Tremor (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265781&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265782,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Myalgia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[DICLOFENAC POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265782&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265787,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arrhythmia (10min - Recovered/Resolved - ),<BR><BR>Heart rate increased (10min - Recovered/Resolved - ),<BR><BR>Injection site haematoma (2d - Recovered/Resolved - ),<BR><BR>Injection site pain (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265787&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265791,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>COVID-19 (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265791&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265792,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,"Arthralgia (2d - Recovered/Resolved - ),<BR><BR>Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (3d - Recovered/Resolved - ),<BR><BR>Myalgia (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","[XYLOMETAZOLINE, XYLOMETAZOLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265792&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265798,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arrhythmia (8d - Recovered/Resolved - ),<BR><BR>Dyspnoea (3d - Recovered/Resolved - ),<BR><BR>Extrasystoles (8d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (3d - Recovered/Resolved - ),<BR><BR>Malaise (6d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>PRADAXA 150 MG HARD CAPSULES [DABIGATRAN ETEXILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLECAINIDE ACETATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265798&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265800,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dizziness (24h - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (12h - Recovered/Resolved - ),<BR><BR>Nausea (57h - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265800&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265801,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (1d - Recovered/Resolved - ),<BR><BR>Chills (8h - Recovered/Resolved - ),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - ),<BR><BR>Ear pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Rhinorrhoea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PANTOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265801&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016265807,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Asthenia (1d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016265807&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016266042,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (3d - Recovered/Resolved - ),<BR><BR>Headache (3d - Recovered/Resolved - ),<BR><BR>Impaired gastric emptying (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016266042&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016266100,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Amnesia (n/a - Unknown - ),<BR><BR>Delirium (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - ),<BR><BR>Somnolence (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016266100&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016266105,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Injection site pain (1d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016266105&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016266131,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (1d - Recovered/Resolved - ),<BR><BR>Myalgia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016266131&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016266210,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016266210&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016266304,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Injection site pain (1d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016266304&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016266357,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Injection site pain (1d - Recovered/Resolved - ),<BR><BR>Injection site swelling (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016266357&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016266424,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Injection site swelling (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016266424&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016266489,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Urticaria (n/a - Not Recovered/Not Resolved - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - n/a]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Antiviral prophylaxis - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016266489&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016266497,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Injection site pain (1d - Recovered/Resolved - ),<BR><BR>Injection site swelling (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016266497&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016266523,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Chills (36h - Recovered/Resolved - ),<BR><BR>Vomiting (36h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016266523&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016266646,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Asthenia (1d - Recovered/Resolved - ),<BR><BR>Decreased appetite (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016266646&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016266736,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,Thrombotic stroke (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - n/a]),"[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CYCLOBENZAPRINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DONEPEZIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESCITALOPRAM, ESCITALOPRAM OXALATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[EZETIMIBE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LORAZEPAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MEMANTINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OLMESARTAN, OLMESARTAN MEDOXOMIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PRIMIDONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016266736&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016266860,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>RYBELSUS 3 MG TABLETS [SEMAGLUTIDE] (S - Diabetes mellitus - Dose not changed - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016266860&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016266863,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (1d - Recovered/Resolved - ),<BR><BR>Nausea (n/a - Recovered/Resolved - ),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Skin burning sensation (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016266863&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016266875,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Irritable bowel syndrome (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[CODEINE] (C - Irritable bowel syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[EZETIMIBE] (C - Blood cholesterol - n/a - [n/a - n/a - n/a]),<BR><BR>[MELOXICAM] (C - Neuralgia - n/a - [n/a - n/a - n/a]),<BR><BR>[MIRTAZAPINE] (C - Insomnia - n/a - [n/a - n/a - n/a]),<BR><BR>[MOMETASONE FUROATE] (C - Sinusitis - n/a - [n/a - n/a - n/a]),<BR><BR>[MOMETASONE] (C - Sinusitis - n/a - [n/a - n/a - n/a]),<BR><BR>[POTASSIUM HYDROGEN CARBONATE, SODIUM ALGINATE] (C - Dyspepsia - n/a - [n/a - n/a - n/a]),<BR><BR>[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - Neuralgia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016266875&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016266909,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,Alopecia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016266909&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016266941,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Headache (2d - Recovered/Resolved - ),<BR><BR>Insomnia (1d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (2d - Recovered/Resolved - ),<BR><BR>Pain (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"ARAVA 10 MG [LEFLUNOMIDE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[ASCORBIC ACID, MAGNESIUM OXIDE, HEAVY, MAGNESIUM] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[CYANOCOBALAMIN, RIBOFLAVIN, THIAMINE NITRATE, PYRIDOXINE HYDROCHLORIDE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[ESCITALOPRAM, ESCITALOPRAM OXALATE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[SODIUM VALPROATE, VALPROIC ACID] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016266941&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016267116,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Cardiac disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016267116&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016267198,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cerebellar ataxia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Diplopia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Prophylaxis - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016267198&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016267321,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Atrial fibrillation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (12d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Illness (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Oedema peripheral (n/a - Unknown - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016267321&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016267378,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vision blurred (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016267378&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016267406,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,Yes,Male,Facial paralysis (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, PERINDOPRIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016267406&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016267419,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Brain death (n/a - Unknown - Other Medically Important Condition),<BR><BR>Brain stem haemorrhage (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016267419&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016267451,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Haemorrhage subcutaneous (16d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Platelet count decreased (n/a - Recovered/Resolved - ),<BR><BR>Thrombocytopenic purpura (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016267451&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016267496,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Back pain (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016267496&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016267588,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (1d - Recovered/Resolved - Disabling),<BR><BR>Balance disorder (1d - Recovered/Resolved - Disabling),<BR><BR>Chills (1d - Recovered/Resolved - Disabling),<BR><BR>Fatigue (n/a - Unknown - Disabling),<BR><BR>Feeling cold (1d - Recovered/Resolved - Disabling),<BR><BR>Muscle rigidity (1d - Recovered/Resolved - Disabling),<BR><BR>Pain (n/a - Unknown - Disabling),<BR><BR>Tremor (1d - Recovered/Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016267588&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016267628,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Arthralgia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Injected limb mobility decreased (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016267628&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016267651,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Aggression (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Head discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Oversensing (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016267651&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016267919,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016267919&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016267928,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Erythema (3d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016267928&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016267942,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Paraesthesia (2d - Recovered/Resolved - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>FLUAD TETRA SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016267942&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016267956,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Confusional state (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Hyperthermia (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Rhabdomyolysis (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>FLUCELVAX TETRA SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[ZUCLOPENTHIXOL DECANOATE] (S - Bipolar disorder - Drug withdrawn - [2864d - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016267956&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016268019,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Atrial fibrillation (n/a - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - Unknown - [n/a - .3mL - n/a]),"APIXABAN [APIXABAN] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (C - n/a - n/a - [n/a - .3mL - n/a]),<BR><BR>[VERAPAMIL, VERAPAMIL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016268019&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016268186,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Haemorrhage subcutaneous (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),"WEGOVY FLEXTOUCH [SEMAGLUTIDE] (C - Overweight - n/a - [n/a - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016268186&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016268205,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Dizziness (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Syncope (0d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016268205&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016268217,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Rash (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),"[DILTIAZEM, DILTIAZEM HYDROCHLORIDE] (C - Anal fissure - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUOCORTOLONE PIVALATE PH. EUR., ANHYDROUS LIDOCAINE HYDROCHLORIDE, FLUOCORTOLONE PIVALATE PH. EUR., LIDOCAINE HYDROCHLORIDE, FLUOCORTOLONE PIVALATE, ANHYDROUS LIDOCAINE HYDROCHLORIDE, FLUOCORTOLONE PIVALATE, LIDOCAINE HYDROCHLORIDE] (C - Haemorrhoids - n/a - [n/a - n/a - n/a]),<BR><BR>[MICONAZOLE NITRATE, HYDROCORTISONE] (C - Eczema infected - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016268217&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016268222,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Angina pectoris (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Chest discomfort (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016268222&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016268225,Spontaneous,2023-11-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Ventricular tachycardia (0d - Recovered/Resolved - Life Threatening),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016268225&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016268462,Spontaneous,2023-11-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site haematoma (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (5d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016268462&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258938,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Dizziness (n/a - Not Recovered/Not Resolved - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258938&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258939,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Dizziness (1d - Recovered/Resolved - ),<BR><BR>Nausea (3h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258939&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258940,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arrhythmia (1h - Recovered/Resolved - ),<BR><BR>Back pain (3h - Recovered/Resolved - ),<BR><BR>Chills (2h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258940&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258941,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Body temperature increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (10h - Recovered/Resolved - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (8h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258941&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258942,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Tinnitus (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258942&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258943,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),[LOPERAMIDE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258943&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258944,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arthralgia (36h - Recovered/Resolved - ),<BR><BR>Body temperature increased (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (2d - Recovered/Resolved - ),<BR><BR>Injection site swelling (2d - Recovered/Resolved - ),<BR><BR>Injection site warmth (2d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (36h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258944&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258945,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Fatigue (16d - Recovered/Resolved - ),<BR><BR>Headache (14d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (2d - Recovered/Resolved - ),<BR><BR>Injection site pain (2d - Recovered/Resolved - ),<BR><BR>Injection site swelling (2d - Recovered/Resolved - ),<BR><BR>Injection site warmth (2d - Recovered/Resolved - ),<BR><BR>Malaise (5d - Recovered/Resolved - ),<BR><BR>Migraine (10d - Recovered/Resolved - ),<BR><BR>Nausea (4d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258945&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258946,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258946&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258948,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>RASILEZ 150 MG FILM-COATED TABLETS [ALISKIREN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258948&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258949,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (2d - Recovered/Resolved - ),<BR><BR>Diarrhoea (6d - Recovered/Resolved - ),<BR><BR>Dry mouth (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (3d - Recovered/Resolved - ),<BR><BR>Malaise (7d - Recovered/Resolved - ),<BR><BR>Myalgia (2d - Recovered/Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Oropharyngeal pain (3d - Recovered/Resolved - ),<BR><BR>Poor quality sleep (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),ADALIMUMAB [ADALIMUMAB] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258949&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258950,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Cough (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Hyperacusis (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (24h - Recovered/Resolved - ),<BR><BR>Injection site pain (24h - Recovered/Resolved - ),<BR><BR>Injection site warmth (24h - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (3d - Recovered/Resolved - ),<BR><BR>Photophobia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (4d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258950&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258951,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Elderly,No,Male,Herpes zoster (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258951&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258952,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258952&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258955,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Atrial fibrillation (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258955&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258956,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258956&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258957,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Headache (n/a - Recovered/Resolved - ),<BR><BR>Injection site pain (n/a - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258957&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258958,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258958&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258959,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Productive cough (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258959&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258960,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Maternal exposure during pregnancy (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258960&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258961,Spontaneous,2023-11-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Oedema (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258961&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258962,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Taste disorder (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258962&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258963,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258963&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258964,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site pruritus (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Malaise (2d - Recovered/Resolved - ),<BR><BR>Myalgia (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258964&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258965,Spontaneous,2023-11-11 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Injection site erythema (n/a - Unknown - ),<BR><BR>Injection site inflammation (n/a - Unknown - ),<BR><BR>Injection site pain (n/a - Unknown - ),<BR><BR>Injection site swelling (n/a - Unknown - ),<BR><BR>Injection site warmth (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258965&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258966,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arrhythmia (n/a - Recovered/Resolved - ),<BR><BR>Dizziness (15min - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258966&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258967,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (3d - Recovered/Resolved - ),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258967&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258968,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Injection site haematoma (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258968&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258969,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Headache (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (3d - Recovered/Resolved - ),<BR><BR>Visual impairment (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258969&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258970,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Deep vein thrombosis (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258970&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258971,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Condition aggravated (n/a - Not Recovered/Not Resolved - ),<BR><BR>Herpes zoster (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258971&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258972,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (5h - Recovered/Resolved - ),<BR><BR>Cyanosis (n/a - Recovering/Resolving - ),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESOMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[THIAMINE HYDROCHLORIDE, RETINOL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258972&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258973,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Eye irritation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[SUMATRIPTAN, SUMATRIPTAN SUCCINATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258973&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258974,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Abdominal pain upper (12h - Recovered/Resolved - ),<BR><BR>Diarrhoea (12h - Recovered/Resolved - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258974&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258975,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258975&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258976,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,"Malaise (24h - Recovered/Resolved - ),<BR><BR>Skin warm (n/a - Recovering/Resolving - ),<BR><BR>Swelling (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - Transient ischaemic attack - Dose not changed - [n/a - 2{DF} - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258976&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258977,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258977&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258978,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258978&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258981,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Vaccination site lymphadenopathy (1wk - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258981&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258982,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Dizziness (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258982&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258984,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nervousness (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[FLUVOXAMINE MALEATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258984&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258985,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (3d - Recovered/Resolved - ),<BR><BR>Fatigue (1d - Recovered/Resolved - ),<BR><BR>Headache (3d - Recovered/Resolved - ),<BR><BR>Herpes zoster (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (3d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258985&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258986,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (n/a - Recovered/Resolved - ),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - ),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Dizziness (n/a - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovered/Resolved - ),<BR><BR>Nasopharyngitis (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258986&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016259044,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Limb discomfort (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016259044&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016259045,Spontaneous,2023-11-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pyrexia (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016259045&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016259046,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Anaphylactic reaction (4d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016259046&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016259047,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Myalgia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016259047&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016259160,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Swollen tongue (0d - Recovered/Resolved - ),<BR><BR>Tongue discolouration (0d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 prophylaxis - Not applicable - [n/a - n/a - Intramuscular use]),<BR><BR>FLUCELVAX TETRA [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (S - Antiviral prophylaxis - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016259160&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016259279,Spontaneous,2023-11-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016259279&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016250878,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016250878&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016250940,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Rash (0d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016250940&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016251007,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Neuropathy peripheral (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),IRBESARTAN [IRBESARTAN] (C - Hypertension - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016251007&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016251086,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Back pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Renal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[ATORVASTATIN] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016251086&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016251304,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Nausea (n/a - Recovered/Resolved - ),<BR><BR>Pain (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - .5mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016251304&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016251440,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspepsia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Illness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Skin discolouration (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016251440&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016251500,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Deep vein thrombosis (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016251500&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016251508,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016251508&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016251651,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Deep vein thrombosis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016251651&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016251787,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016251787&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016252132,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Myocardial infarction (n/a - Unknown - Life Threatening, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016252132&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016252142,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Syncope (1d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016252142&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016252171,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Angina pectoris (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Pericarditis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016252171&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016252226,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016252226&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016252313,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (S - Pneumococcal immunisation - Not applicable - [n/a - 1{DF} - n/a])","NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016252313&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016252354,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Hypersensitivity (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016252354&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016252373,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Arthralgia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016252373&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016252416,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Herpes zoster (2d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016252416&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016252545,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Balance disorder (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016252545&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016253067,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Blood pressure fluctuation (0d - Recovered/Resolved - ),<BR><BR>Language disorder (0d - Recovered/Resolved - ),<BR><BR>Loss of consciousness (0d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (0d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016253067&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016253081,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Presyncope (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016253081&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016253093,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Migraine (1d - Recovered/Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016253093&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016253168,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,Vaccination site pain (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016253168&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016253260,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,Cardio-respiratory arrest (n/a - Unknown - Life Threatening),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016253260&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016253341,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Injection site pain (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016253341&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016253342,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016253342&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016253349,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Death (n/a - Fatal - Results in Death),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010, B/PHUKET/3073/2013-LIKE STRAIN, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/BRISBANE/60/2008, A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, B/MASSACHUSETTS/02/2012, A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010, B/BRISBANE/60/2008, B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010, B/BRISBANE/60/2008-LIKE VIRUS, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, NIB-121), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","NOT AVAILABLE (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[HYPROMELLOSE] (C - Dry eye - n/a - [n/a - n/a - n/a]),<BR><BR>[MACROGOL 4000] (C - Constipation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016253349&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016253353,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016253353&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016253360,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Bronchitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016253360&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016253581,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Fatigue (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016253581&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016253589,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Disturbance in attention (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016253589&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016253878,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Hypertension (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),[CARBASALATE CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016253878&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016253881,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (1d - Recovered/Resolved - ),<BR><BR>Malaise (1d - Recovered/Resolved - ),<BR><BR>Nausea (2d - Recovered/Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016253881&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016253948,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Male,"Ageusia (n/a - Recovering/Resolving - ),<BR><BR>Anosmia (n/a - Recovering/Resolving - ),<BR><BR>Asthenia (n/a - Recovering/Resolving - ),<BR><BR>Cough (n/a - Recovering/Resolving - ),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Dry mouth (n/a - Recovering/Resolving - ),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - ),<BR><BR>Head discomfort (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pain (n/a - Recovering/Resolving - ),<BR><BR>Urinary incontinence (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Immunisation - Not applicable - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016253948&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016254214,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Blood pressure fluctuation (n/a - Recovering/Resolving - ),<BR><BR>Cardiovascular disorder (n/a - Recovering/Resolving - ),<BR><BR>Injection site reaction (7d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[ANHYDROUS LEVOTHYROXINE SODIUM] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[FLECAINIDE ACETATE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[PERINDOPRIL ARGININE] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016254214&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016254500,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Death (0d - Fatal - Results in Death),<BR><BR>Diarrhoea (1d - Fatal - Results in Death),<BR><BR>Vomiting (1d - Fatal - Results in Death)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016254500&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016254566,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016254566&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016255040,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Dizziness (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),SPIKEVAX [ELASOMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016255040&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016255053,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Cardio-respiratory arrest (n/a - Fatal - Results in Death),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN, A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN, B/FLORIDA/4/2006-LIKE STRAIN, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/VICTORIA/361/2011 (H3N2)–DERIVED STRAIN USED (IVR-165), B/WISCONSIN/1/2010-LIKE STRAIN USED (NYMC BX-39) DERIVED FROM B/HUBEI-WUJIAGANG/158/2009, A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/MOSCOW/10/99 (H3N2) - LIKE STRAIN (A/PANAMA/2007/99 REASS. RESVIR-17), B/SICHUAN/379/99-LIKE STRAIN (B/JOHANNESBURG/5/99), A/SOUTH AUSTRALIA/55/2014 STRAIN, A/SWITZERLAND/9715293/2013 (H3N2) - LIKE STRAIN (A/SOUTH AUSTRALIA/55/2014, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, B/MASSACHUSETTS/02/2012, A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/VICTORIA/361/2011 (H3N2)–DERIVED STRAIN USED (IVR-165), B/WISCONSIN/1/2010-LIKE STRAIN USED (NYMC BX-39) DERIVED FROM B/HUBEI-WUJIAGANG/158/2009, A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/WISCONSIN/67/2005 (H3N2), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN, B/MALAYSIA/2506/2004 - LIKE STRAIN, B/BEIJING/184/93-LIKE STRAIN (B/YAMANASHI/166/98), A/SYDNEY/5/97 (H3N2)-LIKE STRAIN (A/SYDNEY/5/97 REASS. RESVIR 13), A/BEIJING/262/95 (H1N1) - LIKE STRAIN (A/BEIJING/262/95 REASS. X-127), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1), A/PERTH/16/2009 (H3N2) - LIKE STRAIN, B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009(H1N1)-LIKE STRAIN (NYMC X-179A), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NIB-65), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009(H1N1)-LIKE STRAIN (NYMC X-179A), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/MASSACHUSETTS/02/2012, A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE STRAIN, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SOUTH AUSTRALIA/55/2014, IVR-175), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED)] (S - Influenza immunisation - n/a - [n/a - 1{DF} - Subcutaneous use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016255053&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016255057,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Hypertension (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016255057&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016255058,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Injection site erythema (3d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016255058&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016255059,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Presyncope (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016255059&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016255075,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Injection site pain (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 2{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016255075&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016255078,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Headache (1wk - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016255078&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016255080,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Tachycardia (3h - Recovered/Resolved - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - COVID-19 immunisation - n/a - [1d - 1{DF} - Intramuscular use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016255080&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016255082,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arrhythmia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Recovered/Resolved - ),<BR><BR>Condition aggravated (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>[A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN, A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN, B/FLORIDA/4/2006-LIKE STRAIN, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/VICTORIA/361/2011 (H3N2)–DERIVED STRAIN USED (IVR-165), B/WISCONSIN/1/2010-LIKE STRAIN USED (NYMC BX-39) DERIVED FROM B/HUBEI-WUJIAGANG/158/2009, A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/MOSCOW/10/99 (H3N2) - LIKE STRAIN (A/PANAMA/2007/99 REASS. RESVIR-17), B/SICHUAN/379/99-LIKE STRAIN (B/JOHANNESBURG/5/99), A/SOUTH AUSTRALIA/55/2014 STRAIN, A/SWITZERLAND/9715293/2013 (H3N2) - LIKE STRAIN (A/SOUTH AUSTRALIA/55/2014, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, B/MASSACHUSETTS/02/2012, A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/VICTORIA/361/2011 (H3N2)–DERIVED STRAIN USED (IVR-165), B/WISCONSIN/1/2010-LIKE STRAIN USED (NYMC BX-39) DERIVED FROM B/HUBEI-WUJIAGANG/158/2009, A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/WISCONSIN/67/2005 (H3N2), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN, B/MALAYSIA/2506/2004 - LIKE STRAIN, B/BEIJING/184/93-LIKE STRAIN (B/YAMANASHI/166/98), A/SYDNEY/5/97 (H3N2)-LIKE STRAIN (A/SYDNEY/5/97 REASS. RESVIR 13), A/BEIJING/262/95 (H1N1) - LIKE STRAIN (A/BEIJING/262/95 REASS. X-127), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1), A/PERTH/16/2009 (H3N2) - LIKE STRAIN, B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009(H1N1)-LIKE STRAIN (NYMC X-179A), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NIB-65), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009(H1N1)-LIKE STRAIN (NYMC X-179A), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/MASSACHUSETTS/02/2012, A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE STRAIN, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SOUTH AUSTRALIA/55/2014, IVR-175), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED)] (S - Influenza immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016255082&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016255090,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Immunisation reaction (2d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),"COAPROVEL [HYDROCHLOROTHIAZIDE, IRBESARTAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016255090&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016255096,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Arthralgia (4d - Unknown - ),COMIRNATY OMICRON XBB.1.5 10 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016255096&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016255140,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Injection site pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Joint range of motion decreased (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pyrexia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016255140&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016255235,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Diarrhoea (1wk - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016255235&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016255291,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Injection site reaction (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016255291&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016255441,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Unknown - ),<BR><BR>Oropharyngeal pain (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016255441&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016255472,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Transient ischaemic attack (4h - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Antiviral prophylaxis - Not applicable - [n/a - n/a - Subcutaneous use])",ELIQUIS [APIXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016255472&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016255746,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rhinorrhoea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016255746&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016255788,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting projectile (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[LETROZOLE] (C - Breast cancer - n/a - [5y - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016255788&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016255822,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016255822&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016255843,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,Urticaria (21d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[VALSARTAN, HYDROCHLOROTHIAZIDE] (C - Hypertension - Unknown - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016255843&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016255957,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Dermatitis allergic (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rash (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[AMOXICILLIN, AMOXICILLIN TRIHYDRATE] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[BENZALKONIUM CHLORIDE, CHLORHEXIDINE DIHYDROCHLORIDE, ISOPROPYL MYRISTATE, LIQUID PARAFFIN, BENZALKONIUM CHLORIDE, ISOPROPYL MYRISTATE, LIQUID PARAFFIN, NEOMYCIN SULFATE, PREDNISOLONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CINCHOCAINE HYDROCHLORIDE, PREDNISOLONE, CINCHOCAINE HYDROCHLORIDE, PREDNISOLONE CAPROATE] (C - Haemorrhoids - n/a - [7d - 2{DF} - n/a]),<BR><BR>[CLOBETASOL PROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[FLUCLOXACILLIN, FLUCLOXACILLIN SODIUM, FLUCLOXACILLIN SODIUM MONOHYDRATE] (C - n/a - n/a - [7d - 4{DF} - n/a]),<BR><BR>[FLUDROXYCORTIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TERBINAFINE, TERBINAFINE HYDROCHLORIDE] (C - Fungal skin infection - n/a - [10d - 2{DF} - n/a]),<BR><BR>[TOPIRAMATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[UREA] (C - n/a - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016255957&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016255967,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Headache (2d - Recovered/Resolved - ),<BR><BR>Migraine (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016255967&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016256012,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blood pressure decreased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016256012&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016256029,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (3d - Recovered/Resolved - ),<BR><BR>Eczema (n/a - Recovering/Resolving - ),<BR><BR>Eczema eyelids (n/a - Recovering/Resolving - ),<BR><BR>Headache (3d - Recovered/Resolved - ),<BR><BR>Malaise (3d - Recovered/Resolved - ),<BR><BR>Myalgia (3d - Recovered/Resolved - ),<BR><BR>Pyrexia (3d - Recovered/Resolved - ),<BR><BR>Skin disorder (n/a - Recovering/Resolving - ),<BR><BR>Swelling of eyelid (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016256029&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016256044,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Blood pressure increased (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Influenza like illness (n/a - Recovering/Resolving - ),<BR><BR>Paraesthesia (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016256044&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016256127,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Heart rate increased (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016256127&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016256157,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016256157&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016256367,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,Yes,Male,Syncope (15s - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Antiviral prophylaxis - Not applicable - [0d - n/a - Intramuscular use])","EBYMECT [METFORMIN HYDROCHLORIDE, DAPAGLIFLOZIN] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>PRADAXA [DABIGATRAN ETEXILATE, DABIGATRAN ETEXILATE MESILATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[PERINDOPRIL, PERINDOPRIL ARGININE, PERINDOPRIL TERT-BUTYLAMIN MONOHYDRATE, PERINDOPRIL TERT-BUTYLAMINE] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016256367&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016256419,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Headache (n/a - Unknown - ),<BR><BR>Hepatitis B (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Unknown - ),<BR><BR>Tinnitus (n/a - Unknown - ),<BR><BR>Tremor (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016256419&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016257047,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Fatigue (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016257047&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016257265,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - ),<BR><BR>Chills (n/a - Unknown - ),<BR><BR>Decreased appetite (n/a - Unknown - ),<BR><BR>Dizziness (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Hyperhidrosis (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - n/a - [1d - n/a - n/a - More in ICSR]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - COVID-19 immunisation - n/a - [1d - n/a - n/a]),<BR><BR>DULOXETINE [DULOXETINE, DULOXETINE HYDROCHLORIDE] (C - Cluster headache - n/a - [n/a - n/a - n/a]),<BR><BR>PREGABALIN [PREGABALIN] (C - Pain in extremity - n/a - [n/a - n/a - n/a]),<BR><BR>TERIFLUNOMIDE [TERIFLUNOMIDE] (C - Relapsing multiple sclerosis - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Antiviral prophylaxis - n/a - [1d - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - Pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016257265&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016257339,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Disabling),<BR><BR>Chills (n/a - Recovering/Resolving - Disabling),<BR><BR>Fatigue (n/a - Recovering/Resolving - Disabling),<BR><BR>Headache (n/a - Recovering/Resolving - Disabling),<BR><BR>Myalgia (n/a - Recovering/Resolving - Disabling),<BR><BR>Nausea (n/a - Recovering/Resolving - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016257339&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016257599,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016257599&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016257663,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cold sweat (n/a - Recovering/Resolving - ),<BR><BR>Dysstasia (n/a - Unknown - ),<BR><BR>Feeling hot (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Hypersomnia (n/a - Unknown - ),<BR><BR>Nasopharyngitis (n/a - Recovering/Resolving - ),<BR><BR>Neck pain (n/a - Recovering/Resolving - ),<BR><BR>Vertigo (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016257663&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016257755,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Feeling hot (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Night sweats (n/a - Unknown - ),<BR><BR>Syncope (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016257755&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258075,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Chills (n/a - Unknown - ),<BR><BR>Cough (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258075&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258090,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"C-reactive protein increased (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Drug eruption (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Fall (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Inflammation (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Rash erythematous (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Viral infection (n/a - Unknown - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258090&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258242,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Myalgia (5d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[CORTISONE] (C - Connective tissue inflammation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258242&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258376,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Pain in extremity (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [2d - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258376&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258384,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Mobility decreased (8d - Recovered/Resolved - ),<BR><BR>Vaccination site erythema (8d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258384&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258390,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Male,"Peripheral swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site oedema (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"FLUAD TETRA SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (C - Influenza immunisation - Not applicable - [n/a - n/a - Intramuscular use]),<BR><BR>JARDIANCE 10 MG FILM-COATED TABLETS [EMPAGLIFLOZIN] (C - Diabetes mellitus - Not applicable - [n/a - n/a - Oral use]),<BR><BR>LYRICA 25 MG HARD CAPSULES [PREGABALIN] (C - Diabetes mellitus - Not applicable - [n/a - n/a - Oral use]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Acute myocardial infarction - Not applicable - [n/a - n/a - Oral use]),<BR><BR>[ATORVASTATIN] (C - Acute myocardial infarction - Not applicable - [n/a - n/a - Oral use]),<BR><BR>[CARVEDILOL] (C - Hypertension - Not applicable - [n/a - n/a - Oral use]),<BR><BR>[ENALAPRIL MALEATE] (C - Acute myocardial infarction - Not applicable - [n/a - n/a - Oral use]),<BR><BR>[METFORMIN HYDROCHLORIDE, VILDAGLIPTIN] (C - Diabetes mellitus - Not applicable - [n/a - n/a - Oral use]),<BR><BR>[OMEPRAZOLE] (C - Nasopharyngitis - Not applicable - [n/a - n/a - Oral use]),<BR><BR>[PREGABALIN] (C - Type 2 diabetes mellitus - Not applicable - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258390&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258393,Spontaneous,2023-11-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Chills (1d - Recovered/Resolved - ),<BR><BR>Vaccination site pain (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 10 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[EZETIMIBE] (C - Hyperlipidaemia - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258393&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258394,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Vaccination site erythema (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258394&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258536,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Back pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>COVID-19 (n/a - Unknown - ),<BR><BR>Cough (n/a - Unknown - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - ),<BR><BR>Shoulder injury related to vaccine administration (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"MICARDIS [TELMISARTAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE BESILATE, ATORVASTATIN CALCIUM, AMLODIPINE, ATORVASTATIN, AMLODIPINE, ATORVASTATIN CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PEONY FLOWER, GLYCYRRHIZA EXTRACT, SHAKUYAKUKANZOTO] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258536&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016258641,Spontaneous,2023-11-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Contusion (n/a - Unknown - ),<BR><BR>Internal haemorrhage (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oral blood blister (n/a - Unknown - ),<BR><BR>Tongue blistering (n/a - Unknown - ),<BR><BR>Urticaria (n/a - Unknown - ),<BR><BR>Vaccination site bruising (n/a - Unknown - ),<BR><BR>Vaccination site erythema (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016258641&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016242054,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Influenza (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN, A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN, B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1) V REASS. X - 179 A, A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/NANCHANG 933/95 (H3N2), A/BAYERN/7/95 (H1N1) - LIKE STRAIN (A/JOHANNESBURG/82/96), B/BEIJING/184/93-LIKE STRAIN (B/HARBIN/7/94), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/CALIFORNIA/7/2004 (H3N2) - LIKE STRAIN (A/NEW YORK/55/2004 REASS. NYMC X-157), B/SHANGHAI/361/2002 - LIKE STRAIN (B/JIANGSU/10/2003), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/MOSCOW/10/99 (H3N2) - LIKE STRAIN (A/PANAMA/2007/99 REASS. RESVIR-17), B/SICHUAN/379/99-LIKE STRAIN (B/JOHANNESBURG/5/99), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), A/CALIFORNIA/7/2009 (H1N1)-DERIVED STRAIN USED NYMC X-181, B/BRISBANE/60/2008, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1)V-LIKE VIRUS, A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H1N1), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H3N2), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[ANASTROZOLE] (C - Breast cancer female - n/a - [n/a - n/a - n/a])...","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016242054&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016242599,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016242599&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016242817,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arthralgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Injection (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016242817&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016242939,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - ),<BR><BR>Syncope (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016242939&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016242959,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cardiac flutter (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cold sweat (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Coordination abnormal (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dehydration (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Ear pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016242959&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016242971,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Rectal haemorrhage (5d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016242971&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016243128,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Blister (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ASCORBIC ACID, BETACAROTENE, BIOTIN, ERGOCALCIFEROL, CYANOCOBALAMIN, FOLIC ACID, NICOTINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, ZINC, CALCIUM, CHROMIUM, COPPER, IODINE, IRON, MAGNESIUM, MANGANESE, PANTOTHENIC ACID, PHOSPHORUS, POTASSIUM, SELENIUM, TOCOPHERYL ACETATE, MOLYBDENUM, ASCORBIC ACID, BETACAROTENE, ERGOCALCIFEROL, CYANOCOBALAMIN, FOLIC ACID, NICOTINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, ZINC, CALCIUM, CHROMIUM, COPPER, IODINE, IRON, MAGNESIUM, MANGANESE, PANTOTHENIC ACID, PHOSPHORUS, POTASSIUM, SELENIUM, MOLYBDENUM, DL-ALPHA TOCOPHEROL ACETATE, D-BIOTIN, ERGOCALCIFEROL, RETINOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016243128&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016243232,Spontaneous,2023-11-09 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Acute kidney injury (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pneumonia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Rhabdomyolysis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016243232&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016243301,Spontaneous,2023-11-09 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fall (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fatigue (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Loss of consciousness (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Somnolence (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Upper limb fracture (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016243301&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016243554,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Alanine aminotransferase increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Aspartate aminotransferase increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Pain (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016243554&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016243968,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Gait disturbance (20min - Recovered/Resolved - Life Threatening),<BR><BR>Respiratory disorder (20min - Recovered/Resolved - Life Threatening),<BR><BR>Seizure (20min - Recovered/Resolved - Life Threatening),<BR><BR>Tremor (20min - Recovered/Resolved - Life Threatening)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use]),"[AMLODIPINE, AMLODIPINE BESILATE] (C - n/a - n/a - ),<BR><BR>[FUROSEMIDE, FUROSEMIDE SODIUM] (C - n/a - n/a - ),<BR><BR>[RAMIPRIL] (C - n/a - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016243968&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016244263,Spontaneous,2023-11-09 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Chest pain (n/a - Fatal - Results in Death),<BR><BR>Malaise (n/a - Fatal - Results in Death),<BR><BR>Nausea (n/a - Fatal - Results in Death),<BR><BR>Pain (n/a - Fatal - Results in Death)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - n/a - n/a])","NOT AVAILABLE (C - n/a - Not applicable - [n/a - 1mg - n/a]),<BR><BR>[DULOXETINE, DULOXETINE HYDROCHLORIDE] (C - n/a - Not applicable - [n/a - 60mg - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - Not applicable - [n/a - 40mg - n/a]),<BR><BR>[MAGNESIUM OXIDE, LIGHT] (C - n/a - Not applicable - [n/a - 1000mg - n/a]),<BR><BR>[MORPHINE SULFATE] (C - n/a - Not applicable - [n/a - 5mg - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - Not applicable - [n/a - 500mg - n/a]),<BR><BR>[POTASSIUM CHLORIDE] (C - n/a - Not applicable - [n/a - 750mg - n/a]),<BR><BR>[VALSARTAN] (C - n/a - Not applicable - [n/a - 80mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016244263&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016244802,Spontaneous,2023-11-09 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Asthenia (n/a - Fatal - Results in Death),<BR><BR>Cardiac arrest (n/a - Fatal - Results in Death),<BR><BR>Hyperhidrosis (n/a - Fatal - Results in Death),<BR><BR>Illness (n/a - Fatal - Results in Death),<BR><BR>Malaise (n/a - Fatal - Results in Death)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>JARDIANCE 10 MG [EMPAGLIFLOZIN] (S - n/a - Not applicable - [n/a - 10mg - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - n/a - n/a])","ELIQUIS 5 MG [APIXABAN] (C - n/a - Not applicable - [n/a - 5mg - n/a]),<BR><BR>IBANDRONIC ACID - SOLUTION FOR INFUSION  (C - n/a - Not applicable - [n/a - 3mg - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - Not applicable - [n/a - 10mg - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - Not applicable - [n/a - 40mg - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - Not applicable - [n/a - 95mg - n/a]),<BR><BR>TRELEGY ELLIPTA [UMECLIDINIUM BROMIDE, FLUTICASONE FUROATE, VILANTEROL, UMECLIDINIUM BROMIDE, FLUTICASONE FUROATE, VILANTEROL TRIFENATATE] (C - n/a - Not applicable - [n/a - n/a - n/a]),<BR><BR>TRESIBA [INSULIN DEGLUDEC] (C - n/a - Not applicable - [n/a - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - Not applicable - [n/a - 100mg - n/a]),<BR><BR>[ASCORBIC ACID, MAGNESIUM OXIDE, HEAVY, MAGNESIUM] (C - n/a - Not applicable - [n/a - 500mg - n/a]),<BR><BR>[DIGOXIN, DIGOXIN PH. EUR.] (C - n/a - Not applicable - [n/a - 62.5mg - n/a]),<BR><BR>[ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM] (C - n/a - Not applicable - [n/a - 40mg - n/a]),<BR><BR>[FLUTICASONE PROPIONATE] (C - n/a - Not applicable - [n/a - 250ug - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - Not applicable - [n/a - 60mg - n/a]),<BR><BR>[GABAPENTIN] (C - n/a - Not applicable - [n/a - 300mg - n/a]),<BR><BR>[INSULIN ASPART] (C - n/a - Not applicable - [n/a - n/a - n/a]),<BR><BR>[ISOSORBIDE 5 MONONITRATE] (C - n/a - Not applicable - [n/a - 30mg - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - Not applicable - [n/a - 100ug - n/a]),<BR><BR>[MOMETASONE FUROATE] (C - n/a - Not applicable - [n/a - n/a - n/a]),<BR><BR>[OXAZEPAM] (C - n/a - Not applicable - [n/a - 15mg - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - Not applicable - [n/a - 500mg - n/a]),<BR><BR>[POTASSIUM CHLORIDE] (C - n/a - Not applicable - [n/a - 750mg - n/a]),<BR><BR>[SODIUM PICOSULFATE] (C - n/a - Not applicable - [n/a - 10[drp] - n/a]),<BR><BR>[SPIRONOLACTONE] (C - n/a - Not applicable - [n/a - 25mg - n/a]),<BR><BR>[ZOPICLONE] (C - n/a - Not applicable - [n/a - 7.5mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016244802&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016245232,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Cough (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Dose not changed - [n/a - 1{DF} - n/a]),"[FLUTICASONE PROPIONATE, SALMETEROL, FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016245232&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016245238,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Male,"Body temperature increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016245238&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016245243,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,"Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (1d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Malaise (1d - Recovered/Resolved - ),<BR><BR>Myalgia (1d - Recovered/Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016245243&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016245245,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Nasopharyngitis (n/a - Recovering/Resolving - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016245245&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016245257,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Nausea (1h - Recovered/Resolved - ),<BR><BR>Pyrexia (2h - Recovered/Resolved - ),<BR><BR>Vomiting (30min - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016245257&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016245351,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pyrexia (220min - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016245351&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016245419,Spontaneous,2023-11-09 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,"Loss of consciousness (n/a - Fatal - Results in Death),<BR><BR>Malaise (n/a - Fatal - Results in Death)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - n/a - n/a])","ARANESP 40 MICROGRAMS [DARBEPOETIN ALFA] (C - n/a - Not applicable - [n/a - 40ug - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - Not applicable - [n/a - 23.75mg - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - Not applicable - [n/a - 40mg - n/a]),<BR><BR>[AMLODIPINE MALEATE] (C - n/a - Not applicable - [n/a - 5mg - n/a]),<BR><BR>[BENSERAZIDE HYDROCHLORIDE, LEVODOPA] (C - n/a - Not applicable - [n/a - 25mg - n/a]),<BR><BR>[DOXAZOSIN MESILATE] (C - n/a - Not applicable - [n/a - 4mg - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - Not applicable - [n/a - 40mg - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - Not applicable - [n/a - 500mg - n/a]),<BR><BR>[POVIDONE, POVIDONE K25] (C - n/a - Not applicable - [n/a - n/a - n/a]),<BR><BR>[SODIUM BICARBONATE BP, SODIUM HYDROGEN CARBONATE] (C - n/a - Not applicable - [n/a - 1g - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016245419&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016245533,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Illusion (n/a - Unknown - Disabling),<BR><BR>Pyrexia (n/a - Recovered/Resolved With Sequelae - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016245533&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016245562,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Contusion (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016245562&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016245726,Spontaneous,2023-11-09 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Oxygen saturation decreased (n/a - Fatal - Results in Death),<BR><BR>Taste disorder (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza - Not applicable - [n/a - n/a - n/a])","NOT AVAILABLE (C - n/a - Not applicable - [n/a - 250mg - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - Not applicable - [n/a - 50mg - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - Not applicable - [n/a - n/a - n/a]),<BR><BR>[ACETYLCYSTEINE] (C - n/a - Not applicable - [n/a - 200mg - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - Not applicable - [n/a - 20mg - n/a]),<BR><BR>[ISOSORBIDE MONONITRATE] (C - n/a - Not applicable - [n/a - 60mg - n/a]),<BR><BR>[LERCANIDIPINE HYDROCHLORIDE] (C - n/a - Not applicable - [n/a - 10mg - n/a]),<BR><BR>[MIRTAZAPINE] (C - n/a - Not applicable - [n/a - 15mg - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - Not applicable - [n/a - 20mg - n/a]),<BR><BR>[UMECLIDINIUM BROMIDE, VILANTEROL TRIFENATATE] (C - n/a - Not applicable - [n/a - 72ug - n/a]),<BR><BR>[ZOPICLONE] (C - n/a - Not applicable - [n/a - 7.5mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016245726&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016245783,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Epistaxis (n/a - Unknown - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Productive cough (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016245783&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016245789,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Abdominal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016245789&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016245794,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Dizziness (2d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016245794&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016245807,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,Tinnitus (n/a - Unknown - Other Medically Important Condition),"COMIRNATY [TOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>RAXTOZINAMERAN [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016245807&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016245864,Spontaneous,2023-11-09 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Deep vein thrombosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oedema peripheral (n/a - Unknown - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - n/a - n/a])","[AMLODIPINE MALEATE] (C - n/a - Not applicable - [n/a - 5mg - n/a]),<BR><BR>[CLOMETHIAZOLE EDISILATE] (C - n/a - Not applicable - [n/a - 300mg - n/a]),<BR><BR>[ENALAPRIL, ENALAPRIL MALEATE] (C - n/a - Not applicable - [n/a - 5mg - n/a]),<BR><BR>[ESCITALOPRAM OXALATE] (C - n/a - Not applicable - [n/a - 20mg - n/a]),<BR><BR>[MAGNESIUM OXIDE, LIGHT] (C - n/a - Not applicable - [n/a - 500mg - n/a]),<BR><BR>[POTASSIUM CHLORIDE] (C - n/a - Not applicable - [n/a - 750mg - n/a]),<BR><BR>[RISPERIDONE] (C - n/a - Not applicable - [n/a - 1mg - n/a]),<BR><BR>[SODIUM PICOSULFATE] (C - n/a - Not applicable - [n/a - 10[drp] - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016245864&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016245934,Spontaneous,2023-11-09 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,"Ear pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),EDARBI [AZILSARTAN MEDOXOMIL] (C - n/a - n/a - [n/a - 40mg - Oral use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016245934&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016246048,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Application site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016246048&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016246118,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pulmonary pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016246118&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016246124,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Unknown - ),<BR><BR>Muscle spasms (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nuchal rigidity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oral disorder (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Swollen tongue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Swollen tongue (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016246124&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016246538,Spontaneous,2023-11-09 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Vaccination site pain (n/a - Unknown - ),<BR><BR>Vaccination site swelling (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016246538&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016246551,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016246551&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016246608,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Axillary pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness postural (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymph node pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site lymphadenopathy (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016246608&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016246890,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arthralgia (5d - Recovered/Resolved - ),<BR><BR>Arthralgia (n/a - Recovered/Resolved - ),<BR><BR>Cough (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),"[BILASTINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ENALAPRIL MALEATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016246890&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016247093,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - ),<BR><BR>Asthenia (n/a - Unknown - ),<BR><BR>Chills (n/a - Unknown - ),<BR><BR>Dizziness (5d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Feeding disorder (3d - Recovered/Resolved - ),<BR><BR>Feeling of body temperature change (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Unknown - ),<BR><BR>Myocarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (5d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Unknown - ),<BR><BR>Retching (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016247093&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016247097,Spontaneous,2023-11-09 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Extrasystoles (n/a - Recovering/Resolving - ),<BR><BR>Heart rate increased (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Palpitations (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016247097&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016247752,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Fall (30min - Recovered/Resolved - ),<BR><BR>Glycosuria (n/a - Unknown - ),<BR><BR>Muscular weakness (1d - Recovered/Resolved - ),<BR><BR>Polyuria (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - Not applicable - [n/a - n/a - n/a]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - n/a - Not applicable - [n/a - n/a - n/a])","BETMIGA 25 MG [MIRABEGRON] (C - n/a - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>LANTUS [INSULIN GLARGINE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>NOVONORM 1MG [REPAGLINIDE] (C - n/a - Unknown - [n/a - 2{DF} - n/a]),<BR><BR>[ACENOCOUMAROL] (C - n/a - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - Unknown - [n/a - 150mg - n/a]),<BR><BR>[TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE] (C - n/a - Unknown - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016247752&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016247798,Spontaneous,2023-11-09 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (3d - Recovering/Resolving - ),<BR><BR>Diarrhoea (0d - Recovered/Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Vomiting (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016247798&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016248077,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Pain (n/a - Recovered/Resolved - ),<BR><BR>Paralysis (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016248077&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016248176,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Body temperature increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),[MIRTAZAPINE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016248176&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016248321,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Chills (n/a - Unknown - ),<BR><BR>Cough (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016248321&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016248334,Spontaneous,2023-11-09 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Vaccination site pain (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016248334&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016248346,Spontaneous,2023-11-09 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Rhinorrhoea (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN, A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN, B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1) V REASS. X - 179 A, A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/NANCHANG 933/95 (H3N2), A/BAYERN/7/95 (H1N1) - LIKE STRAIN (A/JOHANNESBURG/82/96), B/BEIJING/184/93-LIKE STRAIN (B/HARBIN/7/94), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/CALIFORNIA/7/2004 (H3N2) - LIKE STRAIN (A/NEW YORK/55/2004 REASS. NYMC X-157), B/SHANGHAI/361/2002 - LIKE STRAIN (B/JIANGSU/10/2003), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/MOSCOW/10/99 (H3N2) - LIKE STRAIN (A/PANAMA/2007/99 REASS. RESVIR-17), B/SICHUAN/379/99-LIKE STRAIN (B/JOHANNESBURG/5/99), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), A/CALIFORNIA/7/2009 (H1N1)-DERIVED STRAIN USED NYMC X-181, B/BRISBANE/60/2008, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1)V-LIKE VIRUS, A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H1N1), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H3N2), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B] (C - Influenza immunisation - n/a - [1d - n/a - Intramuscular use]),<BR><BR>[SODIUM POLYSTYRENE SULFONATE] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016248346&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016248408,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Tachycardia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016248408&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016248441,Spontaneous,2023-11-09 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,"Diplopia (6d - Recovered/Resolved - ),<BR><BR>IVth nerve disorder (6d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016248441&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016248768,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Back pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016248768&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016248844,Spontaneous,2023-11-09 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,"Dizziness (10min - Recovered/Resolved - ),<BR><BR>Headache (10min - Recovered/Resolved - ),<BR><BR>Malaise (10min - Recovered/Resolved - ),<BR><BR>Nausea (10min - Recovered/Resolved - ),<BR><BR>Syncope (10min - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Antiviral prophylaxis - Not applicable - [0d - n/a - Intramuscular use])","[SIMVASTATIN, EZETIMIBE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016248844&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016248931,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Migraine (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),ADALIMUMAB [ADALIMUMAB] (C - n/a - n/a - [n/a - n/a - Intramuscular use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016248931&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016249547,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016249547&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016249594,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Death (n/a - Fatal - Results in Death),<BR><BR>Herpes zoster (n/a - Unknown - Other Medically Important Condition),<BR><BR>Seizure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016249594&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016249933,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (3d - Recovered/Resolved - ),<BR><BR>Headache (3d - Recovered/Resolved - ),<BR><BR>Malaise (3d - Recovered/Resolved - ),<BR><BR>Myalgia (3d - Recovered/Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016249933&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016250326,Spontaneous,2023-11-09 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain (n/a - Recovering/Resolving - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),"XARELTO [RIVAROXABAN] (C - Thrombosis prophylaxis - n/a - [n/a - 10mg - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE] (C - Hypertension - n/a - [n/a - 10mg - n/a]),<BR><BR>[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - 40mg - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - 100mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016250326&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016250327,Spontaneous,2023-11-09 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Seasonal allergy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Urticaria (7d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),[BUDESONIDE] (C - Asthma - n/a - [n/a - 400ug - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016250327&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016250512,Spontaneous,2023-11-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Joint stiffness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Paraesthesia (n/a - Recovered/Resolved - ),<BR><BR>Vaccination site cyst (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site discomfort (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016250512&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016250717,Spontaneous,2023-11-09 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Chills (2d - Recovered/Resolved - ),<BR><BR>Muscle rigidity (2d - Recovered/Resolved - ),<BR><BR>Muscle spasms (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - ),<BR><BR>Tremor (2d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>FLUAD TETRA SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016250717&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016250729,Spontaneous,2023-11-09 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Malaise (n/a - Recovered/Resolved - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016250729&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016250737,Spontaneous,2023-11-09 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Local reaction (n/a - Recovering/Resolving - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Influenza immunisation - Not applicable - [1d - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016250737&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016250739,Spontaneous,2023-11-09 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Apathy (n/a - Recovered/Resolved - ),<BR><BR>Cognitive disorder (n/a - Recovered/Resolved - ),<BR><BR>Insomnia (n/a - Recovered/Resolved - ),<BR><BR>Memory impairment (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016250739&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016250761,Spontaneous,2023-11-09 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Henoch-Schonlein purpura (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - n/a - Not applicable - [n/a - n/a - Subcutaneous use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016250761&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016250781,Spontaneous,2023-11-09 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Acute myocardial infarction (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>FLUCELVAX TETRA SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (S - Antiviral prophylaxis - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016250781&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016234240,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Local reaction (5d - Recovered/Resolved - ),<BR><BR>Pyrexia (5d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016234240&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016234359,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"JARDIANCE [EMPAGLIFLOZIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VITAMIN D] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016234359&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016234469,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Rash papular (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016234469&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016235075,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016235075&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016235476,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site movement impairment (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pruritus (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016235476&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016235637,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Herpes zoster (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[BISOPROLOL FUMARATE, BISOPROLOL FUMARATE, ACETYLSALICYLIC ACID, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INDAPAMIDE, PERINDOPRIL, INDAPAMIDE, PERINDOPRIL ARGININE, PERINDOPRIL TERT-BUTYLAMINE, INDAPAMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PAROXETINE, PAROXETINE HYDROCHLORIDE HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016235637&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016235646,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Abdominal pain upper (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - Restless legs syndrome - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016235646&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016235796,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Balance disorder (6d - Recovered/Resolved - Disabling),<BR><BR>Dizziness (n/a - Unknown - Disabling),<BR><BR>Dysgeusia (n/a - Recovered/Resolved - Disabling),<BR><BR>Hyperacusis (4d - Recovered/Resolved - Disabling),<BR><BR>Hypertension (n/a - Recovered/Resolved - Disabling),<BR><BR>Nausea (n/a - Recovering/Resolving - Disabling),<BR><BR>Photophobia (4d - Recovered/Resolved - Disabling),<BR><BR>Somnolence (n/a - Recovering/Resolving - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016235796&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016236059,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016236059&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016236197,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Herpes zoster (n/a - Not Recovered/Not Resolved - ),<BR><BR>Skin disorder (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 10 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016236197&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016236385,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Injected limb mobility decreased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use - More in ICSR]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016236385&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016236510,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016236510&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016236660,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016236660&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016236764,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Bell's palsy (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Migraine (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016236764&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016236843,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016236843&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016236853,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016236853&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016237062,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Male,Erythema (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Antiviral prophylaxis - n/a - [0d - n/a - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016237062&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016237295,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016237295&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016237529,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),VUMERITY [DIROXIMEL FUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016237529&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016237572,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,Yes,Female,Nausea (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016237572&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016237592,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Asthenia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Muscular weakness (2d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0mo - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016237592&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016237682,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Injection site erythema (2d - Recovered/Resolved - ),<BR><BR>Injection site swelling (2d - Recovered/Resolved - ),<BR><BR>Pruritus (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016237682&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016237735,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Malaise (n/a - Not Recovered/Not Resolved - Life Threatening),<BR><BR>Medication error (n/a - Unknown - Life Threatening),<BR><BR>Myocardial infarction (n/a - Not Recovered/Not Resolved - Life Threatening)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 30ug - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016237735&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016237886,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016237886&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016238007,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,Bursitis (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016238007&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016238111,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Henoch-Schonlein purpura (n/a - Unknown - Other Medically Important Condition),<BR><BR>Proteinuria (n/a - Unknown - ),<BR><BR>Purpura (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016238111&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016238123,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Tenosynovitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016238123&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016238266,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016238266&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016238322,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,"Anxiety (n/a - Recovered/Resolved - ),<BR><BR>Asthenia (n/a - Recovered/Resolved - ),<BR><BR>Blood pressure increased (n/a - Recovered/Resolved - ),<BR><BR>Discomfort (n/a - Recovered/Resolved - ),<BR><BR>Dizziness (n/a - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Immunisation - Not applicable - [n/a - n/a - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016238322&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016238496,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Erythema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Thrombosis (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016238496&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016238534,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Asthenia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness postural (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016238534&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016238535,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Haematuria (2d - Recovered/Resolved - ),<BR><BR>Haemorrhage urinary tract (2d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ACETYLSALICYLIC ACID] (C - Ischaemic heart disease prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Coronary artery stenosis - n/a - [n/a - n/a - n/a]),<BR><BR>[CODEINE] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[GABAPENTIN] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[IBUPROFEN, IBUPROFEN PH. EUR.] (C - Osteoarthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA QUADRIVALENT VACCINE (RDNA)] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016238535&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016238536,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016238536&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016238561,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016238561&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016238706,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,"Malaise (n/a - Fatal - Results in Death),<BR><BR>Pyrexia (n/a - Fatal - Results in Death),<BR><BR>Sudden death (n/a - Fatal - Results in Death)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - n/a - n/a])","NOT AVAILABLE (C - n/a - Not applicable - ),<BR><BR>[ESCITALOPRAM OXALATE] (C - n/a - Not applicable - ),<BR><BR>[MOMETASONE FUROATE] (C - n/a - Not applicable - ),<BR><BR>[PARACETAMOL] (C - n/a - Not applicable - ),<BR><BR>[SODIUM PICOSULFATE] (C - n/a - Not applicable - ),<BR><BR>[THIAMINE HYDROCHLORIDE, RETINOL] (C - n/a - Not applicable - ),<BR><BR>[VITAMIN D] (C - n/a - Not applicable - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016238706&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016238934,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Cardio-respiratory arrest (n/a - Fatal - Results in Death),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016238934&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016239003,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Influenza like illness (1d - Recovered/Resolved - ),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016239003&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016239017,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Back pain (2d - Recovering/Resolving - ),<BR><BR>Chest pain (2d - Recovering/Resolving - ),<BR><BR>Dyspnoea (2d - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),"COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [63d - .3mL - Intramuscular use]),<BR><BR>VAXZEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - COVID-19 immunisation - Not applicable - [63d - .5mL - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016239017&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016239029,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Vaccination site reaction (4d - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016239029&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016239082,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Immunisation reaction (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Recovering/Resolving - ),<BR><BR>Loss of consciousness (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016239082&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016239218,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vaginal haemorrhage (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016239218&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016239250,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Deafness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"CIMZIA [CERTOLIZUMAB PEGOL] (C - Rheumatoid arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>DENOSUMAB [DENOSUMAB] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>METHOTREXATE [METHOTREXATE] (C - n/a - n/a - [n/a - 15mg - n/a]),<BR><BR>[ASCORBIC ACID, ZINC, COPPER, ALPHA-TOCOPHEROL, MESO-ZEAXANTHIN, LUTEIN, ZEAXANTHIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ASCORBIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BIOTIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CALCIUM CARBONATE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - 5mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016239250&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016239266,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016239266&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016239300,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 HAEMAGGLUTININ ANTIGEN, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016239300&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016239521,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Disabling),<BR><BR>Dyspnoea (1d - Recovered/Resolved - Disabling),<BR><BR>Gait disturbance (n/a - Recovering/Resolving - Disabling),<BR><BR>Malaise (n/a - Unknown - Disabling),<BR><BR>Nausea (n/a - Recovering/Resolving - Disabling),<BR><BR>Presyncope (n/a - Recovering/Resolving - Disabling),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Disabling),<BR><BR>Vomiting (n/a - Recovering/Resolving - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016239521&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016239626,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Deafness unilateral (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021] (S - Influenza immunisation - Not applicable - [1d - .7mL - Intramuscular use])","XARELTO 20 MG FILM-COATED TABLETS [RIVAROXABAN] (C - Cardiovascular event prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN CILEXETIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLECAINIDE ACETATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VERAPAMIL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016239626&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016239627,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016239627&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016239767,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Pericarditis (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [1d - 1{DF} - Intramuscular use]),"[BISOPROLOL FUMARATE] (C - Myocardial ischaemia - n/a - [n/a - 1.25mg - Oral use]),<BR><BR>[D,L-LYSINE ACETYLSALICYLATE] (C - Myocardial ischaemia - n/a - [n/a - 75mg - Oral use]),<BR><BR>[ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM TRIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - 40mg - Oral use]),<BR><BR>[GABAPENTIN] (C - Axonal neuropathy - n/a - [n/a - 800mg - Oral use]),<BR><BR>[OXAZEPAM] (C - Product used for unknown indication - n/a - [n/a - 30mg - Oral use]),<BR><BR>[RAMIPRIL] (C - Myocardial ischaemia - n/a - [n/a - 10mg - Oral use]),<BR><BR>[TIOTROPIUM, OLODATEROL] (C - Emphysema - n/a - [n/a - 2{DF} - Oral use]),<BR><BR>[TRAMADOL HYDROCHLORIDE, PARACETAMOL] (C - Product used for unknown indication - n/a - [n/a - 2{DF} - Oral use]),<BR><BR>[ZOLPIDEM, ZOLPIDEM TARTRATE] (C - Product used for unknown indication - n/a - [n/a - 10mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016239767&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016239828,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Ear pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Mobility decreased (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"DULOXETINE HYDROCHLORIDE [DULOXETINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 30mg - Oral use]),<BR><BR>DUPIXENT [DUPILUMAB] (C - Asthma - n/a - [n/a - 300mg - Subcutaneous use]),<BR><BR>IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - n/a - n/a - [n/a - 800mg - Oral use]),<BR><BR>JARDIANCE [EMPAGLIFLOZIN] (C - n/a - n/a - [n/a - 25mg - Oral use]),<BR><BR>TRULICITY [DULAGLUTIDE] (C - n/a - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>UMECLIDINIUM BROMIDE, FLUTICASONE FUROATE, VILANTEROL [UMECLIDINIUM BROMIDE, FLUTICASONE FUROATE, VILANTEROL] (C - n/a - n/a - [n/a - n/a - Inhalation use]),<BR><BR>XOLAIR [OMALIZUMAB] (C - Chronic spontaneous urticaria - n/a - [n/a - 50mg - Subcutaneous use]),<BR><BR>[ASCORBIC ACID, CALCIUM GLUBIONATE, CALCIUM CARBONATE, CALCIUM, CALCIUM GLUBIONATE, CALCIUM CARBONATE, COLECALCIFEROL, CALCIUM] (C - n/a - n/a - [n/a - 600mg - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE] (C - n/a - n/a - [n/a - 80ug - Inhalation use]),<BR><BR>[BETAMETHASONE DIPROPIONATE] (C - Eczema, Skin fissures - n/a - [n/a - n/a - Topical]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - n/a - n/a - [n/a - 10mg - Oral use]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - 400[iU] - Oral use]),<BR><BR>[EZETIMIBE] (C - n/a - n/a - [n/a - 10mg - Oral use]),<BR><BR>[GLIMEPIRIDE] (C - n/a - n/a - [n/a - 1mg - Oral use]),<BR><BR>[LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - 100mg - Oral use]),<BR><BR>[MAGNESIUM CITRATE] (C - n/a - n/a - [n/a - 250mg - n/a]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - 2000mg - Oral use]),<BR><BR>[MOMETASONE FUROATE] (C - Pruritus - n/a - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - n/a - n/a - [n/a - 10mg - Oral use]),<BR><BR>[NICOTINAMIDE, RIBOFLAVIN, THIAMINE NITRATE, PYRIDOXINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE, NICOTINAMIDE, RIBOFLAVIN, PYRIDOXINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - 80mg - Oral use]),<BR><BR>[PARACETAMOL, TRAMADOL] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - n/a - n/a - [n/a - 10mg - Oral use]),<BR><BR>[SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - Inhalation use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016239828&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016239856,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Depressed level of consciousness (2d - Recovered/Resolved - Life Threatening),<BR><BR>Retrograde amnesia (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016239856&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016239876,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Decreased appetite (2d - Recovered/Resolved - ),<BR><BR>Dizziness (2d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Malaise (2d - Recovered/Resolved - ),<BR><BR>Myalgia (2d - Recovered/Resolved - ),<BR><BR>Nausea (n/a - Recovered/Resolved - ),<BR><BR>Presyncope (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016239876&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016239931,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016239931&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016239960,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Diarrhoea (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Rheumatoid arthritis (n/a - Unknown - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016239960&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016239994,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"COAPROVEL [HYDROCHLOROTHIAZIDE, IRBESARTAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID, D,L-LYSINE ACETYLSALICYLATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INSULIN, INSULIN HUMAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016239994&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016240192,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Adult,No,Male,"Cardiac disorder (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Feeling abnormal (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016240192&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016241100,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Elderly,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016241100&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016241232,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea exertional (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Pulmonary pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016241232&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016241234,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Diarrhoea (2d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016241234&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016241235,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Back pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016241235&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016241236,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (0d - Recovered/Resolved - ),<BR><BR>Dizziness (0d - Recovered/Resolved - ),<BR><BR>Headache (0d - Recovered/Resolved - ),<BR><BR>Nausea (0d - Recovered/Resolved - ),<BR><BR>Vomiting (0d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016241236&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016241237,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Rash macular (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016241237&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016241239,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Food aversion (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016241239&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016241240,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Vaccination site haemorrhage (n/a - Recovered/Resolved - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[MORPHINE, MORPHINE HYDROCHLORIDE] (C - Rib fracture - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016241240&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016241241,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Musculoskeletal stiffness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[ACETYLSALICYLIC ACID, ACETYLSALICYLIC ACID, MAGNESIUM OXIDE] (C - Thrombosis prophylaxis - n/a - [n/a - 75mg - n/a]),<BR><BR>[ALFUZOSIN HYDROCHLORIDE] (C - Dysuria - n/a - [n/a - 10mg - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MESILATE MONOHYDRATE] (C - Hypertension - n/a - [n/a - 5mg - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - Product used for unknown indication - n/a - [n/a - 40mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016241241&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016241242,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Balance disorder (n/a - Recovering/Resolving - ),<BR><BR>Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Visual impairment (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE DIHYDRATE, BECLOMETASONE DIPROPIONATE ANHYDROUS] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016241242&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016241245,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Cold sweat (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016241245&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016241246,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Urticaria (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),"[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016241246&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016241248,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Herpes zoster (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),[ALLOPURINOL] (C - Gout - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016241248&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016241251,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Pelvic pain (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"DULOXETINE [DULOXETINE, DULOXETINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - 60mg - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[OXAZEPAM] (C - Anxiety - n/a - [n/a - 7.5mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016241251&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016241252,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Muscular weakness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016241252&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016241254,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Rash (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),"[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016241254&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016241257,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chest discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Productive cough (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[METOPROLOL, METOPROLOL SUCCINATE, METOPROLOL TARTRATE] (C - Hypertension - n/a - [n/a - 25mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016241257&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016241258,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Rash (n/a - Recovering/Resolving - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016241258&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016241259,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Oedema peripheral (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"PRADAXA [DABIGATRAN ETEXILATE, DABIGATRAN ETEXILATE MESILATE] (C - Thrombosis prophylaxis - n/a - [n/a - n/a - Oral use]),<BR><BR>[AMLODIPINE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[INDAPAMIDE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[METOPROLOL TARTRATE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[ROSUVASTATIN] (C - Cardiac disorder - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016241259&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016241260,Spontaneous,2023-11-08 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Body temperature decreased (1d - Recovered/Resolved - ),<BR><BR>Frostbite (1d - Recovered/Resolved - ),<BR><BR>Pain (1d - Recovered/Resolved - ),<BR><BR>Tremor (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016241260&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016241261,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Erythema (n/a - Recovering/Resolving - ),<BR><BR>Exfoliative rash (n/a - Recovering/Resolving - ),<BR><BR>Pruritus (n/a - Unknown - ),<BR><BR>Swelling face (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016241261&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016241692,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Cough (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - n/a]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B)] (S - Influenza immunisation - Not applicable - [0d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016241692&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016241724,Spontaneous,2023-11-08 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Malaise (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016241724&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016224993,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016224993&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016225152,Spontaneous,2023-11-07 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Musculoskeletal chest pain (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - Intramuscular use]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224)] (C - n/a - n/a - [n/a - n/a - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016225152&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016225231,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Headache (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016225231&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016225365,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Body temperature abnormal (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Heart rate irregular (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016225365&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016225741,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Disabling),<BR><BR>Decreased appetite (n/a - Unknown - Disabling),<BR><BR>Headache (n/a - Recovering/Resolving - Disabling),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Disabling),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Disabling),<BR><BR>Somnolence (n/a - Recovering/Resolving - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"METHOTREXATE [METHOTREXATE] (C - Rheumatoid arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>SPIRONOLACTONE [SPIRONOLACTONE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Portal hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE] (C - Polymyalgia rheumatica - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016225741&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016225973,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Fall (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Syncope (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016225973&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016226310,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016226310&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016226324,Spontaneous,2023-11-07 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Body temperature increased (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016226324&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016226578,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthma (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Oral pruritus (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016226578&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016227133,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016227133&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016227414,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Myelitis transverse (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016227414&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016227635,Spontaneous,2023-11-07 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016227635&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016227737,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Dysphonia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016227737&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016227744,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Rash pruritic (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016227744&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016227750,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Pain in extremity (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016227750&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016227753,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Tinnitus (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016227753&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016227754,Spontaneous,2023-11-07 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,"Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site induration (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Swelling (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - Dose not changed - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016227754&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016227755,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Female,"Extrasystoles (n/a - Recovered/Resolved - ),<BR><BR>Fatigue (8h - Recovered/Resolved - ),<BR><BR>Feeling cold (8h - Recovered/Resolved - ),<BR><BR>Muscular weakness (8h - Recovered/Resolved - ),<BR><BR>Myalgia (8h - Recovered/Resolved - ),<BR><BR>Respiratory rate (8h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016227755&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016227761,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Body temperature increased (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUTICASONE PROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016227761&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016227762,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Decreased appetite (n/a - Not Recovered/Not Resolved - ),<BR><BR>Eructation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Retching (n/a - Not Recovered/Not Resolved - ),<BR><BR>Taste disorder (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016227762&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016227765,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Dyspnoea (n/a - Recovered/Resolved - ),<BR><BR>Hypersensitivity (3h - Recovered/Resolved - ),<BR><BR>Peripheral swelling (3h - Recovered/Resolved - ),<BR><BR>Pharyngeal swelling (3h - Recovered/Resolved - ),<BR><BR>Swelling (3h - Recovered/Resolved - ),<BR><BR>Swelling face (3h - Recovered/Resolved - ),<BR><BR>Swelling of eyelid (3h - Recovered/Resolved - ),<BR><BR>Swollen tongue (3h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016227765&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016227987,Spontaneous,2023-11-07 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Diplopia (1wk - Recovered/Resolved - ),<BR><BR>IVth nerve injury (1wk - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016227987&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016228272,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chest discomfort (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Maternal exposure during pregnancy (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016228272&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016228273,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Palpitations (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016228273&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016228278,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (3d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016228278&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016228302,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016228302&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016228313,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Herpes zoster (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Unknown - ),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016228313&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016228625,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Lymphadenopathy (4d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"LIXIANA [EDOXABAN, EDOXABAN TOSYLATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN, A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN, B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1) V REASS. X - 179 A, A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/NANCHANG 933/95 (H3N2), A/BAYERN/7/95 (H1N1) - LIKE STRAIN (A/JOHANNESBURG/82/96), B/BEIJING/184/93-LIKE STRAIN (B/HARBIN/7/94), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/CALIFORNIA/7/2004 (H3N2) - LIKE STRAIN (A/NEW YORK/55/2004 REASS. NYMC X-157), B/SHANGHAI/361/2002 - LIKE STRAIN (B/JIANGSU/10/2003), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/MOSCOW/10/99 (H3N2) - LIKE STRAIN (A/PANAMA/2007/99 REASS. RESVIR-17), B/SICHUAN/379/99-LIKE STRAIN (B/JOHANNESBURG/5/99), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), A/CALIFORNIA/7/2009 (H1N1)-DERIVED STRAIN USED NYMC X-181, B/BRISBANE/60/2008, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1)V-LIKE VIRUS, A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H1N1), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H3N2), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B] (C - Influenza immunisation - n/a - [1d - n/a - n/a])...","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016228625&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016228885,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Musculoskeletal stiffness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016228885&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016228889,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Elderly,No,Female,"Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (1d - Recovered/Resolved - ),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016228889&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016229431,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Lactose intolerance (n/a - Not Recovered/Not Resolved - Disabling),RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Primary hypothyroidism - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016229431&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016229512,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pyrexia (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016229512&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016230310,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Eye pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vision blurred (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016230310&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016230313,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Extensive swelling of vaccinated limb (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site induration (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016230313&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016230353,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Hemihypoaesthesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hemiparaesthesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Paraesthesia oral (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN, A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN, B/FLORIDA/4/2006-LIKE STRAIN, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/VICTORIA/361/2011 (H3N2)–DERIVED STRAIN USED (IVR-165), B/WISCONSIN/1/2010-LIKE STRAIN USED (NYMC BX-39) DERIVED FROM B/HUBEI-WUJIAGANG/158/2009, A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/MOSCOW/10/99 (H3N2) - LIKE STRAIN (A/PANAMA/2007/99 REASS. RESVIR-17), B/SICHUAN/379/99-LIKE STRAIN (B/JOHANNESBURG/5/99), A/SOUTH AUSTRALIA/55/2014 STRAIN, A/SWITZERLAND/9715293/2013 (H3N2) - LIKE STRAIN (A/SOUTH AUSTRALIA/55/2014, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, B/MASSACHUSETTS/02/2012, A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/VICTORIA/361/2011 (H3N2)–DERIVED STRAIN USED (IVR-165), B/WISCONSIN/1/2010-LIKE STRAIN USED (NYMC BX-39) DERIVED FROM B/HUBEI-WUJIAGANG/158/2009, A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/WISCONSIN/67/2005 (H3N2), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN, B/MALAYSIA/2506/2004 - LIKE STRAIN, B/BEIJING/184/93-LIKE STRAIN (B/YAMANASHI/166/98), A/SYDNEY/5/97 (H3N2)-LIKE STRAIN (A/SYDNEY/5/97 REASS. RESVIR 13), A/BEIJING/262/95 (H1N1) - LIKE STRAIN (A/BEIJING/262/95 REASS. X-127), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1), A/PERTH/16/2009 (H3N2) - LIKE STRAIN, B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009(H1N1)-LIKE STRAIN (NYMC X-179A), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NIB-65), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009(H1N1)-LIKE STRAIN (NYMC X-179A), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/MASSACHUSETTS/02/2012, A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE STRAIN, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SOUTH AUSTRALIA/55/2014, IVR-175), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED)] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016230353&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016230484,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Blood pressure increased (n/a - Unknown - ),<BR><BR>Brain oedema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Electric shock sensation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Eye pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Heart rate increased (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Unknown - ),<BR><BR>Vertigo (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016230484&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016230547,Spontaneous,2023-11-07 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Carotid artery occlusion (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Cerebral infarction (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Coagulopathy (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Hypercoagulation (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary embolism (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Thrombosis (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016230547&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016230554,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Allodynia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Skin disorder (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"CELECOXIB 200 MG  (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>DESLORATADINE 5 MG [DESLORATADINE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>OZEMPIC 0.5 MG [SEMAGLUTIDE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL VALERATE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016230554&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016230986,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (6h - Recovered/Resolved - ),<BR><BR>Pyrexia (12h - Recovered/Resolved - ),<BR><BR>Syncope (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016230986&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016230988,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Abdominal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (8h - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (5h - Recovered/Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016230988&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016230993,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Arrhythmia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"COAPROVEL 150 MG/12.5 MG FILM-COATED TABLETS [HYDROCHLOROTHIAZIDE, IRBESARTAN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016230993&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016230995,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016230995&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016230997,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Skin warm (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016230997&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016230998,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (48h - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Head discomfort (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Hyperacusis (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016230998&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016231047,Spontaneous,2023-11-07 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Application site erythema (n/a - Recovering/Resolving - ),<BR><BR>Feeling hot (n/a - Recovering/Resolving - ),<BR><BR>Pruritus (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site induration (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016231047&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016231084,Spontaneous,2023-11-07 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Confusional state (2h - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016231084&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016231093,Spontaneous,2023-11-07 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Cardiac failure (n/a - Recovered/Resolved - ),<BR><BR>Condition aggravated (n/a - Recovered/Resolved - ),<BR><BR>Dyspnoea (5d - Recovered/Resolved - ),<BR><BR>Tachycardia (5d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016231093&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016231094,Spontaneous,2023-11-07 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Extrasystoles (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypertension (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - n/a]),"COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - n/a - [n/a - 1{DF} - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - COVID-19 immunisation - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016231094&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016231160,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016231160&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016231163,Spontaneous,2023-11-07 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Eosinophilia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),"ABASAGLAR [INSULIN GLARGINE] (S - Type 2 diabetes mellitus - Dose not changed - [n/a - 8[iU] - Subcutaneous use]),<BR><BR>COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>ENTRESTO 49 MG/51 MG FILM-COATED TABLETS [VALSARTAN, SACUBITRIL] (S - Cardiac failure - Drug withdrawn - [15d - 2{DF} - Oral use]),<BR><BR>[D,L-LYSINE ACETYLSALICYLATE] (S - Product used for unknown indication - Dose not changed - [n/a - 1{DF} - Oral use]),<BR><BR>[DIAZEPAM] (S - Product used for unknown indication - Drug withdrawn - [16d - 1{DF} - Oral use]),<BR><BR>[SERTRALINE] (S - Depression - Dose not changed - [n/a - 100mg - Oral use])","[EPLERENONE] (C - n/a - Drug withdrawn - [13d - n/a - n/a]),<BR><BR>[TIAPRIDE, TIAPRIDE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TINZAPARIN, TINZAPARIN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016231163&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016231288,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abnormal faeces (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dyspepsia (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ATENOLOL, ATENOLOL BP] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[CALCIUM CARBONATE, COLECALCIFEROL CONCENTRATE (POWDER FORM) (SDS), COLECALCIFEROL, CALCIUM CARBONATE] (C - Osteoporotic fracture - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016231288&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016231307,Spontaneous,2023-11-07 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Headache (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016231307&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016231308,Spontaneous,2023-11-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dysarthria (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Dyskinesia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Facial spasm (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Gait disturbance (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Hypertonia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Muscle spasticity (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[CLONAZEPAM] (C - Nervous system disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE] (C - Specialist consultation - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Depressed level of consciousness - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016231308&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016231351,Spontaneous,2023-11-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (n/a - Unknown - Disabling),<BR><BR>Dyspnoea (n/a - Unknown - Disabling),<BR><BR>Feeling cold (n/a - Unknown - Disabling),<BR><BR>Headache (n/a - Unknown - Disabling),<BR><BR>Malaise (n/a - Unknown - Disabling),<BR><BR>Pyrexia (n/a - Unknown - Disabling),<BR><BR>Sensitive skin (n/a - Unknown - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ALLOPURINOL] (C - Ill-defined disorder - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Ill-defined disorder - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[COLESTYRAMINE] (C - Ill-defined disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[DOXAZOSIN, DOXAZOSIN MESILATE] (C - Ill-defined disorder - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[EZETIMIBE] (C - Ill-defined disorder - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Ill-defined disorder - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[LERCANIDIPINE HYDROCHLORIDE] (C - Ill-defined disorder - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Ill-defined disorder - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[MEBEVERINE HYDROCHLORIDE] (C - Ill-defined disorder - n/a - [n/a - 3{DF} - n/a]),<BR><BR>[MESALAZINE] (C - Ill-defined disorder - n/a - [n/a - 4{DF} - n/a]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - Ill-defined disorder - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[NAPROXEN, NAPROXEN SODIUM] (C - Ill-defined disorder - n/a - [29d - 2{DF} - n/a]),<BR><BR>[PARACETAMOL] (C - Ill-defined disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Ill-defined disorder - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Ill-defined disorder - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[THIAMINE] (C - Ill-defined disorder - n/a - [n/a - 3{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016231351&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016231647,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Hypersensitivity (n/a - Unknown - Caused/Prolonged Hospitalisation),RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016231647&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016231749,Spontaneous,2023-11-07 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anaphylactic reaction (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Chest discomfort (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Heart rate increased (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Palpitations (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Rash (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"CICLOSPORIN [CICLOSPORIN] (C - Nephrotic syndrome - n/a - [n/a - n/a - Oral use]),<BR><BR>[PREDNISOLONE, PREDNISOLONE ACETATE] (C - Nephrotic syndrome - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016231749&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016231831,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Lymph node pain (n/a - Unknown - ),<BR><BR>Lymphadenopathy (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016231831&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016232047,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016232047&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016232103,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Chills (25min - Recovered/Resolved - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Vertigo (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016232103&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016232116,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (S - Pneumococcal immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016232116&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016232293,Spontaneous,2023-11-07 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Injection site irritation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016232293&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016232358,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Ear inflammation (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Ear pain (n/a - Unknown - ),<BR><BR>Ear pruritus (n/a - Unknown - ),<BR><BR>Nasopharyngitis (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016232358&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016232485,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016232485&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016232530,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,Rash pruritic (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),ANTIBIOTICA [NOT AVAILABLE] (C - Skin infection - Unknown - [n/a - 1{DF} - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016232530&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016232535,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site induration (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016232535&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016232782,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Acne (n/a - Unknown - ),<BR><BR>Dry skin (n/a - Unknown - ),<BR><BR>Erythema (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - ),<BR><BR>Swelling face (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016232782&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016232963,Spontaneous,2023-11-07 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Influenza like illness (n/a - Unknown - ),<BR><BR>Renal transplant (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016232963&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016232991,Spontaneous,2023-11-07 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,Rash (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016232991&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016233251,Spontaneous,2023-11-07 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Lymphadenopathy (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - Drug withdrawn - [1d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016233251&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016218963,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUTICASONE PROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ISPAGHULA, ISPAGHULA HUSK] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LORATADINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016218963&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016219139,Spontaneous,2023-11-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),[ATORVASTATIN] (C - n/a - n/a - [n/a - 10mg - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016219139&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016219218,Spontaneous,2023-11-06 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Blister (2d - Recovered/Resolved - ),<BR><BR>Pruritus (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016219218&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016219277,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016219277&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016219294,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Blood pressure increased (1d - Recovered/Resolved - ),<BR><BR>Tachycardia (1d - Recovered/Resolved - ),<BR><BR>Thyroid hormones increased (1d - Recovered/Resolved - ),<BR><BR>Thyrotoxic crisis (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016219294&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016219339,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (2d - Recovered/Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016219339&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016219446,Spontaneous,2023-11-06 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Pulmonary embolism (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),"[ALPRAZOLAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ENALAPRIL MALEATE, LERCANIDIPINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PAROXETINE HYDROCHLORIDE, ANHYDROUS] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN, EZETIMIBE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016219446&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016219597,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Limb discomfort (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Unknown - ),<BR><BR>Somnolence (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (n/a - Unknown - ),<BR><BR>Vaccination site reaction (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016219597&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016219657,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Dyspnoea (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (2d - Recovered/Resolved - ),<BR><BR>Injection site pain (2d - Recovered/Resolved - ),<BR><BR>Injection site swelling (2d - Recovered/Resolved - ),<BR><BR>Myalgia (5d - Recovered/Resolved - ),<BR><BR>Productive cough (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - ),<BR><BR>Rhinorrhoea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016219657&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016220031,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016220031&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016220793,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Chills (29h - Recovered/Resolved - ),<BR><BR>Fatigue (21h - Recovered/Resolved - ),<BR><BR>Gait disturbance (29h - Recovered/Resolved - ),<BR><BR>Malaise (29h - Recovered/Resolved - ),<BR><BR>Nausea (29h - Recovered/Resolved - ),<BR><BR>Somnolence (29h - Recovered/Resolved - ),<BR><BR>Tremor (29h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"FORXIGA 10 MG FILM-COATED TABLETS [DAPAGLIFLOZIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>METFORMIN HYDROCHLORIDE 850MG TABLET, DAPAGLIFLOZIN 5MG TABLET  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOVOMIX 30 FLEXPEN 100 UNITS/ML SUSPENSION FOR INJECTION IN PRE-FILLED PEN [INSULIN ASPART] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>PANTOPRAZOLE 20 MG - GASTRO-RESISTANT TABLET  (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016220793&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016220897,Spontaneous,2023-11-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Dysgeusia (n/a - Recovered/Resolved - ),<BR><BR>Oedema mouth (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016220897&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016221243,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Body temperature increased (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Cough (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Muscle spasms (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nasopharyngitis (n/a - Recovering/Resolving - ),<BR><BR>Oedema peripheral (n/a - Recovering/Resolving - ),<BR><BR>Somnolence (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site swelling (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 HAEMAGGLUTININ ANTIGEN, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016221243&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016221357,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - ),<BR><BR>Syncope (1h - Recovered/Resolved - ),<BR><BR>Syncope (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016221357&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016221534,Spontaneous,2023-11-06 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Herpes zoster infection neurological (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Post herpetic neuralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash vesicular (n/a - Not Recovered/Not Resolved - ),<BR><BR>Trigeminal neuralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016221534&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016221925,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Arthritis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Blood iron decreased (n/a - Unknown - ),<BR><BR>Fatigue (10d - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016221925&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016221927,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Influenza (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pharyngeal swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Throat tightness (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016221927&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016222016,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Headache (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Sudden hearing loss (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE DIHYDRATE, BECLOMETASONE DIPROPIONATE ANHYDROUS] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016222016&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016222254,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Concussion (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fall (n/a - Unknown - Other Medically Important Condition),<BR><BR>Loss of consciousness (n/a - Recovered/Resolved With Sequelae - Life Threatening, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016222254&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016222256,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Unknown - ),<BR><BR>Product use issue (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN, A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN, B/FLORIDA/4/2006-LIKE STRAIN, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/VICTORIA/361/2011 (H3N2)–DERIVED STRAIN USED (IVR-165), B/WISCONSIN/1/2010-LIKE STRAIN USED (NYMC BX-39) DERIVED FROM B/HUBEI-WUJIAGANG/158/2009, A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/MOSCOW/10/99 (H3N2) - LIKE STRAIN (A/PANAMA/2007/99 REASS. RESVIR-17), B/SICHUAN/379/99-LIKE STRAIN (B/JOHANNESBURG/5/99), A/SOUTH AUSTRALIA/55/2014 STRAIN, A/SWITZERLAND/9715293/2013 (H3N2) - LIKE STRAIN (A/SOUTH AUSTRALIA/55/2014, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, B/MASSACHUSETTS/02/2012, A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/VICTORIA/361/2011 (H3N2)–DERIVED STRAIN USED (IVR-165), B/WISCONSIN/1/2010-LIKE STRAIN USED (NYMC BX-39) DERIVED FROM B/HUBEI-WUJIAGANG/158/2009, A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, A/WISCONSIN/67/2005 (H3N2), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN, B/MALAYSIA/2506/2004 - LIKE STRAIN, B/BEIJING/184/93-LIKE STRAIN (B/YAMANASHI/166/98), A/SYDNEY/5/97 (H3N2)-LIKE STRAIN (A/SYDNEY/5/97 REASS. RESVIR 13), A/BEIJING/262/95 (H1N1) - LIKE STRAIN (A/BEIJING/262/95 REASS. X-127), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1), A/PERTH/16/2009 (H3N2) - LIKE STRAIN, B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009(H1N1)-LIKE STRAIN (NYMC X-179A), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NIB-65), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009(H1N1)-LIKE STRAIN (NYMC X-179A), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/MASSACHUSETTS/02/2012, A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE STRAIN, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SOUTH AUSTRALIA/55/2014, IVR-175), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED)] (S - n/a - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016222256&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016222264,Spontaneous,2023-11-06 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Guillain-Barre syndrome (n/a - Not Recovered/Not Resolved - Life Threatening),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016222264&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016222269,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Pruritus (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site swelling (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016222269&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016222273,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dyspepsia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Productive cough (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Wheezing (7d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016222273&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016222400,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016222400&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016222411,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Brain fog (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Memory impairment (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sneezing (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016222411&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016222416,Spontaneous,2023-11-06 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Polymyalgia rheumatica (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016222416&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016222446,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Cold sweat (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Confusional state (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Heart rate increased (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Myocardial infarction (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Tachycardia (n/a - Unknown - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016222446&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016222447,Spontaneous,2023-11-06 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Musculoskeletal disorder (n/a - Unknown - Disabling),<BR><BR>Pain in extremity (n/a - Recovered/Resolved With Sequelae - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016222447&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016222448,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Epistaxis (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Haemorrhage (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016222448&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016222461,Spontaneous,2023-11-06 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Herpes zoster (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Ophthalmic herpes zoster (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016222461&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016222473,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,12-17 Years,Not Specified,No,Male,African trypanosomiasis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016222473&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016222476,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Illness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Sleep disorder (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN, A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN, B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1) V REASS. X - 179 A, A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/NANCHANG 933/95 (H3N2), A/BAYERN/7/95 (H1N1) - LIKE STRAIN (A/JOHANNESBURG/82/96), B/BEIJING/184/93-LIKE STRAIN (B/HARBIN/7/94), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/CALIFORNIA/7/2004 (H3N2) - LIKE STRAIN (A/NEW YORK/55/2004 REASS. NYMC X-157), B/SHANGHAI/361/2002 - LIKE STRAIN (B/JIANGSU/10/2003), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/MOSCOW/10/99 (H3N2) - LIKE STRAIN (A/PANAMA/2007/99 REASS. RESVIR-17), B/SICHUAN/379/99-LIKE STRAIN (B/JOHANNESBURG/5/99), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), A/CALIFORNIA/7/2009 (H1N1)-DERIVED STRAIN USED NYMC X-181, B/BRISBANE/60/2008, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1)V-LIKE VIRUS, A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H1N1), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H3N2), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TRANEXAMIC ACID] (C - Heavy menstrual bleeding - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016222476&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016222509,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Flatulence (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - n/a - [1d - n/a - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - COVID-19 immunisation - n/a - [1d - n/a - n/a]),<BR><BR>SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.1 [ELASOMERAN, IMELASOMERAN] (C - COVID-19 immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016222509&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016222904,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Polydipsia (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[DESMOPRESSIN, DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE TRIHYDRATE] (C - Diabetes insipidus - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016222904&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016224373,Spontaneous,2023-11-06 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Pyrexia (3d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016224373&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016224906,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Hallucination, olfactory (n/a - Unknown - Other Medically Important Condition),<BR><BR>Parosmia (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016224906&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016224915,Spontaneous,2023-11-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Asthenia (n/a - Unknown - Disabling),<BR><BR>Decreased appetite (n/a - Unknown - Disabling),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016224915&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016218079,Spontaneous,2023-11-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (1d - Recovered/Resolved - ),<BR><BR>Headache (1h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016218079&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016218212,Spontaneous,2023-11-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (6h - Recovered/Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016218212&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016218233,Spontaneous,2023-11-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Lymphadenopathy (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016218233&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016218266,Spontaneous,2023-11-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (2d - Recovered/Resolved - ),<BR><BR>Malaise (1d - Recovered/Resolved - ),<BR><BR>Myalgia (1d - Recovered/Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016218266&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016218322,Spontaneous,2023-11-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (24h - Recovered/Resolved - ),<BR><BR>Chills (6h - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (8h - Recovered/Resolved - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (1d - Recovered/Resolved - ),<BR><BR>Nausea (6h - Recovered/Resolved - ),<BR><BR>Pyrexia (8h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016218322&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016217117,Spontaneous,2023-11-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016217117&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016217708,Spontaneous,2023-11-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016217708&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016218075,Spontaneous,2023-11-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (18h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016218075&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016209067,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016209067&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016209068,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016209068&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016209119,Spontaneous,2023-11-03 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Atrial fibrillation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cardiac failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016209119&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016209292,Spontaneous,2023-11-03 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Injection site pain (2d - Recovered/Resolved - ),<BR><BR>Malaise (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016209292&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016209326,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Arthralgia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016209326&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016209453,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Cardiac flutter (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tenderness (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"METHOTREXATE [METHOTREXATE] (C - Rheumatoid arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.1 [ELASOMERAN, IMELASOMERAN] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016209453&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016209465,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypersomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Mental fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nasopharyngitis (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Speech disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"IDACIO [ADALIMUMAB] (C - Psoriasis - n/a - [n/a - n/a - n/a]),<BR><BR>[BENDROFLUAZIDE] (C - Fluid retention - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016209465&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016209755,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lip swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Rash erythematous (n/a - Unknown - Other Medically Important Condition),<BR><BR>Urticaria (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[ESTRADIOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUOXETINE, FLUOXETINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016209755&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016210044,Spontaneous,2023-11-03 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Cerebrovascular accident (2d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016210044&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016210421,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Headache (n/a - Unknown - ),<BR><BR>Insomnia (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Unknown - ),<BR><BR>Night sweats (n/a - Unknown - ),<BR><BR>Peripheral swelling (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - ),<BR><BR>Vaccination site pain (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016210421&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016210544,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cough (n/a - Recovering/Resolving - ),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - ),<BR><BR>Productive cough (n/a - Recovering/Resolving - ),<BR><BR>Sneezing (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016210544&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016211009,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016211009&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016211011,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,2 Months - 2 Years,Not Specified,No,Female,"Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (3d - Recovered/Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016211011&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016211419,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016211419&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016211451,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cough (n/a - Unknown - ),<BR><BR>Dysphagia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Ear pain (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Influenza like illness (n/a - Unknown - ),<BR><BR>Limb discomfort (n/a - Unknown - ),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016211451&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016211487,Spontaneous,2023-11-03 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,Rash (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),[CYANOCOBALAMIN] (C - n/a - n/a - [n/a - n/a - Oral use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016211487&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016211722,Spontaneous,2023-11-03 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,"Disorientation (60min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Syncope (60min - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"BIOFLAVONÓIDES [BIOFLAVONÓIDES] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[VALPROIC ACID] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016211722&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016211872,Spontaneous,2023-11-03 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Male,Diarrhoea (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016211872&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016211932,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016211932&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016212012,Spontaneous,2023-11-03 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Feeling abnormal (0d - Recovered/Resolved - ),<BR><BR>Tension headache (0d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016212012&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016212025,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Catarrh (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pain in extremity (1d - Recovered/Resolved - Disabling),<BR><BR>Sneezing (n/a - Not Recovered/Not Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016212025&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016212193,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Feeling hot (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Anxiety - n/a - [n/a - n/a - n/a]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016212193&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016212250,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016212250&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016212251,Spontaneous,2023-11-03 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lip swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Swelling face (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Throat tightness (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016212251&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016212316,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Seizure (n/a - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016212316&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016212318,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,Yes,Female,"Muscle contractions involuntary (n/a - Recovered/Resolved - ),<BR><BR>Paraesthesia (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[DESOGESTREL, ETHINYLESTRADIOL] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016212318&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016212386,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Body temperature increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypoxia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Transient ischaemic attack (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016212386&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016212390,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Pericarditis (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROCHLOROTHIAZIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016212390&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016212391,Spontaneous,2023-11-03 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Sudden death (n/a - Fatal - Results in Death),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>SPIRONOLACTONE [SPIRONOLACTONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATENOLOL, ATENOLOL BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LORAZEPAM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016212391&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016212395,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Syncope (20min - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016212395&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016212470,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - n/a - [1d - n/a - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - COVID-19 immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BENDROFLUMETHIAZIDE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hyperthyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[NAPROXEN, NAPROXEN SODIUM] (C - Osteoarthritis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016212470&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016212799,Spontaneous,2023-11-03 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Cardio-respiratory arrest (n/a - Fatal - Results in Death),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021] (S - Influenza immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016212799&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016212896,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Back injury (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Other Medically Important Condition),<BR><BR>Head injury (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Joint injury (n/a - Unknown - Other Medically Important Condition),<BR><BR>Loss of consciousness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Middle insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016212896&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016212897,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016212897&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016212951,Spontaneous,2023-11-03 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,Yes,Female,"Hyperhidrosis (1min - Recovered/Resolved - ),<BR><BR>Nausea (0d - Recovered/Resolved - ),<BR><BR>Somnolence (0d - Recovered/Resolved - ),<BR><BR>Syncope (1min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (0d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Antiviral prophylaxis - Not applicable - [0d - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016212951&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016212962,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Neoplasm malignant (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016212962&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016212970,Spontaneous,2023-11-03 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Lymphadenopathy (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016212970&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016213036,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Neoplasm malignant (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016213036&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016213127,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Pulmonary embolism (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>TACROLIMUS [TACROLIMUS, TACROLIMUS MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MAGNESIUM GLUCONATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016213127&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016213338,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016213338&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016213396,Spontaneous,2023-11-03 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cardiac arrest (n/a - Fatal - Results in Death),<BR><BR>Resuscitation (n/a - Fatal - Results in Death)",COMIRNATY OMICRON XBB.1.5 3 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016213396&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016213457,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cerebrovascular accident (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Myocardial infarction (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016213457&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016213458,Spontaneous,2023-11-03 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Vaccination site pain (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016213458&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016213550,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Myocardial infarction (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016213550&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016213829,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Neoplasm malignant (n/a - Unknown - Other Medically Important Condition),RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016213829&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016214004,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Urinary tract infection bacterial (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016214004&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016214005,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Eye swelling (2d - Recovered/Resolved - ),<BR><BR>Headache (2d - Recovered/Resolved - ),<BR><BR>Hypersensitivity (2d - Recovered/Resolved - ),<BR><BR>Nasal discomfort (2d - Recovered/Resolved - ),<BR><BR>Sneezing (2d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016214005&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016214008,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cardiovascular disorder (7h - Recovered/Resolved - ),<BR><BR>Dizziness (7h - Recovered/Resolved - ),<BR><BR>Fatigue (2h - Recovered/Resolved - ),<BR><BR>Headache (7h - Recovered/Resolved - ),<BR><BR>Pain in extremity (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016214008&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016214175,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016214175&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016214182,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (2d - Recovered/Resolved - ),<BR><BR>Chills (3d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016214182&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016214361,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Pancreatitis chronic (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016214361&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016215223,Spontaneous,2023-11-03 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Vestibular neuronitis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016215223&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016215246,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Not Specified,"Asthenia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (18d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cough (18d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (18d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (18d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (18d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (18d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (18d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Rash (18d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016215246&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016215434,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[CYANOCOBALAMIN, VITAMIN B12] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Dyspepsia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016215434&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016215581,Spontaneous,2023-11-03 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Altered state of consciousness (18min - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Aphasia (30min - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Confusional state (0d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Dizziness (0d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (0d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Speech disorder (0d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Syncope (0d - Recovered/Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[PAROXETINE, PAROXETINE HYDROCHLORIDE, ANHYDROUS] (C - Anxiety - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016215581&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016215884,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cough (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Thyroid disorder - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016215884&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016215930,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Abdominal discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Gastrointestinal disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Gastrooesophageal reflux disease (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016215930&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016216411,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016216411&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016216689,Spontaneous,2023-11-03 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain (5d - Recovered/Resolved - ),<BR><BR>Chills (n/a - Unknown - ),<BR><BR>Diarrhoea (n/a - Unknown - ),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [1d - n/a - n/a])","[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016216689&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016216867,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUTICASONE PROPIONATE, SALMETEROL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016216867&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016217065,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016217065&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016217066,Spontaneous,2023-11-03 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016217066&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016201284,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nocturia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Peripheral coldness (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016201284&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016201296,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Tremor (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016201296&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016201342,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chest discomfort (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Joint stabilisation (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016201342&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016201355,Spontaneous,2023-11-02 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Multiple sclerosis relapse (n/a - Recovering/Resolving - Disabling),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016201355&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016201356,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Confusional state (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Mobility decreased (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Neck pain (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Vision blurred (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016201356&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016201362,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Neuropathy peripheral (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016201362&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016201369,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"APIXABAN [APIXABAN] (C - Pulmonary embolism - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016201369&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016201374,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Blood glucose increased (n/a - Unknown - ),<BR><BR>Blood pressure increased (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Herpes zoster (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016201374&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016201385,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Swelling face (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016201385&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016201404,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Asthenia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Illness (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016201404&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016201596,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (5d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016201596&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016201597,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Joint range of motion decreased (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Sleep disorder (n/a - Unknown - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016201597&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016201782,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",[INFLUENZA VIRUS] (C - Immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016201782&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016202014,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Epistaxis (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),ADALIMUMAB [ADALIMUMAB] (C - Ankylosing spondylitis - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016202014&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016202069,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[LANSOPRAZOLE] (C - Hiatus hernia - n/a - [n/a - n/a - n/a]),<BR><BR>[LETROZOLE] (C - Breast cancer - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[NIFEDIPINE] (C - Blood pressure increased - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016202069&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016202116,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Cystitis (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016202116&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016202131,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fear (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Influenza (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - ),<BR><BR>Nausea (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016202131&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016202150,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Blood pressure increased (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016202150&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016202184,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Back pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Migraine (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016202184&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016202259,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthritis allergic (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Illness (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016202259&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016202414,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016202414&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016202588,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016202588&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016202589,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Back pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate increased (2h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016202589&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016202634,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Inappropriate schedule of product administration (n/a - Unknown - ),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Injection related reaction (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Product administered to patient of inappropriate age (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016202634&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016202816,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Balance disorder (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hydrocephalus (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.1 [ELASOMERAN, IMELASOMERAN] (C - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[FINASTERIDE] (C - Benign prostatic hyperplasia - n/a - [n/a - n/a - n/a]),<BR><BR>[GLIMEPIRIDE] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza - n/a - [n/a - n/a - n/a]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - Benign prostatic hyperplasia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016202816&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016202822,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Cardiac failure (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Circulatory collapse (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pneumonitis (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016202822&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016202870,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - Immunisation - n/a - [302d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016202870&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016203164,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Blood glucose increased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Eye pruritus (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Heart rate increased (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[BECLOMETASONE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[DILTIAZEM, DILTIAZEM HYDROCHLORIDE] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[INSULIN HUMAN, INSULIN HUMAN (RDNA)] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[LORATADINE] (C - Seasonal allergy - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016203164&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016203230,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dizziness (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016203230&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016203382,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Anosmia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Asthenia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Ear pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Feeling abnormal (n/a - Not Recovered/Not Resolved - ),<BR><BR>Feeling cold (n/a - Not Recovered/Not Resolved - ),<BR><BR>Head discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hot flush (n/a - Not Recovered/Not Resolved - ),<BR><BR>Limb discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Taste disorder (n/a - Not Recovered/Not Resolved - ),<BR><BR>Viral upper respiratory tract infection (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016203382&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016203498,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016203498&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016203725,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Night sweats (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016203725&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016203731,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Diplopia (2min - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016203731&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016203761,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dysgeusia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (7d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Muscular weakness (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Parosmia (9d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Tension headache - n/a - [n/a - n/a - n/a]),<BR><BR>[TERBINAFINE, TERBINAFINE HYDROCHLORIDE] (C - Onychomycosis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016203761&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016203936,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016203936&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016204219,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Exposure via breast milk (n/a - Unknown - ),<BR><BR>Lactation insufficiency (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016204219&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016204228,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>OZEMPIC SOLUTION FOR INJECTION IN PRE-FILLED PEN [SEMAGLUTIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016204228&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016204356,Spontaneous,2023-11-02 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Vertigo (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016204356&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016204358,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Abdominal pain lower (n/a - Recovered/Resolved - ),<BR><BR>Chills (n/a - Recovered/Resolved - ),<BR><BR>Feeling hot (n/a - Recovered/Resolved - ),<BR><BR>Pain in extremity (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016204358&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016204504,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Maternal exposure during pregnancy (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vaginal haemorrhage (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - Vitamin supplementation - n/a - [n/a - 400ug - n/a]),<BR><BR>[PROGESTERONE, PROGESTERONE, MICRONISED] (C - Vaginal haemorrhage - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016204504&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016204721,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Appendicitis (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Complicated appendicitis (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Diarrhoea (1d - Recovered/Resolved With Sequelae - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[LOPERAMIDE, LOPERAMIDE HYDROCHLORIDE] (S - n/a - Unknown - [n/a - n/a - n/a])","[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - n/a - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016204721&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016204726,Spontaneous,2023-11-02 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dysarthria (5d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Headache (5d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Maternal exposure during pregnancy (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Slow speech (5d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Tongue movement disturbance (5d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Tremor (5d - Recovered/Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),[PARACETAMOL] (C - Headache - n/a - [n/a - n/a - Oral use]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016204726&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016204931,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Bell's palsy (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[RAMIPRIL] (C - Blood pressure management, Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016204931&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016205182,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Pain in extremity (n/a - Unknown - ),<BR><BR>Thrombosis (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016205182&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016205363,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Arthralgia (n/a - Unknown - ),<BR><BR>Chills (n/a - Unknown - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Vomiting projectile (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016205363&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016205570,Spontaneous,2023-11-02 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Rash pruritic (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016205570&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016205757,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Atrial fibrillation (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"EDOXABAN [EDOXABAN] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (C - COVID-19 immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016205757&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016205812,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anxiety (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Ear pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscle fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016205812&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016205988,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Bedridden (n/a - Recovering/Resolving - ),<BR><BR>Hallucination (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Monoplegia (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - n/a - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - n/a - Not applicable - [n/a - n/a - n/a])","INSULIN HUMAN [INSULIN HUMAN] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[BENDROFLUAZIDE] (C - Adverse event - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, PARACETAMOL PH. EUR., PARACETAMOL, CODEINE PHOSPHATE] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - Dose not changed - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016205988&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016205996,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016205996&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016206474,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016206474&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016206475,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Arthralgia (2d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (2d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Migraine with aura (1d - Recovered/Resolved - ),<BR><BR>Myalgia (3d - Recovered/Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - Dose not changed - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016206475&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016206476,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,Recall phenomenon (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - Breast cancer - Dose not changed - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016206476&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016206477,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Respiratory tract infection (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"APIXABAN 5MG TABLET  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FERROUS FUMARATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016206477&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016206480,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Back pain (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016206480&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016206485,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - Dose not changed - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016206485&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016206492,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (2d - Recovered/Resolved - ),<BR><BR>Headache (2d - Recovered/Resolved - ),<BR><BR>Malaise (4d - Recovered/Resolved - ),<BR><BR>Productive cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016206492&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016206494,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Body temperature increased (1d - Recovered/Resolved - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[THIAMINE HYDROCHLORIDE, DEXPANTHENOL, NICOTINAMIDE, RIBOFLAVIN, PYRIDOXINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016206494&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016206788,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016206788&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016206950,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Hypertension (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016206950&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016206952,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Fungal infection (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016206952&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016206954,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Injection site haematoma (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016206954&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016206957,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016206957&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016207122,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,Yes,Female,Vomiting (2h - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 HAEMAGGLUTININ ANTIGEN, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (C - Antiviral prophylaxis - Not applicable - [0d - n/a - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016207122&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016207299,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Male,"Diarrhoea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (n/a - Unknown - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[GALANTAMINE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[MEMANTINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, OMEPRAZOLE SODIUM] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[QUETIAPINE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016207299&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016207304,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Alanine aminotransferase increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Aspartate aminotransferase increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gamma-glutamyltransferase increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Illness (n/a - Unknown - ),<BR><BR>Liver function test increased (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016207304&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016207442,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Sinus headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016207442&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016207845,Spontaneous,2023-11-02 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Illness (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Peripheral swelling (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Ill-defined disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Ill-defined disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[PROCHLORPERAZINE] (C - Ill-defined disorder - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016207845&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016208048,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lip swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Oral discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia oral (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ALFACALCIDOL] (C - Parathyroid disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a]),<BR><BR>[CALCIUM CARBONATE, CALCIUM LACTATE GLUCONATE] (C - Parathyroid disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[CARBIMAZOLE] (C - Hyperthyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - Seasonal allergy - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Thyroidectomy - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Dyspepsia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016208048&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016208174,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site rash (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016208174&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016208202,Spontaneous,2023-11-02 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cerebrovascular disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Facial paralysis (n/a - Unknown - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"ACTOS [PIOGLITAZONE, PIOGLITAZONE HYDROCHLORIDE] (C - Diabetes mellitus - n/a - [n/a - n/a - Oral use]),<BR><BR>[GLICLAZIDE] (C - Diabetes mellitus - n/a - [n/a - n/a - Oral use]),<BR><BR>[PRAVASTATIN, PRAVASTATIN SODIUM] (C - Dyslipidaemia, Hyperlipidaemia - n/a - [n/a - n/a - Oral use]),<BR><BR>[TENELIGLIPTIN HYDROBROMIDE HYDRATE] (C - Diabetes mellitus - n/a - [n/a - n/a - Oral use]),<BR><BR>[VALSARTAN] (C - Hyperlipidaemia, Hypertension - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016208202&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016208487,Spontaneous,2023-11-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (18d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - Unknown - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016208487&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016194806,Spontaneous,2023-11-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Nausea (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016194806&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016195564,Spontaneous,2023-11-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cerebrovascular accident (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Cognitive disorder (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Dizziness (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Illness (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Nausea (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Nystagmus (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN (A/BRISBANE/59/2007 REASS. IVR-148), A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN (A/URUGUAY/716/2007 REASS. NYMC X-175C), B/BRISBANE/60/2008-LIKE VIRUS, A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN (A/BRISBANE/59/2007 REASS. IVR-148), A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN (A/URUGUAY/716/2007 REASS. NYMC X-175C), B/FLORIDA/4/2006-LIKE STRAIN (B/FLORIDA/4/2006), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), B/MALAYSIA/2506/2004 - LIKE STRAIN (B/MALAYSIA/2506/2004), A/WISCONSIN/67/2005 (H3N2) - LIKE STRAIN (A/HIROSHIMA/52/2005 REASS. IVR-142), ANTIGENS OF THE INFLUENZA VIRUS A/CALIFORNIA/7/2009 (H1N1)-LIKE VIRUS PDM09, ANTIGENS OF THE INFLUENZA VIRUS A/VICTORIA/361/2011 (H3N2)-LIKE VIRUS, ANTIGENS OF THE INFLUENZA VIRUS B/WISCONSIN/1/2010-LIKE VIRUS, B/BRISBANE/60/2008-LIKE VIRUS, A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), A/CALIFORNIA/7/2009 (H1N1)-DERIVED STRAIN USED NYMC X-181, B/MALAYSIA/2506/2004 - LIKE STRAIN (B/MALAYSIA/2506/2004), A/WISCONSIN/67/2005 (H3N2) - LIKE STRAIN (A/WISCONSIN/67/2005 REASS. NYMC X-161-B), A/SOLOMON ISLANDS/3/2006 (H1N1) - LIKE STRAIN (A/SOLOMON ISLANDS/3/2006 REASS. IVR-145), SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/GUANDONG-MAONAN/SWL1536/2019 (H1N1)PDM09-LIKE VIRUS (A/VICTORIA/2454/2019 IVR-207), SQUALENE, CITRIC ACID, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), SQUALENE, CITRIC ACID, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, CITRIC ACID ANHYDROUS, A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/GUANDONG-MAONAN/SWL1536/2019 (H1N1)PDM09-LIKE VIRUS (A/VICTORIA/2454/2019 IVR-207), SQUALENE, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, CITRIC ACID ANHYDROUS, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/BRISBANE/9/2014 (WILD TYPE), SQUALENE, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, CITRIC ACID ANHYDROUS, B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), SQUALENE, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, CITRIC ACID ANHYDROUS, B/MASSACHUSETTS/2/2012-LIKE STRAIN USED B/MASSACHUSETTS/2/2012 WILD TYPE, A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223), SQUALENE, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181)] (S - Immunisation - Not applicable - [1d - n/a - n/a])","[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Anxiety - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016195564&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016196354,Spontaneous,2023-11-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Dysphagia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Swollen tongue (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016196354&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016196391,Spontaneous,2023-11-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016196391&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016197134,Spontaneous,2023-11-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Arthralgia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[NOT AVAILABLE] (S - Blood cholesterol - Dose not changed - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016197134&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016197136,Spontaneous,2023-11-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dyspnoea (10d - Recovered/Resolved - ),<BR><BR>Fatigue (10d - Recovered/Resolved - ),<BR><BR>Malaise (10d - Recovered/Resolved - ),<BR><BR>Musculoskeletal pain (10d - Recovered/Resolved - ),<BR><BR>Myalgia (5d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016197136&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016197149,Spontaneous,2023-11-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016197149&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016197461,Spontaneous,2023-11-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016197461&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016197560,Spontaneous,2023-11-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016197560&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016197703,Spontaneous,2023-11-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Restlessness (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016197703&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016197803,Spontaneous,2023-11-01 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Herpes zoster (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016197803&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016197805,Spontaneous,2023-11-01 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Pain in extremity (n/a - Recovering/Resolving - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016197805&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016197809,Spontaneous,2023-11-01 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Rash pruritic (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),"[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (C - Immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016197809&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016197970,Spontaneous,2023-11-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Body temperature increased (4h - Recovered/Resolved - ),<BR><BR>Chills (5h - Recovered/Resolved - ),<BR><BR>Vibration syndrome (5h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016197970&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016198128,Spontaneous,2023-11-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016198128&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016198463,Spontaneous,2023-11-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016198463&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016198596,Spontaneous,2023-11-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Influenza like illness (5d - Recovered/Resolved - ),<BR><BR>Injection site pain (7d - Recovered/Resolved - ),<BR><BR>Malaise (5d - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016198596&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016198598,Spontaneous,2023-11-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"LEVETIRACETAM TEVA 500 MG FILM-COATED TABLETS [LEVETIRACETAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>MYCOPHENOLATE MOFETIL [MYCOPHENOLATE MOFETIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>PROBIOTICA [NOT AVAILABLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CETOMACROGOL 1000] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DENOSUMAB] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MOMETASONE FUROATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM FLUORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016198598&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016198602,Spontaneous,2023-11-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016198602&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016198762,Spontaneous,2023-11-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Menstrual disorder (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016198762&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016199016,Spontaneous,2023-11-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Dose not changed - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016199016&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016199061,Spontaneous,2023-11-01 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dehydration (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Gait inability (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Heat illness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Motor dysfunction (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Muscular weakness (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Quadriparesis (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"CYMBALTA [DULOXETINE, DULOXETINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>ESOMEPRAZOLE [ESOMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - Oral use]),<BR><BR>FORXIGA [DAPAGLIFLOZIN] (C - Diabetes mellitus - n/a - [n/a - n/a - Oral use]),<BR><BR>JANUVIA [SITAGLIPTIN, SITAGLIPTIN PHOSPHATE, SITAGLIPTIN PHOSPHATE MONOHYDRATE] (C - Diabetes mellitus - n/a - [n/a - n/a - Oral use]),<BR><BR>PREGABALIN [PREGABALIN] (C - Back pain, Sciatica - n/a - [n/a - 4{DF} - Oral use]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BIFIDOBACTERIUM] (C - Enterocolitis - n/a - [n/a - n/a - Oral use]),<BR><BR>[ETHYL LOFLAZEPATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ETIZOLAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MIRABEGRON] (C - Hypertonic bladder - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM HYDRATE] (C - Hypercholesterolaemia - n/a - [n/a - n/a - Oral use]),<BR><BR>[PITAVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PSEUDOGNAPHALIUM OBTUSIFOLIUM, CAPSICUM, CITRULLUS COLOCYNTHIS, MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[RABEPRAZOLE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[REBAMIPIDE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016199061&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016199141,Spontaneous,2023-11-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Aphonia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Cough (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Pneumonitis (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[FORMOTEROL FUMARATE DIHYDRATE, BECLOMETASONE DIPROPIONATE ANHYDROUS] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - .5{DF} - n/a]),<BR><BR>[SALBUTAMOL] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016199141&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016199218,Spontaneous,2023-11-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Deep vein thrombosis (2d - Recovered/Resolved With Sequelae - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016199218&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016199708,Spontaneous,2023-11-01 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Disabling),<BR><BR>Decreased appetite (n/a - Unknown - Disabling),<BR><BR>Diarrhoea (n/a - Unknown - Disabling),<BR><BR>Illness (n/a - Unknown - Disabling),<BR><BR>Influenza like illness (n/a - Unknown - Disabling),<BR><BR>Myalgia (n/a - Unknown - Disabling),<BR><BR>Nausea (n/a - Unknown - Disabling)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - n/a - Not applicable - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA QUADRIVALENT VACCINE (RDNA)] (S - n/a - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016199708&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016199858,Spontaneous,2023-11-01 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Drug eruption (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Rash (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),"FORXIGA [DAPAGLIFLOZIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BENIDIPINE, BENIDIPINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PEMAFIBRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM HYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SITAGLIPTIN PHOSPHATE, SITAGLIPTIN PHOSPHATE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016199858&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016199879,Spontaneous,2023-11-01 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Arrhythmia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Unknown - ),<BR><BR>Blood sodium increased (n/a - Unknown - ),<BR><BR>Orthostatic hypotension (n/a - Unknown - ),<BR><BR>Pulse abnormal (n/a - Recovered/Resolved - ),<BR><BR>Syncope (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vision blurred (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016199879&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016200495,Spontaneous,2023-11-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Male,"Arthralgia (5d - Recovered/Resolved - ),<BR><BR>Chills (5d - Recovered/Resolved - ),<BR><BR>Fatigue (5d - Recovered/Resolved - ),<BR><BR>Myalgia (5d - Recovered/Resolved - ),<BR><BR>Pyrexia (5d - Recovered/Resolved - ),<BR><BR>Somnolence (5d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016200495&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016200499,Spontaneous,2023-11-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Abnormal faeces (n/a - Not Recovered/Not Resolved - ),<BR><BR>Blood glucose decreased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Frequent bowel movements (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (8d - Recovered/Resolved - ),<BR><BR>Hepatic enzyme increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hepatic steatosis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Influenza (3d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016200499&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016200997,Spontaneous,2023-11-01 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Body temperature increased (5h - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016200997&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016185701,Spontaneous,2023-10-31 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Pruritus (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016185701&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016186987,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016186987&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016188040,Spontaneous,2023-10-31 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Chills (n/a - Recovered/Resolved - Disabling),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Fatigue (n/a - Unknown - Disabling),<BR><BR>Gastritis (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Headache (n/a - Recovering/Resolving - Disabling),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Palpitations (n/a - Unknown - Disabling),<BR><BR>Pyrexia (n/a - Unknown - Disabling),<BR><BR>Tachycardia (n/a - Unknown - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016188040&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016188515,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016188515&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016188825,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Postmenopausal haemorrhage (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016188825&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016189114,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Heart rate increased (1h - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016189114&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016189120,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Neuropathy peripheral (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016189120&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016189130,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Product substitution issue (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Dose not changed - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016189130&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016189138,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016189138&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016189139,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Eye inflammation (n/a - Recovering/Resolving - ),<BR><BR>Eye pain (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016189139&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016189597,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (1d - Recovered/Resolved - ),<BR><BR>Bone pain (1d - Recovered/Resolved - ),<BR><BR>Fatigue (1d - Recovered/Resolved - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Injection site swelling (1d - Recovered/Resolved - ),<BR><BR>Myalgia (1d - Recovered/Resolved - ),<BR><BR>Pain (1d - Recovered/Resolved - ),<BR><BR>Somnolence (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - n/a - n/a - [n/a - 30ug - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016189597&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016189689,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Eye swelling (n/a - Recovering/Resolving - ),<BR><BR>Rash (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016189689&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016189693,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Anxiety (n/a - Recovering/Resolving - ),<BR><BR>Asthenia (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Tachycardia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016189693&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016189698,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Muscle spasms (15min - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016189698&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016189701,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Female,Asthma (18h - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>TELMISARTAN 80 MG - TABLET  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FENOTEROL HYDROBROMIDE, IPRATROPIUM BROMIDE MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOCABASTINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MACROGOL 400] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TIOTROPIUM, OLODATEROL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016189701&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016189801,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (3d - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[OLMESARTAN, OLMESARTAN MEDOXOMIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [3d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016189801&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016190094,Spontaneous,2023-10-31 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Pulmonary embolism (n/a - Fatal - Results in Death),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016190094&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016190428,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Visual impairment (8d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ALENDRONATE SODIUM, ALENDRONIC ACID] (C - Osteoporotic fracture - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016190428&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016190438,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016190438&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016190440,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Maternal exposure during pregnancy (n/a - Unknown - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016190440&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016190581,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Eructation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Flatulence (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016190581&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016190734,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016190734&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016190759,Spontaneous,2023-10-31 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Tremor (7h - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016190759&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016190803,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Burning sensation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016190803&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016191079,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016191079&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016191084,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Balance disorder (1wk - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016191084&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016191155,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Mobility decreased (n/a - Unknown - ),<BR><BR>Musculoskeletal stiffness (n/a - Unknown - ),<BR><BR>Pain (n/a - Unknown - ),<BR><BR>Peripheral swelling (n/a - Unknown - ),<BR><BR>Skin discolouration (n/a - Unknown - ),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016191155&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016191163,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Amenorrhoea (n/a - Unknown - ),<BR><BR>Oligomenorrhoea (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016191163&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016191193,Spontaneous,2023-10-31 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Hypersensitivity (n/a - Recovering/Resolving - ),<BR><BR>Hypertension (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia oral (n/a - Unknown - ),<BR><BR>Swollen tongue (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"ESOMEPRAZOLE [ESOMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016191193&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016191261,Spontaneous,2023-10-31 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Status epilepticus (n/a - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016191261&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016191273,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Asthenia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Injection site reaction (n/a - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016191273&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016191290,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Diarrhoea (2h - Recovered/Resolved - ),<BR><BR>Vomiting (2h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016191290&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016191328,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Paraesthesia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016191328&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016191590,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Asthma (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016191590&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016191626,Spontaneous,2023-10-31 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Meningitis (3d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS SPLIT VIRION 4V VACCINE INACTIVATED (INFLUENZA VACCINE)] (C - n/a - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016191626&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016191635,Spontaneous,2023-10-31 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Liver function test increased (n/a - Unknown - ),<BR><BR>Petechiae (n/a - Unknown - ),<BR><BR>Rash (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016191635&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016191752,Spontaneous,2023-10-31 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Angioedema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Migraine (n/a - Unknown - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - n/a])","AERIUS [DESLORATADINE] (C - Hypersensitivity - n/a - [n/a - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - Gout - n/a - [n/a - n/a - n/a]),<BR><BR>[BUPRENORPHINE] (C - Fibromyalgia - n/a - [n/a - n/a - n/a]),<BR><BR>[GABAPENTIN] (C - Fibromyalgia - n/a - [n/a - n/a - n/a]),<BR><BR>[MOMETASONE FUROATE, MOMETASONE FUROATE MONOHYDRATE] (C - Hypersensitivity - n/a - [n/a - n/a - n/a]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Dyspepsia - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Fibromyalgia - n/a - [n/a - n/a - n/a]),<BR><BR>[TAMSULOSIN HYDROCHLORIDE] (C - Prostatism - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016191752&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016191756,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cognitive disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Energy increased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Euphoric mood (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sleep disorder (n/a - Unknown - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>SUPEMTEK [INFLUENZA A VIRUS SUBTYPE H1N1 HAEMAGGLUTININ, RECOMBINANT, INFLUENZA B VIRUS VICTORIA LINEAGE HAEMAGGLUTININ, RECOMBINANT, INFLUENZA A VIRUS SUBTYPE H3N2 HAEMAGGLUTININ, RECOMBINANT, INFLUENZA B VIRUS YAMAGATA LINEAGE HAEMAGGLUTININ, RECOMBINANT] (S - Immunisation - Not applicable - [1d - n/a - n/a])","PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Vesicoureteric reflux - n/a - [n/a - n/a - n/a]),<BR><BR>[CODEINE PHOSPHATE BP, PARACETAMOL PH. EUR., PARACETAMOL BP, CODEINE PHOSPHATE BP, PARACETAMOL DC, PARACETAMOL PH. EUR., CODEINE PHOSPHATE PH.EUR., PARACETAMOL PH. EUR., CODEINE PHOSPHATE PH.EUR., PARACETAMOL, CODEINE PHOSPHATE, PARACETAMOL, CODEINE PHOSPHATE BP, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE] (C - Pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016191756&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016191782,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Balance disorder (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016191782&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016191786,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Body temperature increased (n/a - Recovering/Resolving - ),<BR><BR>Chills (3h - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016191786&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016191791,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Male,"Fatigue (6d - Recovered/Resolved - ),<BR><BR>Headache (6d - Recovered/Resolved - ),<BR><BR>Malaise (6d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUTICASONE PROPIONATE, SALMETEROL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016191791&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016191917,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Disabling),<BR><BR>Back pain (n/a - Recovering/Resolving - Disabling),<BR><BR>Fatigue (n/a - Recovering/Resolving - Disabling),<BR><BR>Injection site reaction (n/a - Recovering/Resolving - Disabling),<BR><BR>Myalgia (n/a - Recovering/Resolving - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016191917&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016191918,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Fatigue (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016191918&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016192318,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Loss of consciousness (1d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ALLOPURINOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[DILTIAZEM, DILTIAZEM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLECAINIDE, FLECAINIDE ACETATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[MESALAZINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016192318&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016192333,Spontaneous,2023-10-31 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Rash (n/a - Recovering/Resolving - ),<BR><BR>Urticaria (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016192333&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016192361,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymph gland infection (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[NORETHISTERONE ACETATE, ESTRADIOL, NORETHISTERONE ACETATE, ESTRADIOL HEMIHYDRATE] (C - Menopause - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016192361&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016192535,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016192535&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016192565,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Not Specified,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Ear pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Gait disturbance (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypotonia (5d - Recovered/Resolved - ),<BR><BR>Limb discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (5d - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016192565&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016192566,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Limb discomfort (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016192566&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016192820,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Atrial fibrillation (1d - Recovered/Resolved - ),<BR><BR>Dizziness (1d - Recovered/Resolved - ),<BR><BR>Fatigue (1d - Recovered/Resolved - ),<BR><BR>Hypotension (1d - Recovered/Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"APIXABAN 5MG TABLET  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016192820&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016192894,Spontaneous,2023-10-31 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Seizure (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Anxiety - n/a - [n/a - n/a - n/a]),<BR><BR>[DONEPEZIL] (C - Dementia Alzheimer's type - n/a - [n/a - n/a - n/a]),<BR><BR>[TIMOLOL, TIMOLOL MALEATE] (C - Glaucoma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016192894&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016193656,Spontaneous,2023-10-31 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Blister (n/a - Recovering/Resolving - ),<BR><BR>Herpes zoster (n/a - Recovering/Resolving - ),<BR><BR>Paraesthesia (n/a - Recovering/Resolving - ),<BR><BR>Scab (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[BUDESONIDE] (C - Asthma - n/a - [n/a - 400ug - Inhalation use]),<BR><BR>[LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - 50mg - Oral use]),<BR><BR>[METOPROLOL TARTRATE] (C - Hypertension - n/a - [n/a - 100mg - Oral use]),<BR><BR>[OXCARBAZEPINE] (C - Epilepsy - n/a - [n/a - 300mg - Oral use]),<BR><BR>[PARACETAMOL] (C - Pyrexia - n/a - [n/a - 1000mg - Oral use]),<BR><BR>[SODIUM VALPROATE] (C - Epilepsy - n/a - [n/a - 2500mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016193656&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016193660,Spontaneous,2023-10-31 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Dizziness (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016193660&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016193661,Spontaneous,2023-10-31 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Lip swelling (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),"[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[CHLORPROTHIXENE HYDROCHLORIDE] (C - Sedative therapy - n/a - [n/a - n/a - Oral use]),<BR><BR>[CLOBETASOL PROPIONATE] (C - Seborrhoeic dermatitis - n/a - [n/a - n/a - Cutaneous use]),<BR><BR>[CLOBETASOL PROPIONATE] (C - Skin disorder - n/a - [n/a - n/a - Cutaneous use]),<BR><BR>[LEVONORGESTREL, LEVONORGESTREL MICRONISED] (C - Contraception - n/a - [n/a - n/a - Intrauterine use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016193661&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016194183,Spontaneous,2023-10-31 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Abdominal pain (2d - Recovered/Resolved - ),<BR><BR>Cold sweat (2d - Recovered/Resolved - ),<BR><BR>Nausea (2d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227)] (S - Influenza immunisation - Not applicable - [1d - .5mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016194183&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016194217,Spontaneous,2023-10-31 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Face oedema (n/a - Recovering/Resolving - ),<BR><BR>Pruritus (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016194217&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016175963,Spontaneous,2023-10-30 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Atrial fibrillation (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[NAFARELIN, NAFARELIN ACETATE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[TIBOLONE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016175963&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016177017,Spontaneous,2023-10-30 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Pulmonary embolism (n/a - Not Recovered/Not Resolved - Disabling),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016177017&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016177027,Spontaneous,2023-10-30 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016177027&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016177334,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016177334&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016178202,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Headache (2d - Recovered/Resolved - ),<BR><BR>Malaise (2d - Recovered/Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016178202&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016178203,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016178203&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016178206,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016178206&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016178208,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016178208&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016178210,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Vaccination site lymphadenopathy (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016178210&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016178211,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Fatigue (3d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016178211&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016178212,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016178212&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016178213,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016178213&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016178215,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Headache (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"DARIFENACIN HYDROBROMIDE 7.5MG - MODIFIED-RELEASE TABLET  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016178215&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016178216,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Body temperature increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016178216&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016178217,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Injection site erythema (n/a - Unknown - ),<BR><BR>Injection site inflammation (n/a - Unknown - ),<BR><BR>Injection site pain (n/a - Unknown - ),<BR><BR>Injection site warmth (n/a - Unknown - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016178217&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016178218,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016178218&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016178219,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016178219&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016178220,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MACROGOL 4000] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016178220&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016178221,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site haematoma (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016178221&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016178223,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016178223&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016178224,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016178224&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016178225,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016178225&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016178537,Spontaneous,2023-10-30 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Acute myocardial infarction (0d - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Cardiac failure acute (0d - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Cardiovascular disorder (0d - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Dyspnoea (0d - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Endotracheal intubation (0d - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pulmonary oedema (0d - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (0d - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Resuscitation (0d - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1)V-LIKE VIRUS, A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187)] (S - n/a - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016178537&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016178920,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Pharyngeal swelling (4h - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016178920&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016179220,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Male,"Facial paralysis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Herpes zoster oticus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016179220&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016179233,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Vaginal haemorrhage (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016179233&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016179543,Spontaneous,2023-10-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Vaccination site oedema (n/a - Recovered/Resolved - ),<BR><BR>Vaccination site pain (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016179543&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016179602,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Eye pain (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016179602&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016179608,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Ear pain (n/a - Recovering/Resolving - ),<BR><BR>Ear swelling (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016179608&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016179612,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016179612&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016179618,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Phlebitis (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016179618&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016179623,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Condition aggravated (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Lichen sclerosus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Sneezing (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016179623&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016179625,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,"Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (S - Graves' disease - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[THIAMAZOLE] (S - Graves' disease - Dose not changed - [n/a - n/a - n/a])",[PREDNISOLONE] (C - n/a - Dose not changed - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016179625&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016179626,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Abdominal pain (1d - Recovered/Resolved - ),<BR><BR>Injection site pain (2d - Recovered/Resolved - ),<BR><BR>Myalgia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016179626&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016179819,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Heart rate irregular (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Presyncope (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"EDOXABAN [EDOXABAN] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>RANEXA [RANOLAZINE] (C - Microvascular coronary artery disease - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[BENDROFLUAZIDE] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[CLOBETASONE BUTYRATE, NYSTATIN, OXYTETRACYCLINE] (C - Plasma cell vulvitis - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTROGEN NOS] (C - Vulvovaginal pain - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Back pain - n/a - [n/a - n/a - n/a]),<BR><BR>[VITAMIN D] (C - Hypovitaminosis - n/a - [n/a - n/a - n/a]),<BR><BR>[ZOPICLONE] (C - Insomnia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016179819&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016179990,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016179990&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016180208,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Heart rate increased (n/a - Unknown - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016180208&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016180216,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Malaise (n/a - Recovering/Resolving - ),<BR><BR>Rhinorrhoea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016180216&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016180224,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (1d - Recovered/Resolved - ),<BR><BR>Injection site erythema (2d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (2d - Recovered/Resolved - ),<BR><BR>Injection site pain (2d - Recovered/Resolved - ),<BR><BR>Menstruation irregular (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016180224&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016180228,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Injection site haematoma (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016180228&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016180261,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Hypogeusia (n/a - Recovering/Resolving - ),<BR><BR>Hyposmia (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUTICASONE PROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016180261&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016180749,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016180749&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016180813,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016180813&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016180852,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Rash pruritic (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016180852&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016180857,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (2d - Recovered/Resolved - ),<BR><BR>Fatigue (5d - Recovered/Resolved - ),<BR><BR>Headache (5d - Recovered/Resolved - ),<BR><BR>Injection site erythema (5d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (5d - Recovered/Resolved - ),<BR><BR>Injection site swelling (5d - Recovered/Resolved - ),<BR><BR>Malaise (5d - Recovered/Resolved - ),<BR><BR>Maternal exposure during pregnancy (n/a - Unknown - ),<BR><BR>Nausea (5d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016180857&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016180858,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Nausea (n/a - Recovering/Resolving - ),<BR><BR>Vertigo (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016180858&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016180859,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Male,Bell's palsy (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[LITHIUM CARBONATE] (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - Dose not changed - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016180859&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016180862,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Hot flush (3d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016180862&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016180866,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,"Hypogeusia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016180866&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016180871,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (2d - Recovered/Resolved - ),<BR><BR>Fatigue (4d - Recovered/Resolved - ),<BR><BR>Headache (3d - Recovered/Resolved - ),<BR><BR>Injection site pain (1wk - Recovered/Resolved - ),<BR><BR>Malaise (3d - Recovered/Resolved - ),<BR><BR>Myalgia (2d - Recovered/Resolved - ),<BR><BR>Nausea (1h - Recovered/Resolved - ),<BR><BR>Vaccination site lymphadenopathy (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016180871&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016180872,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Brain fog (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016180872&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016180873,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Constipation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Extensive swelling of vaccinated limb (n/a - Not Recovered/Not Resolved - ),<BR><BR>Gastrointestinal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pruritus (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016180873&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016180883,Spontaneous,2023-10-30 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,Yes,Female,Lymphadenopathy (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016180883&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016181224,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016181224&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016181467,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016181467&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016181524,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Pruritus (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016181524&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016181532,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Feeling hot (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016181532&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016181534,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (3d - Recovered/Resolved - ),<BR><BR>COVID-19 (n/a - Not Recovered/Not Resolved - ),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016181534&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016181699,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,"Abdominal pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Arthralgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Back pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pelvic pain (n/a - Not Recovered/Not Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016181699&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016181957,Spontaneous,2023-10-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,"Abdominal pain (1d - Recovered/Resolved - ),<BR><BR>Asthenia (1d - Recovered/Resolved - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Myalgia (1d - Recovered/Resolved - ),<BR><BR>Nausea (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016181957&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016181979,Spontaneous,2023-10-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Agitation (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Balance disorder (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Cerebral haematoma (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Cerebral haemorrhage (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Coagulopathy (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Confusional state (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fall (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fibrin D dimer increased (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Nervous system disorder (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pulmonary embolism (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Vertigo (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"SIFROL 0.18 MG [PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE] (C - n/a - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>[INDAPAMIDE, PERINDOPRIL ARGININE] (C - n/a - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>[SOLIFENACIN] (C - n/a - Unknown - [n/a - 10mg - n/a]),<BR><BR>[TAMSULOSIN HYDROCHLORIDE] (C - n/a - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>[ZOLPIDEM, ZOLPIDEM TARTRATE] (C - n/a - Unknown - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016181979&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016182026,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Unknown - ),<BR><BR>Erythema (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Feeling cold (n/a - Unknown - ),<BR><BR>Hyperhidrosis (n/a - Unknown - ),<BR><BR>Illness (n/a - Unknown - ),<BR><BR>Joint swelling (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Musculoskeletal stiffness (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Unknown - ),<BR><BR>Nausea (n/a - Unknown - ),<BR><BR>Oedema peripheral (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Unknown - ),<BR><BR>Presyncope (n/a - Unknown - ),<BR><BR>Tremor (n/a - Unknown - ),<BR><BR>Vaccination site discomfort (n/a - Unknown - ),<BR><BR>Vaccination site movement impairment (n/a - Unknown - ),<BR><BR>Vaccination site pain (n/a - Unknown - ),<BR><BR>Weight bearing difficulty (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])","TACROLIMUS [TACROLIMUS, TACROLIMUS MONOHYDRATE] (C - Liver transplant rejection - n/a - [n/a - 1.5mg - n/a]),<BR><BR>[ASCORBIC ACID] (C - Liver transplant - n/a - [n/a - 500[iU] - n/a]),<BR><BR>[FAMOTIDINE] (C - Gastrointestinal disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Autoimmune thyroiditis, Hypothyroidism - n/a - [n/a - 200ug - n/a]),<BR><BR>[VITAMINS NOS] (C - Liver transplant - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[ZINC] (C - Liver transplant - n/a - [n/a - 220mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016182026&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016182035,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Body temperature increased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),[METOCLOPRAMIDE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016182035&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016182042,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (2d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (3d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Taste disorder (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN CILEXETIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METOPROLOL TARTRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016182042&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016182055,Spontaneous,2023-10-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Injection site erythema (2d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (2d - Recovered/Resolved - ),<BR><BR>Injection site swelling (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016182055&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016182263,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Abdominal pain (2d - Recovered/Resolved - ),<BR><BR>Asthenia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Diabetes mellitus inadequate control (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),"CIALIS 5 MG FILM-COATED TABLETS [TADALAFIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>INSULIN DEGLUDEC [INSULIN DEGLUDEC] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>TRULICITY 3 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN [DULAGLUTIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TESTOSTERONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016182263&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016182421,Spontaneous,2023-10-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Vaccination site nodule (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016182421&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016182429,Spontaneous,2023-10-30 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Urticaria (1d - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - n/a - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016182429&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016182467,Spontaneous,2023-10-30 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Haemorrhagic stroke (n/a - Not Recovered/Not Resolved - Life Threatening),"COMIRNATY OMICRON XBB.1.5 10 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),<BR><BR>PLAVIX [CLOPIDOGREL, CLOPIDOGREL HYDROGEN SULFATE] (S - Product used for unknown indication - Drug withdrawn - [n/a - 1{DF} - Oral use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021] (S - Influenza immunisation - Not applicable - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016182467&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016182852,Spontaneous,2023-10-30 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Anxiety (n/a - Unknown - ),<BR><BR>Dizziness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia oral (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pharyngeal paraesthesia (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[CHLORPHENAMINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROCORTISONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016182852&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016182865,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dyspnoea (1d - Recovered/Resolved - Disabling),<BR><BR>Pyrexia (1d - Recovered/Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016182865&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016183033,Spontaneous,2023-10-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Cardiac arrest (1d - Fatal - Results in Death),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016183033&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016183231,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016183231&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016183348,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Headache (1d - Recovered/Resolved - ),<BR><BR>Malaise (1d - Recovered/Resolved - ),<BR><BR>Vaccination site pain (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016183348&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016183422,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Asthenia (n/a - Recovering/Resolving - Disabling),<BR><BR>Hypoaesthesia (n/a - Recovering/Resolving - Disabling),<BR><BR>Syncope (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),[INFLUENZA VIRUS VACCINE POLYVALENT] (C - Immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016183422&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016183572,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),[DEXTROMETHORPHAN HYDROBROMIDE] (C - n/a - n/a - [3d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016183572&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016183861,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Tachycardia (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016183861&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016184164,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016184164&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016184270,Spontaneous,2023-10-30 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Multiple organ dysfunction syndrome (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016184270&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016184383,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Skin wound (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>WEGOVY FLEXTOUCH [SEMAGLUTIDE] (S - Overweight - Dose not changed - [n/a - 1mg - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","ESOMEPRAZOLE [ESOMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACICLOVIR] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BACLOFEN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BENDROFLUMETHIAZIDE, POTASSIUM CHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CETIRIZINE DIHYDROCHLORIDE] (C - Restlessness - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OXYCODONE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016184383&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016184386,Spontaneous,2023-10-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Swelling face (7d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - 1{DF} - n/a]),"[CYANOCOBALAMIN] (C - Vitamin B12 deficiency - n/a - [n/a - 1mg - Oral use]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - 100mg - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - 1000mg - Oral use]),<BR><BR>[URSODEOXYCHOLIC ACID] (C - Liver disorder - n/a - [n/a - 250mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016184386&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016184388,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Vaccination site mass (n/a - Unknown - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","ESOMEPRAZOLE [ESOMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>WEGOVY FLEXTOUCH [SEMAGLUTIDE] (C - Overweight - n/a - [n/a - 1mg - n/a]),<BR><BR>[ACICLOVIR] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BACLOFEN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BENDROFLUMETHIAZIDE, POTASSIUM CHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CETIRIZINE DIHYDROCHLORIDE] (C - Restlessness - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OXYCODONE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016184388&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016184394,Spontaneous,2023-10-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Angioedema (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Erythema (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lip swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rash (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Taste disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),HYQVIA [HUMAN NORMAL IMMUNOGLOBULIN] (C - Hypogammaglobulinaemia - n/a - [n/a - 200mL - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016184394&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016184835,Spontaneous,2023-10-30 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,Headache (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016184835&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016184906,Spontaneous,2023-10-30 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Asthenia (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - ),<BR><BR>Vomiting (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [0d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016184906&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016184907,Spontaneous,2023-10-30 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Erythema (2d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016184907&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016184908,Spontaneous,2023-10-30 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site inflammation (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - n/a]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B)] (S - Influenza immunisation - Drug withdrawn - [0d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016184908&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016184909,Spontaneous,2023-10-30 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Vaccination site inflammation (1d - Recovered/Resolved - ),<BR><BR>Vaccination site pain (1d - Recovered/Resolved - ),<BR><BR>Vaccination site pruritus (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016184909&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016184911,Spontaneous,2023-10-30 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Malaise (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016184911&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016185097,Spontaneous,2023-10-30 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (1d - Recovered/Resolved - ),<BR><BR>Chills (1d - Recovered/Resolved - ),<BR><BR>Myalgia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016185097&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016173506,Spontaneous,2023-10-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Cardiac flutter (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling jittery (n/a - Not Recovered/Not Resolved - ),<BR><BR>Flushing (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Insomnia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Musculoskeletal stiffness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - ),<BR><BR>Restlessness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site haemorrhage (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"SPIKEVAX [ELASOMERAN] (C - COVID-19 immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[NITROFURANTOIN] (C - n/a - n/a - [2d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016173506&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016163065,Spontaneous,2023-10-27 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Injection site urticaria (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Prophylaxis - Not applicable - [n/a - 4[iU] - Intramuscular use]),"FLUCELVAX TETRA [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (C - Prophylaxis - n/a - [n/a - n/a - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016163065&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016163171,Spontaneous,2023-10-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Gastrointestinal pain (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"ELIQUIS 5 MG FILM-COATED TABLETS [APIXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESOMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016163171&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016163235,Spontaneous,2023-10-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthma (n/a - Unknown - ),<BR><BR>Cardiac disorder (n/a - Recovered/Resolved - ),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Partial seizures (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pulmonary thrombosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pulmonary tuberculosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016163235&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016163263,Spontaneous,2023-10-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Asthenia (n/a - Recovered/Resolved - ),<BR><BR>Chills (n/a - Recovered/Resolved - ),<BR><BR>Immunisation reaction (n/a - Recovered/Resolved - ),<BR><BR>Vertigo (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"PEGASYS [PEGINTERFERON ALFA-2A] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM, HYDRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016163263&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016163280,Spontaneous,2023-10-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Female,Injected limb mobility decreased (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016163280&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016164197,Spontaneous,2023-10-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Confusional state (1d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016164197&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016166112,Spontaneous,2023-10-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,COVID-19 (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016166112&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016166126,Spontaneous,2023-10-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016166126&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016166321,Spontaneous,2023-10-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Erythema (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nightmare (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016166321&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016166434,Spontaneous,2023-10-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Back pain (n/a - Unknown - ),<BR><BR>Menometrorrhagia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Uterine spasm (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016166434&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016166609,Spontaneous,2023-10-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Urticaria (12h - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016166609&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016166958,Spontaneous,2023-10-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Female,"Herpes zoster (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016166958&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016167088,Spontaneous,2023-10-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,Somnolence (2d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016167088&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016167331,Spontaneous,2023-10-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Limb discomfort (n/a - Recovering/Resolving - ),<BR><BR>Micturition urgency (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227)] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016167331&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016167361,Spontaneous,2023-10-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Cerebrovascular accident (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016167361&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016167555,Spontaneous,2023-10-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Dizziness (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016167555&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016167558,Spontaneous,2023-10-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Immunisation reaction (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016167558&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016167560,Spontaneous,2023-10-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Diarrhoea (n/a - Recovered/Resolved - ),<BR><BR>Dizziness (n/a - Recovered/Resolved - ),<BR><BR>Nausea (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016167560&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016167561,Spontaneous,2023-10-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Immunisation reaction (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016167561&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016167595,Spontaneous,2023-10-27 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Vaccination site erythema (n/a - Recovered/Resolved - ),<BR><BR>Vaccination site pruritus (n/a - Recovered/Resolved - ),<BR><BR>Vaccination site swelling (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016167595&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016167777,Spontaneous,2023-10-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dysmenorrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Menstruation delayed (5d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016167777&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016168065,Spontaneous,2023-10-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Abdominal pain (n/a - Recovering/Resolving - Disabling),<BR><BR>Arthralgia (n/a - Recovering/Resolving - Disabling),<BR><BR>Chills (n/a - Recovering/Resolving - Disabling),<BR><BR>Diarrhoea (2d - Recovering/Resolving - Disabling),<BR><BR>Extensive swelling of vaccinated limb (n/a - Recovering/Resolving - Disabling),<BR><BR>Fatigue (n/a - Recovering/Resolving - Disabling),<BR><BR>Musculoskeletal stiffness (n/a - Recovering/Resolving - Disabling),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"ENTRESTO 97 MG/103 MG [VALSARTAN, SACUBITRIL] (C - n/a - n/a - ),<BR><BR>XARELTO 20 MG [RIVAROXABAN] (C - n/a - n/a - ),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - ),<BR><BR>[EPLERENONE] (C - n/a - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016168065&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016168327,Spontaneous,2023-10-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Breast pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016168327&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016168425,Spontaneous,2023-10-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Coagulopathy (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Extensive swelling of vaccinated limb (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Jugular vein thrombosis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"LYRICA 75 MG [PREGABALIN] (C - n/a - n/a - ),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - ),<BR><BR>[VALSARTAN] (C - n/a - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016168425&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016168720,Spontaneous,2023-10-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,Ear pain (8d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Immunisation - n/a - [n/a - n/a - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016168720&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016168894,Spontaneous,2023-10-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Fatigue (n/a - Unknown - ),<BR><BR>Hot flush (n/a - Unknown - ),<BR><BR>Insomnia (n/a - Unknown - ),<BR><BR>Vaccination site oedema (n/a - Unknown - ),<BR><BR>Vaccination site pain (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"JARDIANCE [EMPAGLIFLOZIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[ANHYDROUS CILAZAPRIL, CILAZAPRIL, CILAZAPRIL MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CARVEDILOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[POTASSIUM CHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TETANUS VACCINES] (C - Tetanus immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016168894&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016168917,Spontaneous,2023-10-27 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Anaphylactic reaction (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pallor (2d - Recovered/Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016168917&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016168939,Spontaneous,2023-10-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[EBASTINE] (C - n/a - n/a - [n/a - 20mg - n/a]),<BR><BR>[OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, OMEPRAZOLE SODIUM] (C - n/a - n/a - [n/a - 20mg - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - n/a - n/a - [n/a - 10mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016168939&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016169013,Spontaneous,2023-10-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal discomfort (n/a - Unknown - ),<BR><BR>Back pain (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (8d - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nasal congestion (13d - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Unknown - ),<BR><BR>Pain in extremity (2d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016169013&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016169103,Spontaneous,2023-10-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (3d - Recovered/Resolved - ),<BR><BR>Chest pain (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016169103&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016169129,Spontaneous,2023-10-27 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Pulmonary embolism (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016169129&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016169306,Spontaneous,2023-10-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cerebrovascular accident (12d - Recovered/Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Coagulopathy (12d - Recovered/Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Nervous system disorder (12d - Recovered/Resolved - Life Threatening, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016169306&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016169368,Spontaneous,2023-10-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Lip swelling (n/a - Recovering/Resolving - ),<BR><BR>Pruritus (n/a - Recovering/Resolving - ),<BR><BR>Rash erythematous (n/a - Recovering/Resolving - ),<BR><BR>Skin disorder (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016169368&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016169719,Spontaneous,2023-10-27 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Conjunctivitis (n/a - Unknown - ),<BR><BR>Cough (n/a - Unknown - ),<BR><BR>Face oedema (n/a - Unknown - ),<BR><BR>Respiratory disorder (n/a - Unknown - ),<BR><BR>Skin disorder (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016169719&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016170024,Spontaneous,2023-10-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Chills (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Headache (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Insomnia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[INFLUENZA A VIRUS A/BRISBANE/10/2010 (H1N1) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED)] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016170024&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016170370,Spontaneous,2023-10-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016170370&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016170517,Spontaneous,2023-10-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Dizziness (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Antiviral prophylaxis - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>[ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[FLUTICASONE, SALMETEROL] (C - Product used for unknown indication - n/a - [n/a - n/a - Inhalation use]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016170517&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016170731,Spontaneous,2023-10-27 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,Yes,Female,Malaise (1h - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Antiviral prophylaxis - n/a - [n/a - n/a - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016170731&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016170733,Spontaneous,2023-10-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Unknown - ),<BR><BR>Feeling abnormal (n/a - Unknown - ),<BR><BR>Heart rate increased (2d - Recovered/Resolved - ),<BR><BR>Myocarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - ),<BR><BR>Pericarditis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - 2.5mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016170733&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016170829,Spontaneous,2023-10-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cardiac arrest (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016170829&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016171831,Spontaneous,2023-10-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Blood glucose fluctuation (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Blood glucose increased (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Dehydration (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Nausea (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016171831&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016171841,Spontaneous,2023-10-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Anaemia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Confusional state (8d - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (8d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Sepsis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Serum ferritin increased (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),"LANTUS SOLOSTAR [INSULIN GLARGINE] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[BUMETANIDE] (C - Diuretic therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[CETIRIZINE DIHYDROCHLORIDE] (C - Pruritus - n/a - [n/a - n/a - n/a]),<BR><BR>[LERCANIDIPINE HYDROCHLORIDE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[MECILLINAM, PIVMECILLINAM, PIVMECILLINAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016171841&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016171853,Spontaneous,2023-10-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Basal ganglia infarction (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Basal ganglia stroke (4d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Transient ischaemic attack (4d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),<BR><BR>COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016171853&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016171854,Spontaneous,2023-10-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Dizziness (20d - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Syncope (20d - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[ACETYLSALICYLIC ACID, ACETYLSALICYLIC ACID, MAGNESIUM OXIDE] (C - Thrombosis prophylaxis - n/a - [n/a - 75mg - Oral use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[IBUPROFEN] (C - Arthritis - n/a - [n/a - 400mg - Oral use]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM] (C - Gastric pH decreased - n/a - [n/a - 40mg - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - 1000mg - Oral use]),<BR><BR>[ROSUVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - 10mg - Oral use]),<BR><BR>[TADALAFIL] (C - Erectile dysfunction - n/a - [n/a - 5mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016171854&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016171855,Spontaneous,2023-10-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Dyspnoea exertional (n/a - Unknown - Life Threatening),<BR><BR>Pulmonary embolism (n/a - Not Recovered/Not Resolved - Life Threatening)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016171855&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016172285,Spontaneous,2023-10-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Alanine aminotransferase increased (n/a - Unknown - ),<BR><BR>Aspartate aminotransferase increased (n/a - Unknown - ),<BR><BR>Gamma-glutamyltransferase increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lipase increased (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016172285&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016172313,Spontaneous,2023-10-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Vomiting (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - .3mL - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021] (S - Immunisation - Drug withdrawn - [1d - .7mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016172313&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016172345,Spontaneous,2023-10-27 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Vomiting (3d - Recovered/Resolved - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - .3mL - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021] (S - Immunisation - Drug withdrawn - [1d - .7mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016172345&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016172668,Spontaneous,2023-10-27 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016172668&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016153603,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Rash (n/a - Not Recovered/Not Resolved - ),<BR><BR>Urticaria (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016153603&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016153855,Spontaneous,2023-10-26 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (1d - Recovered/Resolved - ),<BR><BR>Immunisation reaction (1d - Recovered/Resolved - ),<BR><BR>Myalgia (1d - Recovered/Resolved - ),<BR><BR>Vaccination site pain (1d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224)] (S - Influenza immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016153855&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016154053,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Feeling hot (n/a - Recovering/Resolving - ),<BR><BR>Hyperhidrosis (n/a - Unknown - ),<BR><BR>Influenza like illness (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016154053&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016154081,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Palpitations (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Taste disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016154081&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016154089,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Dyspnoea (1d - Recovered/Resolved With Sequelae - Disabling, Other Medically Important Condition),<BR><BR>Mobility decreased (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Parkinson's disease (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Parosmia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"LEVODOPA [LEVODOPA] (C - Parkinson's disease - n/a - [n/a - n/a - n/a]),<BR><BR>[CARBIDOPA] (C - Parkinson's disease - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016154089&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016154112,Spontaneous,2023-10-26 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Aphasia (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Blood pressure diastolic decreased (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Confusional state (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016154112&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016154148,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"APIDRA [INSULIN GLULISINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016154148&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016154185,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Groin pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Product administered to patient of inappropriate age (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016154185&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016154195,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Tonsillitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016154195&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016154226,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"APIXABAN [APIXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[SOTALOL, SOTALOL HYDROCHLORIDE] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016154226&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016154287,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lower respiratory tract infection (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nasal congestion (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Retching (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"AUBAGIO [TERIFLUNOMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL, NORETHISTERONE ACETATE, ESTRADIOL, NORETHISTERONE ACETATE, ESTRADIOL HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LORATADINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MODAFINIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016154287&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016154321,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Insomnia (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Tremor (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXYCARBAMIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016154321&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016154343,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Migraine (11d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016154343&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016154423,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Extrasystoles (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (3d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>PREGABALIN [PREGABALIN] (C - Anxiety disorder - n/a - [n/a - n/a - n/a]),<BR><BR>PRUCALOPRIDE [PRUCALOPRIDE] (C - Constipation - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[ETHINYLESTRADIOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ISOTRETINOIN] (C - Acne - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVONORGESTREL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LITHIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016154423&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016154424,Spontaneous,2023-10-26 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Anaphylactic reaction (1d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"NOVORAPID [INSULIN ASPART] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>TRESIBA [INSULIN DEGLUDEC] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [913d - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - 4{DF} - Inhalation use]),<BR><BR>[GLUCOSE, GLUCOSE MONOHYDRATE, GLUCOSE, ANHYDROUS] (C - Hypoglycaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[MEBEVERINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[PEPPERMINT OIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - Inhalation use]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 3{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016154424&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016154699,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Insomnia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (2d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016154699&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016154715,Spontaneous,2023-10-26 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Blindness (30min - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016154715&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016154934,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site swelling (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[BENDROFLUAZIDE] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016154934&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016155061,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Asthenia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016155061&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016155086,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (0d - Recovered/Resolved - ),<BR><BR>Headache (0d - Recovered/Resolved - ),<BR><BR>Injection site reaction (0d - Recovered/Resolved - ),<BR><BR>Menstrual disorder (0d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227)] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016155086&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016155102,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Confusional state (n/a - Recovered/Resolved - Disabling),<BR><BR>Malaise (n/a - Recovered/Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016155102&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016155213,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Labyrinthitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[TRIVALENT INFLUENZA VACCINE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016155213&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016155469,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016155469&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016155556,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cold sweat (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016155556&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016155589,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Cerebrovascular accident (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016155589&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016155636,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Blood urine present (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Haemorrhage urinary tract (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (3h - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016155636&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016155742,Spontaneous,2023-10-26 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Contusion (n/a - Unknown - ),<BR><BR>Loss of consciousness (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016155742&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016155748,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016155748&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016155811,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Condition aggravated (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Post-acute COVID-19 syndrome (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016155811&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016155906,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Headache (2d - Recovered/Resolved - ),<BR><BR>Illness (1d - Recovered/Resolved - ),<BR><BR>Loss of consciousness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016155906&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016156129,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Joint range of motion decreased (n/a - Unknown - Disabling),<BR><BR>Joint swelling (n/a - Unknown - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016156129&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016156130,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016156130&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016156224,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Body temperature abnormal (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016156224&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016156276,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Menopausal symptoms (n/a - Unknown - ),<BR><BR>Postmenopausal haemorrhage (n/a - Unknown - Other Medically Important Condition),<BR><BR>Uterine haemorrhage (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016156276&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016156755,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Dysmorphism (1d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016156755&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016156776,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Body height decreased (n/a - Unknown - ),<BR><BR>Muscle disorder (n/a - Unknown - ),<BR><BR>Spinal operation (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016156776&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016157437,Spontaneous,2023-10-26 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Vaccination site mass (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016157437&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016157548,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Condition aggravated (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pemphigus (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),NOT AVAILABLE (C - Pemphigus - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016157548&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016157786,Spontaneous,2023-10-26 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Rash (2wk - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rash pruritic (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - 30ug - Intramuscular use]),"[BROMAZEPAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM TRIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROCHLOROTHIAZIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016157786&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016158016,Spontaneous,2023-10-26 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Rash papular (2d - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016158016&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016158147,Spontaneous,2023-10-26 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Paraesthesia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - n/a - n/a - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016158147&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016158560,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),[BUPROPION HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016158560&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016158593,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Heavy menstrual bleeding (n/a - Unknown - Other Medically Important Condition),<BR><BR>Intermenstrual bleeding (n/a - Unknown - Other Medically Important Condition),<BR><BR>Menstrual disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Menstruation irregular (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016158593&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016158631,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016158631&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016158789,Spontaneous,2023-10-26 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Inflammation (n/a - Fatal - Results in Death),<BR><BR>Oxygen saturation decreased (n/a - Fatal - Results in Death),<BR><BR>Pyrexia (n/a - Fatal - Results in Death),<BR><BR>Respiratory arrest (n/a - Fatal - Results in Death)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"LIXIANA [EDOXABAN, EDOXABAN TOSYLATE] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016158789&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016159413,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016159413&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016159538,Spontaneous,2023-10-26 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site induration (n/a - Recovering/Resolving - ),<BR><BR>Injection site reaction (n/a - Recovering/Resolving - ),<BR><BR>Skin disorder (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[ATORVASTATIN, EZETIMIBE] (C - n/a - n/a - ),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - ),<BR><BR>[NEBIVOLOL] (C - n/a - n/a - [n/a - 2.5mg - n/a]),<BR><BR>[ZOLPIDEM, ZOLPIDEM TARTRATE] (C - n/a - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016159538&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016159626,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Abdominal discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Body temperature increased (n/a - Recovering/Resolving - ),<BR><BR>Bowel movement irregularity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016159626&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016159640,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016159640&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016159817,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Atrial fibrillation (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"EDOXABAN [EDOXABAN] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016159817&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016159921,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016159921&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016159929,Spontaneous,2023-10-26 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (7d - Recovered/Resolved - ),<BR><BR>Lymphadenitis (5d - Recovered/Resolved - ),<BR><BR>Lymphadenopathy (2d - Recovered/Resolved - ),<BR><BR>Neck pain (2d - Recovered/Resolved - ),<BR><BR>Neck pain (7d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016159929&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016159998,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Mouth swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Rash erythematous (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tension headache (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Thirst (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016159998&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016160233,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Blood pressure abnormal (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Chills (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Syncope (n/a - Unknown - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[FLUOXETINE] (C - Depression - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016160233&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016160240,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016160240&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016160247,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Body temperature increased (n/a - Recovering/Resolving - ),<BR><BR>Muscular weakness (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016160247&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016160249,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Abdominal distension (n/a - Not Recovered/Not Resolved - ),<BR><BR>Abdominal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016160249&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016160253,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Fatigue (n/a - Unknown - ),<BR><BR>Head discomfort (n/a - Unknown - ),<BR><BR>Tinnitus (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016160253&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016160254,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,International normalised ratio increased (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016160254&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016160256,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Muscular weakness (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016160256&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016160446,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Influenza like illness (1d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016160446&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016160496,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Back pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Eye swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling face (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - n/a - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016160496&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016160676,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (5h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016160676&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016160679,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Cough (n/a - Recovering/Resolving - ),<BR><BR>Epistaxis (45min - Recovered/Resolved - ),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016160679&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016160681,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Urticaria (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016160681&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016160682,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rash pruritic (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),ANTIHISTAMINICUM [NOT AVAILABLE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016160682&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016160683,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Diarrhoea (48h - Recovered/Resolved - ),<BR><BR>Headache (24h - Recovered/Resolved - ),<BR><BR>Malaise (68h - Recovered/Resolved - ),<BR><BR>Pyrexia (48h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016160683&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016160687,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Condition aggravated (n/a - Not Recovered/Not Resolved - ),<BR><BR>Post herpetic neuralgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016160687&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016160688,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016160688&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016160690,Spontaneous,2023-10-26 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Visual impairment (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016160690&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016160692,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Axillary pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Body temperature increased (24h - Recovered/Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (24h - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016160692&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016160694,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (5h - Recovered/Resolved - ),<BR><BR>Body temperature increased (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016160694&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016160736,Spontaneous,2023-10-26 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Male,Eye haemorrhage (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[AZATHIOPRINE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[FINASTERIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016160736&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016160800,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Pain in extremity (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016160800&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016161327,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Nasopharyngitis (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site reaction (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016161327&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016161562,Spontaneous,2023-10-26 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016161562&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016161996,Spontaneous,2023-10-26 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Deafness unilateral (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use])...,"[ALFACALCIDOL] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[CANDESARTAN, HYDROCHLOROTHIAZIDE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[DIGOXIN] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[EZETIMIBE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[WARFARIN SODIUM] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016161996&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016162067,Spontaneous,2023-10-26 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Pericarditis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 30ug - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - Skin irritation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016162067&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016162621,Spontaneous,2023-10-26 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal discomfort (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Bone pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Gastrointestinal disorder (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Lethargy (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Restless legs syndrome (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vision blurred (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Visual impairment (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016162621&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016144825,Spontaneous,2023-10-25 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Injection site erythema (n/a - Unknown - ),<BR><BR>Injection site oedema (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Antiviral prophylaxis - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016144825&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016144897,Spontaneous,2023-10-25 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (0d - Recovered/Resolved - ),<BR><BR>Body temperature increased (0d - Recovered/Resolved - ),<BR><BR>Dizziness (0d - Recovered/Resolved - ),<BR><BR>Headache (0d - Recovered/Resolved - ),<BR><BR>Myalgia (0d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Prophylaxis - Not applicable - [n/a - .3mL - Intramuscular use]),<BR><BR>FLUCELVAX TETRA [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (S - Prophylaxis - n/a - [n/a - .5mL - Intramuscular use])","[EZETIMIBE] (C - Hypercholesterolaemia - n/a - [n/a - n/a - Oral use]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[ROSUVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - n/a - Oral use]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - 50mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016144897&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016145083,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Arthralgia (n/a - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Lymphadenopathy (n/a - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Recovered/Resolved - ),<BR><BR>Vaccination site pain (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016145083&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016145846,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dysmenorrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oligomenorrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site reaction (6d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016145846&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016146304,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Joint range of motion decreased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016146304&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016146745,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Hypoacusis (n/a - Unknown - ),<BR><BR>Sudden hearing loss (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016146745&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016146942,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Diarrhoea (n/a - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovered/Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016146942&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016146943,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Female,"Chills (3d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (3d - Recovered/Resolved - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Malaise (6d - Recovered/Resolved - ),<BR><BR>Nausea (5d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"APIXABAN 5MG TABLET  (C - n/a - Dose not changed - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - Dose not changed - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016146943&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016146945,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arrhythmia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016146945&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016147418,Spontaneous,2023-10-25 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dyspnoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Extensive swelling of vaccinated limb (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hypersensitivity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Injection site reaction (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Oxygen saturation decreased (48h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (24h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Respiratory disorder (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Urticaria (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site induration (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site oedema (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Wheezing (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"ABASAGLAR [INSULIN GLARGINE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>HUMALOG [INSULIN LISPRO] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>RELVAR ELLIPTA [FLUTICASONE FUROATE, VILANTEROL] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>XARELTO [RIVAROXABAN] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[AMIODARONE, AMIODARONE HYDROCHLORIDE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[ANHYDROUS LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM TRIHYDRATE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[NEBIVOLOL] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[THIAMINE NITRATE, PYRIDOXINE HYDROCHLORIDE] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016147418&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016147519,Spontaneous,2023-10-25 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Skin disorder (n/a - Recovering/Resolving - ),<BR><BR>Urticaria (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016147519&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016147561,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cough (n/a - Recovering/Resolving - ),<BR><BR>Increased viscosity of upper respiratory secretion (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use]),"TADALAFIL [TADALAFIL] (C - Allergy to chemicals - n/a - [n/a - 180mg - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - n/a - n/a - [n/a - 20mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016147561&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016148093,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Injection site erythema (5d - Recovered/Resolved - ),<BR><BR>Injection site warmth (5d - Recovered/Resolved - ),<BR><BR>Lymphadenopathy (4d - Recovered/Resolved - ),<BR><BR>Myalgia (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Product used for unknown indication - Not applicable - [n/a - n/a - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016148093&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016148229,Spontaneous,2023-10-25 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Rash (n/a - Not Recovered/Not Resolved - ),<BR><BR>Skin burning sensation (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016148229&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016148245,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016148245&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016148270,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - .3mL - Intramuscular use]),"[AMLODIPINE, IRBESARTAN, IRBESARTAN, AMLODIPINE BESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUINDIONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXYCARBAMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016148270&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016148274,Spontaneous,2023-10-25 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Immunisation reaction (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016148274&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016148277,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Tinnitus (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016148277&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016148359,Spontaneous,2023-10-25 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Chills (1h - Recovered/Resolved - ),<BR><BR>Paraesthesia (1h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016148359&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016148680,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Serum sickness-like reaction (n/a - Recovered/Resolved - Life Threatening),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016148680&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016148977,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Male,Back pain (n/a - Recovering/Resolving - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[PHENPROCOUMON] (S - Atrial fibrillation - Dose not changed - [n/a - n/a - n/a])","NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - n/a - Dose increased - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016148977&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016148983,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[CHARCOAL, ACTIVATED] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016148983&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016149205,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Neuralgic amyotrophy (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling),<BR><BR>Neuritis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling)",COMIRNATY OMICRON XBB.1.5 10 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016149205&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016149749,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Myocarditis (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016149749&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016150068,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Venous thrombosis (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016150068&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016150069,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Abdominal pain (10h - Recovered/Resolved - ),<BR><BR>Diarrhoea (7h - Recovered/Resolved - ),<BR><BR>Headache (10h - Recovered/Resolved - ),<BR><BR>Malaise (10h - Recovered/Resolved - ),<BR><BR>Maternal exposure during pregnancy (n/a - Unknown - ),<BR><BR>Nausea (10h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016150069&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016150130,Spontaneous,2023-10-25 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain (n/a - Recovering/Resolving - ),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Pain (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"AZATHIOPRINE [AZATHIOPRINE] (C - Immune system disorder - n/a - [n/a - n/a - n/a]),<BR><BR>ELIQUIS [APIXABAN] (C - Atrial fibrillation - n/a - [n/a - n/a - Oral use]),<BR><BR>ETANERCEPT [ETANERCEPT] (C - Immune system disorder - n/a - [n/a - n/a - n/a]),<BR><BR>HUMIRA [ADALIMUMAB] (C - Crohn's disease - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>METHOTREXATE [METHOTREXATE] (C - Immune system disorder - n/a - [n/a - n/a - n/a]),<BR><BR>PROLIA [DENOSUMAB] (C - Osteopenia, Osteoporosis - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a]),<BR><BR>[CARVEDILOL] (C - Atrial fibrillation, Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[CICLOSPORIN] (C - Immune system disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - Osteopenia - n/a - [n/a - n/a - Oral use]),<BR><BR>[DOCUSATE SODIUM] (C - Crohn's disease - n/a - [n/a - n/a - Oral use]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - Hypersensitivity - n/a - [n/a - n/a - Oral use]),<BR><BR>[OMEPRAZOLE] (C - Reflux gastritis - n/a - [n/a - n/a - Oral use]),<BR><BR>[VITAMINS NOS] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016150130&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016150536,Spontaneous,2023-10-25 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Male,Axillary pain (1d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016150536&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016150807,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Herpes zoster (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016150807&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016151104,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Adult,No,Female,"Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016151104&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016151117,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Rash pruritic (n/a - Unknown - Other Medically Important Condition),<BR><BR>Urticaria (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - n/a - n/a - [1d - n/a - n/a - More in ICSR]),<BR><BR>[ACETYLSALICYLIC ACID, ACETYLSALICYLIC ACID PH. EUR., ASPIRIN BP] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016151117&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016151176,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Asthenia (n/a - Unknown - ),<BR><BR>Dizziness (n/a - Unknown - ),<BR><BR>Eye movement disorder (n/a - Unknown - ),<BR><BR>Hallucination (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Unknown - ),<BR><BR>Incorrect dose administered (n/a - Unknown - ),<BR><BR>Respiratory rate decreased (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016151176&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016151453,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Migraine (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016151453&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016152140,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Vaccination site pruritus (3d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016152140&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016152161,Spontaneous,2023-10-25 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - ),<BR><BR>Increased need for sleep (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"AVAMYS [FLUTICASONE FUROATE] (C - Rhinitis allergic - n/a - [n/a - 2{DF} - Nasal use]),<BR><BR>GANFORT [TIMOLOL MALEATE, BIMATOPROST] (C - Glaucoma - n/a - [n/a - 1[drp] - Ocular use]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE] (C - Hypertension - n/a - [n/a - 10mg - Oral use]),<BR><BR>[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - 80mg - Oral use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[CARBOMER, CARBOMER 980] (C - Dry eye - n/a - [n/a - 1[drp] - Ocular use]),<BR><BR>[EZETIMIBE] (C - Hypercholesterolaemia - n/a - [n/a - 10mg - Oral use]),<BR><BR>[METOPROLOL SUCCINATE, METOPROLOL TARTRATE] (C - Hypertension - n/a - [n/a - 50mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016152161&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016152465,Spontaneous,2023-10-25 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Blood pressure increased (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Dizziness (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Dysstasia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Nausea (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (n/a - Unknown - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016152465&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016152548,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gastrooesophageal reflux disease (n/a - Unknown - Other Medically Important Condition),<BR><BR>Night sweats (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Sinus headache (4d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[LANSOPRAZOLE] (C - Gastritis - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016152548&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016152759,Spontaneous,2023-10-25 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Trigeminal neuralgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016152759&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016138834,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Brain fog (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Disturbance in attention (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Ear pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ACETYLSALICYLIC ACID] (C - Cardiac disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016138834&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016139249,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Adult,No,Not Specified,"Condition aggravated (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neuropathy peripheral (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nightmare (n/a - Unknown - ),<BR><BR>Pain (n/a - Unknown - ),<BR><BR>Urine analysis abnormal (n/a - Unknown - )",RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016139249&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016139322,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Fatigue (n/a - Unknown - ),<BR><BR>Feeling cold (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016139322&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016139330,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Amnesia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Aphasia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Head discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Mental impairment (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016139330&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016139444,Spontaneous,2023-10-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Dizziness postural (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fall (n/a - Recovering/Resolving - ),<BR><BR>Head injury (n/a - Recovering/Resolving - ),<BR><BR>Syncope (n/a - Recovering/Resolving - Other Medically Important Condition)",RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016139444&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016139453,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Disease recurrence (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Ejection fraction decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Immune system disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Psoriasis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"DAPAGLIFLOZIN [DAPAGLIFLOZIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>EDOXABAN [EDOXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>ENTRESTO [SACUBITRIL VALSARTAN SODIUM HYDRATE, VALSARTAN, SACUBITRIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[EPLERENONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016139453&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016139459,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Syncope (1d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016139459&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016139466,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Influenza like illness (10d - Recovered/Resolved With Sequelae - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016139466&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016139484,Spontaneous,2023-10-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Deep vein thrombosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[WARFARIN, WARFARIN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016139484&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016139617,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,Ventricular tachycardia (n/a - Recovering/Resolving - Other Medically Important Condition),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - n/a - Not applicable - [1d - n/a - n/a])","[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Cardiac failure - n/a - [n/a - n/a - n/a]),<BR><BR>[CASSIA] (C - Constipation - n/a - [n/a - n/a - n/a]),<BR><BR>[DOXAZOSIN, DOXAZOSIN MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[EXEMESTANE] (C - Breast cancer - n/a - [n/a - n/a - n/a]),<BR><BR>[FERROUS FUMARATE] (C - Blood iron decreased - n/a - [n/a - n/a - n/a]),<BR><BR>[LACTULOSE] (C - Constipation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016139617&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016139657,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypersensitivity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site warmth (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016139657&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016139670,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016139670&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016139698,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016139698&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016139733,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Feeling hot (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016139733&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016139743,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Dyspnoea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Wheezing (2d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016139743&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016139745,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Loss of consciousness (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016139745&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016139751,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (4d - Recovered/Resolved - Disabling),<BR><BR>Myalgia (2d - Recovered/Resolved - Disabling),<BR><BR>Nausea (4d - Recovered/Resolved - Disabling),<BR><BR>Pyrexia (1d - Recovered/Resolved - Disabling),<BR><BR>Vomiting (3d - Recovered/Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016139751&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016139837,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Angioedema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling face (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016139837&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016139867,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling cold (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling hot (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [1d - n/a - n/a])",[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016139867&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140043,Spontaneous,2023-10-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Dyspnoea (n/a - Recovering/Resolving - Disabling),<BR><BR>Hyperhidrosis (1d - Recovered/Resolved - Disabling),<BR><BR>Hypertension (n/a - Recovering/Resolving - Disabling),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Tachycardia (n/a - Recovering/Resolving - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140043&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140118,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140118&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140156,Spontaneous,2023-10-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Skin disorder (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Target skin lesion (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[ATORVASTATIN, ATORVASTATIN CALCIUM] (C - n/a - n/a - ),<BR><BR>[HYDROCHLOROTHIAZIDE, NEBIVOLOL] (C - n/a - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140156&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140170,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140170&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140234,Spontaneous,2023-10-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Erythema (6d - Recovered/Resolved - ),<BR><BR>Erythema of eyelid (6d - Recovered/Resolved - ),<BR><BR>Eyelid oedema (6d - Recovered/Resolved - ),<BR><BR>Localised oedema (6d - Recovered/Resolved - ),<BR><BR>Skin disorder (6d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"SIMPONI 50 MG [GOLIMUMAB] (C - n/a - n/a - [n/a - 50mg - n/a]),<BR><BR>TRELEGY ELLIPTA [UMECLIDINIUM BROMIDE, FLUTICASONE FUROATE, VILANTEROL, UMECLIDINIUM BROMIDE, FLUTICASONE FUROATE, VILANTEROL TRIFENATATE] (C - n/a - n/a - ),<BR><BR>[AMLODIPINE BESILATE, PERINDOPRIL ARGININE] (C - n/a - n/a - ),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - ),<BR><BR>[MESALAZINE] (C - n/a - n/a - ),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - 1500mg - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - ),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140234&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140333,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Balance disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (6d - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Disturbance in attention (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (4d - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (2d - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (1d - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pruritus (4d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (C - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.1 [ELASOMERAN, IMELASOMERAN] (C - Immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140333&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140417,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Cerebrovascular accident (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Dizziness (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Memory impairment (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140417&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140555,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Diarrhoea (2h - Recovered/Resolved - ),<BR><BR>Myalgia (2h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140555&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140558,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Dizziness (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140558&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140559,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Blood insulin decreased (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"INSULIN ASPART 100 U/ML - SOLUTION FOR INJECTION  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140559&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140560,Spontaneous,2023-10-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Diplopia (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Vision blurred (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140560&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140563,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Extensive swelling of vaccinated limb (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Heart rate abnormal (1d - Recovered/Resolved - ),<BR><BR>Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140563&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140565,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Male,Rash pruritic (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - Dose not changed - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140565&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140566,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Balance disorder (1d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140566&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140570,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140570&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140572,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140572&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140573,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Dysgeusia (15min - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140573&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140575,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140575&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140579,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Ocular hyperaemia (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140579&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140580,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Maternal exposure during pregnancy (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Uterine contractions during pregnancy (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140580&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140582,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140582&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140583,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Abdominal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140583&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140585,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Facial paralysis (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140585&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140587,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140587&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140655,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling cold (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hot flush (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lip swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Respiratory rate increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sleep paralysis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Swelling face (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[LEVOCETIRIZINE] (C - Angioedema - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140655&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140722,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Ear pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140722&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140841,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Cardiac disorder (n/a - Unknown - ),<BR><BR>Cell death (n/a - Unknown - ),<BR><BR>Necrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sperm concentration decreased (n/a - Unknown - )","RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140841&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140876,Spontaneous,2023-10-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Seizure (1d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140876&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016140950,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Muscle spasms (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[SOLIFENACIN] (C - Primary progressive multiple sclerosis - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016140950&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141015,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Palpitations (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141015&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141022,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Burning sensation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Head discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141022&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141029,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rhinorrhoea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141029&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141032,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141032&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141069,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Bone pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Paralysis (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[LACIDIPINE] (C - Hypertension - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141069&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141137,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Joint range of motion decreased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Medication error (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"DAPAGLIFLOZIN [DAPAGLIFLOZIN] (C - Coronary artery disease - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Coronary artery disease - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Coronary artery disease - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Coronary artery disease - n/a - [n/a - n/a - n/a]),<BR><BR>[GLICLAZIDE] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[ISOSORBIDE MONONITRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141137&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141246,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal discomfort (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141246&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141276,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling of body temperature change (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141276&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141347,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141347&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141350,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site haematoma (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141350&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141449,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Condition aggravated (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Deafness transitory (72h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),"SITAGLIPTIN [SITAGLIPTIN] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID, D,L-LYSINE ACETYLSALICYLATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BETAXOLOL HYDROCHLORIDE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141449&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141525,Spontaneous,2023-10-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Cardiac pacemaker insertion (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Sinoatrial block (n/a - Recovered/Resolved With Sequelae - Caused/Prolonged Hospitalisation),<BR><BR>Syncope (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation, Immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141525&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141526,Spontaneous,2023-10-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Cardio-respiratory arrest (n/a - Fatal - Results in Death),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation, Immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141526&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141615,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Discomfort (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Inflammation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site warmth (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141615&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141624,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Torticollis (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141624&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141641,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Asthenia (n/a - Recovered/Resolved - ),<BR><BR>Dizziness (n/a - Recovered/Resolved - ),<BR><BR>Immunisation reaction (n/a - Recovered/Resolved - ),<BR><BR>Muscle spasms (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141641&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141670,Spontaneous,2023-10-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Hypoaesthesia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [1d - 1{DF} - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B)] (S - Influenza immunisation - n/a - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141670&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141671,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Monocytosis (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 10 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),"[FLUTICASONE PROPIONATE, SALMETEROL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141671&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141674,Spontaneous,2023-10-24 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Rash pruritic (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141674&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141676,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Neuralgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Vertigo (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [1d - 1{DF} - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327)] (S - Influenza immunisation - n/a - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141676&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141678,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Administration site reaction (1d - Recovered/Resolved - ),<BR><BR>Bursitis infective (n/a - Recovering/Resolving - ),<BR><BR>Erysipelas (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141678&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141685,Spontaneous,2023-10-24 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Fall (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 10 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141685&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141786,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Recovered/Resolved - ),<BR><BR>Chills (n/a - Recovered/Resolved - ),<BR><BR>Pain (n/a - Recovered/Resolved - ),<BR><BR>Syncope (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141786&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141897,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Anxiety (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chest discomfort (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site discomfort (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MEBEVERINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PRAVASTATIN, PRAVASTATIN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141897&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141901,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Pyrexia (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141901&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141902,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Abdominal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site haematoma (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141902&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141905,Spontaneous,2023-10-24 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Thalamic infarction (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>VYNDAQEL 61 MG SOFT CAPSULES [TAFAMIDIS] (S - Cardiac amyloidosis - Dose not changed - [n/a - n/a - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141905&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016141987,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Cough (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Middle insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Respiratory rate decreased (3d - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Sneezing (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016141987&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016142044,Spontaneous,2023-10-24 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Injection site reaction (2d - Recovered/Resolved - ),<BR><BR>Peripheral swelling (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016142044&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016142101,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Haemorrhage (2h - Recovered/Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[INFLUENZA VIRUS] (C - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[LERCANIDIPINE, LERCANIDIPINE HYDROCHLORIDE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016142101&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016142144,Spontaneous,2023-10-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Coagulopathy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Deep vein thrombosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Superficial vein thrombosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Thrombophlebitis (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[ANHYDROUS LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM] (C - n/a - n/a - ),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - ),<BR><BR>[DOSULEPIN HYDROCHLORIDE, DOSULEPIN HYDROCHLORIDE BP] (C - n/a - n/a - ),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - n/a - ),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - n/a - n/a - ),<BR><BR>[TAMOXIFEN, TAMOXIFEN CITRATE, TAMOXIFEN CITRATE PH. EUR.] (C - n/a - n/a - ),<BR><BR>[VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE] (C - n/a - n/a - ),<BR><BR>[ZOLPIDEM, ZOLPIDEM TARTRATE] (C - n/a - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016142144&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016142193,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Cough (6h - Recovered/Resolved - ),<BR><BR>Dysphagia (6h - Recovered/Resolved - ),<BR><BR>Dyspnoea (6h - Recovered/Resolved - ),<BR><BR>Injection site pain (6h - Recovered/Resolved - ),<BR><BR>Lip swelling (6h - Recovered/Resolved - ),<BR><BR>Pharyngeal swelling (6h - Recovered/Resolved - ),<BR><BR>Pulmonary pain (6h - Recovered/Resolved - ),<BR><BR>Swollen tongue (6h - Recovered/Resolved - ),<BR><BR>Wheezing (6h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016142193&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016142533,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Rash pruritic (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016142533&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016142842,Spontaneous,2023-10-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016142842&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016142944,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chest discomfort (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016142944&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016142949,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Burning sensation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Erythema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Mass (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DESOGESTREL] (C - Contraception - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016142949&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016142961,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chromaturia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Urine abnormality (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"SPIKEVAX [ELASOMERAN] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - Blood uric acid increased - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016142961&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016142976,Spontaneous,2023-10-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Seizure (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Syncope (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016142976&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016143013,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Arthritis (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pain in extremity (3d - Recovered/Resolved - Disabling),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016143013&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016143028,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Ear pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Facial paralysis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tongue discomfort (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016143028&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016143029,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Herpes zoster (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016143029&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016143170,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016143170&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016143172,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016143172&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016143195,Spontaneous,2023-10-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,"Balance disorder (n/a - Not Recovered/Not Resolved - ),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"METFORMIN HYDROCHLORIDE, DAPAGLIFLOZIN [METFORMIN HYDROCHLORIDE, DAPAGLIFLOZIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ENALAPRIL MALEATE, LERCANIDIPINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUOXETINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016143195&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016143341,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Ageusia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Anosmia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Body temperature increased (48h - Recovered/Resolved - ),<BR><BR>Chills (36h - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site pruritus (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (3d - Recovered/Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Phantom limb syndrome (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016143341&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016143345,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016143345&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016143465,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Diplegia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Monoplegia (3d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016143465&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016143604,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Limb immobilisation (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"BUMETANIDE [BUMETANIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>TRAJENTA [LINAGLIPTIN] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[CODEINE PHOSPHATE BP, PARACETAMOL PH. EUR., PARACETAMOL BP, CODEINE PHOSPHATE BP, PARACETAMOL DC, PARACETAMOL PH. EUR., CODEINE PHOSPHATE PH.EUR., PARACETAMOL PH. EUR., CODEINE PHOSPHATE PH.EUR., PARACETAMOL, CODEINE PHOSPHATE, PARACETAMOL, CODEINE PHOSPHATE BP, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DOCUSATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016143604&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016143890,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (1d - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Headache (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[ALLOPURINOL] (C - Gout - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016143890&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016144094,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Allodynia (5d - Recovered/Resolved - ),<BR><BR>Flushing (5d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016144094&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016144095,Spontaneous,2023-10-24 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Dizziness (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),"[ACETYLSALICYLIC ACID, CODEINE PHOSPHATE HEMIHYDRATE, ACETYLSALICYLIC ACID, CODEINE PHOSPHATE HEMIHYDRATE, MAGNESIUM OXIDE] (C - Headache - n/a - [n/a - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[ENALAPRIL, ENALAPRIL MALEATE] (C - Hypertension - n/a - [n/a - 10mg - n/a]),<BR><BR>[MIRTAZAPINE] (C - Depression - n/a - [n/a - 30mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016144095&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016144096,Spontaneous,2023-10-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Pruritus (n/a - Recovering/Resolving - ),<BR><BR>Rash (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE)] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016144096&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016144097,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Headache (4d - Recovered/Resolved - ),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016144097&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016144098,Spontaneous,2023-10-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Lip swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Swollen tongue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Urticaria (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016144098&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016144099,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Breast discomfort (8d - Recovered/Resolved - ),<BR><BR>Erythema (8d - Recovered/Resolved - ),<BR><BR>General physical health deterioration (14d - Recovered/Resolved - ),<BR><BR>Memory impairment (9d - Recovered/Resolved - ),<BR><BR>Nipple pain (8d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016144099&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016144126,Spontaneous,2023-10-24 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016144126&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016144229,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Ear pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Eye pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeding disorder (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[BENDROFLUMETHIAZIDE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016144229&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016144500,Spontaneous,2023-10-24 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral coldness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Skin burning sensation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016144500&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016144619,Spontaneous,2023-10-24 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Pyrexia (1d - Recovered/Resolved - ),<BR><BR>Vaccination site pain (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016144619&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016131174,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016131174&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016131355,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (2d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),INSULIN HUMAN [INSULIN HUMAN] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016131355&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016131369,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Cluster headache (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016131369&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016131555,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Movement disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016131555&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132075,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132075&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132122,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dysgeusia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Head discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132122&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132295,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132295&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132296,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Body temperature increased (n/a - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132296&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132297,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Headache (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132297&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132300,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (1d - Recovered/Resolved - ),<BR><BR>Injection site erythema (4d - Recovered/Resolved - ),<BR><BR>Injection site haematoma (4d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (4d - Recovered/Resolved - ),<BR><BR>Injection site pain (4d - Recovered/Resolved - ),<BR><BR>Injection site pruritus (4d - Recovered/Resolved - ),<BR><BR>Injection site swelling (4d - Recovered/Resolved - ),<BR><BR>Injection site warmth (4d - Recovered/Resolved - ),<BR><BR>Malaise (2d - Recovered/Resolved - ),<BR><BR>Myalgia (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132300&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132302,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Injection site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132302&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132303,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Intermenstrual bleeding (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132303&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132305,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Heavy menstrual bleeding (n/a - Not Recovered/Not Resolved - ),<BR><BR>Polymenorrhoea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132305&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132306,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (6h - Recovered/Resolved - ),<BR><BR>Injection site pain (2d - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132306&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132309,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132309&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132496,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Disorientation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[AMLODIPINE, AMLODIPINE BESILATE] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM TRIHYDRATE] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a]),<BR><BR>[GLICLAZIDE] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132496&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132695,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132695&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132716,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Gingival bleeding (n/a - Unknown - ),<BR><BR>Peptic ulcer haemorrhage (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaginal haemorrhage (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132716&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132717,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Decreased appetite (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Migraine (6d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (6d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132717&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132731,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Aphthous ulcer (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Dose not changed - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132731&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132734,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Hypertension (2d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132734&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132738,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Cerebral infarction (n/a - Not Recovered/Not Resolved - Life Threatening),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),[VENLAFAXINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132738&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132742,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovered/Resolved - ),<BR><BR>Myalgia (5d - Recovered/Resolved - ),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132742&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132743,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Asthma (n/a - Not Recovered/Not Resolved - ),<BR><BR>Body temperature increased (10h - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132743&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132744,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (4h - Recovered/Resolved - ),<BR><BR>Fatigue (1d - Recovered/Resolved - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Limb discomfort (10h - Recovered/Resolved - ),<BR><BR>Malaise (1d - Recovered/Resolved - ),<BR><BR>Nausea (8h - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132744&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132746,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132746&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132747,Spontaneous,2023-10-23 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Death (n/a - Fatal - Results in Death),<BR><BR>Dyspnoea (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Nausea (n/a - Unknown - ),<BR><BR>Tremor (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132747&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132753,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arrhythmia (n/a - Recovering/Resolving - ),<BR><BR>Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Body temperature increased (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site haematoma (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"DARUNAVIR 300MG TABLET  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>TRUVADA 200 MG/245 MG FILM-COATED TABLETS [EMTRICITABINE, TENOFOVIR DISOPROXIL, EMTRICITABINE, TENOFOVIR DISOPROXIL FUMARATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132753&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132854,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Amnesia (2d - Recovered/Resolved - Disabling),<BR><BR>Delirium (n/a - Unknown - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ALENDRONATE SODIUM, ALENDRONIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DONEPEZIL] (C - Dementia Alzheimer's type - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - Myalgia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132854&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132855,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Cough (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132855&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016132907,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chest pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Death (n/a - Fatal - Results in Death),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016132907&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016133299,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Dose not changed - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016133299&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016133301,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016133301&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016133304,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016133304&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016133305,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Herpes zoster (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016133305&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016133307,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Tinnitus (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016133307&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016133308,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016133308&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016133310,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Oral herpes (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016133310&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016133313,Spontaneous,2023-10-23 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Anaphylactic reaction (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Blood pressure decreased (n/a - Recovering/Resolving - ),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - ),<BR><BR>Malaise (2d - Recovered/Resolved - ),<BR><BR>Oxygen saturation decreased (n/a - Recovering/Resolving - ),<BR><BR>Stridor (n/a - Recovering/Resolving - ),<BR><BR>Tachycardia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),[SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016133313&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016133314,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Fatigue (1d - Recovered/Resolved - ),<BR><BR>Musculoskeletal stiffness (1d - Recovered/Resolved - ),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016133314&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016133318,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Musculoskeletal stiffness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016133318&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016133321,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Herpes zoster (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016133321&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016133322,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Chills (1h - Recovered/Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (2h - Recovered/Resolved - ),<BR><BR>Headache (30s - Recovered/Resolved - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (3h - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016133322&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016133323,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Abdominal pain (1d - Recovered/Resolved - ),<BR><BR>Arthralgia (n/a - Recovered/Resolved - ),<BR><BR>Chills (n/a - Recovered/Resolved - ),<BR><BR>Diarrhoea (1d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovered/Resolved - ),<BR><BR>Malaise (3h - Recovered/Resolved - ),<BR><BR>Myalgia (2d - Recovered/Resolved - ),<BR><BR>Nausea (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - ),<BR><BR>Syncope (2min - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016133323&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016133331,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (2h - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"ADALIMUMAB - SOLUTION FOR INJECTION  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>OLANZAPINE 2.5 MG - TABLET  (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LAMOTRIGINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LISINOPRIL] (C - n/a - n/a - [n/a - 40mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016133331&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016133724,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Headache (10h - Recovered/Resolved - ),<BR><BR>Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site inflammation (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Injection site swelling (n/a - Recovering/Resolving - ),<BR><BR>Injection site warmth (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (1h - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (S - Pneumococcal immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016133724&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016133781,Spontaneous,2023-10-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Male,"Dyspnoea (1d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Respiratory arrest (1d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021 HAEMAGGLUTININ ANTIGEN, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Antiviral prophylaxis - Not applicable - [1d - n/a - Intramuscular use])","APIXABAN 2.5 MG  (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>PREGABALIN 50 MG [PREGABALIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>UMECLIDINIUM BROMIDE, VILANTEROL [UMECLIDINIUM BROMIDE, VILANTEROL] (C - Product used for unknown indication - n/a - [n/a - n/a - Inhalation use]),<BR><BR>[BISOPROLOL FUMARATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[LACTULOSE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[QUETIAPINA] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[ROSUVASTATIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016133781&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016133942,Spontaneous,2023-10-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Deafness unilateral (n/a - Not Recovered/Not Resolved - Disabling),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 30mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016133942&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016133944,Spontaneous,2023-10-23 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Acute kidney injury (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - 1{total} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016133944&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016133948,Spontaneous,2023-10-23 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Hypertension (6h - Recovered/Resolved - ),<BR><BR>Tachycardia (6h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 prophylaxis - n/a - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016133948&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016133953,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dysmenorrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Intermenstrual bleeding (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016133953&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016134006,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Hypertensive crisis (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016134006&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016134063,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016134063&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016134148,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Injection site pain (3d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016134148&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016134212,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (5d - Recovered/Resolved - ),<BR><BR>Heavy menstrual bleeding (n/a - Recovering/Resolving - ),<BR><BR>Hypotonia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016134212&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016134238,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Cerebral infarction (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Hemiataxia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Hemiparesis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY OMICRON XBB.1.5 10 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>FLUCELVAX TETRA [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016134238&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016134443,Spontaneous,2023-10-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,Hypertension (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"[AMLODIPINE, PERINDOPRIL] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[AZATHIOPRINE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[CALCITRIOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[NEBIVOLOL] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[SIMVASTATIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016134443&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016134449,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (12h - Recovered/Resolved - ),<BR><BR>Headache (12h - Recovered/Resolved - ),<BR><BR>Hyperhidrosis (5min - Recovered/Resolved - ),<BR><BR>Malaise (1d - Recovered/Resolved - ),<BR><BR>Myalgia (12h - Recovered/Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Visual impairment (1min - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016134449&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016134452,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Lichen planus (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016134452&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016134453,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Body temperature increased (2d - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site haematoma (n/a - Recovering/Resolving - ),<BR><BR>Lymphadenopathy (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016134453&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016134457,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Headache (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016134457&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016134462,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Pyrexia (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016134462&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016134469,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016134469&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016134470,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Headache (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016134470&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016134656,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Seizure (1d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[NAPROXEN, NAPROXEN SODIUM] (C - Pain in extremity - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016134656&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016134989,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Deafness unilateral (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016134989&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016135001,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Diarrhoea (2h - Recovered/Resolved - ),<BR><BR>Vomiting (2h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016135001&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016135004,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016135004&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016135012,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Urticaria (10h - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016135012&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016135013,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (2d - Recovered/Resolved - ),<BR><BR>Chills (3d - Recovered/Resolved - ),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site pruritus (3d - Recovered/Resolved - ),<BR><BR>Malaise (3d - Recovered/Resolved - ),<BR><BR>Myalgia (2d - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016135013&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016135014,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016135014&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016135017,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Influenza (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016135017&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016135023,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Vaccination site lymphadenopathy (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016135023&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016135027,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Amenorrhoea (n/a - Unknown - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016135027&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016135153,Spontaneous,2023-10-23 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Anaphylactic reaction (n/a - Recovered/Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Unknown - ),<BR><BR>Swollen tongue (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016135153&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016135212,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Peripheral vascular disorder (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Immunisation - n/a - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016135212&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016135567,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Chills (8h - Recovered/Resolved - ),<BR><BR>Ischaemic cerebral infarction (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016135567&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016135569,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site inflammation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Injection site warmth (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>PANTOPRAZOLE 20 MG - GASTRO-RESISTANT TABLET  (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016135569&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016135570,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Elderly,No,Male,"Injection site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Petit mal epilepsy (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[NOT AVAILABLE] (S - Blood cholesterol - Dose not changed - [n/a - n/a - n/a])",LEVETIRACETAM 500 MG - FILM-COATED TABLET  (C - n/a - Dose not changed - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016135570&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016135571,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Eye irritation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rash macular (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016135571&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016135576,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Injection site pain (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (8h - Recovered/Resolved - ),<BR><BR>Vaccination site lymphadenopathy (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LISDEXAMFETAMINE DIMESYLATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016135576&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016135577,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Chest discomfort (4h - Recovered/Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016135577&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016135582,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Product substitution issue (n/a - Unknown - ),<BR><BR>Rash pruritic (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[NITROFURANTOIN ANHYDROUS] (S - Cystitis - Drug withdrawn - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016135582&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016135636,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Headache (3h - Recovered/Resolved - ),<BR><BR>Malaise (36h - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (18h - Recovered/Resolved - ),<BR><BR>Rash (1h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016135636&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016135815,Spontaneous,2023-10-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,Diarrhoea (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),"XARELTO [RIVAROXABAN] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[BISOPROLOL FUMARATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[DRY EXTRACT OF RUSCUS ACULEATUS ROOT (2,5 - 6,5 : 1), EXTRACTION AGENT: WATER, MELILOT FLUID EXTRACT, MELILOTUS OFFICINALIS, RUSCUS ACULEATUS] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[PANTOPRAZOLE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016135815&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016135829,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dyspnoea exertional (n/a - Recovering/Resolving - ),<BR><BR>Influenza like illness (n/a - Recovering/Resolving - ),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 3{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016135829&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016136063,Spontaneous,2023-10-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dry mouth (n/a - Recovering/Resolving - ),<BR><BR>General physical health deterioration (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016136063&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016136103,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Diarrhoea (n/a - Unknown - ),<BR><BR>Nasopharyngitis (n/a - Unknown - ),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016136103&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016136171,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016136171&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016136172,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Thyroid disorder (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - n/a - n/a]),[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016136172&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016136656,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Diarrhoea (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016136656&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016136833,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Unknown - ),<BR><BR>Chest pain (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Swelling (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016136833&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016136884,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,12-17 Years,Not Specified,No,Female,"Headache (n/a - Recovered/Resolved - ),<BR><BR>Pain in extremity (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016136884&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016136957,Spontaneous,2023-10-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Injection site haemorrhage (0d - Recovered/Resolved - ),<BR><BR>Injection site mass (0d - Recovered/Resolved - ),<BR><BR>Injection site swelling (0d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - .5mL - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016136957&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016137444,Spontaneous,2023-10-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Cough (3d - Recovered/Resolved With Sequelae - ),<BR><BR>Headache (3d - Recovered/Resolved With Sequelae - ),<BR><BR>Myalgia (3d - Recovered/Resolved With Sequelae - ),<BR><BR>Nausea (3d - Recovered/Resolved With Sequelae - ),<BR><BR>Oropharyngeal pain (3d - Recovered/Resolved With Sequelae - ),<BR><BR>Taste disorder (3d - Recovered/Resolved With Sequelae - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016137444&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016137449,Spontaneous,2023-10-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Swelling (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[CLOBETASOL PROPIONATE] (C - Skin disorder - n/a - [n/a - n/a - Cutaneous use]),<BR><BR>[DEXAMETHASONE, TOBRAMYCIN] (C - Inflammation - n/a - [n/a - n/a - Ocular use]),<BR><BR>[ENALAPRIL MALEATE] (C - Hypertension - n/a - [n/a - n/a - Oral use]),<BR><BR>[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone therapy - n/a - [n/a - n/a - Vaginal use]),<BR><BR>[FUROSEMIDE, FUROSEMIDE SODIUM] (C - Diuretic therapy - n/a - [n/a - n/a - Oral use]),<BR><BR>[HYDROCORTISONE SODIUM PHOSPHATE] (C - Eye inflammation - n/a - [n/a - n/a - Ocular use]),<BR><BR>[IBUPROFEN] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[KETOTIFEN, KETOTIFEN HYDROGEN FUMARATE] (C - Rhinitis allergic - n/a - [n/a - n/a - Ocular use]),<BR><BR>[MOMETASONE FUROATE] (C - Eczema - n/a - [n/a - n/a - Cutaneous use]),<BR><BR>[OMEPRAZOLE] (C - Prophylaxis against gastrointestinal ulcer - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[POTASSIUM CHLORIDE] (C - Mineral supplementation - n/a - [n/a - n/a - Oral use]),<BR><BR>[POTASSIUM, SODIUM, MACROGOL 3350, CHLORIDE ION, HYDROGEN CARBONATE, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - Constipation - n/a - [n/a - n/a - Oral use]),<BR><BR>[VITAMINS NOS] (C - Vitamin supplementation - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016137449&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016137452,Spontaneous,2023-10-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Disorientation (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016137452&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016137454,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Contusion (n/a - Recovering/Resolving - ),<BR><BR>Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Gastric pH decreased (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site swelling (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016137454&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016137458,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Dizziness (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016137458&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016137462,Spontaneous,2023-10-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Mobility decreased (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","INSULIN ASPART SANOFI [INSULIN ASPART] (C - Diabetes mellitus - n/a - [n/a - 2{DF} - Subcutaneous use]),<BR><BR>TOUJEO SOLOSTAR [INSULIN GLARGINE] (C - Diabetes mellitus - n/a - [n/a - n/a - Subcutaneous use]),<BR><BR>[ALFACALCIDOL] (C - Calcium metabolism disorder - n/a - [n/a - .5ug - Oral use]),<BR><BR>[ALLOPURINOL] (C - Gouty arthritis - n/a - [n/a - n/a - Oral use]),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM] (C - Hypercholesterolaemia - n/a - [n/a - 80mg - Oral use]),<BR><BR>[BISOPROLOL FUMARATE] (C - Cardiac disorder - n/a - [n/a - 5mg - Oral use]),<BR><BR>[CALCIUM ACETATE, MAGNESIUM CARBONATE, CALCIUM CARBONATE, MAGNESIUM CARBONATE, MAGNESIUM CARBONATE HEAVY, CALCIUM ACETATE, MAGNESIUM CARBONATE HEAVY, CALCIUM ACETATE ANHYDROUS] (C - Hyperphosphataemia - n/a - [n/a - n/a - Oral use]),<BR><BR>[COLCHICINE] (C - Gout - n/a - [n/a - n/a - Oral use]),<BR><BR>[COLECALCIFEROL] (C - Vitamin D deficiency - n/a - [n/a - 35ug - Oral use]),<BR><BR>[DIGOXIN] (C - Cardiac disorder - n/a - [n/a - 125ug - Oral use]),<BR><BR>[FERRIC DERISOMALTOSE, FERRIC HYDROXIDE POLYMALTOSE COMPLEX, IRON, IRON(III) ISOMALTOSIDE 1000] (C - Iron deficiency - n/a - [n/a - 1g - Intravenous use]),<BR><BR>[FUROSEMIDE, FUROSEMIDE SODIUM] (C - Diuretic therapy - n/a - [n/a - 125mg - Oral use]),<BR><BR>[GLYCEROL, LACTULOSE] (C - Constipation - n/a - [n/a - 15mL - Oral use]),<BR><BR>[ISOSORBIDE MONONITRATE] (C - Angina pectoris - n/a - [n/a - 30mg - Oral use]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM] (C - Gastric pH decreased - n/a - [n/a - 40mg - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - 1000mg - Oral use]),<BR><BR>[POTASSIUM CHLORIDE] (C - Mineral supplementation - n/a - [n/a - 1500mg - Oral use]),<BR><BR>[RAMIPRIL] (C - Cardiac failure - n/a - [n/a - 1.25mg - Oral use]),<BR><BR>[SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - Constipation - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[SODIUM HYDROGEN CARBONATE] (C - Acidosis - n/a - [n/a - 500mg - Oral use]),<BR><BR>[TAMSULOSIN HYDROCHLORIDE] (C - Dysuria - n/a - [n/a - .4mg - Oral use]),<BR><BR>[WARFARIN, WARFARIN SODIUM, WARFARIN SODIUM BP] (C - Thrombosis prophylaxis - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016137462&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016137466,Spontaneous,2023-10-23 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Abdominal pain (n/a - Unknown - ),<BR><BR>Discomfort (n/a - Unknown - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016137466&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016137467,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Musculoskeletal stiffness (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016137467&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016138200,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Decreased appetite (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling cold (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Neck pain (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016138200&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016138217,Spontaneous,2023-10-23 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - Unknown - [n/a - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016138217&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016120656,Spontaneous,2023-10-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Immunisation reaction (1d - Recovering/Resolving - ),<BR><BR>Myalgia (1d - Recovering/Resolving - ),<BR><BR>Pyrexia (1d - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - Not applicable - [n/a - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224)] (S - n/a - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016120656&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016120724,Spontaneous,2023-10-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Anxiety (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Bipolar disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Depression (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Ideas of reference (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"RISPERIDONE [RISPERIDONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LAMOTRIGINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METOPROLOL, METOPROLOL TARTRATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016120724&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016120817,Spontaneous,2023-10-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (1d - Recovered/Resolved - Disabling),<BR><BR>Asthenia (1d - Recovered/Resolved - Disabling),<BR><BR>Chills (1d - Recovered/Resolved - Disabling),<BR><BR>Decreased appetite (1d - Recovered/Resolved - Disabling),<BR><BR>Dizziness (1d - Recovered/Resolved - Disabling),<BR><BR>Fatigue (1d - Recovered/Resolved - Disabling),<BR><BR>Headache (1d - Recovered/Resolved - Disabling),<BR><BR>Malaise (1d - Recovered/Resolved - Disabling),<BR><BR>Myalgia (1d - Recovered/Resolved - Disabling),<BR><BR>Pain in extremity (1d - Recovered/Resolved - Disabling),<BR><BR>Palpitations (1d - Recovered/Resolved - Disabling),<BR><BR>Vomiting (1d - Recovered/Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016120817&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016120864,Spontaneous,2023-10-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Haemorrhagic stroke (3d - Recovered/Resolved With Sequelae - Life Threatening, Caused/Prolonged Hospitalisation, Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016120864&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016120869,Spontaneous,2023-10-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Gait disturbance (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016120869&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016121031,Spontaneous,2023-10-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Limb discomfort (n/a - Unknown - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (C - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Polycystic ovaries - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016121031&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016121063,Spontaneous,2023-10-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"DULOXETINE [DULOXETINE, DULOXETINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>FESOTERODINE [FESOTERODINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TIZANIDINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016121063&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016121571,Spontaneous,2023-10-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Influenza like illness (3d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016121571&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016121645,Spontaneous,2023-10-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (11d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016121645&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016122045,Spontaneous,2023-10-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Haematoma (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oedema peripheral (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"[ALLOPURINOL] (C - n/a - n/a - [n/a - 100mg - n/a]),<BR><BR>[CHLORTALIDONE, CHLORTALIDONE PH. EUR., CHLORTALIDONE, RESERPINE] (C - n/a - n/a - [n/a - 50mg - n/a]),<BR><BR>[ENALAPRIL, LERCANIDIPINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN HYDROCHLORIDE, SITAGLIPTIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, TRAMADOL] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - 20mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016122045&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016122076,Spontaneous,2023-10-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Syncope (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016122076&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016122337,Spontaneous,2023-10-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Herpes zoster (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016122337&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016122713,Spontaneous,2023-10-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Chills (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Extensive swelling of vaccinated limb (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Injection site reaction (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016122713&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016123251,Spontaneous,2023-10-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,"Abdominal pain (5h - Recovered/Resolved - ),<BR><BR>Arthralgia (5h - Recovered/Resolved - ),<BR><BR>Myalgia (5h - Recovered/Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Antiviral prophylaxis - n/a - [1d - n/a - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016123251&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016124064,Spontaneous,2023-10-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Abdominal pain upper (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (C - n/a - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016124064&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016124188,Spontaneous,2023-10-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,Yes,Female,Dizziness (1h - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"EBYMECT [METFORMIN HYDROCHLORIDE, DAPAGLIFLOZIN] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[ALPRAZOLAM] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[EZETIMIBE, ROSUVASTATIN CALCIUM] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use]),<BR><BR>[TRAZODONE, TRAZODONE HYDROCHLORIDE] (C - Product used for unknown indication - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016124188&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016124260,Spontaneous,2023-10-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Headache (1d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016124260&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016124518,Spontaneous,2023-10-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Balance disorder (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dyspepsia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016124518&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016124876,Spontaneous,2023-10-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Feeling abnormal (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Migraine (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016124876&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016124988,Spontaneous,2023-10-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Delirium (1d - Recovered/Resolved - ),<BR><BR>Enuresis (1d - Recovered/Resolved - ),<BR><BR>Injection site erythema (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016124988&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016125040,Spontaneous,2023-10-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Dizziness (1h - Recovered/Resolved - ),<BR><BR>Hypoaesthesia (1h - Recovered/Resolved - ),<BR><BR>Vision blurred (1h - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 prophylaxis - n/a - [1d - 1{DF} - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Antiviral prophylaxis - n/a - [1d - 1{DF} - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016125040&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016125071,Spontaneous,2023-10-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Injection site rash (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016125071&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016125347,Spontaneous,2023-10-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Tremor (1d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016125347&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016125433,Spontaneous,2023-10-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Disabling),<BR><BR>Dyspnoea (n/a - Unknown - Disabling),<BR><BR>Fatigue (n/a - Unknown - Disabling),<BR><BR>Osteoporotic fracture (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Disabling),<BR><BR>Pyrexia (n/a - Unknown - Disabling),<BR><BR>Tachycardia (n/a - Unknown - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN CALCIUM] (C - Cardiac disorder - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016125433&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016125622,Spontaneous,2023-10-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (11d - Recovered/Resolved - Disabling),<BR><BR>Headache (11d - Recovered/Resolved - Disabling),<BR><BR>Lymphadenitis (11d - Recovered/Resolved - Disabling),<BR><BR>Myalgia (11d - Recovered/Resolved - Disabling),<BR><BR>Pyrexia (11d - Recovered/Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"CYMBALTA [DULOXETINE, DULOXETINE HYDROCHLORIDE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[ANHYDROUS LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016125622&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016126001,Spontaneous,2023-10-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016126001&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016126101,Spontaneous,2023-10-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Neck pain (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Periarthritis (n/a - Not Recovered/Not Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016126101&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016127728,Spontaneous,2023-10-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Rash (n/a - Not Recovered/Not Resolved - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","[ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Hormone therapy - n/a - [n/a - 10ug - Vaginal use]),<BR><BR>[IBUPROFEN] (C - Pain - n/a - [n/a - 400mg - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - 1000mg - Oral use]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Hypercholesterolaemia - n/a - [n/a - 5mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016127728&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016127739,Spontaneous,2023-10-20 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - 1{DF} - n/a]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016127739&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016127741,Spontaneous,2023-10-20 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,Generalised tonic-clonic seizure (0d - Recovered/Resolved - Caused/Prolonged Hospitalisation),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Unknown - [n/a - 1{DF} - Intramuscular use])","CLOPIDOGREL ZENTIVA [CLOPIDOGREL, CLOPIDOGREL HYDROGEN SULFATE] (C - Thrombosis prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE BESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[BENDROFLUMETHIAZIDE, POTASSIUM CHLORIDE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[FINASTERIDE] (C - Dysuria - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVETIRACETAM] (C - Epilepsy - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016127741&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016127752,Spontaneous,2023-10-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Deep vein thrombosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016127752&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016127906,Spontaneous,2023-10-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Decreased appetite (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Depressed mood (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016127906&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016128132,Spontaneous,2023-10-20 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Lymphadenopathy (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 10 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016128132&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016128155,Spontaneous,2023-10-20 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Incision site pain (2d - Recovered/Resolved - ),<BR><BR>Malaise (2d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),<BR><BR>FLUAD TETRA SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Influenza - Drug withdrawn - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016128155&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016128683,Spontaneous,2023-10-20 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Erythema multiforme (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016128683&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016113053,Spontaneous,2023-10-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Gait inability (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Loss of consciousness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016113053&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016113443,Spontaneous,2023-10-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Skin discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Heart rate - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016113443&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016114255,Spontaneous,2023-10-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Ataxia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Gait disturbance (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Listless (n/a - Not Recovered/Not Resolved - ),<BR><BR>Movement disorder (n/a - Not Recovered/Not Resolved - ),<BR><BR>Muscle tightness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016114255&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016114429,Spontaneous,2023-10-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Facial nerve disorder (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Gingival pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hot flush (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Toothache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Trigeminal neuralgia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[BENDROFLUMETHIAZIDE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[DOXAZOSIN, DOXAZOSIN MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[FELODIPINE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),<BR><BR>[PERINDOPRIL, PERINDOPRIL TERT-BUTYLAMINE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016114429&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016114783,Spontaneous,2023-10-19 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,Yes,Female,Hypotension (15min - Recovered/Resolved - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Antiviral prophylaxis - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016114783&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016115042,Spontaneous,2023-10-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Thirst (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016115042&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016116468,Spontaneous,2023-10-19 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,"Chills (0d - Recovered/Resolved - ),<BR><BR>Pyrexia (0d - Recovered/Resolved - ),<BR><BR>Vomiting (12h - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[BETAHISTINE DIHYDROCHLORIDE, BETAHISTINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[DIAZEPAM] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[ESCITALOPRAM, ESCITALOPRAM OXALATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[FLUOXETINE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[SIMVASTATIN] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016116468&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016116874,Spontaneous,2023-10-19 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Chills (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016116874&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016117084,Spontaneous,2023-10-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016117084&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016117095,Spontaneous,2023-10-19 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Coagulopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Epistaxis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fibrin D dimer increased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Haematochezia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Haemorrhage subcutaneous (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[ACETYLSALICYLIC ACID] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN CILEXETIL] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[DYDROGESTERONE, ESTRADIOL, DYDROGESTERONE, ESTRADIOL HEMIHYDRATE] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016117095&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016117820,Spontaneous,2023-10-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Gout (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016117820&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016118332,Spontaneous,2023-10-19 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Syncope (1d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016118332&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016118476,Spontaneous,2023-10-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Electric shock sensation (n/a - Unknown - ),<BR><BR>Influenza like illness (n/a - Recovering/Resolving - ),<BR><BR>Joint lock (n/a - Recovering/Resolving - Disabling),<BR><BR>Migraine (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016118476&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016118503,Spontaneous,2023-10-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016118503&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016118618,Spontaneous,2023-10-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016118618&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016119076,Spontaneous,2023-10-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016119076&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016119157,Spontaneous,2023-10-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Postmenopausal haemorrhage (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016119157&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016119240,Spontaneous,2023-10-19 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Lymphadenitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),"[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[METOPROLOL TARTRATE] (C - Ventricular arrhythmia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016119240&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016119684,Spontaneous,2023-10-19 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUCELVAX TETRA SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE [B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/DELAWARE/55/2019 CVR-45), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/WASHINGTON/02/2019-LIKE VIRUS (B/DARWIN/7/2019, WILD TYPE), A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE STRAIN (A/WASHINGTON/19/2020, WILD TYPE), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/TASMANIA/503/2020, WILD TYPE)] (S - Immunisation - Not applicable - [1d - 1{DF} - n/a])...","[DIENOGEST, ETHINYLESTRADIOL] (C - n/a - Unknown - ),<BR><BR>[SIMETICONE, CLEBOPRIDE] (C - n/a - Unknown - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016119684&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016119764,Spontaneous,2023-10-19 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Back pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Flushing (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016119764&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016119856,Spontaneous,2023-10-19 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Face oedema (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pruritus (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Sneezing (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016119856&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016104484,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Influenza like illness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rash erythematous (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016104484&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016104529,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lymphadenopathy (13d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (2wk - Recovered/Resolved - ),<BR><BR>Neck pain (2wk - Recovered/Resolved - ),<BR><BR>Vaccination site pain (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016104529&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016104978,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Pulmonary pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016104978&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016105022,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Fatigue (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016105022&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016105032,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Injection site erythema (3d - Recovered/Resolved - Disabling),<BR><BR>Injection site rash (n/a - Recovering/Resolving - Disabling),<BR><BR>Injection site swelling (3d - Recovered/Resolved - Disabling),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pyrexia (2d - Recovered/Resolved - Disabling),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Antiviral prophylaxis - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016105032&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016105123,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Balance disorder (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Ear disorder (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016105123&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016105124,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Disorientation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016105124&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016105125,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Eye pain (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"AMGEVITA [ADALIMUMAB] (C - Psoriatic arthropathy - n/a - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Antiviral prophylaxis - n/a - [1d - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood cholesterol - n/a - [n/a - n/a - n/a]),<BR><BR>[FELODIPINE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016105125&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016105162,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chills (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016105162&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016105340,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,Ear pain (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016105340&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016105372,Spontaneous,2023-10-18 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Neuropathy peripheral (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016105372&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016105375,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016105375&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016105391,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Influenza (n/a - Unknown - ),<BR><BR>Nasopharyngitis (n/a - Unknown - ),<BR><BR>Somnolence (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016105391&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016105487,Spontaneous,2023-10-18 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (9d - Recovered/Resolved With Sequelae - Disabling),<BR><BR>Headache (n/a - Recovering/Resolving - Disabling),<BR><BR>Myalgia (9d - Recovered/Resolved With Sequelae - Disabling),<BR><BR>Oropharyngeal pain (n/a - Recovering/Resolving - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016105487&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016105503,Spontaneous,2023-10-18 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Inappropriate schedule of product administration (n/a - Unknown - ),<BR><BR>Musculoskeletal stiffness (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016105503&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016105628,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lymph node pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash erythematous (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"PANTOPRAZOLE [PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Reflux gastritis - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - Specialist consultation - n/a - [n/a - n/a - n/a]),<BR><BR>[CYANOCOBALAMIN, VITAMIN B12] (C - Specialist consultation - n/a - [n/a - n/a - n/a]),<BR><BR>[FERROUS SULFATE] (C - Specialist consultation - n/a - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[NORETHISTERONE] (C - Specialist consultation - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[SENNA ALATA SEED] (C - Specialist consultation - n/a - [n/a - n/a - n/a]),<BR><BR>[VITAMINS NOS] (C - Specialist consultation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016105628&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016105808,Spontaneous,2023-10-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Vertigo (12d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[ACETYLSALICYLIC ACID] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[ANHYDROUS LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM TRIHYDRATE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[OTILONIUM BROMIDE] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016105808&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016105881,Spontaneous,2023-10-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Hypertension (2d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016105881&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016105962,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Headache (2d - Recovered/Resolved - ),<BR><BR>Malaise (2d - Recovered/Resolved - ),<BR><BR>Vaccination site swelling (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016105962&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016105964,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Lymphadenopathy (2d - Recovered/Resolved - ),<BR><BR>Pain in extremity (3d - Recovered/Resolved - ),<BR><BR>Vaccination site pain (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016105964&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016105966,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Chills (1d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Palpitations (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016105966&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016106272,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Balance disorder (n/a - Unknown - Disabling),<BR><BR>Dizziness (n/a - Recovering/Resolving - Disabling),<BR><BR>Illness (n/a - Unknown - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016106272&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016106433,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (2d - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Insomnia (2d - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (2d - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (2d - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pruritus (2d - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site paraesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination site pruritus (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - 75ug - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016106433&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016106440,Spontaneous,2023-10-18 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Musculoskeletal stiffness (n/a - Recovered/Resolved - ),<BR><BR>Poor quality product administered (n/a - Unknown - ),<BR><BR>Product administration error (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016106440&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016106481,Spontaneous,2023-10-18 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Ageusia (n/a - Unknown - ),<BR><BR>Decreased appetite (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Gastrointestinal disorder (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Nausea (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Unknown - ),<BR><BR>Vertigo (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016106481&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016107067,Spontaneous,2023-10-18 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Syncope (1d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Adverse drug reaction - Not applicable - [n/a - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016107067&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016107112,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Gastritis erosive (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[LACIDIPINE] (C - Hypertension - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016107112&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016107193,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sneezing (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - n/a - n/a]),"[ATORVASTATIN] (C - Blood cholesterol - n/a - [n/a - n/a - n/a]),<BR><BR>[MEBEVERINE] (C - Irritable bowel syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016107193&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016107301,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Feeling cold (n/a - Unknown - ),<BR><BR>Vertigo (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016107301&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016107625,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Erythema (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rash (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE, BUDESONIDE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016107625&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016107851,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"RIVAROXABAN [RIVAROXABAN] (C - Cardiac failure - n/a - [n/a - n/a - n/a]),<BR><BR>VALSARTAN, SACUBITRIL [VALSARTAN, SACUBITRIL] (C - Cardiac failure - n/a - [n/a - n/a - n/a]),<BR><BR>[AMIODARONE, AMIODARONE HYDROCHLORIDE] (C - Atrial flutter - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Bundle branch block left - n/a - [n/a - n/a - n/a]),<BR><BR>[EPLERENONE] (C - Cardiac failure - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - Cardiac failure - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016107851&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016107852,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Asthenia (2d - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pelvic floor muscle weakness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016107852&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016108010,Spontaneous,2023-10-18 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Fall (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016108010&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016108074,Spontaneous,2023-10-18 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,"Fall (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"LIXIANA [EDOXABAN, EDOXABAN TOSYLATE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[INDAPAMIDE, INDAPAMIDE HEMIHYDRATE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[TRAZODONE, TRAZODONE HYDROCHLORIDE] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016108074&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016108128,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Abdominal pain upper (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"RELVAR ELLIPTA [FLUTICASONE FUROATE, VILANTEROL] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL, NORETHISTERONE, NORETHISTERONE ACETATE, ESTRADIOL, NORETHISTERONE ACETATE, ESTRADIOL HEMIHYDRATE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[ESTRADIOL] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016108128&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016108197,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Eye discharge (n/a - Recovering/Resolving - ),<BR><BR>Eye inflammation (n/a - Recovering/Resolving - ),<BR><BR>Eye pain (n/a - Recovering/Resolving - ),<BR><BR>Eye swelling (n/a - Recovering/Resolving - ),<BR><BR>Ocular hyperaemia (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Scleral hyperaemia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016108197&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016108315,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Headache (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016108315&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016108333,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Balance disorder (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Poor quality sleep (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - n/a - [1d - n/a - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - COVID-19 immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[SALMETEROL, SALMETEROL XINAFOATE] (C - Chronic obstructive pulmonary disease - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - Constipation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016108333&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016108351,Spontaneous,2023-10-18 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Transient global amnesia (1d - Recovered/Resolved - Disabling),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a]),"[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Back pain - n/a - [n/a - n/a - n/a]),<BR><BR>[NAPROXEN, NAPROXEN SODIUM] (C - Back pain - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016108351&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016108352,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,General physical health deterioration (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016108352&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016108563,Spontaneous,2023-10-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Tachycardia (1h - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016108563&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016108586,Spontaneous,2023-10-18 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Urticaria (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016108586&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016108933,Spontaneous,2023-10-18 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Syncope (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016108933&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016109090,Spontaneous,2023-10-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,"Hypersensitivity (n/a - Recovering/Resolving - ),<BR><BR>Pruritus (n/a - Recovering/Resolving - ),<BR><BR>Rash (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016109090&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016109180,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Rhinorrhoea (3d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016109180&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016109211,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Vaccination site cellulitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016109211&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016109591,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016109591&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016109690,Spontaneous,2023-10-18 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Pericarditis (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016109690&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016110044,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - ),<BR><BR>Chest discomfort (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Oropharyngeal pain (n/a - Unknown - ),<BR><BR>Pain in extremity (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Throat irritation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Throat tightness (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016110044&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016110753,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash macular (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site mass (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016110753&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016111171,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016111171&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016111309,Spontaneous,2023-10-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Pruritus (n/a - Recovering/Resolving - ),<BR><BR>Rash (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016111309&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016111343,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Muscle spasms (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (4d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>PRIVIGEN [HUMAN NORMAL IMMUNOGLOBULIN] (S - Immunodeficiency - Unknown - [n/a - 200mL - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016111343&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016111348,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Diarrhoea (1d - Recovered/Resolved - ),<BR><BR>Vomiting (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016111348&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016111378,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Nasopharyngitis (n/a - Unknown - ),<BR><BR>Vocal cord paresis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016111378&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016111589,Spontaneous,2023-10-18 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Abdominal discomfort (n/a - Unknown - ),<BR><BR>Abdominal distension (n/a - Unknown - ),<BR><BR>Anorectal discomfort (n/a - Unknown - ),<BR><BR>Balance disorder (n/a - Unknown - ),<BR><BR>Dizziness (n/a - Unknown - ),<BR><BR>Nausea (n/a - Unknown - ),<BR><BR>Pollakiuria (n/a - Unknown - ),<BR><BR>Vomiting (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>FLUAD TETRA [B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), B/WASHINGTON/02/2019-LIKE VIRUS (B/VICTORIA/705/2018 BVR-11), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), MF59C.1, SORBITAN TRIOLEATE, POLYSORBATE 80, SODIUM CITRATE, B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), SQUALENE, INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), CITRIC ACID] (S - Influenza immunisation - Not applicable - [1d - 1{DF} - n/a])","COMIRNATY ORIGINAL/OMICRON BA.4-5 [TOZINAMERAN, FAMTOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [1d - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016111589&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016111620,Spontaneous,2023-10-18 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Urticaria (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Drug withdrawn - [1d - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016111620&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016111955,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - ),<BR><BR>Blue toe syndrome (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016111955&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016112290,Spontaneous,2023-10-18 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016112290&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016096352,Spontaneous,2023-10-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Unknown - ),<BR><BR>Nausea (n/a - Unknown - ),<BR><BR>Neuropathy peripheral (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting projectile (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016096352&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016096390,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Male,Face oedema (n/a - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016096390&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016096536,Spontaneous,2023-10-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Generalised tonic-clonic seizure (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Tonic convulsion (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a]),"LEVETIRACETAM [LEVETIRACETAM] (C - Generalised tonic-clonic seizure - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Cerebrovascular accident - n/a - [n/a - n/a - n/a]),<BR><BR>[CARBAMAZEPINE] (C - Generalised tonic-clonic seizure - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL, CALCIUM CARBONATE] (C - Renal impairment - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - Barrett's oesophagus - n/a - [n/a - n/a - n/a]),<BR><BR>[MACROGOL, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - Constipation - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[PHENYTOIN] (C - Generalised tonic-clonic seizure - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016096536&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016096580,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Back pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Product use issue (n/a - Unknown - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016096580&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016096679,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Toothache (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016096679&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016096688,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016096688&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016096720,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Atypical pneumonia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Productive cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016096720&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016096738,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovered/Resolved - Disabling),<BR><BR>Cold sweat (1d - Recovered/Resolved - Disabling),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Disabling),<BR><BR>Dizziness (n/a - Recovering/Resolving - Disabling),<BR><BR>Dyspnoea (n/a - Recovering/Resolving - Disabling),<BR><BR>Hyperhidrosis (1d - Recovered/Resolved - Disabling),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pallor (1d - Recovered/Resolved - Disabling),<BR><BR>Palpitations (1d - Recovered/Resolved - Disabling),<BR><BR>Paraesthesia (1d - Recovered/Resolved - Disabling),<BR><BR>Wheezing (n/a - Recovering/Resolving - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE, BUDESONIDE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[CODEINE PHOSPHATE BP, PARACETAMOL PH. EUR., PARACETAMOL BP, CODEINE PHOSPHATE BP, PARACETAMOL DC, PARACETAMOL PH. EUR., CODEINE PHOSPHATE PH.EUR., PARACETAMOL PH. EUR., CODEINE PHOSPHATE PH.EUR., PARACETAMOL, CODEINE PHOSPHATE, PARACETAMOL, CODEINE PHOSPHATE BP, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE] (C - Arthralgia - n/a - [3d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016096738&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016096840,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (2d - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Emotional disorder (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Local reaction (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Tremor (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Transient ischaemic attack - n/a - [n/a - n/a - n/a]),<BR><BR>[A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN, A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN, B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1) V REASS. X - 179 A, A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/NANCHANG 933/95 (H3N2), A/BAYERN/7/95 (H1N1) - LIKE STRAIN (A/JOHANNESBURG/82/96), B/BEIJING/184/93-LIKE STRAIN (B/HARBIN/7/94), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/CALIFORNIA/7/2004 (H3N2) - LIKE STRAIN (A/NEW YORK/55/2004 REASS. NYMC X-157), B/SHANGHAI/361/2002 - LIKE STRAIN (B/JIANGSU/10/2003), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/MOSCOW/10/99 (H3N2) - LIKE STRAIN (A/PANAMA/2007/99 REASS. RESVIR-17), B/SICHUAN/379/99-LIKE STRAIN (B/JOHANNESBURG/5/99), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), A/CALIFORNIA/7/2009 (H1N1)-DERIVED STRAIN USED NYMC X-181, B/BRISBANE/60/2008, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1)V-LIKE VIRUS, A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H1N1), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H3N2), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B] (C - Immunisation - n/a - [1d - n/a - n/a])...","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016096840&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016096946,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Body temperature abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rash (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016096946&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016097070,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Neuralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ETORICOXIB] (C - Inflammatory pain - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LERCANIDIPINE, LERCANIDIPINE HYDROCHLORIDE] (C - Blood pressure increased - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016097070&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016097217,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,COVID-19 (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016097217&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016097260,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Hypertension (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"RELVAR ELLIPTA [FLUTICASONE FUROATE, VILANTEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CHLORPHENAMINE MALEATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CODEINE PHOSPHATE BP, PARACETAMOL PH. EUR., PARACETAMOL BP, CODEINE PHOSPHATE BP, PARACETAMOL DC, PARACETAMOL PH. EUR., CODEINE PHOSPHATE PH.EUR., PARACETAMOL PH. EUR., CODEINE PHOSPHATE PH.EUR., PARACETAMOL, CODEINE PHOSPHATE, PARACETAMOL, CODEINE PHOSPHATE BP, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE] (C - Ehlers-Danlos syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[DIAZEPAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FAMOTIDINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[KETOTIFEN, KETOTIFEN HYDROGEN FUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - Secondary adrenocortical insufficiency - n/a - [n/a - n/a - n/a]),<BR><BR>[PROCHLORPERAZINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TIOTROPIUM BROMIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016097260&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016097309,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Deafness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Ear pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BENDROFLUMETHIAZIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016097309&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016097400,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Depressed mood (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Overdose (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sleep disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Wrong product administered (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 3mL - n/a]),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (N - COVID-19 immunisation - Not applicable - [n/a - .3mL - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016097400&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016097618,Spontaneous,2023-10-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Pulmonary embolism (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016097618&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016097735,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016097735&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016097780,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,"Cerebral infarction (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Movement disorder (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016097780&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016097862,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Injection site pain (2d - Recovered/Resolved - ),<BR><BR>Injection site reaction (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016097862&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016097872,Spontaneous,2023-10-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Anaphylactic reaction (1d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Blood pressure decreased (1d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Dizziness (1d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Dysgeusia (1d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Heart rate decreased (1d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Oxygen saturation decreased (1d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Rash macular (1d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation),<BR><BR>Wheezing (1d - Recovered/Resolved - Life Threatening, Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016097872&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016097913,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016097913&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016097914,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>General physical health deterioration (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Muscle fatigue (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Presyncope (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016097914&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016098006,Spontaneous,2023-10-17 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Nervous system disorder (n/a - Not Recovered/Not Resolved - ),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[OLMESARTAN MEDOXOMIL, AMLODIPINE, OLMESARTAN MEDOXOMIL, AMLODIPINE BESILATE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016098006&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016098175,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016098175&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016098295,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sinus tachycardia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016098295&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016098333,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Adult,No,Female,"Arthralgia (2d - Recovered/Resolved - Disabling),<BR><BR>Back pain (2h - Recovered/Resolved - Disabling),<BR><BR>Body temperature decreased (2h - Recovered/Resolved - Disabling),<BR><BR>Chills (2d - Recovered/Resolved - Disabling),<BR><BR>Dysphagia (n/a - Unknown - Disabling),<BR><BR>Extensive swelling of vaccinated limb (2d - Recovered/Resolved - Disabling),<BR><BR>Fatigue (n/a - Recovering/Resolving - Disabling),<BR><BR>Headache (2d - Recovered/Resolved - Disabling),<BR><BR>Injection site reaction (2d - Recovered/Resolved - Disabling),<BR><BR>Myalgia (2h - Recovered/Resolved - Disabling),<BR><BR>Nausea (n/a - Recovering/Resolving - Disabling),<BR><BR>Pain in extremity (2h - Recovered/Resolved - Disabling),<BR><BR>Pyrexia (24h - Recovered/Resolved - Disabling),<BR><BR>Tremor (2h - Recovered/Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[ANHYDROUS LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE DIHYDRATE PH.EUR., BECLOMETHASONE DIPROPIONATE PH. EUR., FORMOTEROL FUMARATE DIHYDRATE PH.EUR., BETAMETHASONE DIPROPIONATE (PH. EUR.), FORMOTEROL FUMARATE DIHYDRATE, BECLOMETASONE DIPROPIONATE ANHYDROUS] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[IPRATROPIUM, IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE ANHYDROUS, IPRATROPIUM BROMIDE MONOHYDRATE] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016098333&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016098478,Spontaneous,2023-10-17 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,Yes,Female,"Asthenia (9h - Recovered/Resolved - Disabling),<BR><BR>Syncope (0d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),"GLYXAMBI [LINAGLIPTIN, EMPAGLIFLOZIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMISULPRIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - 40mg - n/a]),<BR><BR>[INDAPAMIDE, AMLODIPINE BESILATE, PERINDOPRIL ARGININE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016098478&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016098533,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site mass (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site warmth (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Migraine - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATENOLOL, ATENOLOL BP] (C - Migraine - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[DESOGESTREL] (C - Oral contraception - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016098533&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016098779,Spontaneous,2023-10-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Seizure (1d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016098779&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016098824,Spontaneous,2023-10-17 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Pruritus (0d - Recovered/Resolved - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/MASSACHUSETTS/2/2012 (YAMAGATA LINEAGE)-LIKE STRAIN (B/MASSACHUSETTS/2/2012, MEDI 237751), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/BRISBANE/60/2008 (VICTORIA LINEAGE)-LIKE STRAIN (B/BRISBANE/60/2008, MEDI 228030), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227), B/AUSTRIA/1359417/2021 LIKE STRAIN-(B/MICHIGAN/01/2021, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A, B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED] (S - Immunisation - n/a - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016098824&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016098888,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Paraesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral coldness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016098888&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016099235,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,Vertigo labyrinthine (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - n/a - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016099235&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016099405,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Taste disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [1d - n/a - n/a]),"[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Autoimmune thyroiditis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016099405&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016099452,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Feeling cold (n/a - Unknown - Other Medically Important Condition),<BR><BR>Illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016099452&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016099508,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Illness (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Palpitations (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"METHOTREXATE [METHOTREXATE] (C - Psoriatic arthropathy - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016099508&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016099542,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Maternal exposure during pregnancy (n/a - Unknown - ),<BR><BR>Nasal congestion (n/a - Unknown - ),<BR><BR>Pain (n/a - Unknown - ),<BR><BR>Poor quality sleep (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016099542&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016099579,Spontaneous,2023-10-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,"Vaccination site erythema (7d - Recovered/Resolved - ),<BR><BR>Vaccination site haematoma (9d - Recovered/Resolved - ),<BR><BR>Vaccination site pain (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - Intramuscular use]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - n/a - n/a - [n/a - .5mL - n/a]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[ANHYDROUS LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[CLONAZEPAM] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[DIOSMIN, DIOSMIN, MICRONIZED] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[FOLIC ACID, FERROUS SULFATE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[OLMESARTAN MEDOXOMIL, HYDROCHLOROTHIAZIDE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PENTOSAN POLYSULFATE SODIUM] (C - n/a - n/a - [n/a - n/a - Cutaneous use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016099579&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016099655,Spontaneous,2023-10-17 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Acute hepatic failure (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Constipation (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Dyspepsia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Liver disorder (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"LIXIANA 60 MG [EDOXABAN, EDOXABAN TOSYLATE] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016099655&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016100375,Spontaneous,2023-10-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Anaphylactic reaction (1d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016100375&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016100505,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Inflammation (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[INFLUENZA VIRUS] (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT)] (C - Prophylaxis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016100505&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016100588,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016100588&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016100590,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Hypertension (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016100590&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016100643,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Catarrh (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016100643&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016100712,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hot flush (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hypopnoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016100712&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016100995,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Asthenia (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Injection site pain (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Insomnia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Renal pain (3d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"EDOXABAN [EDOXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PERINDOPRIL, PERINDOPRIL TERT-BUTYLAMINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016100995&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016101271,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Laryngitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016101271&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016101329,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Scar pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016101329&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016101575,Spontaneous,2023-10-17 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Deep vein thrombosis (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - Not applicable - [n/a - 1{DF} - Intramuscular use]),"[CITALOPRAM HYDROBROMIDE] (C - n/a - Unknown - [n/a - 10mg - n/a]),<BR><BR>[FUROSEMIDE, FUROSEMIDE SODIUM] (C - n/a - Unknown - [n/a - 20mg - n/a]),<BR><BR>[METAMIZOLE SODIUM, METAMIZOLE SODIUM MONOHYDRATE] (C - n/a - Unknown - [n/a - 500mg - n/a]),<BR><BR>[PERINDOPRIL, PERINDOPRIL TERT-BUTYLAMINE] (C - n/a - Drug withdrawn - ),<BR><BR>[POTASSIUM CHLORIDE] (C - n/a - Unknown - [n/a - 500mg - n/a]),<BR><BR>[TIAPRIDE, TIAPRIDE HYDROCHLORIDE] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016101575&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016101641,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016101641&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016101715,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016101715&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016101759,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016101759&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016101760,Spontaneous,2023-10-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016101760&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016101871,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Antiviral prophylaxis - Not applicable - [1d - n/a - n/a])","PREGABALIN [PREGABALIN] (C - Fibromyalgia - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016101871&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016102205,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Headache (5d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016102205&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016102315,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Hypoaesthesia (n/a - Unknown - ),<BR><BR>Paraesthesia (n/a - Unknown - ),<BR><BR>Syncope (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"METHOTREXATE [METHOTREXATE] (C - Arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016102315&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016102370,Spontaneous,2023-10-17 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,"Cerebral haemorrhage (n/a - Fatal - Results in Death),<BR><BR>Hypertensive crisis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016102370&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016102534,Spontaneous,2023-10-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Adult,No,Female,"COVID-19 (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016102534&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016102984,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site rash (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - 1{DF} - n/a]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016102984&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016102990,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Maternal exposure during pregnancy (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016102990&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016102991,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Joint stiffness (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016102991&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016103000,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Productive cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Throat irritation (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - 1{DF} - n/a]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016103000&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016103004,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Rash (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016103004&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016103006,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Dizziness (n/a - Not Recovered/Not Resolved - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Unknown - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016103006&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016103007,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Presyncope (n/a - Recovered/Resolved - ),<BR><BR>Pyrexia (3d - Recovered/Resolved - ),<BR><BR>Vaccination site pain (5d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016103007&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016103009,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Diarrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Rash pruritic (n/a - Recovering/Resolving - ),<BR><BR>Skin texture abnormal (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[FLUOCORTOLONE PIVALATE PH. EUR., ANHYDROUS LIDOCAINE HYDROCHLORIDE, FLUOCORTOLONE PIVALATE PH. EUR., LIDOCAINE HYDROCHLORIDE, FLUOCORTOLONE PIVALATE, ANHYDROUS LIDOCAINE HYDROCHLORIDE, FLUOCORTOLONE PIVALATE, LIDOCAINE HYDROCHLORIDE] (C - n/a - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016103009&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016103010,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Lymphadenopathy (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016103010&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016103018,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Balance disorder (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - ),<BR><BR>Pain (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016103018&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016103023,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Recovering/Resolving - ),<BR><BR>Constipation (n/a - Recovering/Resolving - ),<BR><BR>Diaphragmalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016103023&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016103025,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Hypoacusis (2d - Recovered/Resolved - ),<BR><BR>Tinnitus (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - 1{DF} - n/a]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016103025&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016103029,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Pyrexia (n/a - Not Recovered/Not Resolved - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016103029&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016103130,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016103130&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016103180,Spontaneous,2023-10-17 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Adult,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),<BR><BR>TOZINAMERAN [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016103180&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016103430,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Body temperature abnormal (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Body temperature increased (1d - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Cardiac flutter (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Heart rate abnormal (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Limb discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Unknown - Other Medically Important Condition),<BR><BR>Spinal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tension headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016103430&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016103953,Spontaneous,2023-10-17 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Loss of consciousness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),APREMILAST [APREMILAST] (C - Adverse drug reaction - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016103953&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016088665,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cluster headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Unknown - ),<BR><BR>Erythema (n/a - Unknown - ),<BR><BR>Illness (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Unknown - ),<BR><BR>Palpitations (n/a - Unknown - ),<BR><BR>Pyrexia (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016088665&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016088667,Spontaneous,2023-10-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Diarrhoea (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Fall (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Memory impairment (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Muscular weakness (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016088667&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016088670,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Axillary pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Lymph node pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymphadenopathy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"COMIRNATY [TOZINAMERAN] (C - Asthma - n/a - [1d - n/a - n/a - More in ICSR]),<BR><BR>[COVID-19 VACCINE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUTICASONE PROPIONATE, SALMETEROL, FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUTICASONE PROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Asthma - n/a - [1d - n/a - n/a]),<BR><BR>[SALMETEROL XINAFOATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SALMETEROL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016088670&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016088818,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthritis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Erythema (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Joint swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016088818&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016088819,Spontaneous,2023-10-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Cerebrovascular accident (0d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"EDOXABAN [EDOXABAN] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>LEVETIRACETAM [LEVETIRACETAM] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood cholesterol increased - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[BENZALKONIUM CHLORIDE, DIMETICONE, DIMETICONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CALCIUM CARBONATE, CHOLECALCIFEROL CONCENTRATE (POWDER FORM)] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DIAZEPAM] (C - n/a - n/a - [n/a - 2{DF} - n/a]),<BR><BR>[LIQUID PARAFFIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016088819&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016088861,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tremor (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016088861&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016089541,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Influenza (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (3d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016089541&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016089630,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Neuropathy peripheral (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[TAMOXIFEN, TAMOXIFEN CITRATE] (C - Breast cancer - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016089630&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016089841,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Injection site erythema (2d - Recovered/Resolved - ),<BR><BR>Injection site pain (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016089841&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016089863,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Chills (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Feeling of body temperature change (n/a - Unknown - Disabling, Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[METHYLPHENIDATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016089863&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016090276,Spontaneous,2023-10-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Male,Muscle spasms (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016090276&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016090286,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Back pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dysphagia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Gait disturbance (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nasopharyngitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016090286&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016090287,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,Headache (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016090287&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016090288,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Apathy (n/a - Recovering/Resolving - ),<BR><BR>Blood pressure decreased (n/a - Recovering/Resolving - ),<BR><BR>Dyspnoea exertional (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Syncope (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016090288&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016090290,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site swelling (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016090290&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016090294,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Lymphadenopathy (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016090294&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016090502,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Confusional state (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016090502&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016090503,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Vertigo positional (3d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"ESOMEPRAZOLE [ESOMEPRAZOLE] (C - Hiatus hernia - n/a - [n/a - n/a - n/a]),<BR><BR>FESOTERODINE [FESOTERODINE] (C - Incontinence - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood cholesterol abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Heart rate abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - Osteoporosis postmenopausal - n/a - [n/a - n/a - n/a]),<BR><BR>[DIAZEPAM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FAMOTIDINE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[FENTANYL] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUTICASONE] (C - Bronchiectasis, Sinusitis - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - Fluid retention - n/a - [n/a - n/a - n/a]),<BR><BR>[GLYCERYL TRINITRATE] (C - Angina pectoris - n/a - [n/a - n/a - n/a]),<BR><BR>[ISOSORBIDE MONONITRATE] (C - Angina pectoris - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Cancer surgery - n/a - [n/a - n/a - n/a]),<BR><BR>[LIOTHYRONINE] (C - Cancer surgery - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - Bronchiectasis - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL SULFATE] (C - Bronchiectasis - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM IODIDE (131 I)] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016090503&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016090592,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[SARS-COV-2, STRAIN CZ02, PRODUCED IN VERO CELLS, INACTIVATED] (C - COVID-19 immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016090592&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016090632,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Conjunctivitis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016090632&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016090898,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Erythema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling hot (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site mass (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Neuralgia - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FELODIPINE] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016090898&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016091410,Spontaneous,2023-10-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Abdominal distension (2d - Recovered/Resolved - ),<BR><BR>Dizziness (2d - Recovered/Resolved - ),<BR><BR>Pain (2d - Recovered/Resolved - ),<BR><BR>Vomiting (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),"PREGABALIN 50 MG [PREGABALIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>PREGABALIN 75 MG [PREGABALIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CLORAZEPATO DIPOTÁSSICO] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ESCITALOPRAM, ESCITALOPRAM OXALATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, OMEPRAZOLE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SOLIFENACIN SUCCINATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016091410&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016091496,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Periarthritis (n/a - Recovered/Resolved With Sequelae - Disabling),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016091496&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016092061,Spontaneous,2023-10-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Abdominal pain (3d - Recovered/Resolved - ),<BR><BR>Headache (3d - Recovered/Resolved - ),<BR><BR>Pyrexia (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016092061&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016092124,Spontaneous,2023-10-16 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Bone pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016092124&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016092132,Spontaneous,2023-10-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Bone pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016092132&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016092248,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Headache (n/a - Unknown - ),<BR><BR>Migraine (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016092248&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016092444,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Haemorrhage (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Unknown - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Neuropathy peripheral (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral coldness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016092444&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016092743,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Arthralgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),RITUXIMAB [RITUXIMAB] (C - Cancer in remission - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016092743&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016092871,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Recovered/Resolved - ),<BR><BR>Diarrhoea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovered/Resolved - ),<BR><BR>Headache (n/a - Recovered/Resolved - ),<BR><BR>Nasopharyngitis (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016092871&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016093375,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Limb discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site warmth (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ACETYLSALICYLIC ACID] (C - Carotid arteriosclerosis - n/a - [n/a - 75mg - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - 50mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016093375&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016093517,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Vertigo (2d - Recovered/Resolved With Sequelae - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016093517&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016094602,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016094602&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016094819,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Herpes zoster (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site erythema (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site vesicles (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016094819&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016094822,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Asthenia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Feeling cold (n/a - Not Recovered/Not Resolved - ),<BR><BR>Head discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Tinnitus (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[BENDROFLUMETHIAZIDE, POTASSIUM CHLORIDE] (C - Hypertension - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016094822&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016094837,Spontaneous,2023-10-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Dizziness (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016094837&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016094838,Spontaneous,2023-10-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Transient global amnesia (0d - Recovered/Resolved - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),"[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE)] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[BENDROFLUMETHIAZIDE, POTASSIUM CHLORIDE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN POTASSIUM] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[METOPROLOL SUCCINATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[POTASSIUM CHLORIDE] (C - Mineral supplementation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016094838&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016094847,Spontaneous,2023-10-16 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Erythema (n/a - Recovering/Resolving - ),<BR><BR>Feeling hot (n/a - Recovering/Resolving - ),<BR><BR>Pruritus (n/a - Recovering/Resolving - ),<BR><BR>Swelling (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),"OPATANOL [OLOPATADINE, OLOPATADINE HYDROCHLORIDE] (C - Rhinitis allergic - n/a - [n/a - 2{DF} - Ocular use]),<BR><BR>[ATORVASTATIN, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM TRIHYDRATE] (C - Hypercholesterolaemia - n/a - [n/a - 10mg - Oral use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE)] (C - Product used for unknown indication - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[DICLOXACILLIN] (C - Infection - n/a - [n/a - 1000mg - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - n/a - Oral use]),<BR><BR>[PHENOXYMETHYLPENICILLIN, PHENOXYMETHYLPENICILLIN POTASSIUM] (C - Tooth infection - n/a - [n/a - 800mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016094847&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016094859,Spontaneous,2023-10-16 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Back pain (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rash pruritic (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Skin burning sensation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016094859&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016095209,Spontaneous,2023-10-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Feeling hot (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Rash erythematous (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition),<BR><BR>Urticaria (n/a - Recovering/Resolving - Life Threatening, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016095209&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016095678,Spontaneous,2023-10-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Anaphylactic reaction (n/a - Recovered/Resolved - Life Threatening, Other Medically Important Condition),<BR><BR>Oxygen saturation decreased (n/a - Recovered/Resolved - Life Threatening),<BR><BR>Rash macular (n/a - Recovered/Resolved - Life Threatening)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"ALOGLIPTIN [ALOGLIPTIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016095678&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016095825,Spontaneous,2023-10-16 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Pancreatitis (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"DAPAGLIFLOZIN [DAPAGLIFLOZIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>MIRABEGRON [MIRABEGRON] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>RIVAROXABAN [RIVAROXABAN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>VALSARTAN, SACUBITRIL [VALSARTAN, SACUBITRIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DOCUSATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[EPLERENONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FINASTERIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FUROSEMIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[GLICLAZIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[GLYCERYL TRINITRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SOLIFENACIN] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016095825&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016084485,Spontaneous,2023-10-14 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Musculoskeletal stiffness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myofascial pain syndrome (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - n/a - n/a]),[PARACETAMOL] (C - Migraine - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016084485&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016087253,Spontaneous,2023-10-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Herpes ophthalmic (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - n/a - Unknown - [n/a - n/a - n/a]),"[ATORVASTATIN, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM TRIHYDRATE] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016087253&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016087635,Spontaneous,2023-10-14 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Male,"Erythema (2d - Recovered/Resolved - ),<BR><BR>Pruritus (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016087635&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016076726,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Blood pressure decreased (n/a - Unknown - ),<BR><BR>Nausea (1d - Recovered/Resolved - ),<BR><BR>Syncope (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016076726&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016076751,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (30min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness postural (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Face injury (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling cold (30min - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"APIXABAN [APIXABAN] (C - Pulmonary embolism - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Peripheral swelling - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016076751&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016076753,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Swollen tongue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tremor (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vision blurred (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[BUTYLSCOPOLAMINE, HYOSCINE BUTYLBROMIDE] (C - Irritability - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Prophylaxis - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Depression - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016076753&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016077102,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Burning sensation (n/a - Recovered/Resolved - ),<BR><BR>Dizziness (n/a - Recovered/Resolved - ),<BR><BR>Hypersensitivity (n/a - Recovered/Resolved With Sequelae - Life Threatening),<BR><BR>Miosis (n/a - Recovered/Resolved - ),<BR><BR>Pallor (n/a - Recovered/Resolved - ),<BR><BR>Paraesthesia oral (n/a - Recovered/Resolved - ),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"RELVAR ELLIPTA [FLUTICASONE FUROATE, VILANTEROL] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[AZELASTINE HYDROCHLORIDE, FLUTICASONE PROPIONATE] (C - Hypersensitivity - n/a - [n/a - n/a - n/a]),<BR><BR>[LORATADINE] (C - Hypersensitivity - n/a - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - Hypersensitivity - n/a - [n/a - n/a - n/a]),<BR><BR>[NORETHISTERONE ACETATE, ESTRADIOL, NORETHISTERONE, ESTRADIOL HEMIHYDRATE] (C - Hormone replacement therapy - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[TIOTROPIUM, TIOTROPIUM BROMIDE, TIOTROPIUM BROMIDE MONOHYDRATE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016077102&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016077305,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016077305&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016077327,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - ),<BR><BR>Balance disorder (n/a - Unknown - ),<BR><BR>Chills (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Loss of consciousness (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - ),<BR><BR>Pain (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016077327&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016077543,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arthralgia (n/a - Unknown - ),<BR><BR>Arthropathy (n/a - Unknown - ),<BR><BR>Back pain (n/a - Unknown - ),<BR><BR>Gait disturbance (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - ),<BR><BR>Myalgia (n/a - Unknown - ),<BR><BR>Pain (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Unknown - ),<BR><BR>Polyarthritis (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016077543&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016077822,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - ),<BR><BR>Vaccination failure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016077822&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016077824,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Myalgia (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016077824&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016078324,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Herpes zoster (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016078324&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016078427,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Syncope (n/a - Recovered/Resolved - Other Medically Important Condition),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (S - Immunisation - Not applicable - [1d - n/a - n/a])","[INDAPAMIDE, INDAPAMIDE HEMIHYDRATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016078427&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016078571,Spontaneous,2023-10-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Cardiac arrest (n/a - Recovered/Resolved With Sequelae - Life Threatening),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[LERCANIDIPINE, LERCANIDIPINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016078571&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016078644,Spontaneous,2023-10-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain (n/a - Unknown - Disabling),<BR><BR>Chills (n/a - Unknown - Disabling),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Disabling),<BR><BR>Dizziness (n/a - Recovering/Resolving - Disabling),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Headache (n/a - Recovering/Resolving - Disabling),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Pyrexia (2d - Recovered/Resolved - Disabling),<BR><BR>Vomiting (1d - Recovered/Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016078644&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016078903,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Somnolence (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016078903&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016079173,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Balance disorder (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition),<BR><BR>Burning sensation (n/a - Unknown - ),<BR><BR>Peripheral coldness (n/a - Unknown - ),<BR><BR>Tremor (n/a - Recovered/Resolved - Disabling, Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[ANHYDROUS LEVOTHYROXINE SODIUM] (S - n/a - Unknown - [n/a - n/a - n/a])","CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016079173&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016079460,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Back pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[CANDESARTAN, CANDESARTAN CILEXETIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016079460&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016079700,Spontaneous,2023-10-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016079700&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016080011,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vaccination failure (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016080011&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016080284,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Bone pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Brain fog (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016080284&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016080392,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Asthenia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cold sweat (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (2d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016080392&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016080406,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthma (n/a - Not Recovered/Not Resolved - ),<BR><BR>Disease recurrence (n/a - Not Recovered/Not Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Glaucoma (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site erythema (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[ASCORBIC ACID, CALCIUM GLUBIONATE, CALCIUM CARBONATE, CALCIUM, CALCIUM GLUBIONATE, CALCIUM CARBONATE, COLECALCIFEROL, CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[DESOGESTREL, ETHINYLESTRADIOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LORAZEPAM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016080406&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016080635,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Anosmia (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016080635&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016080657,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Feeling hot (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain of skin (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Stress (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Anxiety - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016080657&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016080745,Spontaneous,2023-10-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Arrhythmia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Loss of consciousness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Visual impairment (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016080745&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016080757,Spontaneous,2023-10-13 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Arthralgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Feeling drunk (2d - Recovered/Resolved - ),<BR><BR>Hypertension (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016080757&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016080957,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,Oral herpes (n/a - Recovering/Resolving - ),COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016080957&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016081133,Spontaneous,2023-10-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016081133&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016081473,Spontaneous,2023-10-13 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Asthma (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Cardio-respiratory arrest (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Movement disorder (n/a - Unknown - ),<BR><BR>Pneumonia bacterial (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Respiratory failure (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation),<BR><BR>Sepsis (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016081473&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016081886,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Dermatitis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016081886&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016081894,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Blindness (n/a - Not Recovered/Not Resolved - Disabling),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016081894&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016081895,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Cough (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dry throat (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016081895&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016081997,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016081997&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016082273,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Sinus headache (n/a - Recovering/Resolving - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016082273&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016082654,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Unknown - ),<BR><BR>Fatigue (3d - Recovered/Resolved - ),<BR><BR>Musculoskeletal stiffness (3d - Recovered/Resolved - ),<BR><BR>Myalgia (3d - Recovered/Resolved - ),<BR><BR>Neck pain (3d - Recovered/Resolved - ),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site erythema (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site swelling (n/a - Unknown - ),<BR><BR>Visual impairment (2d - Recovered/Resolved - )","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Influenza immunisation - Not applicable - [1d - n/a - n/a])","[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016082654&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016082999,Spontaneous,2023-10-13 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Rash (n/a - Recovering/Resolving - ),"COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/MICHIGAN/45/2015, NYMC X-275), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, IVR-186), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021] (S - Influenza immunisation - Not applicable - [1d - .7mL - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016082999&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016083044,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Diarrhoea (n/a - Unknown - ),<BR><BR>Dyspepsia (n/a - Unknown - ),<BR><BR>Heart rate irregular (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - ),<BR><BR>Vision blurred (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016083044&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016083642,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016083642&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016084032,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Balance disorder (n/a - Recovered/Resolved - ),<BR><BR>COVID-19 (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Loss of personal independence in daily activities (n/a - Recovered/Resolved - ),<BR><BR>Somnolence (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016084032&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016084133,Spontaneous,2023-10-13 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Deep vein thrombosis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Muscle spasms (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Muscle tightness (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pain in extremity (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Peripheral swelling (n/a - Unknown - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),"[ALENDRONATE SODIUM, ALENDRONIC ACID] (C - Osteoporosis - n/a - [n/a - 70mg - n/a]),<BR><BR>[ANHYDROUS LEVOTHYROXINE SODIUM, LEVOTHYROXINE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS EP] (C - Hypothyroidism - n/a - [n/a - 50ug - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (C - Influenza immunisation - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[LOSARTAN POTASSIUM, HYDROCHLOROTHIAZIDE] (C - Hypertension - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[SIMVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - 40mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016084133&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016084148,Spontaneous,2023-10-13 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Depressed level of consciousness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Hypersensitivity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Musculoskeletal stiffness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain (n/a - Unknown - ),<BR><BR>Pruritus (n/a - Unknown - ),<BR><BR>Vaccination site mass (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site swelling (n/a - Unknown - ),<BR><BR>Vaccination site urticaria (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016084148&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016068560,Spontaneous,2023-10-12 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Hypotension (n/a - Unknown - ),<BR><BR>Pyrexia (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - .3uL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016068560&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016068729,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal discomfort (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Flatulence (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Gastric dilatation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaccination site haemorrhage (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 30ug - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016068729&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016068743,Spontaneous,2023-10-12 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Hypoaesthesia oral (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Skin burning sensation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016068743&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016068764,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Confusional state (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Lethargy (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - ),<BR><BR>Somnolence (2d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016068764&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016068799,Spontaneous,2023-10-12 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Ear congestion (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in jaw (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Throat tightness (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[PROGESTERONE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016068799&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016068822,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Amnesia (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Headache (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Influenza like illness (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Vomiting (n/a - Unknown - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"NOVORAPID [INSULIN ASPART] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>TOUJEO [INSULIN GLARGINE] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - Blood cholesterol increased - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016068822&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016068929,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Facial pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"LANTUS [INSULIN GLARGINE] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>NOVORAPID [INSULIN ASPART] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016068929&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016068961,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016068961&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016069668,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Blood pressure increased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Palpitations (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016069668&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016069713,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Thirst (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[INFLUENZA VIRUS] (C - Asthma, Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016069713&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016069819,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Dizziness postural (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fall (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016069819&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016069833,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Balance disorder (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cognitive disorder (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Confusional state (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Coordination abnormal (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Disorientation (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Gait disturbance (5d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hypersomnia (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Speech disorder (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vascular dementia (4d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016069833&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016069941,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"IMATINIB [IMATINIB, IMATINIB MESILATE] (C - Chronic myeloid leukaemia - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016069941&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016069979,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Diarrhoea (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition),<BR><BR>Hypoaesthesia (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016069979&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016070088,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ACICLOVIR, ACICLOVIR SODIUM] (C - Genital herpes - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - Headache - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016070088&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016070105,Spontaneous,2023-10-12 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,"Asthenia (30min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (30min - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hypotension (30min - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),<BR><BR>[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (S - Immunisation - Not applicable - [n/a - n/a - Intramuscular use])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016070105&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016070208,Spontaneous,2023-10-12 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Male,"Movement disorder (n/a - Not Recovered/Not Resolved - ),<BR><BR>Muscle tightness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Neck pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016070208&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016070369,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Back pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016070369&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016070440,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Influenza like illness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (1d - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tremor (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016070440&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016070701,Spontaneous,2023-10-12 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Dyspnoea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Urticaria (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016070701&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016070750,Spontaneous,2023-10-12 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Cardiac failure (n/a - Unknown - Other Medically Important Condition),RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016070750&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016070776,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Gait disturbance (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Rash (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"METHOTREXATE [METHOTREXATE] (C - Rheumatoid arthritis - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXYCHLOROQUINE] (C - Rheumatoid arthritis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016070776&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016070802,Spontaneous,2023-10-12 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dizziness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling abnormal (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Flushing (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016070802&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016070912,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Breast pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Breast tenderness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Lymph node pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016070912&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016071177,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Back pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Somnolence (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[GLICLAZIDE] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016071177&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016071199,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (n/a - Recovered/Resolved With Sequelae - ),<BR><BR>Fatigue (n/a - Unknown - ),<BR><BR>Loss of consciousness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (1d - Recovered/Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - n/a - Not applicable - [n/a - n/a - n/a])","[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Decreased activity - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016071199&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016071239,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Abdominal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016071239&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016071273,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Bone pain (n/a - Unknown - Disabling),<BR><BR>Decreased appetite (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Feeling cold (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Hyperhidrosis (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Hypoaesthesia (n/a - Unknown - Disabling),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"AZATHIOPRINE [AZATHIOPRINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>LINAGLIPTIN [LINAGLIPTIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>PREGABALIN [PREGABALIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PREDNISOLONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[SULFAMETHOXAZOLE, TRIMETHOPRIM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[VITAMIN D] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016071273&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016071316,Spontaneous,2023-10-12 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Adverse event (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chest pain (1d - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Transient ischaemic attack (1d - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016071316&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016071443,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Body temperature increased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Constipation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016071443&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016071581,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Body temperature increased (n/a - Recovering/Resolving - ),<BR><BR>Heart rate increased (n/a - Recovering/Resolving - ),<BR><BR>Tachycardia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016071581&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016071705,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016071705&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016071738,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Amnesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Confusional state (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Mental impairment (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016071738&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016071849,Spontaneous,2023-10-12 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,Vaccination site erythema (7d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - Intramuscular use]),"MICARDISPLUS [HYDROCHLOROTHIAZIDE, TELMISARTAN] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[ALPRAZOLAM] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[BROMAZEPAM] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - Oral use]),<BR><BR>[PREGABALIN] (C - n/a - n/a - [n/a - n/a - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016071849&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016071951,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Abdominal pain (6h - Recovered/Resolved - Disabling),<BR><BR>Pain (n/a - Recovered/Resolved - Disabling),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"BEMPEDOIC ACID [BEMPEDOIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016071951&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016072184,Spontaneous,2023-10-12 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Elderly,No,Female,Rash maculo-papular (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 10 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016072184&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016072667,Spontaneous,2023-10-12 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Seizure (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016072667&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016072978,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016072978&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016073039,Spontaneous,2023-10-12 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,Yes,Male,Rhinorrhoea (1d - Recovered/Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016073039&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016073158,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Contusion (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Limb injury (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016073158&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016073219,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Dysuria (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016073219&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016073238,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Back pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016073238&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016073242,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Postmenopausal haemorrhage (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016073242&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016073244,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[COLECALCIFEROL, CALCIUM CARBONATE] (C - Osteopenia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016073244&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016073257,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016073257&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016073572,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"Arthralgia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling cold (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Mobility decreased (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Night sweats (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pollakiuria (n/a - Unknown - Other Medically Important Condition),<BR><BR>Restlessness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Thirst (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016073572&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016073577,Spontaneous,2023-10-12 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chest pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Confusional state (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Oxygen saturation decreased (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Transient ischaemic attack (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"ANORO [UMECLIDINIUM BROMIDE, VILANTEROL] (C - Wheezing - n/a - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID, ACETYLSALICYLIC ACID PH. EUR., ASPIRIN BP] (C - Transient ischaemic attack - n/a - [n/a - n/a - n/a]),<BR><BR>[CLOZAPINE] (C - Psychotic disorder - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - Vitamin D deficiency - n/a - [n/a - n/a - n/a]),<BR><BR>[FERROUS SULFATE] (C - Iron deficiency - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - Blood folate decreased - n/a - [n/a - n/a - n/a]),<BR><BR>[LAMOTRIGINE] (C - Mood swings - n/a - [n/a - n/a - n/a]),<BR><BR>[PROPRANOLOL, PROPRANOLOL HYDROCHLORIDE] (C - Tachycardia - n/a - [n/a - n/a - n/a]),<BR><BR>[SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - Anxiety - n/a - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - Blood cholesterol - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM FLUORIDE] (C - Dental caries - n/a - [n/a - n/a - n/a]),<BR><BR>[SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - Constipation - n/a - [n/a - n/a - n/a]),<BR><BR>[TRIPTORELIN] (C - Paraphilia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016073577&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016073609,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Lower respiratory tract infection (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016073609&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016073610,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Not Specified,"Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"PREGABALIN [PREGABALIN] (C - Neuralgia - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016073610&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016074034,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Amnesia (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016074034&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016074101,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Asthenia (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Post procedural complication (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016074101&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016074215,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Cardiac flutter (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Heart rate increased (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE, BUDESONIDE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016074215&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016074869,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Contusion (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016074869&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016074958,Spontaneous,2023-10-12 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Joint range of motion decreased (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (2d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016074958&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016075103,Spontaneous,2023-10-12 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,Herpes zoster (n/a - Recovering/Resolving - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","FORXIGA [DAPAGLIFLOZIN] (C - Type 2 diabetes mellitus - n/a - [n/a - 10mg - Oral use]),<BR><BR>[ACETYLSALICYLIC ACID] (C - Thrombosis prophylaxis - n/a - [n/a - 75mg - Oral use]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE] (C - Hypertension - n/a - [n/a - 10mg - Oral use]),<BR><BR>[BETAMETHASONE, BETAMETHASONE VALERATE] (C - Eczema - n/a - [n/a - n/a - Cutaneous use]),<BR><BR>[DEXAMETHASONE, TOBRAMYCIN] (C - Cataract - n/a - [n/a - 1{DF} - Ocular use]),<BR><BR>[DEXAMETHASONE, TOBRAMYCIN] (C - Product used for unknown indication - n/a - [n/a - 1{DF} - Ocular use]),<BR><BR>[DICLOFENAC SODIUM] (C - Product used for unknown indication - n/a - [n/a - 1{DF} - Ocular use]),<BR><BR>[DOXAZOSIN, DOXAZOSIN MESILATE] (C - Hypertension - n/a - [n/a - 4mg - Oral use]),<BR><BR>[ENALAPRIL MALEATE, HYDROCHLOROTHIAZIDE, ENALAPRIL, HYDROCHLOROTHIAZIDE] (C - Hypertension - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[GLYCERYL TRINITRATE] (C - Angina pectoris - n/a - [n/a - 1{DF} - n/a]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - Type 2 diabetes mellitus - n/a - [n/a - 1000mg - Oral use]),<BR><BR>[METOPROLOL TARTRATE] (C - Hypertension - n/a - [n/a - 200mg - Oral use]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - Gastrooesophageal reflux disease - n/a - [n/a - 40mg - Oral use]),<BR><BR>[PARACETAMOL] (C - Pain - n/a - [n/a - 1000mg - Oral use]),<BR><BR>[POTASSIUM, SODIUM, MACROGOL 3350, CHLORIDE ION, HYDROGEN CARBONATE, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - Constipation - n/a - [n/a - 1{DF} - Oral use]),<BR><BR>[PREDNISOLONE, PREDNISOLONE ACETATE, PREDNISOLONE ACETATE PH. EUR., PREDNISOLONE PIVALATE, PREDNISOLONE PIVALATE PH. EUR.] (C - Eye disorder - n/a - [n/a - 1{DF} - Subconjunctival use]),<BR><BR>[SIMVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - 40mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016075103&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016075105,Spontaneous,2023-10-12 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,Urticaria (n/a - Recovering/Resolving - ),"COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a]),<BR><BR>[B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)] (S - Influenza immunisation - Not applicable - [n/a - 1{DF} - n/a])","[AMLODIPINE, AMLODIPINE BESILATE] (C - Hypertension - n/a - [n/a - 5mg - Oral use]),<BR><BR>[ATORVASTATIN] (C - Hypercholesterolaemia - n/a - [n/a - 10mg - Oral use]),<BR><BR>[THIAMAZOLE] (C - Hyperthyroidism - n/a - [n/a - .25mg - Oral use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016075105&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016075545,Spontaneous,2023-10-12 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Bedridden (5d - Recovered/Resolved - Disabling),<BR><BR>Brain fog (n/a - Recovering/Resolving - Disabling),<BR><BR>Chills (n/a - Unknown - Disabling),<BR><BR>Confusional state (5d - Recovered/Resolved - Disabling),<BR><BR>Dizziness (5d - Recovered/Resolved - Disabling),<BR><BR>Fatigue (n/a - Recovering/Resolving - Disabling),<BR><BR>Feeling abnormal (5d - Recovered/Resolved - Disabling),<BR><BR>Feeling hot (5d - Recovered/Resolved - Disabling),<BR><BR>Illness (4d - Recovered/Resolved - Disabling),<BR><BR>Pain (n/a - Unknown - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Unknown - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016075545&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016059954,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Pain (n/a - Unknown - ),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016059954&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016060217,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016060217&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016060557,Spontaneous,2023-10-11 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Arrhythmia (n/a - Unknown - Other Medically Important Condition),RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016060557&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016060807,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016060807&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016060877,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Lymphadenopathy (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[A/BRISBANE/59/2007 (H1N1)-LIKE STRAIN, A/BRISBANE/10/2007 (H3N2)-LIKE STRAIN, B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1) V REASS. X - 179 A, A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/NANCHANG 933/95 (H3N2), A/BAYERN/7/95 (H1N1) - LIKE STRAIN (A/JOHANNESBURG/82/96), B/BEIJING/184/93-LIKE STRAIN (B/HARBIN/7/94), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/CALIFORNIA/7/2004 (H3N2) - LIKE STRAIN (A/NEW YORK/55/2004 REASS. NYMC X-157), B/SHANGHAI/361/2002 - LIKE STRAIN (B/JIANGSU/10/2003), A/NEW CALEDONIA/20/99 (H1N1) - LIKE STRAIN (A/NEW CALEDONIA/20/99 REASS. IVR-116), A/MOSCOW/10/99 (H3N2) - LIKE STRAIN (A/PANAMA/2007/99 REASS. RESVIR-17), B/SICHUAN/379/99-LIKE STRAIN (B/JOHANNESBURG/5/99), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), A/CALIFORNIA/7/2009 (H1N1)-DERIVED STRAIN USED NYMC X-181, B/BRISBANE/60/2008, A/SWITZERLAND/9715293/2013 (H3N2)-LIKE STRAIN (A/SWITZERLAND/9715293/2013, NIB-88), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1), A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/BRISBANE/60/2008-LIKE VIRUS, A/CALIFORNIA/7/2009 (H1N1)V-LIKE VIRUS, A/PERTH/16/2009 (H3N2) - LIKE STRAIN (A/VICTORIA/210/2009 REASS. NYMC X-187), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/TEXAS/50/2012 (H3N2) – DERIVED STRAIN USED (NYMC X-223A), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/MASSACHUSETTS/2/2012 -DERIVED STRAIN USED (NYMC BX-51B), A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN USED (NYMC X-223A) DERIVED FROM A/TEXAS/50/2012, A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H1N1), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H3N2), INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[BECLOMETASONE DIPROPIONATE] (C - Asthma - n/a - [n/a - n/a - n/a])...","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016060877&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016060930,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Not Specified,"Chills (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Tremor (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"DUORESP SPIROMAX [BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>IMRALDI [ADALIMUMAB] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>NOVORAPID [INSULIN ASPART] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ASCORBIC ACID, CALCIUM GLUBIONATE, CALCIUM CARBONATE, CALCIUM, CALCIUM GLUBIONATE, CALCIUM CARBONATE, COLECALCIFEROL, CALCIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUOXETINE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016060930&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016061532,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Joint stiffness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Migraine (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016061532&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016061854,Spontaneous,2023-10-11 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Male,Haematuria (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),XARELTO [RIVAROXABAN] (C - Anticoagulant therapy - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016061854&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016061861,Spontaneous,2023-10-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Atrial fibrillation (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016061861&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016061898,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Back pain (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Musculoskeletal stiffness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Neck pain (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016061898&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016061902,Spontaneous,2023-10-11 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Male,Death (n/a - Fatal - Results in Death),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),"[BUMETANIDE] (C - n/a - n/a - [n/a - 1mg - n/a]),<BR><BR>[ESCITALOPRAM, ESCITALOPRAM OXALATE] (C - n/a - n/a - ),<BR><BR>[ROSUVASTATIN] (C - n/a - n/a - )","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016061902&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016062014,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Bone pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Decreased appetite (n/a - Unknown - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myocarditis (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016062014&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016062471,Spontaneous,2023-10-11 00:00:00,Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Arthralgia (n/a - Unknown - ),<BR><BR>Chills (n/a - Unknown - ),<BR><BR>Pain in extremity (n/a - Unknown - ),<BR><BR>Poor quality product administered (n/a - Unknown - ),<BR><BR>Product administration error (n/a - Unknown - ),<BR><BR>Vaccination site pain (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016062471&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016062712,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Chest pain (1d - Recovered/Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"IBUPROFEN [IBUPROFEN, IBUPROFEN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CETIRIZINE, CETIRIZINE DIHYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016062712&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016062767,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Blood glucose increased (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cognitive disorder (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016062767&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016062794,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Coordination abnormal (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Illness (n/a - Recovering/Resolving - Disabling, Other Medically Important Condition),<BR><BR>Muscle twitching (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016062794&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016063160,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Balance disorder (n/a - Recovering/Resolving - ),<BR><BR>Injection related reaction (1d - Recovered/Resolved - ),<BR><BR>Mental impairment (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016063160&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016064231,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Elderly,No,Not Specified,"COVID-19 (n/a - Unknown - ),<BR><BR>Sudden death (n/a - Fatal - Results in Death)",RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016064231&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016064306,Spontaneous,2023-10-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Breast engorgement (n/a - Not Recovered/Not Resolved - ),<BR><BR>Sensory disturbance (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016064306&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016064532,Spontaneous,2023-10-11 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Stomatitis (n/a - Unknown - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016064532&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016064644,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Body temperature abnormal (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Ear pain (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Pain in extremity - n/a - [n/a - n/a - n/a]),<BR><BR>[CANDESARTAN, CANDESARTAN CILEXETIL] (C - Blood pressure measurement - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE] (C - Gastrooesophageal reflux disease - n/a - [n/a - n/a - n/a]),<BR><BR>[SILDENAFIL, SILDENAFIL CITRATE] (C - COVID-19 immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016064644&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016064749,Spontaneous,2023-10-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Decreased appetite (4d - Recovering/Resolving - ),<BR><BR>Influenza like illness (4d - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular use]),"COMIRNATY [TOZINAMERAN] (C - COVID-19 immunisation - Not applicable - [251d - 1{DF} - Intramuscular use]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - COVID-19 immunisation - Not applicable - [82d - 1{DF} - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016064749&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016064856,Spontaneous,2023-10-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Hyperhidrosis (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Loss of consciousness (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Muscle spasms (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pallor (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Syncope (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[ACETYLSALICYLIC ACID] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[PERINDOPRIL, PERINDOPRIL ARGININE, PERINDOPRIL TERT-BUTYLAMIN MONOHYDRATE, PERINDOPRIL TERT-BUTYLAMINE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[SIMVASTATIN] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016064856&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016065169,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain upper (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Arthralgia (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Cough (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[FLUOXETINE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TIBOLONE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016065169&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016065239,Spontaneous,2023-10-11 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Rash (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - .3mL - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016065239&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016065262,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chest pain (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Palpitations (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016065262&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016065682,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Disorientation (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Night sweats (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"COMIRNATY [TOZINAMERAN] (C - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>LANTUS [INSULIN GLARGINE] (C - Type 1 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>NOVORAPID [INSULIN ASPART] (C - Type 1 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (C - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[LOSARTAN, LOSARTAN POTASSIUM] (C - Type 1 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Type 1 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[TAMSULOSIN, TAMSULOSIN HYDROCHLORIDE] (C - Prostatomegaly - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016065682&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016065687,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016065687&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016066205,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Asthenia (n/a - Recovering/Resolving - ),<BR><BR>Dizziness (n/a - Recovering/Resolving - ),<BR><BR>Herpes zoster (n/a - Recovering/Resolving - ),<BR><BR>Malaise (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016066205&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016066340,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Disabling),<BR><BR>Diarrhoea (n/a - Unknown - Disabling),<BR><BR>Dizziness (n/a - Unknown - Disabling),<BR><BR>Illness (n/a - Unknown - Disabling),<BR><BR>Influenza like illness (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Mobility decreased (n/a - Unknown - Disabling),<BR><BR>Nausea (n/a - Unknown - Disabling),<BR><BR>Pain (n/a - Unknown - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016066340&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016066739,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Musculoskeletal stiffness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Unknown - Other Medically Important Condition),<BR><BR>Swelling face (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016066739&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016066821,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016066821&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016066826,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Elderly,No,Not Specified,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Sudden death (n/a - Fatal - Results in Death)",RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016066826&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016067151,Spontaneous,2023-10-11 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,Suspected COVID-19 (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016067151&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016052119,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Joint stiffness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Peripheral coldness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tremor (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016052119&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016052496,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Hypertension (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016052496&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016052655,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Chills (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain of skin (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site mass (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"COMIRNATY ORIGINAL/OMICRON BA.1 [TOZINAMERAN, RILTOZINAMERAN] (C - COVID-19 immunisation - n/a - [1d - n/a - n/a]),<BR><BR>COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.1 [ELASOMERAN, IMELASOMERAN] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016052655&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016053231,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition),<BR><BR>Tremor (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - n/a - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016053231&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016053449,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Local reaction (n/a - Not Recovered/Not Resolved - ),<BR><BR>Noninfective gingivitis (n/a - Not Recovered/Not Resolved - ),<BR><BR>Oral infection (n/a - Not Recovered/Not Resolved - ),<BR><BR>Stomatitis (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016053449&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016054168,Spontaneous,2023-10-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,Yes,Female,Rash papular (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - Not applicable - [n/a - n/a - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016054168&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016054246,Spontaneous,2023-10-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,Yes,Male,Rash papular (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [0d - n/a - Intramuscular use]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED] (C - Influenza immunisation - Unknown - [0d - n/a - Intramuscular use])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016054246&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016054285,Spontaneous,2023-10-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Skin disorder (0d - Recovered/Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Urticaria (0d - Recovered/Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016054285&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016054358,Spontaneous,2023-10-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dyspnoea (0d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Oxygen saturation decreased (0d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Respiratory disorder (0d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"LIXIANA [EDOXABAN, EDOXABAN TOSYLATE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>ULTIBRO BREEZHALER [GLYCOPYRRONIUM BROMIDE, INDACATEROL MALEATE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE BESILATE, PERINDOPRIL ARGININE, AMLODIPINE, PERINDOPRIL] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[BUDESONIDE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM TRIHYDRATE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[MESALAZINE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[MOXONIDINE] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016054358&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016054402,Spontaneous,2023-10-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Anaphylactic reaction (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016054402&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016054417,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Conjunctival haemorrhage (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Hypertension (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - Immunisation - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016054417&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016054436,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Influenza (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[EZETIMIBE] (C - Blood cholesterol - n/a - [n/a - n/a - n/a]),<BR><BR>[NORTRIPTYLINE, NORTRIPTYLINE HYDROCHLORIDE] (C - Ear pain - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016054436&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016054437,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Dry skin (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Erythema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Maternal exposure during pregnancy (n/a - Unknown - ),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[COLECALCIFEROL, CALCIUM CARBONATE] (C - Pregnancy - n/a - [n/a - n/a - n/a]),<BR><BR>[COVID-19 VACCINE] (C - Immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[DIPHTHERIA, TETANUS, PERTUSSIS, HEPATITIS B (RDNA) AND HAEMOPHILUS INFLUENZAE TYPE B CONJUGATE VACCINE (ADSORBED)] (C - Pertussis - n/a - [n/a - n/a - n/a]),<BR><BR>[FOLIC ACID] (C - Pregnancy, Vitamin supplementation - n/a - [n/a - 5mg - n/a - More in ICSR]),<BR><BR>[HEPARIN, HEPARIN SODIUM] (C - Pregnancy - n/a - [n/a - n/a - n/a]),<BR><BR>[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]),<BR><BR>[SARS-COV-2, SPIKE PROTEIN, RECOMBINANT, EXPRESSED IN SF9 CELLS DERIVED FROM SPODOPTERA FRUGIPERDA] (C - Immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016054437&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016054438,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,Tinnitus (n/a - Not Recovered/Not Resolved - ),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016054438&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016054494,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Balance disorder (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Dizziness postural (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016054494&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016054495,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (1d - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pyrexia (1d - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016054495&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016054497,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Injection site pain (2d - Recovered/Resolved - ),<BR><BR>Pain in extremity (2d - Recovered/Resolved - ),<BR><BR>Vaccination site pain (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016054497&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016054500,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Injection site pain (3d - Recovered/Resolved - ),<BR><BR>Vaccination site pain (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 1{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016054500&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016054676,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Chills (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016054676&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016054710,Spontaneous,2023-10-10 00:00:00,Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Eye discharge (n/a - Unknown - ),<BR><BR>Occupational exposure to product (n/a - Unknown - ),<BR><BR>Skin injury (n/a - Unknown - ),<BR><BR>Thermal burns of eye (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016054710&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016054739,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Blood pressure increased (n/a - Unknown - ),<BR><BR>Tremor (n/a - Unknown - ),<BR><BR>Typical aura without headache (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016054739&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016055005,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Influenza (1d - Recovered/Resolved - ),<BR><BR>Pyrexia (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016055005&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016055222,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Procedural nausea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (2d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"ROTIGOTINE [ROTIGOTINE] (C - Restless legs syndrome - n/a - [n/a - n/a - n/a]),<BR><BR>[CAFFEINE PH. EUR., PARACETAMOL PH. EUR., CAFFEINE, PARACETAMOL PH. EUR., PARACETAMOL, CAFFEINE] (C - Pain - n/a - [n/a - n/a - n/a]),<BR><BR>[NEBIVOLOL] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016055222&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016055322,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dysstasia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"SPIRONOLACTONE [SPIRONOLACTONE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Neuropathy peripheral - n/a - [n/a - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a]),<BR><BR>[GABAPENTIN] (C - Neuropathy peripheral - n/a - [n/a - n/a - n/a]),<BR><BR>[LISINOPRIL, LISINOPRIL DIHYDRATE] (C - Blood pressure abnormal - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016055322&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016055374,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Abdominal pain (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Asthenia (2d - Unknown - Other Medically Important Condition),<BR><BR>Headache (2d - Unknown - Other Medically Important Condition),<BR><BR>Insomnia (2d - Unknown - Other Medically Important Condition),<BR><BR>Malaise (2d - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (2d - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016055374&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016055375,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),ETANERCEPT [ETANERCEPT] (C - Ankylosing spondylitis - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016055375&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016055539,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal distension (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Brain fog (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Dizziness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Heart rate (n/a - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Tremor (n/a - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016055539&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016055565,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Chills (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nervous system disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in jaw (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Sleep disorder due to general medical condition, insomnia type (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[PREDNISONE] (C - Eosinophilic granulomatosis with polyangiitis - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016055565&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016055674,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Chest pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Malaise (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016055674&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016055750,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chills (4d - Recovered/Resolved - ),<BR><BR>Decreased appetite (n/a - Recovering/Resolving - ),<BR><BR>Delirium (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Feeling cold (3d - Recovered/Resolved - ),<BR><BR>Rash (n/a - Unknown - ),<BR><BR>Skin irritation (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[AMITRIPTYLINE, AMITRIPTYLINE HYDROCHLORIDE] (C - Back pain - n/a - [5d - n/a - n/a]),<BR><BR>[AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]),<BR><BR>[CODEINE] (C - Back pain - n/a - [13d - n/a - n/a]),<BR><BR>[GABAPENTIN] (C - Back pain - n/a - [22d - n/a - n/a]),<BR><BR>[NORTRIPTYLINE, NORTRIPTYLINE HYDROCHLORIDE] (C - Back pain - n/a - [23d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016055750&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016055837,Spontaneous,2023-10-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Headache (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"XARELTO 20 MG [RIVAROXABAN] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016055837&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016055984,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"ELIQUIS [APIXABAN] (C - n/a - n/a - [1186d - n/a - n/a]),<BR><BR>[ACICLOVIR, ACICLOVIR BP] (C - Herpes simplex - n/a - [n/a - n/a - n/a]),<BR><BR>[CLONAZEPAM] (C - Anxiety - n/a - [n/a - n/a - n/a]),<BR><BR>[DILTIAZEM, DILTIAZEM HYDROCHLORIDE] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]),<BR><BR>[EZETIMIBE] (C - Angina pectoris - n/a - [n/a - n/a - n/a]),<BR><BR>[HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE] (C - Urticaria - n/a - [n/a - n/a - n/a]),<BR><BR>[LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]),<BR><BR>[METHADONE] (C - Erythromelalgia - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016055984&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016056156,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Diarrhoea (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (4d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vaccination site pain (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016056156&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016056406,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vaginal haemorrhage (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016056406&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016056471,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Feeling cold (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016056471&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016056694,Spontaneous,2023-10-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Adult,No,Female,"Ageusia (3d - Recovered/Resolved - ),<BR><BR>Decreased appetite (3d - Recovered/Resolved - ),<BR><BR>Diarrhoea (3d - Recovered/Resolved - ),<BR><BR>Dizziness (3d - Recovered/Resolved - ),<BR><BR>Dyspnoea (3d - Recovered/Resolved - ),<BR><BR>Malaise (3d - Recovered/Resolved - ),<BR><BR>Neck pain (3d - Recovered/Resolved - ),<BR><BR>Sinus pain (3d - Recovered/Resolved - ),<BR><BR>Vomiting (3d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE DISPERSION FOR INJECTION COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) [RAXTOZINAMERAN] (S - n/a - n/a - [1d - 1{DF} - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016056694&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016056872,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Muscular weakness (n/a - Not Recovered/Not Resolved - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Nausea (3d - Recovered/Resolved - ),<BR><BR>Syncope (2d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016056872&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016056902,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Hemiparesis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Skin burning sensation (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016056902&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016057111,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,Herpes zoster reactivation (n/a - Recovering/Resolving - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016057111&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016057212,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,Vaccination site nerve damage (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016057212&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016057316,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016057316&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016057750,Spontaneous,2023-10-10 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Balance disorder (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vertigo (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016057750&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016059540,Spontaneous,2023-10-10 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Incorrect dose administered (n/a - Unknown - ),<BR><BR>Interchange of vaccine products (n/a - Unknown - ),<BR><BR>Vaccination site pain (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016059540&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016042261,Spontaneous,2023-10-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pain of skin (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Vascular headache (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016042261&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016044243,Spontaneous,2023-10-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Emphysema (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Respiratory distress (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Transient ischaemic attack (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016044243&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016045173,Spontaneous,2023-10-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Chest pain (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Herpes zoster (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pain of skin (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016045173&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016045264,Spontaneous,2023-10-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Fatigue (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Myalgia (2d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Peripheral swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Vaccination site erythema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"ADALIMUMAB [ADALIMUMAB] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016045264&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016045392,Spontaneous,2023-10-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Nausea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[RABEPRAZOLE, RABEPRAZOLE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016045392&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016045706,Spontaneous,2023-10-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Ear pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Eye discharge (n/a - Unknown - Other Medically Important Condition),<BR><BR>Facial pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Toothache (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016045706&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016045774,Spontaneous,2023-10-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Headache (n/a - Not Recovered/Not Resolved - ),<BR><BR>Limb discomfort (n/a - Recovering/Resolving - ),<BR><BR>Nausea (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016045774&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016045809,Spontaneous,2023-10-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Asthenia (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - Disabling),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Disabling)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016045809&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016046066,Spontaneous,2023-10-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Diarrhoea (48h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (48h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Headache (48h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Influenza (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Myalgia (48h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Pain in extremity (48h - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (48h - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016046066&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016046490,Spontaneous,2023-10-09 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Arthralgia (n/a - Recovered/Resolved - ),<BR><BR>Joint range of motion decreased (n/a - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016046490&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016047089,Spontaneous,2023-10-09 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Injection site erythema (n/a - Recovering/Resolving - ),<BR><BR>Injection site reaction (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site warmth (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016047089&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016049958,Spontaneous,2023-10-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Atrial fibrillation (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Chest pain (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Dyspnoea (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Heart rate increased (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Palpitations (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition),<BR><BR>Tachycardia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016049958&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016050270,Spontaneous,2023-10-09 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Anxiety (n/a - Unknown - ),<BR><BR>COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Major depression (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016050270&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016050615,Spontaneous,2023-10-09 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Fall (n/a - Unknown - ),<BR><BR>Presyncope (n/a - Unknown - ),<BR><BR>Syncope (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016050615&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016032084,Spontaneous,2023-10-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016032084&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016032109,Spontaneous,2023-10-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",RAXTOZINAMERAN [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016032109&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016032460,Spontaneous,2023-10-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Not Specified,"Chills (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Insomnia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016032460&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016033543,Spontaneous,2023-10-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Chest discomfort (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Illness (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Myalgia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Pyrexia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition),<BR><BR>Wheezing (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Influenza immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016033543&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016033757,Spontaneous,2023-10-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Dyspnoea (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Lethargy (n/a - Unknown - Other Medically Important Condition),<BR><BR>Malaise (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Renal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Suspected COVID-19 (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016033757&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016033929,Spontaneous,2023-10-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthma (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE, BUDESONIDE] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[MONTELUKAST, MONTELUKAST SODIUM] (C - Asthma - n/a - [n/a - n/a - n/a]),<BR><BR>[SALBUTAMOL, SALBUTAMOL SULFATE] (C - Asthma - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016033929&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016034539,Spontaneous,2023-10-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Faeces discoloured (n/a - Unknown - Other Medically Important Condition),<BR><BR>Retching (n/a - Unknown - Other Medically Important Condition),<BR><BR>Vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"INSULIN ASPART [INSULIN ASPART] (C - Type 1 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>INSULIN DETEMIR [INSULIN DETEMIR] (C - Type 1 diabetes mellitus - n/a - [n/a - n/a - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[AMYLASE, LIPASE, PROTEASE, PANCREALIPASE, PANCREAS POWDER, PANCREAS POWDER FROM PORCINE, PANCREATIN, PANCREATIN BP, PANCRELIPASE AMYLASE, PANCRELIPASE PROTEASE, LIPASE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ASCORBIC ACID, BETACAROTENE, BIOTIN, ERGOCALCIFEROL, CYANOCOBALAMIN, FOLIC ACID, NICOTINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, ZINC, CALCIUM, CHROMIUM, COPPER, IODINE, IRON, MAGNESIUM, MANGANESE, PANTOTHENIC ACID, PHOSPHORUS, POTASSIUM, SELENIUM, TOCOPHERYL ACETATE, MOLYBDENUM, ASCORBIC ACID, BETACAROTENE, ERGOCALCIFEROL, CYANOCOBALAMIN, FOLIC ACID, NICOTINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, ZINC, CALCIUM, CHROMIUM, COPPER, IODINE, IRON, MAGNESIUM, MANGANESE, PANTOTHENIC ACID, PHOSPHORUS, POTASSIUM, SELENIUM, MOLYBDENUM, DL-ALPHA TOCOPHEROL ACETATE, D-BIOTIN, ERGOCALCIFEROL, RETINOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CALCIUM CARBONATE, CHOLECALCIFEROL CONCENTRATE (POWDER FORM), COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016034539&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016034784,Spontaneous,2023-10-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Dementia (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016034784&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016034812,Spontaneous,2023-10-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Arthralgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Body temperature increased (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Hyperhidrosis (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Pollakiuria (3d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Vomiting (1d - Recovered/Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016034812&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016034867,Spontaneous,2023-10-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016034867&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016037289,Spontaneous,2023-10-06 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Immune thrombocytopenia (n/a - Recovering/Resolving - Life Threatening, Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (C - Immunisation - n/a - [1d - n/a - n/a]),<BR><BR>[ACRIVASTINE, DIPHENHYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE, ZINC ACETATE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[OMEPRAZOLE, OMEPRAZOLE MAGNESIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016037289&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016039129,Spontaneous,2023-10-06 00:00:00,Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Blood pressure systolic increased (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Cold sweat (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling abnormal (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Feeling cold (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Nausea (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016039129&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016039927,Spontaneous,2023-10-06 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Lip ulceration (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Pharyngeal ulceration (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Tongue ulceration (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016039927&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016023517,Spontaneous,2023-10-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Male,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016023517&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016024771,Spontaneous,2023-10-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Male,"Dizziness (n/a - Unknown - ),<BR><BR>Headache (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016024771&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016025311,Spontaneous,2023-10-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Decreased appetite (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Feeling cold (n/a - Recovering/Resolving - ),<BR><BR>Hyperhidrosis (n/a - Recovering/Resolving - ),<BR><BR>Musculoskeletal stiffness (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016025311&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016025373,Spontaneous,2023-10-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal pain upper (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[CEFALEXIN] (C - Urinary tract infection - n/a - [n/a - n/a - n/a]),<BR><BR>[NAPROXEN, NAPROXEN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[TAMOXIFEN, TAMOXIFEN CITRATE] (C - Breast cancer - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016025373&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016025394,Spontaneous,2023-10-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016025394&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016025670,Spontaneous,2023-10-05 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Abdominal pain upper (n/a - Recovering/Resolving - ),<BR><BR>Chills (n/a - Recovering/Resolving - ),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (n/a - Recovering/Resolving - ),<BR><BR>Palpitations (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - ),<BR><BR>Retching (n/a - Recovering/Resolving - ),<BR><BR>Tachycardia (n/a - Recovering/Resolving - ),<BR><BR>Vomiting (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016025670&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016025892,Spontaneous,2023-10-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Dizziness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oropharyngeal discomfort (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Pharyngeal swelling (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Skin discolouration (n/a - Unknown - Other Medically Important Condition),<BR><BR>Throat tightness (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016025892&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016027211,Spontaneous,2023-10-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Brain fog (n/a - Unknown - Other Medically Important Condition),<BR><BR>Facial paralysis (n/a - Unknown - Other Medically Important Condition),<BR><BR>Headache (4d - Unknown - Other Medically Important Condition),<BR><BR>Hypoaesthesia (n/a - Recovered/Resolved With Sequelae - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016027211&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016028720,Spontaneous,2023-10-05 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Fatigue (n/a - Unknown - Other Medically Important Condition),<BR><BR>Feeling cold (1d - Unknown - Other Medically Important Condition),<BR><BR>Headache (n/a - Unknown - Other Medically Important Condition),<BR><BR>Injection related reaction (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Nocturia (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),[INFLUENZA VIRUS] (C - Immunisation - n/a - [1d - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016028720&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016030409,Spontaneous,2023-10-05 00:00:00,Healthcare Professional,Non European Economic Area,Not available,Not Specified,Elderly,No,Male,"Asthenia (n/a - Unknown - ),<BR><BR>Fall (n/a - Recovering/Resolving - ),<BR><BR>Muscular weakness (n/a - Unknown - ),<BR><BR>Pulse abnormal (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Intramuscular use]),"[ACETYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CANAGLIFLOZIN] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[CILOSTAZOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[MIGLITOL] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[NATEGLINIDE] (C - n/a - n/a - [n/a - n/a - n/a]),<BR><BR>[PRAVASTATIN, PRAVASTATIN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016030409&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016016553,Spontaneous,2023-10-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Back pain (n/a - Unknown - ),<BR><BR>Fatigue (n/a - Unknown - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016016553&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016017219,Spontaneous,2023-10-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Fatigue (n/a - Not Recovered/Not Resolved - ),<BR><BR>Headache (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016017219&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016017399,Spontaneous,2023-10-04 00:00:00,Healthcare Professional,European Economic Area,Not available,More than 85 Years,Not Specified,No,Female,"Hypertension (2d - Recovered/Resolved - ),<BR><BR>Paraesthesia (2d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016017399&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016018347,Spontaneous,2023-10-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Headache (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Recovering/Resolving - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),SPIKEVAX [ELASOMERAN] (C - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016018347&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016018725,Spontaneous,2023-10-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Contusion (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Erythema (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016018725&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016019159,Spontaneous,2023-10-04 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Arthralgia (1d - Recovered/Resolved - ),<BR><BR>Chills (1d - Recovered/Resolved - ),<BR><BR>Erythema (1d - Recovered/Resolved - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Headache (1d - Recovered/Resolved - ),<BR><BR>Injection site reaction (1d - Recovered/Resolved - ),<BR><BR>Malaise (1d - Recovered/Resolved - ),<BR><BR>Myalgia (1d - Recovered/Resolved - ),<BR><BR>Pain in extremity (1d - Recovered/Resolved - ),<BR><BR>Palpitations (1d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016019159&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016020509,Spontaneous,2023-10-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Asthenia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Brain fog (n/a - Unknown - Other Medically Important Condition),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Influenza (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Influenza like illness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Migraine with aura (1d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Muscular weakness (n/a - Unknown - Other Medically Important Condition),<BR><BR>Myalgia (n/a - Unknown - Other Medically Important Condition),<BR><BR>Oropharyngeal pain (n/a - Unknown - Other Medically Important Condition),<BR><BR>Rhinorrhoea (n/a - Unknown - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),AZATHIOPRINE [AZATHIOPRINE] (C - n/a - n/a - [n/a - n/a - n/a]),"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016020509&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016021413,Spontaneous,2023-10-04 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Immunodeficiency (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016021413&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016007610,Spontaneous,2023-10-03 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,"Sudden death (n/a - Fatal - Results in Death),<BR><BR>Syncope (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016007610&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016008527,Spontaneous,2023-10-03 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Chills (0d - Recovered/Resolved - ),<BR><BR>Influenza (0d - Recovered/Resolved - ),<BR><BR>Injection site reaction (0d - Recovered/Resolved - ),<BR><BR>Malaise (0d - Recovered/Resolved - ),<BR><BR>Myalgia (0d - Recovered/Resolved - ),<BR><BR>Nausea (0d - Recovered/Resolved - ),<BR><BR>Pyrexia (0d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"[ACETYLSALICYLIC ACID] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[OLMESARTAN MEDOXOMIL, AMLODIPINE, HYDROCHLOROTHIAZIDE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - n/a - Unknown - [n/a - 10mg - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016008527&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016003293,Spontaneous,2023-10-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Amenorrhoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Limb discomfort (n/a - Not Recovered/Not Resolved - ),<BR><BR>Somnolence (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016003293&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016003297,Spontaneous,2023-10-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Diplopia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Dizziness (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Migraine with aura (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Visual field defect (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),<BR><BR>Visual impairment (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016003297&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016003629,Spontaneous,2023-10-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Headache (n/a - Recovering/Resolving - ),<BR><BR>Limb discomfort (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - Intramuscular use]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016003629&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016003865,Spontaneous,2023-10-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Asthenia (n/a - Recovering/Resolving - ),<BR><BR>Bone pain (n/a - Recovering/Resolving - ),<BR><BR>Diarrhoea (n/a - Recovering/Resolving - ),<BR><BR>Fatigue (n/a - Recovering/Resolving - ),<BR><BR>Injection site induration (n/a - Recovering/Resolving - ),<BR><BR>Myalgia (n/a - Recovering/Resolving - ),<BR><BR>Vaccination site pain (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016003865&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016004155,Spontaneous,2023-10-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Breast pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Dyspnoea (n/a - Not Recovered/Not Resolved - ),<BR><BR>Musculoskeletal chest pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Painful respiration (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016004155&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016004268,Spontaneous,2023-10-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Male,"Back pain (n/a - Not Recovered/Not Resolved - ),<BR><BR>Malaise (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016004268&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10016005921,Spontaneous,2023-10-02 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Pain in extremity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Postmenopausal haemorrhage (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),"[A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A), B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/GUANGDONG-MAONAN/SWL1536/2019 (H1N1)PDM09 - LIKE VIRUS (A/GUANGDONG-MAONAN/SWL1536/2019, CNIC-1909), A/HONG KONG/2671/2019 (H3N2) - LIKE VIRUS (A/HONG KONG/2671/2019, IVR-208), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, NYMC X-263B), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A), A/BRISBANE/02/2018 (H1N1)PDM09-LIKE VIRUS (A/BRISBANE/02/2018, IVR-190), A/KANSAS/14/2017 (H3N2)-LIKE VIRUS (A/KANSAS/14/2017, NYMC X-327), B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224)] (C - Immunisation - n/a - [1d - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10016005921&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015993018,Spontaneous,2023-09-29 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Female,"Hallucination (0d - Recovered/Resolved - Other Medically Important Condition),<BR><BR>Sensory disturbance (0d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015993018&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015993802,Spontaneous,2023-09-29 00:00:00,Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"Abdominal pain (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Arthralgia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Chills (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Diarrhoea (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Fatigue (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Injection site reaction (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Malaise (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Myalgia (n/a - Unknown - Caused/Prolonged Hospitalisation),<BR><BR>Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation)",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"ELIQUIS 5 MG [APIXABAN] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>TADALAFIL 20 MG  (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[ALLOPURINOL] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[AMIODARONE, AMIODARONE HYDROCHLORIDE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[OLMESARTAN MEDOXOMIL] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015993802&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015997068,Spontaneous,2023-09-29 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"COVID-19 (n/a - Unknown - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Unknown - Other Medically Important Condition),<BR><BR>Interchange of vaccine products (n/a - Unknown - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a]),<BR><BR>SPIKEVAX [ELASOMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]),<BR><BR>TOZINAMERAN [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015997068&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015988158,Spontaneous,2023-09-28 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,Not Specified,Not Specified,No,Female,Thrombosis (n/a - Unknown - Other Medically Important Condition),COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015988158&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015990148,Spontaneous,2023-09-28 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Not Specified,No,Female,"Myalgia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pain in extremity (n/a - Not Recovered/Not Resolved - ),<BR><BR>Peripheral swelling (n/a - Not Recovered/Not Resolved - ),<BR><BR>Vaccination site warmth (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]),"CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[ACETYLSALICYLIC ACID] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[EZETIMIBE, ROSUVASTATIN] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[LERCANIDIPINE, LERCANIDIPINE HYDROCHLORIDE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[METFORMIN HYDROCHLORIDE] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[NEBIVOLOL] (C - n/a - Unknown - [n/a - n/a - n/a]),<BR><BR>[PARACETAMOL, CODEINE PHOSPHATE] (C - n/a - Unknown - [n/a - n/a - n/a])","<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015990148&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015977975,Spontaneous,2023-09-27 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Angioedema (n/a - Recovering/Resolving - Other Medically Important Condition),<BR><BR>Paraesthesia (n/a - Not Recovered/Not Resolved - ),<BR><BR>Pruritus (n/a - Not Recovered/Not Resolved - ),<BR><BR>Urticaria (n/a - Not Recovered/Not Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015977975&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015981566,Spontaneous,2023-09-27 00:00:00,Non Healthcare Professional,Non European Economic Area,Not available,65-85 Years,Not Specified,No,Male,"COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),<BR><BR>Drug ineffective (n/a - Not Recovered/Not Resolved - Other Medically Important Condition)","COMIRNATY OMICRON XBB.1.5 [RAXTOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - .3mL - n/a]),<BR><BR>[A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181), A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B), B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180), INFLUENZA VACCINE] (S - Immunisation - Not applicable - [1d - n/a - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015981566&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015969718,Spontaneous,2023-09-26 00:00:00,Non Healthcare Professional,European Economic Area,Not available,65-85 Years,Elderly,No,Female,"Headache (4d - Recovered/Resolved - ),<BR><BR>Malaise (4d - Recovered/Resolved - ),<BR><BR>Vaccination site pain (4d - Recovered/Resolved - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 5{DF} - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015969718&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015950120,Spontaneous,2023-09-22 00:00:00,Non Healthcare Professional,European Economic Area,Not available,18-64 Years,Adult,No,Male,"Chills (n/a - Recovering/Resolving - ),<BR><BR>Pyrexia (n/a - Recovering/Resolving - )",COMIRNATY OMICRON XBB.1.5 30 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - n/a - n/a]),Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015950120&_xpt=1&_xf=pdf"">ICSR</a>"
EU-EC-10015879533,Spontaneous,2023-09-11 00:00:00,Healthcare Professional,European Economic Area,Not available,18-64 Years,Not Specified,No,Female,"Abdominal discomfort (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Arrhythmia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Chronic fatigue syndrome (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation),<BR><BR>Hypertension (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)","COMIRNATY OMICRON XBB.1.5 3 MICROGRAMS/DOSE [RAXTOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 4{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 2{DF} - n/a]),<BR><BR>COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a - 3{DF} - n/a])",Not reported,"<a target=""_blank"" href=""https://dap.ema.europa.eu/xmlpserver/PHV%20DAP/Reports/ICSR.xdo?_xpf=&_xt=form&SR_ID=10015879533&_xpt=1&_xf=pdf"">ICSR</a>"